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IV. Abstract 
Post-translational modifications like phosphorylation, glycosylation and ubiquitylation, are changes 
proteins are subjected to after translation and are essential in the regulation of the function, folding and 
interaction of proteins. Similarly, the modification of biomolecules has become a main tool in chemical 
biology to gain new insights into their molecular mechanisms and to alter and fine-tune their activity.  
The dysregulation of post-translational modifications is often associated with disease. A prime example 
is the hyperphosphorylation of the tau protein, which is thought to be one of the two main contributors 
to the outbreak of Alzheimer’s disease. The abnormally hyperphosphorylated tau protein is the main 
component of neurofibrillary tangles, one of the pathological hallmarks of the neurodegenerative 
disease. The origin and role of these hyperphosphorylations, which render a highly soluble and mostly 
unstructured protein into insoluble aggregates, is a key question in Alzheimer research. First steps 
towards a tau semi-synthesis that allow for the site-specific introduction of phosphorylations in the 
proline-rich domain were taken by identifying suitable ligation sites, finding the ideal sequential ligation 
strategy, providing reliable protein expression protocols and optimizing the synthesis of the synthetic 
peptides equipped with phosphorylated residues. 
Furthermore, this thesis explored the use of the Staudinger-phosphonite reaction in the synthesis of 
photo-cleavable phosphonamidates to modify biomolecules in a reversible manner. This conjugation 
method allowed for the chemoselective modification of an azido-containing target molecule with a 
borane-protected P(III) reagent that was equipped with two photo-cleavable 2-nitrobenzyl substituents 
and one alkyne for functionalization by Click Chemistry. UV irradiation induced the phosphonamidate 
P-N bond cleavage and resulted in the release of the target molecule with an additional amine 
functionality. In this regard, first steps were undertaken to develop a traceless variant of this cleavage. 
The application of the photo-cleavable phosphonamidates was demonstrated in streptavidin-mediated 
immobilization assays, which is just one example for the use of this valuable methodology. 
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V. Zusammenfassung 
Posttranslationale Modifikationen wie Phosphorylierung, Glykosylierung und Ubiquitinierung sind 
chemische Veränderungen, die ein Protein nach Beendung der Translation durchläuft. Sie sind 
unerlässlich für die Regulierung der Funktion, Struktur und Interaktion von Proteinen. Die Einführung 
von Modifikationen in Biomoleküle ist zudem ein wichtiges Hilfsmittel in der Chemischen Biologie, 
um neue Informationen über ihr Verhalten zu erlangen und ihre Aktivität zu verändern. 
Die Fehlregulierung von posttranslationalen Modifikationen steht häufig in direkter Verbindung zum 
Ausbruch von Krankheiten. Ein Beispiel dafür ist das Mikrotubuli-assoziierte Tau Protein, welches eine 
Schlüsselrolle in der Alzheimer Erkrankung hat. Im Laufe der Krankheit wird das Tau Protein 
zunehmend hyperphosphoryliert, was sowohl zu einem Funktionsverlust bei der Stabilisierung der 
Mikrotubuli als auch bei dem Erhalt neuronaler Systeme führt und schließlich mit der Bildung von 
nicht-löslichen Aggregaten endet. Die genauen Mechanismen hinter dieser Fehlregulierung sind noch 
nicht bekannt und deren Verständnis zu einer großen Herausforderungen der Alzheimerforschung 
gehört. Diese Doktorarbeit hat sich mit der Entwicklung einer neuen semi-synthetischen 
Ligationsstrategie beschäftigt, die es ermöglichen soll die Rolle einzelner Phosphorylierungen und 
anderer posttranslationaler Modifikationen in der Prolin-reichen, zentralen Region des Tau Proteins zu 
untersuchen. Hierfür wurden geeignete Ligationsstellen identifiziert, verschiedene 
Ligationsmöglichkeiten geprüft und die Expression und Synthese der einzelnen Fragmente optimiert. 
Desweiteren wurde im Rahmen dieser Doktorarbeit eine neuartige Anwendung der Staudinger-
Phosphonit Ligation entwickelt, die es ermöglicht mithilfe von Boran-geschützten P(III) Verbindungen 
azidhaltige Moleküle zu lichtspaltbaren Phosphonamidaten zu modifizieren. Die P(III) Bausteine 
beinhalteten dabei nicht nur zwei lichtspaltbare 2-Nitrobenzyl-Substituenten, sondern erlaubten zudem 
über eine zusätzliche Alkingruppe die vielfältige Funktionalisierung mittels Click Chemie. Die 
Bestrahlung durch UV Licht induziert die Spaltung der P-N Bindung der Phosphonamidate und setzte 
das Ursprungsmolekül mit einer zusätzlichen Aminfunktion frei. Dahingehend wurden erste Schritte 
unternommen, damit die Lichtspaltung keine Modifikation mehr am Ursprungsmolekül hinterlässt. Die 
Anwendung der lichtspaltbaren Phosphonamidate wurde in Streptavidin-basierten Immobilisierungen 
gezeigt. Dieses ist nur ein Beispiel für das vielfältige Potential dieser Weiterentwicklung der Staudinger-
Phosphonit Ligation.   
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1 Motivation 
Alzheimer’s disease has become a widespread disease that affects all demographic groups across the 
world and is now the 6th leading cause of death in the US. The cost of AD has risen to $259 billion in 
2017 in America alone and it is expected to go up by 500 % until 2050 if no alternative treatment 
methods are found. To this point, the exact cause for the outbreak of AD still lies in the dark. Two 
pathological hallmarks of AD are neuritic plaques, mainly consisting of the protein amyloid-β, and 
neurofibrillary tangles, which are a result of the aggregation of the tau protein.  
Research has predominantly focused on the role of amyloid-β in the past, but the interest in tau is steadily 
rising. Usually highly soluble and devoid of almost any secondary structure, tau acts as a stabilizer for 
microtubulin. In AD, tau is hyperphosphorylated, leading to a change in structure and solubility, which 
eventually reveals itself in the formation of insoluble aggregates and neurofibrillary tangles. To this 
point, the reason for the hyperphosphorylation is unknown, although a lot of effort has been investigated 
to solve the riddle behind the disequilibrium of post-translational modifications. Of particular interest 
is the dysregulation within the proline-rich domain. It is located in the middle of the protein and features 
a number of disease-relevant phosphorylation motifs, like the AT-8 (pS202/pT205/pS208) and AT-100 
(pT212/pS214) epitopes. One of the reasons why it has not been studied in more detail is the absence 
of suitable methodology to introduce site-specific phosphorylations within the proline-rich domain of 
the full-length tau protein. Biochemical tools can produce heterogeneous mixtures of phosphorylated 
tau by treatment with kinases, the phosphorylation sites can be mutated out to remove the functionality 
or phosphorylation mimetics like aspartic acid can be used to mirror post-translational modifications, 
but these methods can only deliver an approximation of the effects the site-specific modifications would 
induce. Figuring out the origin and the effect of individual phosphorylations in the hyperphosphorylated 
tau protein will be key to finding an effective treatment for AD.  
Protein semi-synthesis combines tools of biology and chemistry and is so far the only methodology with 
the power to generate homogeneously phosphorylated tau proteins. It is based on the native chemical 
ligation and the expressed protein ligation, which allow the formation of a native amide bond between 
peptides and proteins. Thanks to the extended toolbox of solid-phase based peptide synthesis, any site-
specific modification can be introduced into large proteins via a synthetic fragment inserted by 
chemoselective ligation. Through this methodology, pure and full-length tau proteins with defined post-
translational modifications patterns can be produced and studied to obtain a better understanding of the 
influence of individual modifications on tau structure and function. 
Chemoselective reactions like the native chemical ligation have enriched the field of chemical biology 
and biotechnology by providing a set of tools that allow the site-specific labelling of target molecules 
with, for example, cell-penetrating peptides to help them cross the cell membrane, with fluorescent 
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molecules to track the molecule’s position or with immobilization tags for enrichment purposes. In some 
cases, it can be useful to attach the modifications via cleavable linkers that permit their removal upon a 
specific impulse, like already used in targeted drug delivery to allow site-specific activation of prodrugs 
and to overcome side effects. By installing a target-specific guide to the drug, its transport can be 
directed to a location of interest and its cleavage will ensure the drug’s full activity at the site. The 
development of a versatile and selective labelling tool that can be cleaved under mild conditions is 
therefore of high interest in chemical biology. 
The development and application of two types of chemoselective reactions – cleavable and non-
cleavable – will be explored further in the context of this thesis. On one hand, the Staudinger-
phosphonite ligation will be used as a basis for a novel photo-cleavable phosphonamidate tag that allows 
for the site-specific functionalization of an azido-containing molecule and its subsequent mild release 
for future biotechnological applications. On the other hand, the principle of native peptide ligation and 
expressed protein ligation will be used to derive a new semi-synthetic scheme towards the site-selective 
modification of the proline-rich domain of tau, a tool which will provide the possibility to study the 
effect of individual phosphorylations on other post-translational modifications on this important protein. 
INTRODUCTION 
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2 Introduction 
2.1 Chemoselective modifications in peptides & proteins 
A key interest in biology and chemistry is to understand the functionality and mechanism of 
biomolecules in their natural environment. Another interest lies in the alteration and fine-tuning of 
the function of biomolecules to, for instance, allow for their site-specific delivery and to increase 
their in vivo stability. Chemists are contributing to this field by developing chemoselective reactions 
that can add residue- and site-specific modifications into biomolecules. A chemoselective reaction 
is a reaction that proceeds with a high specificity towards a particular functional group and is not 
hindered by the presence of a wide range of other molecules in the vicinity. At the same time, the 
reaction has to progress at fast rates, be highly stable and the employed reagents have to be soluble 
under aqueous conditions. Preferably, the end product should be stable to a wide range of pHs to 
ensure full functionality for the final application. [1] 
Research in this area is fueled by the mounting emergence of peptide- and protein-based 
pharmaceutical products. [2][3] Both of these species frequently require high-yielding and, most 
importantly, reproducible late-stage modifications. Approximately 30 % of the peptides that have 
entered clinical development since 2010 are conjugates. Decoration with PEG units , for example, 
serves to increase the half-life time of the conjugate, while the attachment of polysaccharides can 
influence the binding properties to receptors. [4] To be able to conduct safe clinical trials and to obtain 
reproducible data, it is important to generate conjugates with a high degree of homogeneity.  
Chemoselective reactions exploit the different properties of the functional groups that can be found 
in biomolecules. A number of residue-specific reactions that target natural amino acids like lysines, 
cysteines and tyrosines have been reported in literature. These conjugation methods often lack in 
site-specificity and therefore generate heterogeneous products. Other methodologies rely on the use 
of advanced protein engineering. The extension of laboratory-based protein expression to non-
canonical amino acids allows to generate homogeneous and site-specifically labelled proteins. Some 
unnatural functionalities that pop up in this context are aldehydes and ketones, which can be 
modified with hydrazides, aminooxy groups and thiosemicarbazides, but also azides, which are 
addressable by distinct reactions with alkynes and phosphines.  
2.1.1 Addressing naturally occurring amino acids 
To avoid extensive biochemical engineering, the unique characteristics of naturally occurring amino 
acids can be used as reactive handles in chemoselective reactions. [5] Hydrocarbon aliphatic chains 
are difficult to modify, with the exception of metal-catalyzed C-H functionalization, although these 
methods, of course, lack any regional specificity. [6] Amino acids with non-ionizable side chains like 
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asparagine and glutamine are equally challenging to target. A rare example was delivered by 
Popp et al., who described the use of dirhodium catalysts to induce a proximity-induced reaction of 
carboxamides with diazo reagents. [7] Cysteines, lysines and serines have reactive nucleophilic side 
chains and can be targeted by electrophiles. Thanks to the polarizability and size of the sulfur atom, 
cysteine is the most reactive of the three, followed by lysine and then serine. Despite its lower 
nucleophilicity in comparison to cysteine, lysine and serine, methionine can be modified to yield 
sulfones and sulfoniums with highly electrophilic reagents at low pH. [8] In a more recent example, 
Lin et al. took advantage of the high oxidative potential of methionine and reacted it with strained 
oxaziridines to yield sulfimides. The reaction was highly chemoselective, also in the presence of 
cysteine residues. [9] The phenol ring of tyrosine also has unique properties that can be exploited in 
chemoselective reactions. 
The basic nature of lysines (pKa ⁓ 10.5) and their high abundance make them a suitable target for 
modification with electrophiles. The reaction of NHS-modified reagents with lysine residues is 
perhaps the best-commonly used method to install fluorophores, purification tags and isotopic labels 
to all types of proteins for in-cell experiments, microscopy assays or SPR studies, to just name a 
few, regardless of its shortcomings in selectivity when the reaction is performed in the presence of 
cysteines (see Scheme 1 – pathway (a)). [10] The high reactivity of NHS esters and their easy synthesis 
certainly adds to their applicability. By adjusting the number of equivalents and optimizing the mode 
of addition, a higher selectively towards specific lysine residues can be achieved, depending on their 
position in the protein, solvent exposure and local pH. [11] The ε-amines can also react with 2-
formylbenzeneboronic acid to form stable iminoboronates (see Scheme 1 – pathway (b)). Imines are 
usually prone to hydrolysis, but the interaction between the imine nitrogen and the borane enhance 
their stability. They can be broken up by the addition of glutathione, which leads to a full release of 
the boronate. The reversible nature of this conjugation make it an attractive methodology for cell 
delivery, exploiting the high glutathione concentration inside of cells. [12] More recently, Faustino et 
al. used the same boronic acid as reversible N-terminal cysteine protecting group, where competing 
internal lysine residues did not cross-react with the reagent, either because of the reversibility of the 
conjugate or the higher reactivity of the cysteine. [13] The group of Fukase developed a lysine-
specific, but not site-specific labeling using unsaturated (E)-ester aldehydes. These first form 
irreversible 1,2-dihydropyridines via a reductive amination, followed by a 6π-azaelectrocyclization 
of the intermediate Schiff bases (see Scheme 1 – pathway (c)). This reaction preferably occurs with 
lysines at the protein surface and less so with internal or secondary amines at the N-terminus. The 
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reaction proceeds in high yields and also works on small amounts of protein, which makes it an 
interesting reagent for labeling expensive protein probes. Tanaka et al. used this methodology for 
tracking the movement of somatostatin in mice with PET imaging by installing a DOTA-probe head 
to the reagent. [14] To improve the site-selectivity of the labeling probe and potentially avoid 
attachment to or near the active site as well as the interaction surface of the biomolecule, the probe 
could be further modified to contain a targeting moiety that was cleavable after successful 
incorporation. [15] 
Cysteines (pKa ⁓ 8.4) belong to the rarest amino acids and are therefore a favored target of 
chemoselective reactions to obtain homogeneous protein or peptide conjugates. Lysines are more 
abundant than cysteines and will compete in the reaction. By lowering the pH, the selectivity towards 
cysteines can be increased, as the amines will be protonated and therefore less reactive.  
Cysteines can be alkylated by alkyl halides (see – a)), undergo disulfide formation or react with 
maleimides. [16] Maleimide chemistry in particular is an established and widely-used conjugation 
method to modify proteins with fluorophores and lipids and is used regularly in the production of 
antibody-drug conjugated (ADCs) (see Scheme 2 – b)). Despite their wide use, thiosuccinimide 
conjugates are known to undergo retro-Michael additions and are furthermore prone to hydrolysis. 
Additionally, they do not exclusively react with cysteines, but can also undergo side reactions with 
amine residues. [17] Baker’s group introduced second-generation bromomaleimides (NGAs) that 
contain one or two leaving groups at the double bond and feature a higher selectivity to thiols over 
amines in comparison to the previous generation (see Scheme 2 – c)). [18] By the addition of TCEP, 
the conjugation was fully reversible. Thanks to these characteristics, NGAs were employed as linker 
molecules to bridge larger biomolecules like proteins with a desired modification. [19]  
Scheme 1: (a) NHS-ester, (b) iminoboronates and (c) conjugation via reductive amination to 1,2 
dihydropyridine and 6π-azaelectrocyclization. 
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Tyrosines are susceptible to electrophilic aromatic substitutions and are particularly inclined to 
undergo oxidation reactions, thanks to their electron-rich ring and the phenol moiety, which directs 
any reactions to the ortho position of the ring. Their high hydrophobicity usually means that they lie 
protected within the protein and are consequently not addressable. By targeting rarer outer-surface 
tyrosines, single modifications can be introduced. The group of Francis has contributed a large set 
of reactions to achieve this goal. This includes diazo couplings (see Scheme 2 – d)) [20,21], Mannich-
type reactions (see Scheme 2  – e)) and cerium-catalyzed oxidations (see Scheme 2 – f)) [22]. [23] 
Another interesting modification is an ene-type reaction by Ban et al., where cyclic 
diazodicarboxamides react with the aromatic ring of tyrosine in a manner that strongly reminds of 
pericyclic reactions. [24] 
2.1.2 Unnatural functionalities as superior targets for modification 
Regardless of the effort that has so far been invested in finding chemoselective reactions for naturally 
occurring amino acids, they often not only lack in residue selectivity, but more importantly site-
selectivity to be widely applicable. The use of non-natural amino acids is an interesting alternative 
to achieve high conjugation specificity in biomolecules, because their functionality is not present in 
nature and the reactions that target them are specific to this reactive group alone.  
One of the earliest examples of a reaction fulfilling the necessary requirements for a chemoselective 
reaction was the condensation of ketones or aldehydes with hydroxylamines to yield oximes or 
hydrazines to form hydrazones. Rideout reported the use of hydrazone formation in a cellular 
environment by assessing the cytotoxicity of self-assembling toxins consisting of decanal and N-
amino-N’-1-octylguanidine in human erythrocytes and Rose demonstrated the use of the oxime 
ligation with unprotected peptides as early as 1994. [25][26] Today, it it is commonly used to add labels, 
like fluorescent tags, to help analyze the function of proteins in microscopy and FRET experiments. 
Scheme 2: Cysteines can react with (a) alkyl halides, (b) maleimides and (c) bromomaleimides. Tyrosines 
undergo conjugations (d) with diazo reagents, (e) via Mannich-type reactions or (f) via cerium-catalyzed 
oxidations. 
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[27] Potential drawbacks are the slightly acidic pHs needed for the ligation and, when compared to 
other chemoselective reactions, slow kinetics.  
Other functionalities have emerged since then, most prominently azides, which are featured in 
several relevant reactions and have established themselves as one of the most reliable functional 
groups. Ranking top in speed, though, are inverse-electron demand Diels-Alder reactions between 
strained alkenes or alkynes with tetrazines, which can, depending on the type of alkene used, 
compete with the speed of enzymatic reactions.  
2.1.2.1 Azides as reaction partner 
The azide group stands out due to its versatility, stability and size. In organic chemistry, azides serve 
as nitrogen source and can react with a number of electrophiles, nucleophiles and radicals to yield 
pyridines, imidazoles and carboamides, to name just a few. [28] It does not occur naturally and its 
site-specific incorporation into large biomolecules opened up an entirely new avenue for its use.  
It is commonly used in a collection of Staudinger-based ligations that, thanks to their constant 
development and growing range of applications, are gaining more momentum. In addition, the 
well-established Click reaction, either catalyzed by the addition of copper or by using strain as 
driving force, is a common tool in bioorthogonal chemistry. 
2.1.2.2 A plethora of Staudinger ligations 
A well-known reaction involving azides in organic chemistry is the Staudinger reaction, where an 
azide functionality is mildly reduced to an amine using triphenylphosphine as reducing agent.  
Consequently, azides are an attractive masking group for amines. [29] 
Hermann Staudinger and Jules Meyer first described the reaction between a phenyl azide and a 
phosphine, either triethylphosphine or triphenylphosphine in 1919. [29] In their initial publication, 
Scheme 3: A The Staudinger reaction by Staudinger and Meyer and B the Staudinger ligation as published 
by Saxon et al. 
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they were unable to identify the products of the reaction, but they noted correctly that the expulsion 
of nitrogen from the reaction leads to the formation of a phosphor-imine. 
As Scheme 3A shows, the mechanism starts with a nucleophilic attack of the phosphine on the outer 
nitrogen of the azide to form a highly reactive phosphazide. A four-membered transition state is 
formed after an internal cyclization and promotes the release of nitrogen from the molecule. The 
generated iminophosphorane is in equilibrium with its aza-ylide form, which can be reacted with a 
variety of other molecules, like carbon dioxide or ketenes. [30] During the Staudinger reduction it is 
promptly hydrolyzed with water to yield phosphine oxide and the desired amine. Alternatively, it 
can undergo an aza-Wittig reaction with ketones or aldehydes to yield imines [31], useful in the 
synthesis of secondary and complex primary amines, or assist in a Schmidt reaction with pre-
activated carboxylic acid derivatives to form amides. [32,33]  
Its use in biological environments was first reported by the group of Bertozzi in 2000, where azides 
were used in a slightly altered version of the Staudinger reaction entitled the Staudinger ligation. [34] 
To circumvent the direct hydrolysis of the aza-ylide intermediate, Saxon et al. modified one of the 
phenyl substituents of the phosphine with a proximal methyl ester that can act as electrophilic trap 
and catch the intermediate. Instead of releasing the amine, the phosphine hydrolysis results in the 
formation of a stable amide bond (see Scheme 3B). In a first application, cells were fed with the 
azido-containing acetylmannosamine derivative ManNAz, which was first converted to the 
corresponding sialic acid and then incorporated into the cellular membrane via the sialic acid 
biosynthesis pathway, The azido functionality was then labelled with a biotin-containing phosphine 
reagent. Side-reactions of the phosphine reagent, like for example reduction of protein disulfides, 
were not observed. 
The laboratory of Bertozzi and Raines simultaneously reported traceless versions of the Staudinger 
ligation, which allowed the formation of a natural amide bond between the two reaction partners and 
resulted in the release of a phosphine oxide. Bertozzi suggested the use of a cleavable phosphinoester 
Scheme 4: The traceless Staudinger ligation, as published by Saxon and Bertozzi as well as Nilsson and 
Raines, and its mechanism. 
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(see Scheme 4), where the acyl unit attached to the aryl ring represents one component, while the 
other is supplied in the form of an azide. Upon formation of the aza-ylide, the nucleophilic nitrogen 
attacks the carbonyl. This is then cleaved from the aromatic ring and a covalent bond to the nitrogen 
forms instead. Hydrolysis of the amidophosphonium salt results in the release of the final product. 
In this case, the close positioning of the phosphine to the acyl unit is of great importance, because it 
promotes the formation of a six-membered intramolecular intermediate over the hydrolysis of the 
phosphine. The group also investigated the use of an aromatic phosphinothiol, because the thioester 
has a higher reactivity in nucleophilic reactions. Only little product formation was observed in this 
reaction and the predominant product originated from aza-ylide hydrolysis. [35] The group of Raines 
discovered that the use of an aliphatic thiol attached to the phosphine greatly enhances the reaction. 
The intramolecular transfer proceeds via a more strained five-membered ring, which enhances the 
formation of the amidophosphonium salt and increases the overall yield. Furthermore, the higher 
pKa value of the aliphatic thiol slows down the hydrolysis rate of the thioester and gives it a longer 
reactivity. The use of thioesters as precursor for amide bond formation closely relates to the concept 
of native chemical ligation, where a peptide with a C-terminal thioester reacts with an N-terminal 
cysteine peptide via a transesterification and a S- to N-acyl shift to yield a natural amide bond 
between the two components. The advantage of the traceless Staudinger ligation is that it is not 
limited to cysteine ligation sites, as all C-terminal carboxylic acid can be activated with the 
phosphinothiol reagent. Nilsson et al. showed the potential of using the methodology in peptide 
chemistry by the synthesis of dipeptides, confirming the wide applicability and range of the traceless 
Staudinger ligation. [32] 
The initial Staudinger ligation was the starting point for the development of two more important 
ligations following a similar principle. The inherent instability of the P-N bond was, up to this point, 
Scheme 5: The symmetrical and unsymmetrical Staudinger-phosphite ligations. Green circles: Electron-
donating α-substituted alkoxy substituents. Red circles: Electron-withdrawing α-substituted alkoxy 
substituent. 
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always a key requirement for the success of the Staudinger ligation. Kabachnik et al. were the first 
to describe the reaction of phenyl azides with alkyl phosphites in 1956, but the potential of this 
modified Staudinger ligation in biological applications was not further explored until the group of 
Hackenberger made use of it to modify azido-phenylalanine residues in proteins. By using 
phosphites instead of phosphines, and thereby introducing an additional potential leaving group 
alternative, an intact P-N bond could be generated (see Scheme 5A). [36][37] 
The mechanism proceeds in a similar manner as for the Staudinger ligation. After the nucleophilic 
attack of the phosphite onto the azide, a phosphorimidate is formed after nitrogen expulsion. 
Electron-deficient azides will react faster than electron-rich azides in the Staudinger ligation, 
because they are more susceptible to a nucleophilic attack of the phosphite. Hydrolysis of the newly 
formed phosphorimidate can either lead to the generation of the desired phosphoramidate as final 
product or in P-N bond cleavage. A hydrolysis study by Chaturvedi et al. with 18O-labelled H2O 
revealed that the process proceeds by nucleophilic attack at the α-carbon of the substituent as well 
as on the phosphorus center. [38] The pathway of hydrolysis from the phosphorimidate to the amidate 
therefore depends heavily upon the electronic nature of the phosphite substituents and the azide. [39] 
When reacting a symmetrical phosphite with an electron-deficient azide, P-N elimination is favored 
at the phosphorimidate stage, whereas electron-donating azides are likely to drive the expulsion of 
the alcohol substituent. Electron-withdrawing substituents at the phosphite will favor premature P-
N bond hydrolysis, while electron-donating substituents will promote the formation of the desired 
phosphoramidate.  
Symmetrical phosphites are useful in the design of phosphonamidates containing a multitude of the 
same modification to achieve a superior effect, like for example PEGylation. [40] In asymmetrical 
phosphites, on the other hand, the different leaving group propensities of electron-donating and 
electron-withdrawing substituents can be exploited to yield unsymmetrical phosphoramidates with 
two different substituents (see Scheme 5B). [41] Here, Boehrsch et al. showed that the electronic 
nature of the α-substituted alkoxyl substituent played a major role in the structure of the final 
phosphoramidate. Electron-donating α-substituted alkoxy substituents, like long alkyl chains, were 
less likely to be eliminated during the hydrolysis than electron-withdrawing ones like benzylic 
alcohols. The exploitation of these characteristic led to the synthesis of phosphoramidates with 
different substituents. 
Two applications of the Staudinger-phosphite ligation stand out in literature. On one hand, this 
ligation was used in the design of PEGylated peptides and proteins in an attempt to improve their 
stability in cellular environments. [41] Nischan et al. could demonstrate the increased stability of BH3 
apoptosis-inducing peptides in Jurkat cells when equipping the peptide with a N-terminal azido-
phenylalanine and using a phosphoramidate linkage to conjugate small to medium sized PEG chains. 
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[40] The usefulness of this approach was further shown by Hoffmann et al.. They addressed the 
challenge of handling unglycosylated EPO, which is largely insoluble and difficult to refold because 
of its high hydrophobicity, by adding two PEG moieties via the Staudinger-Phosphite ligation. They 
discovered that PEGylation was able to assist in the correct folding of the protein and also improved 
its stability in the cell cytoplasm in comparison to untreated EPO and presented PEGylation as a 
potential mimic of glycosylation. [42]  
The second impressive feature of the Staudinger-phosphite ligation lies in its potential role in the 
synthesis of phosphorylated tyrosine and lysine. The generation of phosphoramidate analogues of 
tyrosine by the Staudinger-phosphite ligation were first published by Serwa et al.. [37][41] A phosphite 
with three photocleavable substituents was installed into a peptide carrying an azido-phenylalanine 
residue. Irradiation then yielded the desired phosphorylation mimic, which could successfully be 
detected by anti-phosphotyrosine antibodies. In light of the high chemoselectivity of this approach, 
combined with its high yields despite being carried out under physiological conditions, the 
Staudinger-phosphite reaction could be a prospective tool for discovering novel functions of tyrosine 
phosphorylation.  
Little is known about the occurrence and biological role of phospholysines so far, potentially because 
there is a lack of suitable detection methods, like specific antibodies and information about their 
stability. Bertran et al. presented two ways of generating peptides carrying phosphorylated lysine 
residues, either via in-solution synthesis [43] or on solid support. [44] Thanks to their successful 
synthesis, new information about their stability at different pH values could be gathered and new 
insights for their detection in proteins could be gained., hopefully pathing the way towards finding 
out more about this mysterious post-translational modification. [45] 
Scheme 6: The Staudinger-phosphite reaction is an ideal tool for the site-specific incorporation of 
phosphorylated tyrosine analogues, as well as cysteine and lysine phosphorylations. 
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To broaden the scope of the reaction, the Staudinger ligation was also adapted to phosphonites, 
which are equipped with one alkyl and two alkoxy substituents. Previous experiments had shown 
that phosphonites have ten to hundred times faster reaction kinetics than phosphites, depending on 
which alkoxy-substituents are used. [30] With this in mind, Vallée et al. tested the stability and 
reactivity studies of differently substituted phosphonites in Staudinger-phosphonite ligations with 
peptides and proteins. They found that an α-sp2-hybridized carbon at the phosphorus increased the 
stability of the phosphonite to oxidation by air, but that the compound was prone to quick hydrolysis 
in the presence of water. To increase the stability of the starting material, the phosphorus was borane-
protected and freshly deprotected before every ligation (see Scheme 7A). [46]  
To increase the stability and the versatility of the phosphonite, the design was changed as depicted 
in Scheme 7A. [47] The new phosphonite building block consists of two alkoxy substituents as well 
as one alkyne. The alkyne is addressable by copper-catalyzed click reactions, thanks to the borane 
protecting group that ensures a chemoselective reaction of the first azide with the alkyne instead of 
the P(III) center. This feature allows the functionalization of the phosphonite with any azido-
containing compound and thereby significantly broadens the applicability and flexibility of the 
Staudinger-phosphonite ligation. After the functionalization of the alkyne and before performing the 
Staudinger-phosphonite ligation, the P(III) center will have to be deprotected from the borane group, 
either by heating the molecule with DABCO in an aprotic solvent or by microwave irradiation with 
ethanol. The free P(III) can then undergo the ligation and upon hydrolysis forms a phosphonamidate 
with one alkoxy-substituent, an intact P-C bond and a P-N bond. 
A drawback of the Staudinger-phosphonite reaction is the low water solubility of the reagents and 
the short life-time of the phosphonite in aqueous solutions after P(III) deprotection. One way to 
Scheme 7: Overview of the versatile Staudinger-phosphonite ligation, yielding stable phosphonamidates. 
A: Original Staudinger-phosphonite ligation, B: The improved P(III) design allows for straight-forward 
functionalization of the phosphorus compound. 
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improve this is by introducing alkoxy-PEG substituents instead of ethyls, which act as solubility and 
stability enhancer. Alternatively, PEG units can be introduced through a click reaction with a PEG-
containing azide. Both of these measures turned out to greatly increase the half-life times of the 
reactive phosphorus species and permitted reactions on intact proteins in buffered conditions. [48] 
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2.1.2.3 “The” Click reaction: Huisgen’s 1,3 dipolar cycloaddition  
Sharpless introduced the term “click chemistry” for a set of selected chemical transformations in 
2001. [49] The selection criteria strongly reminded of the key qualities of chemoselective reactions. 
They include a wide scope, a modular incorporation and quickly removable and harmless side 
products. Furthermore, the reactions have to proceed under simple reaction conditions in either easy-
to-remove solvents or benign solvents like water with readily available starting materials. The 
success of the reaction is often governed by a high thermodynamic driving force, which ensures that 
only a single reaction pathway – and therefore only one product – is pursued. Lastly, the final product 
should be regiospecific and generated in a high yield. Sharpless identified some classes of chemical 
reactions that are “click reactions”, including cycloadditions (both 1,3-dipolar cycloadditions and 
Diels-Alder type reactions), addition to C-C double bonds, nucleophilic addition reactions to 
strained system and non-aldol carbonyl chemistry (see Scheme 8). [50] 
The ultimate triumph of the 1,3-dipolar cycloaddition as useful reaction in biological and 
pharmaceutical sciences might be surprising if one looks at the beginnings of this transformation. 
First reported by Michael in the 19th century and studied in marvelous detail by Huisgen in the 20th 
century, the 1,3-dipolar cycloaddition only proceeded sluggishly at best, despite the use of higher 
reaction temperatures and pressures. [51] 
It was the discovery of Sharpless [52] and Meldal [53] that the reaction of azides and terminal alkynes 
was vastly accelerated (up to 107 times in comparison to the non-catalyzed version) by copper 
catalysis which brought the attention back onto the potential of this transformation. The use of a 
metal catalyst also ensures regioselectivity and the transformation’s scope is impressive, as 
electronic and steric factors do not have a significant effect on the reaction efficiency.  
Scheme 8: Overview of 1,3-dipolar cycloadditions. A: Thermally motivated cycloaddition results in the 
formation of different regioisomers. B: Copper-assisted cycloaddition forms only one regioisomers. C: The 
strain-promoted cycloaddition avoids the use of cytotoxic copper. 
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On one hand, the use of copper as a catalyst solved one of the main problems of this reaction in 
further applications by increasing the speed of the reaction. Even though the overall reaction is 
highly exothermic, and therefore thermodynamically preferred, the high activation barrier 
significantly hindered a smooth progression of the reaction. Furthermore, similar HOMO-LUMO 
energy levels of the alkyne and the azide resulted in a mix of 1,2,3-triazole regioisomers. The 
addition of copper guarantees the required spatial proximity and electronic properties of the azides 
for the bond formation to proceed. [49] On the other hand, the cytotoxic effect of copper in biological 
systems had to be considered for applications in chemical biology.  
The catalytic cycle involves the formation of a dinuclear copper complex. [54] [Cu]a first coordinates 
to the alkyne, which significantly lowers the pKa of the terminal proton, allowing its removal by a 
base and the formation of a reactive copper acetylide. This step is essential and if a non-basic solvent 
is used, a base has to be added separately to ensure its completion. A second [Cu]b then coordinates 
via a π-interaction to the acetylide and will act as a stabilizing donor during the catalytic cycle. [55] 
Next, the acetylide β-carbon will undergo a nucleophilic attack on the electrophilic, exterior nitrogen 
N3 atom of the azide, leading to a coordination of N1 with [Cu]b followed by ring closure. The final 
expulsion of copper from the triazole proceeds by protonolysis. 
The choice of copper catalyst and additives varies between reactions and depends on the solvent and 
temperature used. Cu(I) is the catalytically active species and it can either be supplied directly or be 
generated in situ from Cu(II). A set of stable Cu(I) complexes are known, like [Cu(CH3CN)4]PF6 or 
[Cu(CH3CN)4]OTf, while the use of copper iodide is often discouraged, because it promotes the 
formation of side products like polynuclear acetylide complexes and remove copper from the 
productive catalytic cycle. Another prominent side reaction is the Glaser coupling, an acetylenic 
coupling in the presence of O2 and basic water. To circumvent this, the copper-catalyzed alkyne-
azide cycloaddition (CuAAC) should be carried out in degassed solvents. The addition of an excess 
of base like 2,6-lutidine and DIPEA also helps to increase the yields and improve the reliability of 
Scheme 9: The reaction mechanism of the copper-assisted dipolar cycloaddition as described by Worrell et 
al.  
INTRODUCTION 
 
16 
 
the reaction with Cu(I). [56] Due to these drawbacks, the use of Cu(II) with a reducing agent like 
sodium ascorbate is widely spread. [50] Again, care has to be taken with the choice of the cuprous 
salt. Copper acetate, for example, can also partake in an acetylenic coupling, which will equally 
result in the formation of undesired side reactions. A better option is copper sulfate, as originally 
proposed by Sharpless’ group. Despite these considerations, the copper-assisted 1,3-dipolar 
cycloaddition is one of the most robust and widely spread conjugation reactions, thanks to its 
superior scope and the formation of thermally and hydrolytically stable products.  
The major drawback of this reaction is the use of cytotoxic copper. While not critical in organic 
chemistry or for ex vivo studies, the use of cytotoxic copper in live organisms should be avoided. 
Its removal after reaction is possible, but the additional purification procedures result in lower yields 
and are time-consuming. Bertozzi’s group addressed this issue by trying to eliminate the use of 
copper altogether. Based on the observation of Wittig and Krebs that the reaction of the cyclooctyne 
with an azide resulted in a strong reaction [57], they assumed that the ring strain might be sufficient 
to decrease the activation barrier and increase the reaction rate. [58]  
Since then, a number of suitable strained alkynes for in vivo applications have been described. While 
the first cyclooctyne molecules were significantly faster than the uncatalyzed cycloadditions, they 
were not faster than the Staudinger ligation. By adding electron-withdrawing substituents to the 
cyclooctyne (Figure 1, DIFO) and fusing aryl rings to its side to generate dibenzocyclooctynes 
(Figure 1, DIBO), the second-order kinetics could be increased step by step and their use in vivo 
could be demonstrated. [59] The group of Van Delft published the bicyclononyne (Figure 1, BCN), 
where an additional cyclopropane was fused to the cyclooctyne to increase ring strain and the steric 
hindrance around the alkyne was further reduced by placing the reactive handle at the other side of 
the molecule. [60] The further discovery of other strained systems will continue to be a fine balance 
between finding fast reactants and reactants that are sufficiently stable to remain intact before 
reaction. 
  
Figure 1: A selection of strained cyclooctynes developed for copper-free cycloadditions. 
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2.2 Cleavable tags in life science 
As already discussed in the previous chapter, one of the goals of chemical biology is to target 
biomolecules with chemical means for analytical purposes, for tracking and detection. The advances 
in this field have provided the scientific community with valuable information about the structure, 
behavior and interaction of biomolecules. In some cases the attachment, be it for labelling, transport 
or enrichment, can affect the overall behavior of the biomolecule or hinder the analysis. When this 
is the case, their selective removal from the biomolecule could be of interest. This adds an additional 
chemical challenge: Besides the successful incorporation of a functional moiety into a molecule of 
interest, its chemoselective removal needs to proceed without harming the rest of the molecule. 
In MS-based proteomics, for example, protein enrichment can help to improve detection by 
increasing the concentration of the proteins of interest and decreasing the background noise. One 
commonly used method for enrichment relies on the strong biotin-streptavidin interaction. Here, a 
mixture of biotin-labelled and not labelled proteins is passed over streptavidin-coated beads, 
resulting in the immobilization of all biotin-containing compounds while other proteins and 
impurities can be washed off. Due to the strong interaction between biotin and streptavidin, harsh 
release conditions are necessary to elute the immobilized species, like high concentrations of 
denaturing salts, high pH and/or heat. This results in the simultaneous release of protein degradation 
products, non-specific binding proteins and streptavidin, all of which can hinder the MS analysis. 
Especially the study of acid- and heat-labile modifications is rendered difficult by these elution 
conditions. By installing a chemoselective, cleavable linker between the target biomolecule and the 
biotin label, milder cleavage conditions can be used for the release to improve the analysis.  
In another example, tumor-targeted delivery employs cleavable tumor-targeting peptides to enhance 
the drug’s therapeutic window by refining its delivery to its place of action. The prodrug will consist 
of three separate entities: The targeting peptide will be responsible for bringing the drug to right 
location in the organism and can also assist with the internalization of the drug. A cleavable linker 
Figure 2: The concept of a cleavable bond is analogous to two items that are connected by a lock which 
requires the correct key to open. Equally, two functional moieties can be linked together by a cleavable bond 
that responds to a stimulus like pH, UV light or a specific reagent.  
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will connect the peptide to the drug molecule, which remains inactive as long as it is still attached 
to its transporter. The properties of the cleavable linker will be adapted to the environment at the 
target site to ensure the site-specific release. Once released, the drug becomes active and operates 
via its mode of action at the target site. When perfectly optimized, the advantage of tumor-targeted 
delivery is that the drug cannot act until it is delivered to its target, thereby increasing the drug’s 
effectiveness and reducing side reactions.  
Whether protein purification, [61] targeted delivery [62] or other areas like imaging [63], the demand for 
cleavable linkers has led to the development of several systems that react to a variety of different 
reagents and external conditions to ensure high-yielding bonds cleavage upon a given impulse.  
2.2.1 Different cleavage strategies 
Bond cleavages in organic synthesis have served as inspiration for the development of bio-applicable 
bond cleavages. Not all methodologies are applicable to biomolecules – harsh treatment with strong 
acids or bases, the employment of metal-based catalysts or the supply of heat to give the bond 
cleavage additional thermodynamic drive will result in protein degradation, loss of information and 
side product formation. Instead, research focused on mild and high-yielding approaches, which 
provide a high spatiotemporal control over the release, either by a given external impulse or internal 
change in condition. Table 1 shows different cleavage methodologies that have been discussed in 
recent literature and will be touched upon in more detail below.  
Cleavage condition Cleavable linker Application 
Reducing reagents Disulfide linkage, diazo linkage Drug delivery, imaging, 
protein modification 
   Enzymes TEV, trypsin, thrombin, serine 
hydrolase 
Protein purification, cysteine 
masking, drug delivery  
   Nucleophilic reagents Hydrazones, bis-arylhydrazones, 
thioesters, sulfones 
Imaging and protein 
modification 
   Electrophilic reagents Acetals, phosphoramidate, diaryl 
dialkoxysilanes 
Protein purification and drug 
delivery 
   Irradiation 2-nitrobenzyl linkers, phenacyl 
esters, coumarin, bis-arylhydrazones 
Enrichment and purification 
One methodology uses reducing agents for chemoselective cleavage. Disulfide formation between 
two unidentical cysteines proceeds best by pre-activating one cysteine with, for example, Ellman’s 
reagent or alkoxycarbonylsulfenyl chlorides, thereby making it susceptible for attack by a second 
thiol. [64] Any accessible cysteine residue can be addressed by disulfide bridging – and liberated 
again after cleavage – which renders this methodology particularly interesting. Disulfides are 
particularly useful for in-cell cleavages, because the intracellular concentration of the reducing agent 
Table 1: A selection of chemoselective cleavable systems that allow for the release of the target molecule. 
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glutathione is significantly higher than the extracellular concentration, which induces disulfide 
cleavage upon cell entry. Qian et al. recently published tracelessly cleavable cell-penetrating 
arginine-containing (poly)sulfides for the intracellular delivery of proteins, including enzymes and 
antibodies. [65] Native lysine residues of the target molecule were first modified with a self-
immolating linker connected to a disulfide-bridged trans-cyclooctene. The trans-cyclooctenes were 
then further reacted with tetrazine-modified arginine-rich (poly)sulfides, which helped to transport 
the molecule of interest into the cell (see Figure 3A). Once inside, the disulfide bridges were cleaved 
and the self-immolating linker eliminated itself from the molecule to release the natural untagged 
target molecule.  
It should be noted that disulfide bridges are known for pre-mature cleavage and disulfide exchange 
reactions that can result in unspecific labelling, which limits their scope of use. [66] To render the 
disulfide bridges more stable, Gartner et al. developed sterically hindered disulfides that showed no 
reduction when exposed to 10 mM DTT and only cleaved slowly with 10 mM TCEP. [67] 
Diazo linkages, on the other hand, are cleaved selectively upon the addition of sodium dithionite 
(see Figure 3B). Verhelst et al. reported the use of cleavable diazobenzene derivatives for 
chemoselective protein enrichment, where a cathepsin-specific molecule was connected to a biotin 
tag via a cleavable diazobenzene linkage. When rat liver homogenate was treated with this 
conjugate, cathepsins were successfully enriched and then eluted from streptavidin beads with 
sodium dithionite. The cleavage efficiency of the diazo bond depends on the pH of the buffer (it 
should be between 6.5 and 8.5), the concentration of the reductant and the substitution pattern of the 
azobenzene. [68] The scope of diazo linkages in chemical biology was limited for some time, because 
of a lack of methods to directly introduce them into proteins without having to use an additional 
Figure 3: A Disulfide-containing cleavable linker that cleaves upon exposure to a high concentration of 
reducing agents. The self-immolating qualities of the 1,6 benzyl carbamate linker will ensure a traceless 
removal from the molecule of interest (green circle), while the trans-cyclooctene can be modified with a 
tetrazine-functionalized moiety (red line). B Diazo linkages are cleaved by the addition of sodium dithionite 
at pH 6.5-8.5. 
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chemoselective handle, like an azido moiety for cycloaddition reactions with alkyne-functionalized 
proteins. Subsequent dithionite cleavage then released a modified protein with parts of the 
chemoselective handle still attached. Hooker et al. described the introduction of diazonium 
compounds at tyrosine residues as early as 2003, but the method was limited to highly activated 4-
nitrobenzenediazonium ions, while other derivatives completely lacked reactivity or required high 
pHs. [20] Recently, Addy et al. published the diazo bond formation between 5-hydroxytryptophan (5-
HT) and a 4-carboxybenzenediazonium ion, which proceeded more than 4500 faster than with 
tyrosine. Furthermore, they were able to incorporate 5-HT site-selectively into a protein by amber 
suppression, where they could then selectively form and cleave a diazo bond at physiological pH. 
While looking highly promising, this new conjugation reaction has not yet been tested with 
extensively functionalized diazonium ions.  
Enzymes-mediated cleavages are well-established in the purification of recombinantly generated 
proteins. Affinity tags, like His- and GST-tags, are added via an enzymatically cleavable linker to 
the N- or C-terminus of a target protein by genetic manipulation and allow to enrich and purify the 
molecule of interest. Afterwards, the affinity tags can be removed enzymatically from the protein to 
liberate the N- or C-terminus (Figure 4A). The enzyme selection depends on the residues located at 
the different termini as well as the folding and stability of the target protein to temperature, pH and 
salts. [69] They also depend on the nature of the biomolecule, since unspecific cleavage can be 
observed when parts of a protein sequence share a high similarity to the cleavage motif. 
Enzymatically cleavable tags can also be used as temporary protecting groups (PG). Factor Xa, for 
example, was shown to efficiently cleave after N-terminal cysteines sites, which has rendered it 
useful as a cysteine PG in sequential native chemical ligations and protein ligations to avoid 
intramolecular cyclization reactions. [70] Wawro et al. recently demonstrated the use of a lipase-
mediated bond cleavage in the production and purification of PEGylated proteins (Figure 4B). A 
benzamide was functionalized with a maleimide on one and an octa(ethylene glycol) (PEG8) with a 
Figure 4: A The introduction of short peptidic sequences that encodes for a peptidase cleavage site is a mild 
and highly-specific method to disconnect two entities. B A lipase-mediated ester bond hydrolysis can 
liberate PEGylated molecules as hydroxyl, while the other functional module is released as carboxylic acid.  
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biotin attached on the other side and then incorporated into β-lactoglobulin A via maleimide 
chemistry with the single free cysteine of the protein. The protein was immobilized on streptavidin-
coated beads and a lipase was used to cleave the ester bond connecting the biotin and the PEG8 
chain. This resulted in the successful isolation of PEGylated β-lactoglobulin A. [71] 
Hydrazone ligation was first described on protein level by King et al., who coupled an aromatic 
aldehyde with an acyl hydrazine to yield a stable hydrazone bond that hydrolyzed slowly at neutral 
pH. [72] With the advances in genetic engineering, the introduction of non-natural amino acids 
carrying an aldehyde moiety hydrazones can be incorporated into proteins without an additional 
linker system. [73] The potential reversibility of the system was recognized early onwards and it was 
suggested that hydrazone exchange reactions or hydrolysis can be accelerated by the addition of 
hydrazones at pH 4-5. [74] Furthermore, it was shown that the presence of aniline can promote 
acylhydrazone formation and exchange as well as oxime formation by transimination. [75] With this 
in mind, Park et al. developed an acylhydrazone cleavage that proceeded at pH 5.8 in the presence 
of 100 mM aniline and 20 mM SDS, which was further accelerated by heating it to 50 °C. The 
application of these conditions resulted in the release of 85 % of a hydrazone-biotin conjugated 
protein from streptavidin beads for proteomic analysis. [76] Bis-aryl hydrazones (as depicted in Figure 
5A) have a higher hydrolytic stability than the acyl derivates [77] and can form under physiological 
conditions, especially in the presence of a nucleophilic amine catalyst. [78][79] Dirksen et al. presented 
three methods to cleave and cap bis-aryl hydrazones, all of which rely on the presence of aniline to 
create a dynamic hydrazone exchange system. [80] Aniline will undergo transimination with the 
hydrazone to form a hydrazine and an imine that can undergo further modification. Firstly, the imine 
can be capped with hydroxylamine, rendering the compound stable for further analysis. Secondly, 
any aminooxy compound can be used to functionalize the imine further e.g. with a fluorophore for 
detection after release. Lastly, the addition of a second aldehyde can be used to cap the regenerated 
Figure 5: A Bis-aryl hydrazones undergo transimination with anilines and thereby initiate cleavage between 
two entities. B Sulfonyl groups are cleavable at slightly basic pH and if a short (2-(alkylsulfonyl)-ethyl) 
carbamate linker is used, CO2-elimination will result in the traceless release of amines.  
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hydrazine. This offers the possibility to further functionalize both former bis-aryl hydrazone 
components.  
Although sulfonyl-based cleavable linkers have been explored before, Cowell et al. were the first to 
report biologically compatible release conditions (see Figure 5B). While stable at acidic and neutral 
pHs, the linker eliminates at mild basic pHs. Overnight treatment in 100 mM ammonium bicarbonate 
pH 8 is sufficient to disconnect the two entities and release an amine without trace. The linker was 
successfully applied to biotin-mediated affinity chromatography and to cell surface labelling. While 
very mild and easy to install, the instability at slightly basic pHs will limit its scope in the future. 
Dialkoxysilanes feature a fluoride- and acid-labile Si-O bond and are well-known as alcohol 
protecting groups. They have to be installed via a second reactive handle into a biomolecule. They 
were first utilized as removable tags for biomolecules by Lin et al. in 1991 [81] and were furthermore 
employed for the purification of synthetic oligodeoxynucleotides. [82] The silicon-oxygen bonds 
could be cleaved through the addition of acids like HF or, alternatively, potassium fluoride. The 
group of Tirrell developed a diphenyldialkoxysilane (see Figure 6),  for protein enrichment with 
biotin, which is cleavable in 0.5 hr with 10 % formic acid (> 98 %) or with 5 % formic acid (> 95 
%). While their cleavage system was used for the enrichment and MS-detection of GFP, the use of 
acid in biological systems can result in protein degradation and side product formation. The high 
acid lability can be accounted to the diphenyl substitution of the silicon. Other dialkoxysilane 
derivatives are cleavable by fluoride ions, although the bond breakage proceeds slowly in 
comparison to the previously described acid-induced cleavage and requires 16 hrs for completion. 
[83] 
2.2.2 Photo-induced cleavages 
Photo-cleavage linkages are amongst the most favored chemoselective cleavages, because they can 
proceed at a reasonable speed in mild buffers. When developing photo-cleavable groups, some 
criteria have to be considered. The overall molecule has to be soluble in aqueous media, which can 
be challenge due to the (mostly) aromatic structure of photo-cleavable groups. The release should 
take place at wavelengths that do not harm the biological environment, so cleavages with excellent 
efficiencies of release above 300 nm are preferable. The efficiency of release is defined by the 
quantum yield Φrel, which corresponds to the amount of released cargo, nrel, divided by the number 
Figure 6: Diphenyldialkoxysilanes are sensitive to acid and will cleave within 0.5 hr with 10 % formic acid. 
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of photons emitted at the irradiation wavelength, np. The cleavage products should not absorb at the 
same wavelength and not be reactive in its release environment to avoid side reactions.  
The probably best-known and studied photocleavable groups are based on the structure of 2-
nitrobenzyl alcohol (2-NB). While so widely spread, this group has surprisingly many 
disadvantages. On one hand, the released ortho-nitrosobenzaldehydes can absorb at the cleavage 
wavelength and thereby compete with the excitation wavelength. On the other hand, the aldehydes 
have an intrinsic reactivity that can lead to undesired reactions after cleavage. Furthermore, the 
release of the 2-NB conjugates is much slower than for some other groups. The mechanism of release 
was revised by Il’ichev et al. in 2004 and is shown in Scheme 10.  
The first reaction step is a hydrogen transfer from the ortho-alkyl substituent to the nitro group. This 
results in the formation of an aci-nitro tautomer. An irreversible, intramolecular cyclization from 
the tautomer forms an hemiacetal intermediate. The rate-determining step in the release of the cargo 
is the step-wise hydrolysis of the hemiacetal to release an alcohol and 2-nitrosobenzalydehyde.  
Other derivatives of 2-NB with better release efficacies and less reactive side products have been 
published, some of which are shown in Figure 8. Substitution at the benzyl position, with a methyl 
for example, significantly increases the quantum yield and has the pleasant side effect that a ketone 
instead of an aldehyde is released upon irradiation. [84] An electron-withdrawing substituent at the 
benzylic position has an even more pronounced effect on the quantum yield, but the difficult 
synthesis of these derivatives have prevented their wide-spread use so far. [85] Meanwhile, different 
Scheme 10: Mechanism of the photo-cleavage of 2-nitrobenzyl alcohol. After a hydrogen transfer from 
the ortho-alkyl substituent and the formation of an aci-nitro tautomer, a hemiacetal intermediate is formed 
by an intramolecular cyclization. It is hydrolyzed to release 2-nitrosobenzaldehyde. 
Figure 7: Photo-induced cleavage is one of the mildest cleavage conditions available. 
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substitution patterns of the aromatic ring with methoxy, or carboxylic acids can serve to increase 
solubility of the whole linker. [86][87] The addition of new substituents also affected the absorption 
wavelength of the photo-cleavable, which increased to over 350 nm, and decreased their quantum 
yield in comparison to the unmodified 2-NB.  
Trentham’s group used 2-NB to study the mechanism of ATP release using “caged” ATP, so 
protected adenosine triphosphate, in 1988. [88] It furthermore finds frequent use in automated DNA 
synthesis, where it protects the 2‘-O of the synthetic nucleotides, in the controlled cargo release in 
biological environments and in material science. [89][90] 
While 2-NB based photo-linker are certainly the most established, other photo-active groups like 
phenacyl, coumarin and arylmethyl derivatives have been described, all of which release alcohols 
or carboxylic acids.  
Phenacyl derivatives are well understood and frequently used, because they are easy to incorporate 
into the target compound. Upon cleavage, they release (carboxylic) acids, carbonates or alcohols. 
The cleavage mechanism of phenacyl esters proceed via a hydrogen abstraction by the excited 
carbonyl group from a suitable hydrogen donor (see Scheme 11A). O-Alkylphenacyl groups cleave 
through an intramolecular 1,5-abstraction that leads to the formation of photoenols. Upon hydrolysis, 
these can expulse a leaving group from the α-carbon (see Scheme 11B). 
Arylmethyl derivates, on the other hand, cleave by an irradiation-induced alcoholysis. The 
irradiation of a benzyl-protected alcohol or carboxylic acid at 254 nm in water consequently results 
Figure 8: Different 2-NB derivatives sorted by their quantum yield (increasing from left to right). 
Scheme 11: A Photocleavage of a α-substituted phenacyl ester, releasing a carboxylic acid. B Cleavage 
mechanism of an o-alkylphenacyl derivative. 
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in the release of a benzyl alcohol and the uncaged partner. The first application of a photo-cleavable 
benzyl group was as protecting group in peptide synthesis. [91] 
Lately, the interest in amine-releasing photo-protectable groups has increased and the use of 
phenacyl anilinium salts and aminobenzyl groups have been reported for this purpose. The later was 
suggested by Wang et al. in 2016, where a 3-(diethylamino)benzyl group was used as protecting 
group for primary, secondary and even tertiary amines (see Scheme 12). While the mechanistic 
features of the cleavage are not yet fully elucidated, the initial step upon irradiation is thought to be 
a C-N bond cleavage, resulting in the release of the free amine and a benzylic cation that is quenched 
by the solvent.  
Photocleavable tags have been introduced into biomolecules by NHS-conjugation to lysines (see 
Figure 9A), [92] via reactive handles like azides or alkynes (see Figure 9B) [93] or by maleimide 
conjugation to cysteines. [94] Alternatively, they were also added site-specifically into peptides 
during SPPS (see Figure 9C) [95] and then further incorporated into proteins by expressed protein 
ligation, as shown by Reimann et al., who used a tracelessly photocleavable biotin tag for the 
purification of a protein ligation mixture to separate the unligated and the ligated protein. [96] 
  
Scheme 12: Cleavage of a 3-(diethylamino) benzyl group from a tertiary amine by irradiation in a protic 
solvent releases a tertiary amine. 
Figure 9: Incorporation of photocleavable tags by A: NHS-conjugation to lysines, B: CuAAC chemistry with 
an azido-handle or C: by selective attachment to a lysine side chain during SPPS. 
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2.3 Incorporation of non-canonical amino acids into proteins 
The use of non-canonical amino acids for the precise placement of modifications into peptides and 
proteins requires extensive biochemical engineering. Several approaches can be envisioned to 
achieve this goal. A set of biochemical approaches have succeeded in implementing up to three non-
canonical amino acids into proteins, although the success depends heavily on the nature of the 
proteins and the unnatural building block. Another tactic exploits the advantages of another 
significant contribution to chemoselective reactions – the native chemical ligation (NCL) and, in 
extension, the expressed protein ligation (EPL) – which allows the formation of a native amide bond 
between a N-terminal cysteine and a C-terminal thioester of two distinguished peptides generated 
by solid-phase peptide synthesis (SPPS) or/and recombinant protein expression. The continuous 
development of these ligations opens up new avenues and possibilities in the design and 
modifications of large biomolecules. This chapter aims to give a brief introduction into this highly 
interesting and dynamic field.  
2.3.1 Biochemical methodologies 
The integration of unnatural amino acid building blocks into larger biomolecules is one of the most 
important achievements in protein chemistry up to date. Normally, the natural protein synthetic 
machinery allows for the incorporation of 20 naturally occurring amino acids (AA) and, in some 
cases, pyrrolysine and seleno-cysteine (see Figure 10). In this complex biological process, a template 
called messenger RNA (mRNA) encodes for the protein sequence using a triplet code. A total of 64 
codons code for 20 natural AAs and a set of start and stop codons that mark the beginning and the 
end of the template. In bacteria, the ribosome is a macromolecule consisting of two subunits, a 
smaller 30S and a larger 50S protein, and it acts as a connecting hub between the mRNA and the 
aminoacyl-tRNA synthetase. The aminoacyl-tRNA synthetase (RS) is specific for each amino acid 
as well as for the codon it binds to and is responsible for loading the correct amino acid onto the 
mRNA template. In a typical workflow, the 30S subunit binds to a start codon on the mRNA, with 
the help of a set of initiation factors and an initiator tRNA, formylated fMet-tRNA, which the 
organism can remove after protein synthesis is completed. After anchoring the 30S and 50S subunits, 
the chain is continuously elongated by the ribosome by translocation in 3’ direction. It periodically 
recruits the correct aminoacyl-tRNA, transfers the amino acid to the growing protein and ejects the 
unloaded tRNA. Once a stop codon is reached, release factors are recruited and the ribosome loses 
contact to the mRNA, while disassembling into its subunits.  
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Biochemists frequently use bacteria, in particular the strain E. coli, to produce full-length proteins 
in the laboratory. The bacteria serve as protein synthesis machines and, under standard conditions, 
contain their own enzymes and are capable of providing all amino acids by themselves. When it 
comes to expanding the genetic code and introducing non-natural amino acids or post-translational 
modifications, this molecular machinery reaches its limit and requires, at least to a certain extent, 
manipulation from the outside. Two methods have found wide-range use, namely amber suppression 
and selective pressure incorporation.  
2.3.1.1 Selective pressure incorporation 
One way to achieve incorporation of unnatural amino acids in E. coli is to exploit the existing 
machinery of the bacterial protein synthesis apparatus and utilize the promiscuity of the tRNA 
synthetases when they are placed under strong selective pressure. The aminoacyl-tRNA of 
methionine (MetRS) was shown to be able to activate a range of methionine analogues as early as 
1957 [97]. To achieve selective pressure incorporation, engineered auxotrophic strains of bacteria that 
cannot produce one (or more) of the natural amino acids on their own are used. By supplementing 
the desired unnatural building block, the bacteria will be forced to accept this alternative amino acid, 
despite the worse fit. The group of Tirrell was one of the pioneers to show the tRNA synthetase’s 
ability to effectively incorporate unnatural amino acids carrying chemoselective functionalities like 
alkenes and alkynes [98] and to suggest an overproduction of MetRS to overcome low yields and 
incorporation efficiencies. [99] Bertozzi’s group then found out that MetRS was able to activate and 
incorporate azidohomoalanine without prior overproduction of MetRS, marking the first time an 
azido group was inserted into proteins without the use of extensive biochemical engineering and 
advanced enzyme manipulations. [100] Other methionine analogues include norleucine, ethionine and 
telluromethionine. (Figure 11) [101] Selective pressure incorporation is not limited to methionine 
Figure 10: The ribosome acts as connecting hub between the aminoacyl-tRNA-synthetase and the mRNA 
that encodes for the protein sequence as triplet code. The aminoacyl-tRNA-synthetase is specific for each 
amino acid, ensuring the correct read-out of the template. 
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analogues. Budisa et al. were, for example, able to incorporate thiaproline by exploiting the 
promiscuity of the ProRS in a proline auxotrophic strain. [102] The use of natural amino acyl tRNA 
synthetases limit the scope of amino acid analogues that can be incorporated into proteins. By 
introducing single or multiple mutations into the binding pockets of the respective tRNA 
synthetases, the spectrum of introducible amino acids can grow significantly. Mutations in the 
PheRS, for example, resulted in the successful incorporation of chloro- [103], iodo-, cyano-, azido- 
and ethynylphenylalanine derivatives. [104] 
2.3.1.2 Expansion of the genetic code 
In 1989, Noren and Schultz presented a revolutionary way for the site-specific incorporation of 
unnatural amino acids into proteins. [105] By using an acetylated suppressor tRNA that was able to 
bind unnatural amino acid building blocks, they were able to “switch” the stop codon to an encoding 
codon and incorporate a residue of interest. This methodology was subsequently named amber 
suppression, because the stop codon UAG frequently used for these operations belongs to the group 
of three amber stop codons that usually recruit release factors RF1 and RF2 to dissociate the protein 
synthesis machinery. [106] To achieve acceptable yields, the suppressor tRNA has to be engineered 
and optimized for each unnatural amino acid. [107] As the RF1 factor always competes with the tRNA 
for binding to the amber codon, one frequently observed side product is the early termination of the 
protein, resulting in the formation of a heterogeneous mixture of proteins. 
Interestingly, this concept was not unknown to nature. The methanogenic archaea 
Methanosarcinales, which are known for their ability to convert methylamines into methanes, were 
shown to contain an unique tRNA and tRNA synthetase to permit the incorporation of pyrrolysine 
Figure 11: Different methionine and phenylalanine analogues that can be incorporated by selective 
pressure incorporation are displayed. 
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(Pyl) at a UAG amber codon. [108][109] Further analysis revealed that the PylRS displayed a high side 
chain promiscuity and a low selectivity for the α-amine. Furthermore, the binding selectivity to the 
UAG anticodon is low. Thanks to these features, the PylRS-tRNAPyl and its mutants have been able 
to site-selectively modify proteins with over 100 non-canonical amino acids at amber codon sites in 
E. coli, C. elegans, D. melanogaster and S. cerevisiae. [110] This included sterically challenging 
amino acids equipped with moieties suitable for strain-promoted click chemistry [111] and masked 
amino acids that with difficult-to-access post-translational modifications. [112] 
Schultz’s lab contributed a number of orthogonal tRNA/RS pairs that addressed the incorporation 
of tyrosine and phenylalanine derivatives like O-methyl-L-tyrosine [113], O-allyl-L-tyrosine [114] and 
O-acetyl-L-phenylalanine. [115] 
The combination of selective pressure incorporation and the expansion of the genetic code has 
enabled researchers to dive deeper into protein structure and analysis, equip biomolecules with 
radioactive trackers, fluorophores, cell-penetrating peptides and post-translational modifications like 
ubiquitins and glycosylations. It also paved the way to detect new, efficient chemoselective reactions 
that generate stable covalent bonds in good yields and little time.  
2.3.2 Chemoselective peptide ligation and protein semi-synthesis 
Originally, protein semi-synthesis referred to the reassembly of a protein from fragments generated 
by chemical or enzymatic means. The autocatalytic condensation of protein fragments generated by 
CNBr treatment were observed for cytochrome c and the pancreatic trypsin inhibitor and allowed 
for the incorporation of unnatural modifications into the respective proteins. [116] Other ways to 
achieve protein semi-synthesis include enzyme-mediated protein ligation strategies by mutating the 
active sites of enzymes to carry out, for example, acylations or promote peptide ligations [117][118] and 
oxime-and hydrazone forming reactions that can link synthetic and recombinant peptides together. 
[119][26] 
Figure 12: Examples of non-canonical amino acids that have been incorporated by expanding the genetic 
code and making use of the amber stop codon. 
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Today, protein semi-synthesis mostly represents the chemical ligation of unprotected peptides and 
proteins. The overall concept describes the modification and manipulation of a specific region in 
peptides and proteins with building blocks outside the usual repertoire of 20 canonical amino acids. 
This includes the installation of post-translational modifications, reporter molecules like 
fluorophores and affinity labels as well as single non-canonical amino acids and switching units like 
photocaging units. These complex tasks push, if not overreach, the possibility of DNA manipulations 
usually employed in biochemistry.  
2.3.2.1 Peptide synthesis  
Merrifield’s peptide synthesis from the 1960s revolutionized the field of synthetic peptides, because 
it allowed their step-wise synthesis with fully protected natural and unnatural building blocks. It 
relied on the use of a solid support as a basis for peptide elongation and fast removal of coupling 
reagents. This new technique permitted the synthesis of peptides containing up to roughly 50 amino 
acids. [120] Merrifield’s Bzl/Boc protocol depended on the use of the highly hazardous and difficult-
to-handle hydrofluoric acid. Besides the experimental difficulties, the continuous use of strong and 
oxidizing acids also limited the use of this methodology to acid-stable targets. To overcome this, 
Scheme 13: A schematic overview of SPPS. The peptide is extended on a solid support with fully protected 
amino acid building blocks. The extension proceeds from the C- to the N-terminus of the peptide. In a coupling 
cycle, the N-terminus is protected (-PG1) and then reacted with a pre-activated amino acid to form an amide 
bond. The peptide is removed from the solid support and all side-chain protecting groups (PG2-4) are cleaved. 
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Sheppard’s group came up with an easier and more convenient protocol based on Fmoc-chemistry, 
which is by far the best-known and most applied procedure nowadays. [121] 
To avoid epimerization, the protocol proceeds from the C- to the N-terminus. All reactive side chains 
of the amino acid building blocks are protected with suitable groups to avoid their interference 
during the synthesis and improve their stability to the conditions applied during attachment, growth 
and cleavage of the completed peptide. At the start of peptide synthesis, the first amino acid is 
covalently attached to a solid support bearing a linker with a reactive terminal group. Following this 
initial linkage, a series of repetitive steps are carried out until the end of the peptide is reached. 
These steps are as follows (see  Scheme 13): 
1) Deprotection of the N-terminal amino acid: The N-terminus is liberated, so that it can react 
with a pre-activated carboxyl group of the next amino acid.  
2) Activation of the next amino acid: The next amino acid in line must be activated prior to the 
coupling, since the free carboxyl is not electrophilic enough to react with the N-terminus of 
the growing peptide chain. It is therefore first converted to an activated, highly-reactive 
carboxyl ester.  
3) Coupling of the next amino acid: The activated amino acid is added to the solid supported 
peptide and reacted in the presence of base.  
 Acid-labile support Base-labile support 
Boc-strategy [122] Fmoc-strategy Fmoc-based 
N-terminal protecting 
group 
Boc/Bzl 
 
Fmoc Fmoc 
C-terminal activating 
reagent 
HBTU, HOBt/DIC HBTU/HOBt, HCTU, 
PyBOP 
HBTU/HOBt, HCTU, 
PyBOP 
Coupling solvent with 
base 
DMF with DIPEA DMF/NMP/DCM 
with DIPEA  
DMF/NMP/DCM with 
DIPEA  
N-terminal 
deprotection 
TFA (100%) Piperidine, 
piperazine/DBU [123] 
Piperidine 
Final deprotection HF, scavengers [124] TFA, scavengers 3:1 dioxane:1 M NaOH 
 
After full extension of the peptide, it is cleaved from the solid support using suitable reagents. 
Table 2: The differences in protecting groups, activation procedures and reagents between acid-labile and 
base-labile supports are described. 
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Preferably, the side chains and the peptide are simultaneously removed from the support in a one-
step procedure, but this only possible for the synthesis on acid-labile, not base-labile support. Table 
2 gives an overview of three different procedures often employed in peptide synthesis. 
The choice of method depends on various factors, including handling issues, the desired building 
blocks of the peptide and the character of the C-terminus. Some amino acids, like for examples the 
fluorophore 5,6-carboxyfluorescein, degrade during basic cleavage from the solid support. Other 
building blocks, including some phosphorylated amino acids, have a higher stability at basic than 
acidic pH. A careful analysis of the peptide’s components is therefore necessary to determine the 
best synthetic route to follow.  
2.3.2.2 Native Chemical Ligation  
Longer peptides or smaller proteins can no longer be synthesized on solid support in a single 
synthesis run. Despite high coupling yields of 95-99 % in each step, the overall yield drops 
significantly the larger the peptide gets. As a solution, Kent’s laboratory developed the native 
chemical ligation (NCL) that allows the connection of two unprotected peptide fragments by 
Scheme 14: The principle of the native chemical ligation. The N-terminal cysteine of a peptide will undergo 
a nucleophilic attack on a peptide thioester, followed by an intramolecular transthioesterication. An 
irreversible N,S-acyl shift leads to the formation of a native amide bond between the two reaction partners. If 
needed, the cysteine can be desulfurized after ligation to yield an alanine. 
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formation of a native amide bond. [125] For the ligation to proceed, one peptide has to be equipped 
with a thioester at the C-terminus, while the second peptide requires a N-terminal cysteine. The 
ligation itself is a two-step process: The first reversible step is a chemo- and regioselective 
transthioesterification, leading to the formation of a thioester intermediate. In a second irreversible 
step, an intramolecular S, N-acyl shift forms a native peptide bond, as illustrated in Scheme 14. The 
ligation can be performed with fully unprotected peptides in aqueous conditions at pH 7 at room 
temperature and gives near quantitative conversions. [125] 
The nature of the thioester has a considerable effect on the ligation rate. S-alkyl and S-aryl thioesters 
can both undergo the reversible intramolecular transthioesterification, although it should be noted 
that S-aryl thioesters react much faster than their alkyl counterparts. The rate of reaction can be 
summarized as follows:  
S-phenyl thioesters < S-benzyl thioesters < S-alkyl thioesters 
Due to the electron-pulling properties of the aryl substituents, S-aryl thioesters are better leaving 
groups than S-alkyl thioesters. Consequently, they react faster in ligation reactions. Equally, the 
stability of aryl thioesters towards hydrolysis is noticeably reduced in comparison to alkyl thioesters 
and they therefore require careful handling to achieve good ligation yields. Dawson et al. reported 
the possibility of performing a thiol-thioester exchange prior to ligation to enhance the reaction rate, 
where the less reactive S-benzyl and S-alkyl thioesters are exchanged in situ with thiophenol to 
create highly reactive S-phenyl thioesters that then proceed immediately to react with the presented 
cysteine-containing peptide. [126] Siebenhaar et al. analyzed the stability of some protein thioesters 
and discovered that MMBA showed greater stability than MPAA to hydrolysis, while MesNa is 
superior to both (see Figure 13). [127] 
The amino acid residues located next to the C-terminal ligation site also affect the reaction kinetics, 
because they can potentially cause steric hindrance. Hackeng et al. analyzed the ligation with all 20 
natural amino acids at the C-terminal ligation site. They identified the most problematic residues to 
be valine, isoleucine and proline, but threonine and leucine also showed reduced activity and the 
Figure 13: Some S-phenyl, S-benzyl and S-alkyl thioesters often used for NCL. S-alkyl thioesters are most 
stable in aqueous solution, whereas S-phenyl and S-benzyl thioesters have better reaction kinetics. 
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ligation took more than 24 hours to complete. Surprisingly, cysteine and histidine reacted equally 
fast as the least hindered amino acid glycine, suggesting that the side chains can help to catalyze the 
transthioesterification. [128] 
Yan et al. suggested the use of metal-catalyzed hydrogenolytic desulfurization to convert the 
cysteine employed in ligation to an alanine after NCL. [129] This opened the possibility to perform 
traceless ligations at sites that naturally feature an alanine residue, thereby widening the repertoire 
of NCL. The use of Ni-Raney resulted in the epimerization of secondary alcohols [130] and the 
employment of Pd catalysts led to the premature deprotection of thiazolidines, which are commonly 
used as N-terminal cysteinyl protecting groups. [131] As a result of the side reactions observed during 
the metal-catalyzed desulfurizations, Wan et al. developed a reliable desulfurization system relying 
on the reductive capabilities of TCEP together with the radical initiator VA-044 and t-BuSH. [132] 
Thanks to the methodology’s high compatibility with other functionalities, including glycosides, 
Acm protecting groups and methionines, it is widely used today. Recently, Jin et al. published a mild 
desulfurization method that foregoes the use of a radical initiator and uses boranes like NaBH4 and 
LiBEt3H as additives instead. They hypothesized that the cysteine reduction proceeds via an in situ 
generated phosphorus-borane complex. [133] 
2.3.2.2.1 Non-cysteine native chemical ligations 
One of the limitations of NCL is the availability of cysteine residues at the ligation site. Since its 
first publication, the ligation has been continuously developed to make it applicable to a wider range 
of targets.  
INTRODUCTION 
 
35 
 
Removable thiol auxiliaries were heavily investigated to serve as a reactive handle for NCL at first. 
[134] Two types were developed: N-linked auxiliaries and side-chain auxiliaries. N-linked auxiliaries, 
while easy to attach, are often too bulky to be applicable to ligation sites other than glycine. The 
steric hindrance is a result of their attachment to the N-terminus, where they form a secondary amine. 
The first NCL auxiliary was published by Canne et al.. It consisted of a simple ethanethiol 
attachment to a N-terminal Gly residue and could be removed by the addition of zinc under acidic 
conditions after the ligation was completed. [135] Low et al. then took this further and employed 1-
phenylethanethiol as an auxiliary in the protein synthesis of the 106-aa long cytochrome b562 that 
lacks any natural cysteine residues. The mechanism of the auxiliary-mediated ligation, the 
rearrangement and removal are depicted in Figure 14. The add-on was stable to Boc-SPPS, but 
removable by HF after ligation. These conditions do have a considerable drawback, since the acyl 
shift is reversible at acidic pH. [136] Offer et al. suggested the use of a thiophenol derivate and 
increased the nucleophilicity of the thiol by adding methoxy groups in para and meta position. This 
permits the auxiliary’s cleavage with TFA after ligation, while still providing enough stability during 
Boc-SPPS. [137] A photo-cleavable o-nitrobenzyl auxiliary suitable for Boc- and Fmoc-SPPS avoids 
the use of acid after ligation altogether and is therefore an alternative for ligations with peptide 
carrying acid-sensible modifications. [138] Two factors are important when evaluating the rate of the 
acyl shift and the overall peptide ligation. The rearrangement proceeds faster when the 
transthioesterification occurs via a 5-membered transition state. Furthermore, β-branching is 
preferable to α-branching, because it produces less steric hindrance at the ligation site. Keeping this 
in mind, Loibl et al. came up with an alternative N-linked auxiliary that also tolerates ligations at 
other sites than glycine. As an additional bonus, the elimination of the linker goes via a radical 
mechanism that avoids the use of acidic conditions and prevents the S,N acyl reversal shift. [139] The 
Figure 14: The mechanism of the auxiliary-mediated ligation with 1-phenylethanethiol (Low et al.). 
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Seitz group also published the non-aromatic auxiliary 4-mercaptobutyrate that is even smaller and 
cleavable under mildly basic conditions. [140] Moreover, both of these auxiliaries can be easily 
installed at the N-terminus by reductive amination.  
The sugar-assisted ligation (SAL) relies on the use of a thiol-containing carbohydrate side-chain 
auxiliary. Hence, this tool is useful for synthesis of proteins modified by carbohydrates. Brik et al. 
published the procedure in 2006, featuring a β-thioacetamido glucosamine as ligation promoter (see 
Scheme 15). [141] After ligation, the thiol is eliminated without affecting the integrity of the sugar. 
The removal of the thiol is not compatible with other thiols in the peptide, which must therefore be 
protected accordingly. Unfortunately, the ligation proceeded slowly and was limited to unhindered 
ligation sides, thereby reducing its scope. Two years after the publication of the sugar-mediated 
ligation, an interesting extension of this methodology replaced the sugar with a base-labile 
cyclohexane that is attached to a glutamic or aspartic acid and is completely traceless upon 
saponification. [142] 
Because of the just discussed limitations of auxiliaries, other approaches were developed to allow 
ligation at non-cysteine sites. Payne et al. described a methodology that permitted amide bond 
formation by direct aminolysis between a C-terminal thioester peptide and a second peptide that did 
not contain a N-terminal cysteine functionality. Like described in NCL, the yield of reaction 
depended on the nature of the C-terminal residue of the thioester peptide, but the major side reactions 
observed were the fast thioester hydrolysis and the competing acetylation reaction with ε-amines of 
lysine residues. It could be increased by the use of an amine-free buffer and the addition of a co-
solvent like NMP to reduce thioester hydrolysis. While the reaction rate was overall slower than for 
NCL, this cysteine-free ligation approach was used in the assembly of a glycosylated MUC-1 
tandem-repeat glycoprotein. [143] 
Scheme 15: Mechanism of β-thioacetamido glucosamine as ligation promoter, as published by Brik et al. 
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Furthermore, thiol-modified amino acids were developed that can replace cysteine in ligation and, 
after a desulfurization step, yield the natural amino acid at the ligation site. The first derivatization 
was performed on phenylalanine by Crich et al., who also demonstrated the feasibility of 
desulfurization after ligation by removing the β-thiol with nickel boride. [144] The success of this 
approach motivated the construction of more amino acid derivatives, as depicted in Figure 15. [145] 
Payne’s β-mercaptoaspartate is of particular interest, because the desulfurization of this building 
block works in the presence of cysteines by incubation with 2 % thiophenol at 37 °C overnight. 
Equally important in this aspect are seleno-based ligations, where a selenol replaces the sulfur at the 
ligation site for NCLs and EPLs. [146] Thanks to the increased predisposition of selenols to form 
radicals, their selective deselenization in the presence of thiols is possible and a true alternative to 
cysteine-mediated ligation. [147] 
Only two amino acids, penicillinamine [148] and γ-thioproline [149] are commercially available up to 
date. It should be noted that the development of these amino acids is also of importance to overcome 
problems with ligations at sterically hindered ligation. Penicillinamine, for example, was able to 
form a native amide bond at the challenging Leu-Val [148] and Asn-Val [150] junctions, an impressive 
feature for future syntheses. 
Figure 15: The majority of the natural amino acids have been equipped with a thiol moiety that enables them 
to replace cysteine at the ligation site. 
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2.3.2.2.2 Synthesis of peptidic C-terminal thioester 
One of the most challenging aspects of NCL is the synthesis of peptide thioesters, especially when 
using Fmoc-based SPPS. In the beginning stages of this technique, only Boc-SPPS was able to 
deliver functional thioesters. Early Boc-SPPS suffered from drawbacks like trifluoroacetylation 
during the final deprotection and deletion sequences from aldehyde side products on the resin. With 
the development of new solid supports other than the original Merrifield resin (hydroxymethyl-
functionalized) and the improvement of coupling reagents, Boc-SPPS has become more reliable. 
Nevertheless, the conditions required still limited the use of native chemical ligation to laboratories 
experienced with handling highly hazardous chemistry.  
Hojo and co-workers’ original protocol for thioester peptide synthesis via Boc-SPPS was based on 
the conversion of an amino acid into the corresponding mercaptopropionic acid-thioester first. The 
new building block featured an open carboxylic acid and was used for attachment to the solid 
support. From there on, the peptide was elongated. [151] Hackeng et al. simplified this procedure by 
developing the TAMPAL resin which circumvented the synthesis of additional building blocks. It 
consists of the established Boc-SPPS MHBA resin modified with leucine linked to 
mercaptopropionic acid via an amide bond (see Figure 16). [128] A few years later, a thiophenylester 
resin was published that yields S-phenyl thioesters for direct ligation without the need of additives. 
[152] A potential advance for Boc-SPPS supported thioester synthesis was a report of Raz et al. in 
2016, where Merrifield’s resin is used as a basis for a HF-free cleavage protocol, but no HF is 
employed for the release of the peptide. Instead, a cocktail of TFA:TMSBr:thioanisole:EDT 
(1:0.05:0.05:0.025) is used to produce peptidic phenyl thioesters. [153] 
A set of reliable and straightforward methodologies have been put forward that rely on the use of 
Fmoc-SPPS and that are useful when the acid-labile functionalizations have to be incorporated into 
the peptidic building blocks. This includes phosphorylated and glycosylated amino acids, which are 
of high interest in the study of post-translational modifications. The lability of thioester linkages to 
the continuous cycles of Fmoc deprotection was the biggest challenge to overcome. Clippingdale et 
al. described the use of 1 % DBU in DMF for Fmoc deprotection to avoid the premature aminolysis 
of the thioester. An associated undesired side reaction was the epimerization of the amino acid 
Figure 16: Structure of TAMPAL and thiophenylester, both based on MHBA resin. 
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adjacent to the thioester. [154] The more reliable solution proved to be the preparation of precursors 
that could be readily converted into reactive thioesters after cleavage and purification.  
Liu’s group published a protocol based on hydrazide chemistry (see Scheme 16). The peptide is 
synthesized on a hydrazine-functionalized 2-chlorotrityl resin and affords an acyl hydrazine 
functionalized C-terminus upon cleavage from the resin. The acyl hydrazine is then activated in 
solution prior to ligation to the corresponding acyl azide with NaNO2 at pH 3, followed by the 
addition of a thiol, preferably MPAA. C-terminal aspartic and glutamic acid as well as asparagine 
peptide hydrazides cannot be produced, because of an intramolecular cyclization between the 
hydrazine and the side-chains. Furthermore, branching with Gly has been reported. [155]  
Dawson‘s group developed the frequently used Nbz thioester precursor (see Scheme 17). Rink 
Amide resin is first functionalized with 3,4-diaminobenzoic acid (Dbz), before standard Fmoc-SPPS 
is used to complete the peptide. The Dbz is cyclized by reacting it with nitrophenyl chloroformate 
and base before peptide cleavage, yielding a precursor peptide with a C-terminal 
N-acyl-benzimidazolinone (Nbz). Activation is carried out by the addition of a thiol like MesNa or 
Scheme 16: Liu's simple thioester precursor is a peptide hydrazine. This is then activated at acidic pH with 
sodium nitrite, before a thiol exchange leads to the formation of a peptide thioester. 
Scheme 17: Dawson's thioester precursor requires, besides an initial functionalization step, also a cyclization 
reaction before peptide cleavage. The Nbz-precursor is then activated by thiol addition. 
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MPAA in buffer at pH 7. [156] Problems with branching at the 4-position of the Dbz were addressed 
by amine methylation [157] or the separation installation of an Alloc protecting group that has to be 
removed prior to cyclization. [158] This way also paved the way to using the Dbz-resin for C-terminal 
glycines, which were previously only difficult to install without the risk of branching. 
Other thioester precursors rely on intramolecular N,S shifts for activation, some of which are shown 
in Scheme 18. One of the simpler systems involves the use of N-methyl cysteine at the C-terminus 
of the peptide. The tertiary amide bond is more labile than the secondary amine bond and it will 
already rearrange during peptide cleavage with TFA. After rearrangement, the thioester can be 
replaced by another, more reactive thiol for ligation. [159] The drawback of the N-alkyl cysteine 
thioester precursors are the slow N- to S-acyl shifts at neutral pH. This was addressed by Terrier et 
al. by installing an intramolecular proton donor to accelerate the N-protonation during the 
rearrangement. The SEAlide system developed by Otaka’s group uses N-aminoacyl-N-
sulfanylethylaminobenzoic acid as a C-terminal moiety that shifts once phosphate ions are added, 
possibly because they promote the deprotonation of the thiol and thereby induce the attack of the 
thiol on the amide. [160] Melnyk’s SEAoff/on system requires the presence of TCEP to open and become 
available for ligation. [161] While a reliable and effective system for ligation, the resin 
functionalization is not trivial. An advantage is its wide applicability to all amino acids, including 
Scheme 18: N-methyl cysteine, SEAlide and SEA precursors are all cleaved from resin as amides that become 
activated to thioesters by N,S-acyl shift. 
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charged and sterically hindered ones. Remarkably, it even enables ligation at C-terminal prolyl sides. 
[162] 
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2.3.2.2.3 Sequential native chemical ligations 
Single NCLs can reliably generate small proteins of about 100 to 130 amino acids. Shorter peptides 
are easier to produce in high yields at good purities than the generation of long sequences that are 
prone to deletion sequences due to incomplete coupling steps and increasingly difficult purifications. 
It could therefore be of advantage to link a series of small peptides rather than synthesizing it as a 
large polypeptide in one go, because the physical properties of the starting materials and products 
Scheme 19: Proteins can be assembled by sequential native chemical ligations starting either from the C- or 
the N-terminus. The direction of ligation will have an influence on the type of thioester and the cysteine 
protecting group. 
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usually differ enough to ensure a straight-forward purification. The development of sequential 
ligations has therefore been a significant step towards generating longer proteins. Peptide fragments 
can be linked to each other either from N- to C-terminus or from C- to N-terminus, depending on 
which thioester and N-terminal amino acid is used.  
The two approaches are outlined in Scheme 19. The C-to N-terminal ligation strategy requires a 
peptide with an active thioester (peptide A), a second fragment equipped with a protected cysteine 
at the N-terminus at one end and an active thioester at the other (peptide B) and, finally, a peptide 
carrying an open N-terminal cysteine (peptide C). The first ligation will be performed between 
peptides B and C. The middle fragment BC can then be purified, but ideally should be used without 
purification. After cysteine deprotection, the next ligation with peptide A will yield the desired 
polypeptide ABC.  
The N-to C-terminal ligation equally requires two peptides with an active thioester (peptide D) and 
a N-terminal cysteine (peptide F) respectively. The middle fragment needs an open cysteine for 
ligation and an inactive C-terminal thioester precursor (peptide E). Peptide D and E will be reacted 
first, followed by the activation of the thioester precursor to generate a reactive thioester for the 
second ligation with peptide F.  
With the current methodologies in hand, impressive protein syntheses delivered new insights into 
the role of post-translational modifications on protein behavior and structure. Furthermore, the 
current results proof the value of a chemical-driven approach to solve biological questions that could 
so far not be addressed by biochemical means and suggests that the advance of this technology will 
become a valuable tool in biology in the future.  
α-synuclein has been a much-studied protein in the field of protein synthesis because of its role in 
the pathology of Parkinson’s disease. To study the effect of post-translational modifications on α-
synuclein’s structure and function, the 140-aa long protein can be split into medium-length synthetic 
peptides that are then assembled to a full protein by sequential ligations. 
Fauvet et al. published a protocol for synuclein ligation that requires two ligations to yield the 
full-length protein. The groups of Lashuel and Brik initially targeted a four-fragment ligation, but 
the properties of the peptides favored the synthesis of a long C-terminal peptide of 72 amino acids 
over a ligation of two separate fragments. They designed three peptides: syn[1-29]-SR, Thz-syn[31-
68]-SR and Cys-syn[70-140] (see Scheme 20). The ligation sites were placed next to alanine residues 
that could be produced by the desulfurization of cysteines after ligation so that the final protein 
consists of the wild-type sequence without mutations. The thioesters were synthesized as Nbz-
precursors first, but were converted to the respective thioesters with MesNa before purification and 
storage. The ligations were performed from N-to C-terminus. The first ligation proceeded in high 
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yields of 97 %, while the methoxylamine-promoted deprotection of the Thz group to yield the 
ligation-reactive cysteine and the second ligation were isolated at 91 % yield. In the final step, the 
cysteines were desulfurized with a radical initiator to generate two alanines at the ligation sites. A 
comparison of CD, multi-angle light microscopy and aggregation propensity between the synthetic 
and recombinantly expressed protein revealed no significant structural differences and underlines 
the potential of this approach. [163] 
This ligation strategy was used by Dikiy et al. to evaluate the significance of the phosphorylation of 
residue Y39. [164] Total protein synthesis was the method of choice, because the enzyme known to 
induce this modification also phosphorylates Y125. The authors were able to show that pY39 
influences the structure and function of α-synuclein. Similarly, the effects of nitration at the same 
tyrosine were thoroughly studied. [165] 
Protein synthesis has been used to produce histones, which consist of tightly packed chromatin that 
acts as DNA storage, with a variety of different post-translational modifications to determine their 
effect on the structural properties of chromatin and how they influence essential biological functions 
like transcription and translation. The group of Brik was the first to publish a full protein synthesis 
scheme that permitted the site-specific introduction of a ubiquitin modification into the middle of 
the sequence of histone H2B to generate pure H2BK34Ub (see Scheme 21). [166] 
Scheme 20: A three-fragment sequential ligation strategy to obtain full-length α-synuclein. (Fauvet et al.) 
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In this approach the fragment H2B[1-57]-NHNH2 was synthesized by ligation of fragments 
H2B[1-20]-Dbz and H2B[21-57], the latter of which contained an o-nitrobenzyl (o-NB) protected 
δ-mercaptolysine handle at residue 34 for ubiquitin attachment. H2B[1-57] featured a C-terminal 
hydrazine, which was activated by the addition of NaNO2 at pH 3. To avoid lactamization of the 
activated hydrazide with the C-terminal lysine residue, Lys57 was protected with the photocleavable 
Nvoc group. H2B[58-125] was Thz-deprotected at the N-terminus and then reacted with the 
activated H2B[58-125] in the presence of MPAA. The third ligation completed the linear sequence 
of H2B with a ligation handle on residue 34 for further protein manipulations. In the final step, a 
ubiquitin thioester is ligated to the photo-deprotected mercaptolysine and a universal desulfurization 
converts all cysteines and the mercaptolysine to alanines and lysine respectively. The synthesized 
protein correctly assembled into histone octamers with H2A, H3 and H4 and could furthermore be 
incorporated into a more complex chromatin structure.  
Scheme 21: A sequential ligation strategy, allowing the synthesis of site-specifically ubiquitinated 
H2BK34Ub. H2B[1-57] with an o-nitrobenzyl (o-NB) protected δ-mercaptolysine at position 34 was 
synthesized by native chemical ligation between H2B[1-20] and H2B[21-57]K34K(εS(o-NB)). The full-
length histone was assembled by ligation between H2B[1-57] K34K(εS(o-NB)) and H2B[Cys58-125]. After 
photo-deprotection of the mercaptolysine, ubiquitin was attached by ligation and overall desulfurization 
resulted in the isolation of pure H2BK34Ub.  
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Li et al. designed an alternative route for histone H3 that requires one step less than Brik’s procedure 
and solely relies on the use of acyl hydrazine precursor peptides (see Scheme 22). [167] The protein 
was split into three fragments, where the N-terminal fragment H3[1-46]K4K(Me3) was equipped 
with a trimethylated lysine at K4. The middle H3[Cys47-90] featured the N-terminal cysteine 
protecting group p-boronobenzyloxycarbonyl (Dobz) that is stable to the activation conditions of the 
acyl hydrazine precursor and therefore allowed a synthesis in C-to N-terminal direction. Thz, 
commonly used as cysteine protecting group in peptide ligations, was previously shown to degrade 
during the precursor conversion. [168] H3[Cys47-90] and the C-terminal fragment H3[Cys92-135] 
were ligated first, before H3[1-46] containing the modification was attached to complete the protein. 
The natural cysteine residues in the histone were protected by Acm groups, which remained intact 
during the desulfurization of the ligation sites. All steps, including the final Acm removal, could be 
performed in a one-pot manner and yielded the desired protein product.  
  
Scheme 22: Three-fragment protein synthesis strategy for histone H3 featuring a trimethylated K4 
modification (Li et al.). The NaNO2-stable N-terminal protecting group Dobz at Cys57 allows for the 
ligation to proceed from the C- to the N-terminus.  
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2.3.2.3 Expressed Protein Ligation 
EPL is an extension of NCL and was first reported on by Muir et al. in 1998, where a protein thioester 
was first linked to a peptide with a N-terminal cysteine via an amide bond. In this methodology, the 
protein is expressed as an intein fusion protein which can be cleaved by thiolysis and release a 
reactive protein thioester. [169] The ultimate benefit of this procedure is that the size limit associated 
with NCL is removed, since large parts of the desired target can be recombinantly expressed in 
bacterial or insect cultures. EPL enables the semi-synthesis of new complex targets and therefore 
constitutes one of the most important findings in protein chemistry.  
2.3.2.3.1 Inteins as a basis for EPL 
The principle of the intein fusion protein is based on protein splicing that was first discovered in 
living organisms in the 1980s. Natural splicing involves the excision of an intein from two flanking 
exteins and the subsequent linkage of two exteins by a native amide bond. The process is 
autocatalytic, with all necessary features and perquisites present in the intein itself, so no other co-
factors or energy sources are needed for the process to occur. It can take place as soon as all elements 
have fully translated from the mRNA template. Over 100 different inteins are known to this date and 
they all share a structural homology.  
The intein – the protein of desire (POI) – is surrounded by exteins EN and EC and the cleavage 
mechanism relies on the same elements as NCL, as shown in Scheme 23. The first step involves a 
N, S- acyl transesterification, which results in the shift of extein EN to the side chain of the attacking 
cysteine (or in some inteins, serine), placed at the N-terminus of the POI. Next, another 
transesterification step leads to the transfer of extein EN to a cysteine/serine/threonine next to 
extein EC. This effectively removes extein EN from the N-terminus of the POI, generating a branched 
protein, where the exteins are now in close proximity to one another. Finally, the free amide of a 
conserved asparagine residue at the C-terminus of the POI undergoes an intramolecular cyclization, 
leading to the release of the POI. A final transesterification step forms a native amide bond between 
the two exteins. [170] 
Scheme 23: Mechanism of self-splicing, where an internal inteins auto-catalyzes its own excision from the 
flanking exteins. 
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The thiolysis of the intein fusion protein to release an active thioester follows a similar route. The 
most commonly used system is called IMPACT and permits the step-wise purification of cell lysate 
and the discharge of the POI as a thioester, either at the N- or the C-terminus. The POI is immobilized 
on chitin beads with a chitin binding domain (CBD) adjacent to the intein, ensuring that only intein-
expressing proteins are fished out from the recombinant protein expression. The protein is then 
eluted by a thiol-induced intein cleavage. MesNa, DTT and thiophenol are commonly used thiols 
for release. The cleavage mechanism is outlined in Scheme 24. The selective cleavage at the N-
terminus can only take place, because of an Asn/Ala mutation at the C-terminus of the intein. [116] 
Alternatively, the IMPACT system also allows for the release of terminal cysteine proteins. [116][171]  
Drawbacks of the IMPACT system are the potential premature intein cleavage and slow thiolysis 
rates, especially when aiming for alkyl thioesters, although this can often be remedied by cleavage 
optimization. 
There are two possible routes to follow when performing an EPL between a peptide and a protein 
using the IMPACT system:  
1) On-bead ligation: After protein expression, the cell lysate is passed over a solid phase to 
immobilize the intein-containing protein with the additional handle attached to the C-
terminus of the intein. IMPACT system uses the chitin-binding domain for immobilization 
on chitin beads, although it has to be noted that other handles like GST have been used for 
the same purpose. After immobilization and thorough washing, the beads are treated with 
Scheme 24: The IMPACT system allows for the isolation and release of a POI as thioester directly from the 
cell lysate from a recombinant protein expression. 
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buffer containing thiols for cleavage and the peptide to be ligated. Hence, the ligation is 
carried out at the same time as the thiolysis. This ensures a quick ligation and minimizes 
thiol hydrolysis. Nevertheless, concentration-dependent side products can form and not all 
proteins are soluble enough in buffer without chaotropic and solubilizing reagents.  
2) Elution and ligation: The protein thioester is released with buffer containing the thiol only 
and can then be purified by size exclusion chromatography, if necessary, before being used 
for ligation. This is advantageous when the protein is only soluble at suitable ligation 
concentrations in the presence of chaotropic reagents like urea or guanidium hydrochloride 
or the bead elution produces side products.  
Sequential ligations where a peptide fragment is inserted between two recombinant proteins are also 
possible with IMPACT. Cotton et al. inserted a synthetic tripeptide containing a 5-(dimethylamino)-
naphthalene-1-sulfonamide (Dns) fluorophore between the SH3 and SH2 domain of the Abelson 
nonreceptor tyrosine kinase (AbI). [172] As shown in Scheme 25, Abi-SH2 was ligated to a synthetic 
peptide thioester equipped with Dns and a N-terminal cysteine that was protected by a Factor Xa 
cleavage site to avoid an internal cyclization reaction. After the first ligation, the enzymatic cleavage 
afforded a reactive ligation site and was able to react with the AbI-SH3 thioester. This was the first 
display of a sequential ligation involving two recombinant proteins and one synthetic peptide.  
Another system used for protein semi-synthesis relies on split inteins for protein trans-splicing (see 
Scheme 26). Unlike to regular protein splicing, the intein is divided into two parts (IN and IC), with 
Scheme 25: The IMPACT has been used in a sequential EPL, where a synthetic peptide was inserted between 
two recombinant proteins. 
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extein fragments attached to the C- or N-terminus respectively. The intein fragments have a high 
affinity for each other and will associate under native conditions. The reconstitution of the two parts 
and their correct folding is the essential step in the full functionality of the system, but details of the 
mechanism are still under investigation. The refolding allows a series of backbone rearrangements 
to take place to connect the exteins and release it as a POI, while excising the reconstituted intein. 
[173] 
To apply this principle in protein semi-synthesis, a shortened version of the intein was developed, 
named mini-intein.  It is roughly 140 amino acids long and it is split into a 100-aa long IN and a 40-
aa long IC. [174] This subdivision makes only the C-terminus available to and modifiable by SPPS, 
although it must be pointed out that the sequence attached to the intein cannot be exceedingly long 
due to the length limitations of SPPS. IN, on the other hand, is attached to the second ligation partner 
and produced by recombinant expression. Lew et al. first demonstrated the potential of split-inteins 
in protein semi-synthesis. [175] Giriat et al. then went on to use split-inteins for protein semi-synthesis 
in living cells. A GFP was modified to feature an IN intein and transfected into mammalian cells. A 
short synthetic peptide bearing a FLAG motif and a CPP linked via a disulfide bridge, meanwhile, 
was transported into the cell and released from the CPP as a result of the increased intracellular thiol 
concentration. This liberated the cysteine permitting the rearrangement of the split-intein and 
initiated ligation with its GFP counterpart. [176] This was possible, because the high binding affinity 
between the two intein fragments allowed them to be used under highly diluted conditions. 
Olschewski et al. used NCL to overcome the synthetic and limitations associated with the IC. By 
Scheme 26: During trans-splicing, two separated inteins fused to exteins EN and EC reassemble and thereby 
enable the linkage of the exteins to produce a POI. 
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producing IC with a C-terminal thioester by SPPS, they could modify the split-intein with any N-
cysteinyl peptide by ligation. This allowed them to synthesize a double-lipidated prion protein for 
incorporation into the plasma membrane of living cells. [177] Up to then, the methodology was limited 
to C-terminal modifications, which reduced its applicability. An alternative approach removed this 
restriction and enabled the incorporation of a N-terminal synthetic fragment. Sun et al. published 
split-inteins consisting of a 11-aa long IN and a 142-aa long IC, suitable for exactly this purpose. [178] 
Other small inteins have been developed in recent years. Unfortunately, their binding affinity and 
splicing efficiency remains low in comparison to the full-length version. [179]  
The group of Muir developed an interesting alternative method for the generation of thioesters. 
While the IMPACT is widely used because of its easy accessibility, it can have drawbacks for some 
proteins. Inteins are known for their premature cleavage, not only during expression, but also during 
immobilization onto solid support and the side products formed are tiresome to separate from the 
desired thioester. Furthermore, thiolysis often proceeds sluggishly and needs optimization efforts to 
generate sufficient yields. Vila-Perelló et al. therefore came up with a split-intein based approach to 
thioester formation, as shown in Scheme 27. [180] 
This system takes advantages of the high binding affinity of the split-inteins and fast-on rates. On 
top of this, the splicing has short half-lives of just over one minute and the N-terminal IN becomes 
highly activated to thiol replacement once the transesterification has taken place. Above all, this 
method prevents any premature cleavage of the intein, because the association of the two split-inteins 
is a perquisite for the thiolysis to occur. For these reasons, this methodology could prove useful in 
future ligations.  
  
Scheme 27: Split-inteins can be used to produce protein thioesters (Vila-Perello et al.). 
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2.3.2.3.2 Expressed protein ligation in protein semi-synthesis 
EPL has provided the field of chemical biology with a versatile toolbox to study large proteins with 
site-specific modifications which were unattainable with simple NCL before and thereby heavily 
influenced the way in which biological functions can be explored. Experience has shown that a 
remarkable number of semi-synthetic proteins show no difference in structure and biological 
behavior than their expressed counterparts, despite being assembled from fragments under 
denaturing conditions. Up to date, EPL has been used in the study of individual post-translational 
modifications in a variety of different protein classes, ranging from ion channels [181] and 
enzymes [182] to histones [183] and membrane proteins [184] have been studied using protein semi-
synthesis. 
Ubiquitination, a “marker” for protein degradation that is attached to a protein via lysine residues, 
is believed to play a role in the disease-driven aggregation of α-synuclein in PD. Lashuel’s group 
published a semi-synthetic strategy to install a single ubiquitination at K7 in the protein. [185] Here, 
ubiquitin was first expressed as an intein cleavage protein to obtain a C-terminal thioester. α-
synuclein was assembled from a synthetic peptide Syn[1-18] with a mercaptolysine residue at K7 
and a recombinantly expressed Syn[Cys19-140]. The ubiquitin thioester was then ligated to the α-
synuclein to obtain the desired target protein. While still a simple design and also possible to achieve 
Ub4-1K12Syn[1-140] 
Scheme 28: Multi-step semi-synthesis of ubiquitinylated α-synuclein Ub4-1K12Syn[1-140]. 
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by NCL, this path is shorter, requires less synthesis and fewer purifications, resulting in an overall 
higher yield.  
An impressive combination of ligation techniques was used to obtain a tetra-ubiquitinated α-
synuclein. [186] The synthesis route is depicted in Scheme 28. First, α-synuclein was assembled using 
EPL to feature a mercaptolysine residue as attachment handle at Lys12. A ubiquitin dimer was 
formed between a ubiquitin thioester equipped with a Thz-protected mercaptolysine at K48 and a 
ubiquitin carrying a N-methyl cysteine amide at the C-terminus as ligation auxiliary. The dimer was 
ligated to α-synuclein using standard ligation conditions. K48 was then deprotected and a second 
dimer was attached to obtain a tetra-ubiquitinylated α-synuclein. This was then used further in 
biological assays to access the effect of polyubiquitination on the α-synuclein aggregation behavior. 
Similarly, histones have been modified with ubiquitin by using EPL. Fierz et al. set out to study the 
effect of ubiquitination on the stability of H2A and H2B nucleosomes. [187] They chose Lys119 in 
H2A and Lys120 in H2B as modification sites, which are the best-known ubiquitination sites for 
these histone subtypes. They have previously been shown to regulate transcription and DNA repair, 
but the underlying mechanisms are currently still unknown. Protein semi-synthesis was used to 
establish the role of the individual modifications on the overall stability of the nucleosomes by two 
subsequent EPLs (see Scheme 29). Since Lys119 and Lys120 are located at the C-terminus of the 
protein, the histone can be split into one short peptide and one longer recombinant protein thioester. 
The short synthetic peptide H2A[114-128] was decorated with a Thz-protected penicillinamine at 
the N-terminus for EPL with the protein thioester H2A[1-113] and a Lys(Mtt) at Lys119, which 
allowed for a late-stage introduction of an additional cysteine residue on the lysine side chain. The 
cysteine acted as reactive handle for the incorporation of the ubiquitin to yield H2A[114-128] with 
Scheme 29: Protein semi-synthesis of ubiquitinylated histone H2A at Lys 119. The full-length protein was 
generated in two steps. First, the ubiquitin was attached to an H2A fragment via a mercaptolysine handle, 
then the histone sequence was complete with a second ligation to yield the target protein. 
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a Lys119(Ub) modification after the first ligation. The branched synthetic protein e was then 
extended by EPL with H2A[1-113] after thiazolidine deprotection of penicillinamine with 
methoxylamine. In a final step, a full desulfurization removed any thiol-containing amino acid, 
including a natural cysteine at position 76, which was shown to have no effect on the reactivity and 
functionality of the protein. A similar scheme was followed for the synthesis of ubiquitinylated H2B. 
The stability of nucleosomes containing modified H2A and H2B was evaluated and it was 
determined that the ubiquitination only has little effect on the nucleosomes. This study is yet another 
example of the versatility of EPL as a biochemical tool to study post-translational protein 
modifications.  
While EPL is useful to discover more about the role of post-translational modifications, it finds 
application in other research fields as well. Protein immobilization, for example, is an essential step 
in a lot of biological and diagnostic screening applications and the development of suitable 
methodologies that allow for the selective and homogeneous attachment to solid surfaces is of 
importance to obtain reliable hits. Protein thioesters have been used as attachment handles to 
cysteine-modified solid surfaces, as illustrated by GFPs and SH3 domains. [188] Instead of direct 
attachment to solid surfaces, protein thioesters were also tagged with immobilization tags containing 
biotin to enable their selective interaction with streptavidin beads. [189] 
Peptide and protein cyclization is another field of application, where EPL has been successfully 
used. While peptide cyclization via established SPPS methods and in solution approaches is mostly 
the method of choice, difficult sequences are in some cases easier to synthesize by recombinant 
expression and inducing cyclization by EPL. Furthermore, this route allows for the generation of 
large peptide libraries. For this purpose, the peptide sequence is expressed with a C-terminal 
thioester and a protected N-terminal cysteine. The protection usually consists of a short TEV or FXa 
cleavable sequence. The removal of the tag and the addition of thiols are therefore direct inducers 
of cyclization. This application has been shown in vitro [190] as well as in vivo. [191] 
Finally, EPL is also a powerful tool to generate isotopically labelled proteins for NMR. [192] It has, 
for example, been used to discover more about the structural behavior of the intrinsically 
unstructured protein PQBP1. [193] In another case, a 140 kDa multidomain protein named CheA was 
labelled by a combination of EPL and trans-splicing, which further highlights the usefulness of this 
methodology to produce large proteins by semi-synthesis. [194]  
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2.4 The Tau protein 
2.4.1 Tau structure 
2.4.1.1 Isoforms  
Tau is encoded by the MAPT gene on human chromosome 17. Alternative splicing of exons 2, 3 
and 10 leads to six different isoforms of the protein and is under developmental regulation – while 
all isoforms can be found in the adult human brain, the fetal brain only features the shortest form. 
[195] The splicing is influenced by small non-coding microRNA (miRNA) and RNA-binding proteins. 
It is suggested, for example, that the inclusion of exon 3 is regulated by the transcription factor NRF2 
by binding to intron 1. [196] The splicing of exon 10, on the other hand, is regulated by 
phosphorylation of the splicing factor SC35 that binds to the 5’ end of exon 10 and promotes its 
inclusion in the protein. [197] There is also evidence that FUS, a nuclear DNA/RNA binding protein 
found primarily in the nucleus and an essential part of the spliceosomal complex that binds to 
numerous mRNAs, can directly bind to multiple sites on the tau transcript and regulate exon 10 
splicing. FUS knockdown primary rat hippocampal neurons have shown increased levels of 4R tau 
and characteristic aggregates in FTLD and ALS were shown to contain FUS proteins. [198] Silent 
point mutations in the tau gene as well as kinase dysregulation can alter exon 10 splicing. [199] 
The roles of exons 2 and 3 are not fully elucidated yet, though there is evidence that their presence 
alters the binding properties of tau to cell membrane proteins. The inclusion of exons 2 and 3 are 
associated with a set of cell membrane proteins like ApoA1 when both exons are present, or 
synaptophysin when the exons are missing. [200] They also have a substantial effect on the 
aggregation potential of tau. Inclusion of exon 2 increases the nucleation rate and enhances 
aggregation, while the additional inclusion of exon 3 counteracts this effect again. Isoforms lacking 
both exons do not aggregate. [201] 
Exon 10 contains a microtubule binding region that, unlike the other three identical repeats, has a 
slightly different sequence. If exon 10 included in the transcription, the protein is known as tau 4R 
Figure 17: Due to alternative splicing mechanisms, tau has six possible isoforms. 
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- if not, it is referred to as tau 3R. Unsurprisingly, the additional interaction domain increases the 
binding affinity of 4R to microtubules in comparison to 3R. [202] In healthy brains, the ratio of 4R to 
3R is 1:1 and a disequilibrium alone was shown to result in neurodegeneration. [203] Up- or 
downregulation of 4R and 3R, and therefore the presence or absence of exon 10, is associated with 
several tauopathies. PSD, CBD and HD show high 4R content, while 3R is the sole isoform found 
in PiD. AD is one of the few tauopathies where both isoforms play an important role. [204] 
2.4.1.2 Primary structure 
Tau is a highly hydrophilic and water-soluble protein with remarkable stability towards acid and 
heat. In total, 80 residues within the tau sequence are serines and threonines and are perfect targets 
for post-translational modification, especially by phosphorylation and glycosylation. In contrast, 
there are only few hydrophobic residues. [200] The longest isoform also consists of 56 negatively, 58 
positively charged amino acids and only 8 aromatic residues. The protein’s overall charge is basic, 
although the N-terminal tail is mostly acidic. Interestingly, the sequence encoded by exon 2 and 3 
add acidic character to tau, while exon 10 contributes to the protein’s basicity. [205] Furthermore, the 
threonine and alanines are not randomly placed across the protein, but can be found predominantly 
in the N-terminal tail. [206]  
 
 
pI[205,207] 3.8 11.4 9.8 10.8 
proline content low high low low 
threonine 
content 
high high low low 
sequence 
conservation 
high low low low 
The protein can be divided into two domains of opposing charge: The highly conserved assembly 
domain in the C-terminal region responsible for binding to microtubules and the less conversed 
N-terminal projection domain. [208] They are linked by a proline-rich element in the middle of the 
protein carrying seven PXXP motifs characteristic for interaction with Src homology 3 (SH3) 
domains. It also contains several SerPro and ThrPro motifs that are targets by Pro-directed kinases. 
2.4.1.3 Secondary and tertiary structure of monomeric tau 
Tau is an intrinsically unstructured protein that, like other proteins from the same category, lacks an 
overall well-defined structure and has a high conformational flexibility. It can shift shapes rapidly 
Figure 18: A summary of key physical characteristics of the longest isoform of tau., 
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and undergo quick structure refinements to perform its cellular function. It has a globular structure 
with an unusually large volume. Due to its diffuse structural features, crystallographic analysis of 
the intrinsically unstructured tau monomers is not possible, unless they are presented when bound 
to antibodies or other surrogate binding partners [209]. Instead, scientists turned to spectroscopic 
methods to discover more of its structure, including nuclear magnetic resonance (NMR), circular 
dichroism spectroscopy (CD) and Fourier transform infrared spectroscopy (FTIR) [210].  
Early evidence of a rod-like structure of tau was questioned when it was revealed that some 
antibodies bind to discontinuous epitopes in recombinant tau. [211] Mapping of Alz-50, an antibody 
raised against AD brain homogenate, showed that its binding affinity depends on two separate 
regions in the protein – one region contains the N-terminal residues 5-15, the second region lies in 
the microtubule-binding repeat domain encompassing residues 312-322. [212,213] Further studies 
indicated that the binding affinity of Alz-50 is greater to tau filaments than to monomers, most likely 
because the epitope is stabilized in its aggregated for, while denaturation of tau prior to antibody 
detection greatly diminished its labelling capability.  [213] 
Jeganathan et al. published a thorough FRET study in 2006, in which the N-terminal residue 17, the 
C-terminal residues 432 and 435 and residues 291 and 322 within the second and third repeat region 
were tested in a step-wise manner (see Figure 19). [214] 1,5-IAEDANS was introduced as a FRET 
donor on single cysteine mutations at the positions in question and single tryptophan mutations 
spread across the length of the protein served as FRET acceptor. This study revealed (a) that the 
residues 291 to 310 and 310 to 322 in the repeat regions are within 20 Ǻ from each other, (b) that 
the C-terminal residues 432 and 435 are about 23 Ǻ apart from the repeats and (c) that the N-terminus 
interacts strongly with the C-terminus. Although these interactions are weak and do not lead to a 
stabilized conformation of tau, since slightly denaturing conditions already result in a loss of signal, 
this was the first indication that the protein adapts a “paper-clip conformation”. In another FRET 
study from 2012 Elbaum-Garfinkle et al. used a polymer model algorithm to calculate distances and 
suggested a S-like rather than a paper-clip shape, because the distance between the termini and the 
MTBR region is smaller than between the termini themselves. [215] Furthermore, the study of tau 
fragments showed that the MTBR is more compact in isolation than in full-length form.  
Figure 19: Comparison of tau structure by Jeganathan et al. and Elbaum-Garfinkle et al. 
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The rough structure described by FRET were confirmed in a detailed NMR study by Mukrasch et 
al., which was the first full-length study of the longest isoform. [216] 98 % of the non-proline backbone 
and 83 % of the proline signals were assigned. Paramagnetic relaxation enhancement (PRE), spin 
relaxation rates and a closer look at the 3JNH-αH, which are influenced by the backbone torsion angles, 
were used to give a thorough overview of the structural elements. [216] Overall, tau has an extended 
chain conformation with a number of long-range transient contacts and a large hydrodynamic radius. 
The highly mobile fifty residues at the N-terminus favor a compact conformation, supported by a 
high number of turns, and it interacts with the proline-rich region and repeats R1 and R3. The high 
flexibility of the projection domain can be partially explained by the reduced number of hydrophobic 
and the increase of negatively charged residues. Because the proline residues restrict the backbone 
movement, the proline-rich region is more rigid. Two interacting polyproline-II helical 
conformations from 216 to 223 and from 232 to 239 are separated by a short β-structure. 
Furthermore, the proline-rich domain bends to interact with the repeat R3 from the microtubulin-
binding domain. The repeat regions R1 to R4 are less flexible due to a high content of β-structure. 
R1 and R2, meanwhile, are more compact than R3 and R4, which serve as a contact point for the C-
terminal domain. It should be noted that the gain in rigidity is important, because it helps the protein 
to quickly adopt binding interactions with microtubules and other binding partners. Interestingly, 
these parts are also essential for PHF formation. With the exception of a short α-helical element 
reaching from 428 to 437, the C-terminal domain is unstructured. It is, however, in contact with the 
repeat regions and the N-terminus, to form the already reported paper-clip conformation. 
2.4.1.4 Quaternary structure 
When properly initiated, tau loses its transient secondary structure and forms inclusions of different 
morphologies. This depends on the percentage ratio of 3R/4R in the filaments, on sequence 
mutations and patterns of modification. They can range from symmetrical helixes to disarranged 
ribbon-like structures and differ in the parallel, anti-parallel or mixed arrangement of protofilaments. 
[217] The two common filament structures in AD and Down syndrome are paired helical filaments 
(PHFs) and straight filaments (SF). [218] Electron microscopy studies revealed C-shaped subunits 
arranged in a twisted double-helical ribbon and with largely unstructured C- and N-terminal units 
pointing outside to form a fuzzy coat. PHFs have a width between 8-20 nm, while SF have a constant 
width of around 15 nm and they differ in the arrangement of the subunits. [219] 
The analysis of these structures is hindered by regional structural differences that make it difficult 
to obtain pure filaments, even in the same brain sample, and the challenge to reproduce in vivo 
filaments in in vitro cultures. Recently, Fitzpatrick et al. published the most detailed cryo-EM 
structures of tau filaments from AD patients so far (see Figure 20). [220] The core structure of both 
filaments is made up of the R3 and R4 domains from V306-F378 as well as 10 amino acids C-
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terminal to the repeats. The “fuzzy coat” contains varying N- and C-terminal sequences, depending 
on which of the six tau isoform is present in the filament. At least parts of R1 and R2 are usually 
present in the fuzzy coat in a β-structure. The two protofilaments in the core structure interact at 
residues K317, T319 and K321 in PHFs and SFs. While the contact is symmetrical in PHFs, though, 
it is one-sided in SFs, highlighting their morphological difference. At a closer look, the characteristic 
C-structure is composed of a combination of cross-β packing and rare β-helices, which can only 
form with hydrophobic residues on the inside, polar residues on the outside and with arch-forming 
glycine at the end of the motifs. This study revealed that the use of shorter tau fragments, like the 
much employed K18 and K19 fragments that cover either three or four repeats of the MTBD are not 
suitable to study tau aggregation.  
It is still unclear how the formation of aggregates comes about other than that mutations and a 
multitude of post-translational modifications increase tau’s aggregation propensity. Addressing this 
issue, Ambadipudi et al. showed that tau can behave like liquid droplets under reducing conditions. 
Turbidity measurements revealed a protein-liquid-liquid phase separation (LLPS) of K18 tau at 100 
µM concentration at 37 °C. [207] The high concentration necessary for droplet formation was 
significantly reduced upon MARK2 phosphorylation of K18 to 2 µM, which is close to the tau 
concentration present in nerve cells. LLPS results in increased local protein concentrations, 
molecular crowding and possibly protein structural changes. While high protein concentrations 
alone were not sufficient to induce protein oligomerization in liquid droplets, the high accumulation 
of positive charges in a small space can attract aggregation-inducing reagents like heparin, which 
are often part of tau aggregation experiments. This is a new way to think about how tau molecules 
are forced together to form PHF and SF structures as described above and also questions some 
established experimental procedures.  
Figure 20: Cryo-EM structure of cross-sections of PHF and SF depicting the filament core ranging from 
V306-F378. Two protofilaments are arranged next to each other in a C-shape and are in contact at residues 
K317, T319 and K321 either in symmetry (PHF) or stronger at one protofilament than the other (SF). Figure 
copyright: © Nature Publishing Group by Fitzgerald et al. 
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2.4.2 The physiological role of tau 
A correctly functioning neuronal system consists of clearly differentiated, interacting neuronal cells 
(see Figure 21). Each neuron has a unique morphology and is defined by branching axons and 
dendrites. Hundreds of little dendrite arms receive information encoded as electrical impulses from 
their surroundings. The impulse travels down the axon and is then further transmitted as an action 
potential via a single axon terminal that is protected by a myelin sheath. Neurons permanently 
change structure and activity with age and experience. The cytoskeleton is optimized to maintain 
the network’s plasticity by providing three distinct structures:  
1) Microtubules consist of polymerized α- and β- tubulin dimers and are involved in the 
expansion, stability and shrinkage of the neurite network. Additionally, they provide 
structure stability to intracellular compartments and support active axon transport. 
2) Neurofilaments are characterized by rod-like structures with projecting sidearms from the 
surface. They are predominantly found in axons near the plasma membrane and they 
regulate axon volume and conductivity.  
3) Actin microfilaments have a diverse composition and are the main interaction partner for 
neuronal proteins like motors, crosslinkers and anchoring proteins. They can be found 
primarily in the presynaptic termini of dendritic spines and growth cones, where their 
highest concentration is near the cell membrane. They are usually dispersed in small 
oligomers, except for the bundles in the growth cones. The axon is lined with actin, which 
acts as elastic and stable support. Other roles include, but are not limited to, cell migration, 
growth cone mobility, intracellular communication and the regulation of tight junctions.  
Initially, neuronal polarization leads to the development of a single neurite into an axon by increasing 
the concentration of actin and actin-associated proteins at the growing neurite, while the rest of the 
neurites remain dendrites. In a step-wise process, the axon terminal is separated from the neuron 
body and the neuron develops distinct somatodendritic and axonal compartments. The growth cone 
Figure 21: A clearly differential neuronal cells and its most important features. 
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expands through a mix of actin assembly, microfilament cross-linking and myosin motors. The 
microtubules, although not directly located in the growth cone, are pulled into the growth direction 
and are needed for the successful neurite elongation. Neurofilaments only play a secondary role in 
the extension, but do have a significant effect on the stabilization of the neurite. Upon reaching the 
surface of other neurons, the formation of a pre-synaptic site is initiated, and the network connection 
is completed. [221] 
Tau’s most prominent role is to maintain cellular multiplication mechanisms by initiating and 
stabilizing microtubules. Its role in signaling and neuronal development as well as the large number 
of binding partners are clear hints that tau is a multifunctional protein that affects various other 
cellular mechanisms that have so far not been elucidated.  
2.4.2.1 Assembly of microtubules 
Tau is an axonal protein and its main role is to mediate microtubule assembly, elongation and 
plasticity. [200] Microtubules are protofilaments, a cylinder of linear polymers, made up of α- and 
tubulin heterodimers arranged in a head-to-tail fashion, as depicted in Figure 22. [222] They make up 
the so-called mitotic spindle, the essential machinery for the divide of cells during mitosis, which is 
in a particularly delicate equilibrium between assembly and disassembly.  
The assembly of microtubules is a step-wise addition of heterodimers to the end of the 
protofilaments. The energy required for the process is supplied by the hydrolysis of β-tubulin bound 
GTP to GDP. While the initial rate of hydrolysis is slow, it speeds up during the actual process. [223] 
To overcome the intrinsic instability of microtubules, microtubule-associated proteins (MAPs), of 
which tau is a member, interact with the polymer to prevent its degradation. The MAP-conserved 
repeats R1-R4, which show a high amino acid similarity to parts of α-tubulin, and interact with the 
inside surface of β-tubulin. [224]   
More precisely, the interaction involves the primary amino acid sequences 240KSRLQTAPV248, 
275VQINKKLDLS285 and 297IKHV300, [225] the last two of which are encoded in exon 10 and are 
therefore only present in 4R tau, explaining its higher binding affinity in comparison to 3R. [226] 
Furthermore, the basic residues upstream of the PGGG motif in repeats 1, 2 and 3 have an enhancing 
Figure 22: Tau interacts with microtubules via its repeats and helps to stabilize them. Microtubules are 
protofilaments consisting of heterodimers of α- and β-tubulin. Legend: red: α-tubulin, blue: β-tubulin. 
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binding effect, because they permit salt-bridge formation with the glutamic acids on the 
microtubules. The microtubule-binding domain alone has been shown to have a strongly reduced 
affinity to microtubules, emphasizing the importance of the flanking regions in binding. It has been 
suggested that the flanking regions take on a guiding role for binding, while the microtubule-binding 
domain acts as a catalyst for microtubule polymerization. The region of influence spans from Ser214 
up to Asn381, including sequences 225KVAVVRT231 and 240KSRLQTAPV248 of the proline-rich 
domain and 370KIETHKLTFREN381 further upstream. [227][228] Sequence 225KVAVVRT231 is a 
conserved sequence of the whole MAP family, while 240KSRLQTAPV248 is closely located to the 
regulatory sequence 231TPPKSP236, which is targeted by kinases and isomerases alike.  
Neither the acidic C-terminus, nor the positively charged N-terminus are involved in the microtubule 
interaction, but they have other regulatory functions. The N-terminal “projection domain” has been 
reported to regulate the binding and spacing between individual microtubules. [229] Meanwhile, it has 
been suggested that the C-terminus can help to bundle microtubules into dense parallel strands by 
acting as an hydrophobic zipper. [230] 
2.4.2.2 Post-synaptic signaling 
Although tau is mainly known as an axonal protein, it was also shown to affect 
post-synaptic signaling pathways in dendritic spines, where it is naturally only 
present in low amounts. N-methyl-D-aspartate (NMDA) receptors are 
glutamate receptors in nerve cells that, upon activation, allow an influx of Ca2+ 
through the cell membrane. Ca2+ influx plays an important role in synaptic 
plasticity and supports memory and learning. Ittner et al. described a pathway 
where tau helps to regulate the activation of NMDA receptors. The N-terminus 
of tau interacts with Fyn, a key Src kinase in the regulation of NMDA 
signaling, and aids its accumulation in the dendritic spines. Phosphorylation 
of the NMDA receptor by Fyn then leads to the recruitment of the postsynaptic 
density protein PSD-95. It forms a protein complex that induces binding of 
other regulatory proteins to initiate a glutamate-dependent excitotoxic response, resulting in cell 
damage or death. In the absence of tau, Fyn can no longer be transported into the dendritic spines 
and excitotoxicity is reduced. [231] This is of high interest, because high levels of excitotoxicity have 
previously been implicated in AD.  A study by Xia et al. suggests that the localization of tau to the 
dendrites is regulated by phosphorylation of the epitopes AT180, 12E8 and PHF-1 and that binding 
to microtubules ensures a site-specific enrichment of tau. [232] Recently, Miyamoto et al. questioned 
the role of the NMDA receptor in the tau-dependent induction of excitotoxicity, because excitatory 
postsynaptic currents remain unaffected by reduced tau concentrations. Instead, they proposed that 
Fyn-mediated phosphorylation of tau at Y18 alone is enough to enhance excitotoxicity at high 
Figure 23: Tau 
interacts with Fyn 
and thereby induces 
cell death. 
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pathogenic glutamate concentrations and that no phosphorylation of the NMDA receptor is 
necessary. [233] 
2.4.2.3 Neuronal networking  
As described earlier, microtubules are one of the three main components of neuronal cells. It is not 
far-fetched to assume that tau as a microtubule-binding protein is involved in the regulation of MT 
growth, stability and degradation in neuronal development. Determining the effects of tau in live 
cells remains a challenge, especially since results from early in vitro experiments were not 
transferable to tau knockout (KO) mice. Four known tau KO mice exist up-to-date and they often 
show contradicting tau deletion effects, which makes it difficult to draw conclusions. [234] This is not 
surprising when considering the diversity of tau isoform expression, wide-ranging effects of tau on 
signaling and process regulation and the presence of other MAP proteins that can likely, if not fully, 
then at least partially compensate the loss of tau production.  
Reduced tau level result in motor impairments at an advanced age, likely due to defects in the 
peripheral motor system resulting from hypomyelination and degeneration of myelination fibers of 
the sciatic nerve. [235] Surprisingly, tau elimination does not impair with the cognitive abilities of tau 
KO mice, although the migration of neurons was affected and the structure and movement of 
mitochondria in the leading edge of the neurons was altered.  
Overall, neurons suffering from tau deficiency have a smaller cell soma, with a less-branched 
dendritic system and fewer synaptic connections. [236] This observation correlates well with an in 
vitro analysis localizing tau in the neuronal plasma membrane, where it is an essential building block 
for the growth of the neuronal network. The binding takes place through the N-terminus. [237] The 
absence of tau is furthermore associated with a decreased differentiation of the dendritic network in 
neurons of young mice, further supported by the observation that tau collaborates with End-binding 
proteins (EBP) to differentiate primary neurons. [238] EBP 1 and 3 are tracking proteins found at the 
tip of growing MTs and they act as stimulators of growth and rescue as well as inhibitors of MT 
catastrophes. [239] Tau regulates its axon localization and thereby help to promote neuronal polarity 
and axon outgrowth. In the absence of tau in tau KO mice, the axon formation slows down notably, 
perhaps due to the mislocalization of EBP. [240] By analysis of neuronal activity in intact neuronal 
circuits and cortical neurons, it was shown that tau is needed to ensure neuronal plasticity and 
transmission. Its deletion impairs with long-term depression in the hippocampus, a process that 
reduces the efficacy of neuronal synapses and is a regulator of memory decay and spatial memory 
formation. [241] Finally, tau is also linked to the successful environmental enrichment of neurons and 
so supports the brain’s adaptability to environmental stimuli and correlates neuron network growth. 
[238] 
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2.4.2.4 Interaction with heat-shock proteins  
Heat-shock proteins (Hsp) are small molecular chaperones that, together with other co-chaperones, 
help to mediate the folding, maturation and degradation of proteins. They are further involved in 
protein metabolism and cell-cycle control. [242] Hsps are regulated by the heat-shock factor 1 (HSF1), 
which is normally localized in the cytosol, but is transferred into the nucleus upon activation by heat 
stress, where it binds to heat shock promotors and induces expression of Hsps. [243] Two groups of 
chaperones that are associated with tau folding and degradation are Hsp70 and Hsp90. Together, 
they make up more than 1% of cellular proteins. 
Hsp70 are ubiquitously expressed proteins with roles in protein trafficking, polypeptide folding, 
refolding and degradation of aggregated peptide products. Recognition of client proteins in early 
folding stages functions through short and highly exposed hydrophobic sequences rich in leucine. 
[244] Hsp70 will first and foremost attempt to correctly fold its client. Should this fail, it will help to 
degrade it with a set of co-chaperones. Hsp90 is responsible for correct folding and maintenance, as 
well as final maturation of proteins. In a simplified scheme, Hsp70 and Hsp40 recruit proteins and 
then transfer it to Hsp90 by the co-chaperone STI1, a Hsp-organizing protein. [245] Reduction of 
Hsp90 results in an increased expression of Hsp70 and Hsp40 and enhances protein degradation. 
Through binding to Hsp70 via a set of close hydrophobic residues, the tau protein will gain in 
compaction and expose other, more distant hydrophobic parts on the surface. Hsp90 can then use its 
large substrate-binding interface to create a series of low-affinity hydrophobic interactions over a 
broad surface area. Interestingly, binding to Hsp90 includes the microtubule-binding repeats. [246] It 
is certain that Hsps are involved in the correct folding and degradation of normal and 
hyperphosphorylated tau. Augmented levels of Hsp70 and Hsp90 were reported to have a positive 
effect on tau solubility and binding affinity to microtubules, suggesting that Hsps also play a role in 
microtubule control. [247] Depending on the co-chaperone involved in an Hsp90-dependent process, 
Hsp90 can either serve to protect and refold or degrade phosphorylated tau species. CHIP, a C-
terminal Hsp70-interacting protein known as co-chaperone of Hsp70 and Hsp90 with ubiquitin 
enzyme activity, promotes degradation of hyperphosphorylated tau by competing with co-
chaperones serving the refolding. [248]  
Figure 24: Hsp90 helps to promote dephosphorylation by recruiting the co-chaperone and phosphatase 
FKBP51. 
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Other co-chaperones of Hsp90, like FKBP51, serve to protect tau from proteasomal degradation and 
increase the amount of soluble tau. The co-chaperone’s function relies heavily on its PPIase activity, 
which catalyzes the trans-cis isomerization of incorrectly folded tau protein. When this fails, tau 
aggregation is further enhanced. [249] The related FKBP52 was shown to prevent binding of tau to 
microtubules and cells overexpressing FKBP52 showed reduced neurite outgrowth. [250] The 
regulation of tau folding and degradation is highly sensitive and current knowledge suggests small 
discrepancies in the network arising from ageing of the organism can already have devastating 
effects on the neuronal structure and activity.  
2.4.2.5 Interaction with DNA in the nucleus and nucleolus 
Although tau’s activity was first connected to microtubule assembly as early as 1975, [251] the protein 
was supposedly first detected in the nucleus as PHFs in 1988 [252] and its presence was confirmed by 
Greenwood et al. in 1990 by immunostaining with the tau-specific Tau-1 antibody. [253] Later on, it 
was demonstrated that 14 % of total tau in LA-N-5 neuroblastoma cells was localized in chromatin 
fractions also containing DNA and associated proteins and that most of the nucleolar tau is found in 
the nucleolus. [254] More precisely, tau localizes to the dense fibrillar component (DFC) in the 
nucleolus and the nucleolar organizing regions (NOR), where rRNA is synthesized, stored and 
processed for ribosome biogenesis. [255] NORs are regions of GC-rich rRNA located directly by the 
centromere in acrocentric chromosomes and are essential parts of the nucleolus (see Figure 25). In 
contrast to the central and peripheral nervous system (CNS/PNS), where longer tau isoforms are 
found, the nucleus contains only the shortest 2kb tau transcripts. [256] 
Evidence for the interaction with DNA was preceded by a report that RNA can inhibit spontaneous 
tubulin assembly in non-neuronal cell extracts, because it disrupts tau binding to microtubules by 
binding to it instead. [257] A NMR study by Qi et al. detailing the interaction of tau fragments with 
DNA gave some insight about the tau-DNA interactions. The fragments encompassing the PRD 
(tau[165-245]) and the MTBD (tau[244-372]) were incubated with 22-bp long DNA sequences and 
Figure 25: Acrocentric chromosome with a long q-arm and a short p-arm that is separated into a GC-rich 
NOR and pericentromeric satellite DNA. 
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the resulting shifts in the 1H-15N-HSQC were analyzed by NMR. It was found the tau-DNA 
interaction was focused in the second half of PRD, more precisely around amino acids 209-246, and 
in the R2 repeat of the MTBD ranging from 267 to 289, both with a similar KD. There was no 
difference observed between GC- and AT-rich sequences, which suggests a sequence independent 
interaction with the DNA backbone. Phosphorylation of the fragments by mouse brain extract 
diminishes all DNA binding, possibly because of an overall net charge change. [258] Most likely, the 
interaction involves charged residues like Lys and Arg as well as polar amino acids like Ser and Thr, 
all of which are present in the PRD. The interaction of the MTBD relies on hydrophobicity instead. 
[259] 
The exact role of tau in the nucleus is still up for debate, also because of the limited availability of 
in vivo data. Furthermore, conclusions from mice studies are treated with caution when drawing 
parallels to the human brain. In vitro studies revealed that tau binding to double-stranded DNA 
(dsDNA) increases its Tm. [260] Going further, tau has been shown to protect DNA from radical- and 
heat-induced damage, in a similar fashion as heat-shock proteins do. [256] Sultan et al. showed that 
heat-shock treatment or oxidative stress of cortical primary cultures of neurons as well as adult 
neurons resulted in an increase of tau in the nucleus. At the same time, the amount of phosphorylated 
tau decreased, as tested with the Tau-1 antibody. While recovering, the levels of tau gradually 
returned to their initial amounts. This suggests a protective mechanism by tau, which was confirmed 
by immunoprecipitation, where the amount of tau-DNA complex was twice as high in heat-stressed 
cells than in untreated cells. In agreement with this, tau deficiency resulted in heat-stress induced 
DNA damage. [261] 
Mutations of tau in the nucleus resulted in chromosomal defects, strongly hinting that tau is involved 
in maintaining chromosome structure and function [262] and heterochromatin compaction. [263] A 
study by Sjöberg et al. reported that tau interacts directly with α-satellite pericentromeric 
heterochromatin, which is located right next to the centromere of the chromosome. Furthermore, tau 
associates with rDNA-containing NOR regions directly next to pericentromeric DNA sequences. 
This suggests that tau might be a link between rDNA and pericentromeric heterochromatin and 
participate in rRNA silencing. [264] More recently, tau was reported to be of importance in rDNA 
transcription and metabolism. [265] Tau binds to the minor groove of DNA, as shown by competition 
with confirmed minor groove binders. [261] Strikingly, this feature is directly associated with 
regulating the stability and activity of DNA-protein complexes, so tau could additionally possess a 
transcriptional activation or inhibition function. [266] 
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2.4.3 Tau post-translational modifications and first insights into regulatory 
mechanisms  
The function of tau is heavily dependent on its post-translational modifications (PTMs). Small 
changes in charge and hydrophobicity can lead to considerable alterations of the protein’s structure 
and function. Some reported PTMs like phosphorylation and glycosylation are more appreciated 
than others, like for example acetylation and nitration. As research dedicates more time to find out 
more about the molecular causes of tau aggregation, they become increasingly important and the 
picture of PTM interactions turns out to be dense, competitive and fluctuating.  
2.4.3.1 Phosphorylation 
Phosphorylation occurs on serine, threonine and tyrosine residues. In total, tau contains 80 targetable 
serines and threonines and 5 additional tyrosine sites (see Figure 26). This renders about 20 % of the 
residues addressable to phosphorylation. The addition of negative charges to the protein reduces the 
overall net charge and hinders its interaction with the microtubules and their polymerization process. 
Phosphorylation naturally regulates neuronal plasticity and flexibility and two to three 
phosphorylations per protein are considered normal. A dysregulation of the system leading to 
hyperphosphorylation is associated with the development and outbreak of several tauopathies.  
The phosphorylation status of tau is regulated by a not yet fully elucidated set of kinases and 
phosphatases. There are three different classes of kinases: The serine and threonine specific 
proline-directed protein kinases (PDPKs) and non-PDPKs as well as the tyrosine protein kinases 
(TPK). The kinases can regulate each other and determine the extent and rate of modification. 
Protein kinase A (PKA), for example, can serve as a “pre-modifier” of tau by phosphorylating key 
residues that subsequently trigger phosphorylation by glycogen synthase kinase-3 (GSK-3). Cyclin-
dependent kinase-5 (Cdk-5), on the other hand, inhibits GSK-3 activity in healthy neurons. [267,268] 
Additionally, a set of phosphatases, while responsible for the removal of the phosphate, can also 
interfere with kinase activity. 70 % of the dephosphorylation is performed by the phosphoprotein 
phosphatase 2A (PP2A). Other phosphatases are PP2B and PP1, as well as metal-dependent protein 
phosphatases like PP2C. Due to the complex regulatory mechanisms of tau phosphorylation and the 
promiscuity of the kinases involved, assigning roles to individual or specific groups of 
phosphorylation, regardless of natural or pathological pathways, remains a challenge. Some 
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phosphorylation patterns have been highlighted for their importance in the development of 
tauopathies. 
Phosphorylation in AD will be discussed in more detail in 2.4.4.4.3 Before exploring 
hyperphosphorylation as a disease-inducing factor, it is important to emphasize that increased 
phosphorylation, although not to the same extent as in tauopathies, is also connected to other 
physiological functions and does not always correlate to the outbreak of neurodegenerative diseases. 
Neurons use transient and reversible phosphorylation on various occasions to adapt to environmental 
circumstances or drive neuronal development. In the latter, the amount of tubulin is much increased 
in comparison to already fully developed neurons and hyperphosphorylated tau might help to prevent 
microtubule bundling.  
Elevated phosphorylation levels of tau have also been observed in hibernating rodents. Hibernation 
requires the brain to minimize its energy requirements by, for example, reducing the neuronal 
connectivity and reducing signaling by phosphorylating essential enzymes and proteins. Tau is 
affected by this regulatory mechanism and a surprising amount becomes modified, likely to protect 
the protein from proteases, to put to “sleep” its role as MAP and to avoid apoptosis. Downregulation 
of phosphatases is a recognized cellular effect of hibernation and once the brain awakes again, they 
can convert tau back to its physiologically most useful form. Therefore, phosphorylation might be 
an adaptation of the brain to harsh environmental conditions. [269] In a study examining the 
phosphopattern in artic ground squirrels, Su et al. found six modification sites, namely S199, T205, 
S214, S262, S396, and S404, out of which only three, S199, S262 and S404 are dephosphorylated 
after rousing. [270] These three phosphorylations have been previously described to have a synergistic 
effect on each other – pS262 disrupts binding to microtubules and pS199/pS404 fail to keep MTs 
stable after initial polymerization. [271] 
Anesthesia and the resulting hypothermia, another strong external environmental impulse, equally 
results in reversible tau hyperphosphorylation, probably due to an accompanying decrease of 
Figure 26: A selection of threonine (green) and serine phosphorylation sites (orange) on the longest isoform 
of tau. While the N-terminus is not heavily functionalized, the proline-rich domain (residues 160-250) 
contains many prominent serine and threonine phosphorylation sites, including the AT-100 and the AT-8 
epitope. The C-terminal part of tau also features a high number of serine phosphorylations.  
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phosphatase PP2A. [272] Run et al. identified six critical phosphorylation sites in mice, T181, S199, 
T205, T212, S262 and S404, that are in abundance after 1 hr of anesthesia and observed a massive 
increase of modification once hypothermia set in during longer periods of unconsciousness. [273] 
Finally, various publications pointed out that hyperphosphorylated tau can help neurons evade 
apoptosis and in vitro tau dephosphorylation experiments in the presence of phosphatase facilitated 
cell death. [274]  
While an extensive amount of phosphorylation is connected to the development of tauopathies, it is 
clear that as long as the phosphorylation are of transient and reversible nature, they maintain 
important physiological regulatory roles of tau. 
2.4.3.2 Glycosylation 
Saccharide monomers or polymers influence protein structure and serve as recognition sites for other 
molecules for cell-cell, cell-matrix and cell-molecule communication. They influence processing, 
targeting and can act as molecular switches. They can be N- or O- linked and their diversity stems 
from the almost unlimited branching possibilities. 
N-linked glycans are attached via asparagine during protein translation in the ER and Golgi 
apparatus. This does not seem to be part of normal tau modification and has so far only been detected 
in connection with AD. There are three possible N-glycosylation sites in tau and the detected 
glycosylations vary in size and diversity, including high-type mannose sugar chains, truncated 
glycans and small amounts of sialylation. [275] N-glycosylation renders tau a better phosphorylation 
target and could precede hyperphosphorylation. [276] 
O-linked glycans occur on serines and threonines and are only installed in the Golgi apparatus once 
protein translation is completed. Again, their diversity can vary greatly. Fairly simple glycans often 
serve as primers and are installed first, but the chain can be extended further after attachment to the 
protein. One of the best studied O-glycosylation is the single, dynamic and cytoplasmic modification 
O-GlcNAc, attached by the O-GlcNAc transferase (OGT) and detached by O-GlcNAcase. It is best 
known for its interplay with phosphorylation. Liu et al. were the first to show that O-glycosylation 
is a relevant modification in human tau and that it has a reciprocal relationship with phosphorylation, 
so glycosylation can antagonize phosphorylation. They show that phosphorylation sites S199, S202, 
S205, T212, S214, S262 and S396 are negatively regulated by this post-translational modification. 
Furthermore, by mimicking the low glucose concentration commonly observed in AD in mice, the 
amount of undesired phosphorylation increased. [277] Yuzwa et al. developed a S400 specific 
antibody [278] and Smet-Nocca et al. published a study showing the reciprocal relationship between 
phosphorylation and glycosylation in the motif S396/S400/S404, also known as the PHF-1 epitope 
(see Figure 27). Cdk-5 phosphorylates S404, thereby priming the phosphorylation of S400 and S396 
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by GSK-3β. Analysis on the short tau fragment[392-411] showed that O-GlcNAcylation of S400 
considerably reduces S396 and S404 phosphorylation by downregulating CDK5 and interrupting 
the modification cascade initiated by S404 phosphorylation. [279] 
Recently, a negative relationship between N- and O- glycosylation and O-GlcNAcylation was 
proposed, where an overall increase in O-GlcNAcylation and a lower about of glycosylation was 
observed in AD brains. A possible explanation for this observation could be an ER stress response. 
[280] 
2.4.3.3 Nitration 
Nitration can naturally occur on thiols, aldehydes, lipids and tyrosines. Nitration has not been 
investigated to the same extent as phosphorylations or glycosylation, consequently little is known 
about its physiological role. There are suggestions that nitration of cytoskeleton proteins, including 
tau, occur under normal conditions and play a role in stabilization of the cytoskeleton during 
neuronal differentiation, as demonstrated in neuronal-like, NGF-treated PC12 cells. [281] It has also 
been reported that there is an interplay between nitration and phosphorylation, where they counteract 
each other’s effects. [282] 
Nevertheless, nitration is thought to be mostly pathological. It is the result of oxidative damage, 
where an overproduction of reactive oxygen and nitrogen species cannot be compensated by 
antioxidative measures anymore. Superoxide anions and nitric oxides react with each other instead 
Figure 27: Glycosylation of S400 can reduce phosphorylation in the motif S396/400/404 by downregulated 
CDK-5 and interrupting the phosphorylation cascade leading to S396 modification. 
Figure 28: Pathways of tyrosine nitration by peroxynitrite and nitric oxide radicals. 
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and form highly reactive peroxynitrites (ONOO-), which in turn react with tyrosine result to form 3-
nitrotyrosine (3-NT), as shown in Figure 28. Horiguchi et al. was the first to develop an antibody 
that could detect 3-NT in tau aggregates from AD patients [283] and Reynolds et al. located the 
modifications primarily to the most exposed residues Y18, Y29, to a lesser extent on Y197 and 
Y394, but not on Y310, in a study with expressed tau. [284] On a different note, they reported another 
species formed by oxidation alone. Tyrosine diradicals cross-linked to form 3,3’-dityrosine 
derivatives when exposed to high peroxynitrite concentrations, which resulted in tau aggregation. 
Nitration occurred at lower peroxynitrite concentrations and could inhibit tau polymerization, but 
simultaneously also hindered tau to stabilize MTs. [285] Of the four potential tyrosine nitration sites, 
only nY197 could be detected in healthy mice brains, suggesting that this position is not only 
disease-related, but could be part of a normal regulatory mechanism. [286] 
2.4.3.4 Acetylation 
Lysine residues in tau are targets of acetylation by acetyltransferases like the CREB-binding protein 
(CBP) and p300. Similar as in the event of phosphorylation, this post-translational modification 
influences the overall net charge and can modulate tau’s structure and activity. Generally, an 
increase in acetylation leads to a decrease in phosphorylation.  
Of particular interest are acetylations in the four KXGS motifs (K259/290/321/353) in the MTBD, 
because these have been detected in transgenic and non-transgenic mice alike. [287,287] Cook et al. 
reported that pseudo-acetylations of all four Ks in these regions, where K to Q mutations mimic the 
effect of acetylations, resulted in aggregation-resistant tau species. The use of histone deacetylase 
(HDAC)6 to remove acetylations in the MTBD showed that deacetylation results in an increase of 
phosphorylation on the 12E8 epitope (pS262/356), an epitope associated with tau proteotoxicity in 
early AD stages. This effect was also tested in mice, where a reduction of (HDAC)6 activity resulted 
in an increase of phosphorylated tau. [288] Individual pseudo-acetylation of K321 could prevent the 
phosphorylation of the pathologically highly relevant S262, adding another hint that acetylation 
could be another competitive mechanism to protect the neurons from hyperphosphorylation by 
disrupting electrostatically stabilized PHF structures. [289]  
Acetylations unrelated to the KXGS motifs have shown different effects. Trzeciakiewicz et al. 
presented evidence that a dual modification of K280/281 in the MTBD impairs with MT stabilization 
and promotes tau aggregation. They suggest that dephosphorylation is a direct response to 
acetylation to balance the net charge after detecting up-regulation of phosphatase activity. In this 
particular case, the AT-8 epitope was targeted by PP2A to try, although unsuccessfully, to reactivate 
MT binding. [290] The single modification of K172 and K280 have also been connected to an increase 
in neurotoxicity and could moreover not be detected in non-AD mice. [287] Similarly, acetylation of 
K174 was detected in human AD samples by mass spectrometry and modification at this position 
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were connected to cognitive defects in mice models. [291] Pseudomimetics of acetylation at K274/281 
was also related to the destabilization of the axon initial segment, the transition between the axon 
and the somatodendritic compartment, due to a down-regulation of its controlling proteins and a 
mislocalization of tau in the somatodendritic compartment. [292] In a final note, Cohen et al. reported 
tau’s unusual activity as acetyltransferase, which would allow tau to self-regulate its acetylation 
state, at least to a certain extent, without enzymatic help. [293] 
2.4.3.5 Cysteine oxidation 
Tau only has two natural cysteines located at positions 291 and 322. They can form intramolecular 
disulfide bridges and cause structural compaction. The intramolecular disulfide bridge is preferable 
to intermolecular disulfide bridging between the C291 residues, which leads to the antiparallel 
positioning of the tau molecules and enhances PHF formation. [294] In general, there is the notion that 
aging and the accompanying higher redox potential of neurons could be a factor influencing the 
cysteines’ propensity to oxidize and that this type of tau aggregation is independent from a 
misregulation of post-translational modifications like phosphorylation and glycosylation.  
An in vitro study testing the effect of oxidative reactions like H2O2 and peroxynitrite on porcine tau 
revealed that oxidation results in the formation of disulfide protein species, which were reducible by 
TCEP. Landino et al. showed that dimerized tau loses its ability to promote microtubule 
polymerization, but did not fully lose its MT interaction properties. Furthermore, they observed an 
increase in tau oligomers, but not in aggregation, because there was no decrease of soluble tau 
observed by SDS-PAGE analysis. [295]  
More recently, the theory that cysteine oxidation leads to tau oligomer formation was taken up by 
Soeda et al., who tested the efficiency of capping cysteines to prevent the formation of toxic tau 
oligomers. 1,2-dihydrobenzene, a compound able to bypass the blood brain barrier (BBB), was 
chosen from a library of compounds and was tested in vitro and in vivo. As shown in Scheme 30, 
the compound bound covalently to the cysteines and a reduction of oligomer formation was attested, 
because it increased tau’s propensity to form β-sheets that are unable to aggregate. [296] 
  
Scheme 30: 1,2-dihydrobenzenes could cap cysteines in tau and thereby prevented the formation of disulfide 
bridges. 
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2.4.4 Tauopathies  
2.4.4.1 Discovery of tau as contributor to neurodegenerative diseases 
The first description of dementia originates from the early 20th century by the psychiatrist Aloysius 
Alzheimer, who treated a female patient with early symptoms of – what would later be named – 
Alzheimer’s disease. By silver staining her brain during the dissection he found, besides the already 
known extracellular senile plaques (SP), degenerating neurons in the cortex containing intracellular 
bundles. He named these neurofibrillary tangles, short NFTs. The use of electron microscopy opened 
new avenues for the analysis of NFTs and in 1963, Kidd et al. as well as Todd et al. described them 
as two filaments in a helix, with the narrowest point being roughly 15 nm and the widest 30 nm. 
Their structure gave them their name “paired helical filaments” (PHFs). Another minority species, 
straight filaments (SF), had a maximum width of 15 nm. [218,297] Furthermore, it was discovered that 
PHFs consisted of repeating symmetrical subunits, where each subunit has three domains. The 
stability of NFTs to heat and solubilizing agents as well as the large number of colocalized proteins 
in the tangles rendered  further analysis of the filaments difficult and consequently it took another 
20 years until the content of the NFTs was confirmed to be tau.  
Brion et al. successfully prepared antisera from tau and MAP2 proteins, which were extracted and 
purified from adult rat brains to analyze whether these microtubulin stabilizing proteins could be 
located in AD brain samples. They found that tau antisera strongly labeled NFTs and diseased 
neurites, thus establishing that tau is one of the components of NFTs. [298] The next step was the 
isolation of tau from NFTs. By preparing large fractions of purified and enriched PHFs and 
eventually solubilizing these in formic acid, a 12-kD protein could be isolated. This was not 
recognizable by existing tau antibodies and was also not responsive to PHF specific antibodies like 
MN423. Resch et al. reported that the small-molecule ligand thiazin-red was able to bind to PHFs 
and the 12-kD protein alike, suggesting that a structural similarity between the two might exist yet. 
[299] The determination of the protein sequence did not give more conclusive results, because there 
was no match with already sequenced proteins at that time. It was only when the cDNA of tau was 
sequenced and compared to a human brain library that a striking similarity to tau was determined 
and discovered to be the main component of PHFs.  
2.4.4.2 Different forms of dementia 
Every clinical syndrome is linked to a set of symptoms and deficiencies in cognition, memory and 
movement. Often the symptoms are too alike to allow for a definitive diagnosis over the type of 
tauopathy the patient suffers. The onset of disease usually occurs years after first physiological 
changes. 
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A rough classification of some common tauopathies are listed in Table 3 below:  
Class Name of tauopathy Tau repeats 
(ratio 3R:4R) 
Length of tau found in 
PHFs (kDa) 
I Frontotemporal dementia (FTD) 
Parkinsonism (linked to FTDP-17) 
Niemann-Pick type C 
Down syndrome 
Dementia pugilistica 
Alzheimer’s disease (AD) 
1:1 60, 64, 69 (minor: 72, 74) 
II Progressive supranuclear palsy (PSP) 
Corticobasal degeneration (CBD) 
Argyrophilic grain disease (AgD) 
FTDP-17 
< 64, 69 
III Pick’s disease > 60, 64 
IV Myotonic dystrophy type 1 (DM1) 1:0 60 (minor: 64, 69) 
AD is associated with forgetfulness, anomia and a reduced capability to remember objects, all while 
maintaining a fluent speech. PSP, on the other hand, is characterized by a loss in coordinated 
mobility, spine flexibility and disturbed eye movements, followed by speech impairment. CBD 
features memory dysfunction and motor abnormalities. Generally, tauopathy-related forgetfulness 
build ups in the hippocampus and the entorhinal cortex. Problems with movement arise from 
subcortical structures. [300] 
2.4.4.3 Tau in Alzheimer’s disease 
In its healthy, well-regulated state tau is highly soluble and mostly unstructured, with only little 
propensity to form secondary or tertiary structures. In AD, just like in the other tauopathies, tau 
begins to form dimers, oligomers and eventually higher polymers with a tendency to form insoluble 
aggregates like NFTs, which are considered a hallmark for AD. Throughout the disease, the 
appearance of NFTs correlates directly to neuron loss and while they spread from one neighboring 
brain region to the next, they continue to kill off neuronal cells. Eventually, neuronal death exceeds 
the number of NFTs by far, with over 50 % of all neurons dead in AD brains. [301] A second hallmark 
of AD are extracellular neuritic plaques (NPs) that consist of amyloid-β protein and that are center 
of the so-called “amyloid cascade theory” (see 2.4.4.5). 
Table 3: Tauopathies are separated into different classes that differ by the ratio of 3R:4R tau. 
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An accepted categorization for the analysis of AD progression is the Braak staging system, which 
consists of six stages and connects the symptoms to the spread of the disease. [302] The outbreak of 
the disease, corresponding to stages I and II, starts in the brain stem and then spreads slowly into the 
transentorhinal cortex and the hippocampus of the temporal lobe. First visual signs are first memory 
impairments of recent events and in some cases first cases of disorientation. This is followed by the 
spread of the disease to the frontal, parietal and occipital lobe, referred to as stages III and IV, 
resulting in an increasingly diminishing vocabulary, growing disorientation and problems with 
concentration and understanding. In the final stages V and VI, the disease has reached the motor and 
primary sensory neurons in the neocortex and the patients displays strong motor deficiencies and 
recognition problems. Interestingly, there is a direct correlation between the progression of AD 
symptoms and the amount and distribution of NFTs in the neurons.  
2.4.4.4 Causes for tau aggregation  
With the knowledge in hand that NFTs contain mostly tau protein, research has been intensified to 
find out the causes of aggregation. By now, it seems clear that several factors are responsible for the 
behavioral change in tau: (1) Specific mutations in the tau protein sequence leads to a reduction or 
complete loss of tau binding affinity to MTs and can increase their propensity to aggregate, (2) 
hyperphosphorylation results in an equal loss of binding affinity, because of the change in net charge 
and (3) the tau protein is target of proteolytic activity that produces short, and very toxic tau 
fragments. Perhaps one of the most striking discoveries has been tau’s ability to aggregate despite 
no evident changes in post-translational modifications, but based on proteolytic cleavage alone. 
2.4.4.4.1 Gene mutations 
Over 80 mutations have so far been discovered in the tau protein. These are changes that either 
influence the tau primary sequence and thereby reduce MT binding affinity or alter the complex 
splicing mechanism and change the equilibrium between the tau isoforms. However, none of these 
mutations have so far been identified in AD.  
Figure 29: AD progression, as defined by Braak et al., gradually spreads from the transentorhinal regions 
and the hippocampus in the temporal lobe (stages I and II) to the frontal, parietal and occipital lobe (stages 
III and IV). 
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Instead, they are associated with Parkinsonism linked to chromosome 17 (FTDP-17). Here, these 
mutations change the ratio between 3R and 4R tau, with the expression tilting towards the less affine 
MT binder 3R. This leaves more unbound tau in the cytoplasm that can be targeted by 
phosphorylation. This suggests that a different kind of initiator is needed for the unwanted tau 
behavior in AD.  
2.4.4.4.2 Truncation  
The 12-kDa tau fragment originally isolated from PHFs consisted of 93-95 amino acids and 
contained three repeats. Further analysis confirmed that it had an overhang of 15 amino acids at the 
end of the repeats and stopped at E391. It consequently lacked the flexible C-terminal tail. 
Analogously the protein only started 15 amino acid before the repeats, so the entire N-terminal part 
was missing as well. [303] 
This minimal core is created by continuous cleavages until it has reached a form in which dimer 
formation is kinetically favored, because the binding affinity to each other is higher than that to 
tubulin. Once it has dimerized, it can no longer be targeted by proteases. The dangerous 
characteristics of this short protease-stable tau fragment were revealed by Wischek et al. in 1996. 
[304] While still performed in vitro and therefore only serving as an indication that the same 
phenomenon could occur in live organisms, they demonstrated that full-length tau can form dimers 
with tau lacking the C-terminus after Ala390. Furthermore, through repetitive digestion cycles with 
the protease pronase and the addition of fresh full-length tau protein, it was shown that the N- and 
C- termini were continuously cleaved, whereas the core region remained stable in its growing 
oligomer structure. This was the first evidence that low concentrations of toxic tau can seed and 
propagate oligomer formation, which reminds a lot of prion-like recruitment processes. Transferring 
this knowledge into cells proved difficult, because overexpression of truncated tau resulted in high 
cell cytotoxicity. Harrington et al. were finally able to develop a novel fibroblast cell line that could 
express the truncated form of tau at the ER in low levels. By co-transfecting this cell line with the 
full-length 4R tau, they were able to confirm that the propagation mechanism shown in vitro also 
applied to in vivo models. In this model, tau did not bind to MTs, but was immediately referred to 
the truncation and aggregation pathway without the involvement of hyperphosphorylation. [305] 
2.4.4.4.3 Hyperphosphorylation 
Hyperphosphorylated tau is extensively modified and contains about three times the number of 
phosphorylations as normal tau. Highly phosphorylated tau breaks up the transient and only semi-
stable secondary structures and facilitates the formation of β-sheets in the MTBD, while the N- and 
C-terminal regions of the protein are not involved in the oligomerization. Instead, their physiological 
role seems to be the prevention of such aggregation. The oligomerization eventually results in the 
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formation of insoluble NFTs that deposit in the soma and in lower concentrations also in the neurites. 
Despite the widespread formation of NFTs, about 40 % of the hyperphosphorylated tau remains 
soluble.  
Hyperphosphorylated tau does not only prevent tau from promoting MT assembly, but it also 
disrupts microtubules by extracting tau from already polymerized tubulin due to its superior binding 
affinity in comparison to tubulin. [306] The oligomerization between normal tau and 
hyperphosphorylated tau leads to the formation of the characteristic SFs observed in AD pathology. 
This effect is reversible by dephosphorylation, which does not occur in developing tauopathies. [307] 
While tau plays an important role in the assembly and stability of microtubules, other MAPs can 
compensate, at least to a certain extent, for tau’s role in tau KO mice. An interesting question is 
therefore why MAPs do not replace tau once it becomes hyperphosphorylated. An investigation by 
Alonso et al. revealed that hyperphosphorylated tau can also sequester MAP protein from MTs. [308]  
The amount of functional tau is decreased by about 35 % in AD patients compared to healthy 
individuals. [306] More strikingly, the total amount of tau is four to eight times higher than normal. 
The level of mRNA expression meanwhile remains steady during AD progression, so the reason for 
the rise in tau levels likely lies in a decline of tau turnover rates. The two pathways of degradation, 
autophagy or ubiquitinoylation, fail to keep tau at normal levels. In fact, polyubiquitylated proteins 
are found in NFTs, suggesting that ubiquitinylation itself is not so much affected, but the rate of 
clearance is too slow in comparison to the aggregation process. [309] It was furthermore suggested 
that hyperphosphorylation could have an inhibitory effect on proteasome degradation activity. The 
inactivation of proteasome degradation is associated with an overall increase of phosphorylation, 
although the two sites S214 and T231 were largely unphosphorylated. This was explained with 
increased activity of JNK phosphatase upon protease deactivation. [310] Additionally, it was 
suggested that CHIP-mediated ubiquitylation of tau is downregulated. [311] 
With the high abundance of phosphorylation sites in tau, it is still largely unknown which 
phosphorylation sites are part of natural regulatory mechanisms and which ones belong to AD 
relevant pathology. A set of antibodies against specific phosphorylation patterns have been 
generated to help detect epitopes in AD brains and serve as immunomarkers. The epitopes AT-8 
(pS202/pT205/pS208), AT-100 (pT212/pS214) and PHF-1 (S396/S404) are associated with 
hyperphosphorylation and neurodegeneration. Epitope AT-100, linked to chromatin changes in 
neurodegenerative neurons, is featured in nuclear tau of neuronal and non-neuronal cells and its 
presence increases with age. [312] S214, itself a AGC phosphorylation site, was further shown to 
promote phosphorylation by GSK-3 at other phosphorylation sites. [267] The AT-8 epitope, until 
recently believed to consist of only two phosphorylation sites at S202 and T205, is commonly used 
to verify the progression of AD postmortem. Up until now, a closer investigation of the epitope’s 
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role in aggregation was also hindered by the difficulty of achieving a full phosphorylation of S208. 
To solve this issue, Despres et al. have shown that S208 can be phosphorylated by rat brain extract 
in a set of NMR experiments and that the full AT-8 epitope causes tau aggregation within four days 
without the usual addition of poly-anion polymerization inducers like heparin. [313]  
The PHF-1 antibody recognizes S396 and S404 [314] in early tau inclusions. Phosphorylation at this 
epitope occurs early on in tau pathology, even before any conformational changes are observed, and 
about 50% of all early phosphorylated tau aggregates show this modification. The epitope becomes 
increasingly phosphorylated during the progression of disease and could be a precursor to other toxic 
forms, like C-terminal cleavage. The epitope might be particularly susceptible to modification, 
because it is located at an exposed location in the C-terminus. [315] Interestingly, S400 is a known 
site of glycosylation and influences the post-translational modifications on the residues surrounding 
it.    
A recent study by Morris et al. took a closer look at post-translational modification patterns of tau 
in wild-type and human APP transgenic mice. [287] The use of mass spectrometry allowed them to 
detect even small amounts of modification and to compare the degree of their occurrence in the two 
mouse types. They were able to detect 63 modifications, out of which 22 were previously unreported 
and involved largely neglected alterations to lysine and arginine residues. The phosphorylation sites 
were mainly located in the MTBD and to a smaller extent the C-terminus. Similarly, lysine 
modifications were accumulative in the MTBD and featured mostly ubiquitinylation as well as 
acetylation, which suggests a competitive relationship between the two post-translational 
modifications. The comparison between the two mouse types revealed a high similarity in 
modification sites and only nine additional modifications, mainly phosphorylation sites, were 
present in APP transgenic mice. It has to be noted that none of them occurred in large abundance. 
Interestingly, no tau that was simultaneously modified by acetylation and phosphorylation were 
found, suggesting another close antagonistic interplay. Overall, this suggests a tighter tau regulation 
than previously anticipated and opens more questions about the start of hyperphosphorylation. 
In conclusion, it can be said with certainty that hyperphosphorylation leads to a change in secondary 
structure that no longer permits it to bind to microtubules as a stabilizing agent and instead promotes 
the removal of normal tau and MAPs from polymerized tubulin. Consequently, it influences the 
neuronal plasticity and signal transmission and leads to memory malfunctions. Furthermore, it 
manages to evade cellular regulatory mechanisms that would manage its removal from the cytoplasm 
and stays in solution. The failure in removal is, perhaps, the most troublesome of its properties, 
because its presence acts as a seed and promotes the conversion of other, still “intact” tau molecules 
into prions and, eventually, aggregates. 
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2.4.4.4.4 Prion-like mechanisms 
Prions are trigger proteins that can initiate wrong protein folding. A “seed”, or misfolded protein, 
has the capability to force other correctly folded proteins to change shape and aggregate with the 
seed. This lump of badly folded proteins will increase with size first and, once it has reached a certain 
size, will break into smaller pieces. The smaller fragment can in turn promote more protein 
misfolding and spread the pathology at an exponentially growing speed. Filaments represent the 
stable end of aggregation. [316] 
It remains up to discussion in which form tau is most toxic. The misfolded tau species serving as a 
seed adapt a β-sheet structure and tau prion formation proceeds through a dimer stage [317], then 
continues to oligomers. NFTs represent the end stage of tau aggregation and have consequently been 
heavily investigated as prime toxic species. This revealed that cells containing NFTs struggle with 
protein imbalances of synaptic and calcium binding proteins [318], that NFTs lead to the activation of 
caspase pathways and cause morphological changes in neurons. [319]  
There is mounting evidence that the role of NFTs is not as straightforward as assumed at first. Data 
has emerged where NFTs were not direct influencers of post-synaptic signaling or influence genes 
in memory generation. [320] Furthermore, when comparing NFT-positive and NFT-negative cells 
from P301L mice models, all cells displayed morphological changes like reduced dendritic 
complexity, shorter axons and a depolarized resting membrane potential, regardless of whether 
NFTs were present or not. [321] Instead, they might be a way to remove more toxic, soluble tau 
oligomers from solution. Hsp-70 recognizes tau oligomers, not aggregates, and was thereby able to 
reverse the inhibitory effect of tau oligomers on anterograde axonal transport. This could suggest 
that the soluble form is more toxic to the cell than the aggregate. [322] Other studies provide evidence 
that the pre-tangle stage, in which tau has already undergone a certain degree of faulty 
phosphorylation and conformational changes, is enough to cause pathological effects. [323] Lasagna-
Reeves et al. furthermore showed that injection of tau oligomers into wild-type mice induced 
Figure 30: Tau seeding to form dimers and oligomers, then to PHFs which group together to NFTs. The 
oligomers transfer to other cells by 1) macropinocytosis, 2) clathrin-mediated endocytosis and 3) exosomes. 
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synaptic and mitochondrial dysfunction and negatively affected memory formation, while none of 
these effects were observed for tau monomers or fibrils. [324]  
Mitochondria take on an important role in the development of the disease. Due to the demand of 
synaptic plasticity of the neurons, mitochondria are needed in the soma and the dendrites to act as 
energy supply. It has been reported that fast axonal transport is impaired upon tau oligomerization, 
either by directly competing with mitochondria as cargo or by disrupting the binding to the kinesin 
motor needed for the transport along the microtubules. Other disrupted functions by tau oligomers, 
but not NFTs, are calcium regulation and membrane integrity. They might be connected to each 
other, since broken membranes can lead to an unwanted influx of calcium ions. Furthermore, 
impairment of the NMDA receptor lead to problems in maintaining stable calcium levels. [325] De 
Calignon et al. argued that NFT-tangles containing neurons survive longer than one would expect. 
[326] 
One of the reasons tau was not accepted as a prion protein for several years, despite its propensity 
to induce protein aggregation, was the lack of evidence for a cell-to-cell propagation. Today, though, 
it has been shown that tau aggregates can be transferred in vitro and in vivo. Frost et al. were able to 
show that tau oligomers can be taken up into cells from the extracellular space and proceed to act as 
seed in the infected cell. [327] Iba et al. demonstrated that injected synthetic preformed tau tangles in 
mice overexpressing P301S mutated human tau could propagate from cell to cell. The spreading tau 
aggregates all resembled NFTs more than tau monomers or small oligomers, because they showed 
a high resistance to protease treatment and could be labelled by the NFT specific thioflavin stain. 
[328] The exact pathway has not been elucidated so far. The size of the tau oligomer seems to play a 
significant role in determining which transportation pathway is chosen. For tau monomers and small 
oligomers, clathrin-mediated endocytosis seems to be method of choice, while larger oligomers are 
transported by macropinocytosis after binding extracellularly to heparin.  
2.4.4.5 The alternative amyloid-β cascade theory  
When discussing protein activity in AD, amyloid-β (Aβ) is mentioned in one breath with tau. Before 
tau’s relevance in AD increased, the small protein held a dominating role in research about onset 
and progression of AD for almost two decades.  
Besides the intracellular NFTs, the extracellular room in AD brains is covered with NPs, which are 
often at the center of accumulated microglial cells and astrocytes. Interestingly, these precede tau 
tangle formation. NPs are composed of Aβ, a protein of either 40 or 42 amino acids length and 
derived from the amyloid precursor protein gene (APP) located on chromosome 21. APP is cleaved 
by β-secretase, a APP cleaving enzyme, and ƴ-secretase, a multiprotein complex consisting of a 
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minimum of four proteins (nicastrin, anterior pharynx-defective 1, presenilin, presenilin enhancer 2) 
to generate Aβ.  
After the discovery of the missense “London” mutation on APP and its connection to sporadic AD, 
the amyloid cascade hypothesis was published by Hardy et al. in 1992. [329] Today, the theory is split 
into two parts, dealing on one hand with inherited forms of AD, on the other with sporadic AD cases. 
Missense mutations in the APP or presenilin 1 or 2 genes result in a relative increase of Aβ42 over 
Aβ40. Up to date, over 200 mutations in the involved genes have been identified and linked to faulty 
APP processing. The increased concentration of Aβ42 causes its accumulation and oligomerization 
in the cortex and harms synaptic transmission. Microglial and astrocytic cells are activated to tend 
to inflammatory responses to Aβ deposits, consequently increasing oxidative stress, confusing 
neuronal ionic homeostasis and driving astrocytosis. The outcome is the misregulation of kinases 
and phosphatases, the formation of tau-containing NFTs, synaptic dysfunction and neuronal loss. 
According to the theory, non-genetic forms of AD, which make up 90 % of all AD cases, arise 
mainly, although not solely, from a failure of Aβ clearance. Mutations in the gene of apolipoprotein 
E (ApoE), a mediator of cholesterol metabolism and transport, and other lipid transporters have been 
found that influence this process. A faulty Aβ degradation is also responsible for rising Aβ42 levels 
in the brain, which will go through the same event cascade as already described above. [330] 
Doubts have been raised over whether the role of Aβ in AD development is exaggerated or not. No 
clear relationship between AD progression, the expression of Aβ and the formation of neuritic 
plaques have been identified. While neuritic plaques are a pathological hallmark of AD, the 
increasingly severe symptoms cannot be correlated to an equally significant increase in Aβ or 
neuritic plaques. Nevertheless, NPs can clearly influence signaling events that can induce neuronal 
dysfunction and there doesn’t necessarily have to be a correlation in number to have negative effects. 
Furthermore, the absence of NPs in some neuropathological studies does not preclude the lack of 
Aβ oligomers, which have been shown to damage synaptic structure and function.  
There are many plausible reasons for the involvement of Aβ in AD. Despite this, it becomes clear 
that Aβ cannot be the only agent to induce AD. It is therefore interesting to look at the connection 
between tau and Aβ. Jin et al. showed in a set of experiments in primary hippocampal neurons that 
injection of Aβ dimers results in cytoskeletal abnormalities that are dependent on tau expression. 
Furthermore, they observed that tau hyperphosphorylation was induced by the addition of Aβ 
dimers. These effects could be reversed by treating the cells with an Aβ antibody, suggesting that 
Aβ is an initiator of AD. [331] This confirmed earlier experiments demonstrating that P301L mutant 
mice infected with Aβ42 fibrils showed five times more NFT aggregates than non-infected mice and 
that mice cross-overs of species overexpressing Aβ and tau P301L respectively showed enhanced 
NFT formation. [332]  
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With this evidence in hand, it cannot be denied that Aβ is an important factor in the early 
development of AD. The exact reason for NP formation remains to be studied. Genetic factors only 
explain about 10 % of all AD cases and the dysregulation of Aβ in sporadic AD is still not well 
understood, although recent finding about ApoE and the oxidative stress induced by microglia 
suggest that cholesterol metabolism and the innate immune system are affected by Aβ. It should be 
noted that the superior toxicity of tau is evident, also in the absence of Aβ, as seen in other 
tauopathies that are not co-characterized by Aβ toxicity. Targeting tau in disease is only possible 
when mechanisms of toxicity are studied further and toxicity-driving pathways are identified. A 
success will not only help AD patients, but also serve all people suffering from tauopathy-induced 
dementia. 
2.4.5 Different approaches to study tau hyperphosphorylation 
Hyperphosphorylation of tau is undeniably involved in the propagation of AD, because it affects the 
binding affinity to microtubules and can act as seed for tau prion formation. All tau aggregates 
contain hyperphosphorylated tau, a common attribute of all tauopathies, and reversal of 
phosphorylation by the addition of phosphatases can resolubilize the aggregates. With this 
information in hand, one of the prime questions remaining is how the regulation of phosphorylation 
fails and how hyperphosphorylation of specific residues promote aggregation. As previously 
described, a connection between phosphorylation patterns has been described. Individual or groups 
of phosphorylations can either change tau’s structure to expose more phosphorylation sites or they 
can prime further modifications. To develop effective, and selective, treatments against tauopathies, 
perhaps even at early stages, and to combat the loss of kinase control, it is essential to identify the 
most important phosphorylation sites, find the responsible kinase for this modification and then work 
out a strategy to suppress this mechanism. 
Different state-of-the-art approaches have been used to address this problem, which will be briefly 
discussed, before a less precedented methodology in the study of tau proteins will be introduced. 
2.4.5.1 Tau is often not studied as full-length protein 
The longest isoform of tau is 441 amino acids long, highly flexible and, once hyperphosphorylated, 
difficult to handle. Additionally, aggregation of full-length tau is slow and delivers low yields. To 
overcome these issues, shorter tau fragments are often used in in vitro experiments. The effect of 
some kinases and phosphatases, for example, have been tested on the tau fragments K18 and K19. 
[333] K18 consists only of the R1 to R4 regions, so includes residues 244 to 372, while K19 is even 
shorter with repeats R1, R3 and R4 only. Both contain the critical hexapeptides 275VQIINK280 and 
306VQIVYK311 that have been identified as essential for aggregation and both fragments are able to 
form filaments and aggregates. Other variants are being used for structural analysis by NMR and for 
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electron microscopy analysis include the F4 (residues 208-324) or the newer F8 (residues 192-324) 
fragment. 
While using shorter variants makes their handling and analysis easier, especially when using fine 
techniques such as NMR which deliver notoriously broad signals due to the disordered structure of 
tau, it cannot be excluded that the deletion of the C- and N-termini influence their aggregation 
behavior, their biological reactivity and their effect on other involved proteins like enzymes. As 
demonstrated by Fitzpatrick et al., the K18 and K19 fragments, although able to aggregate by 
themselves, do not cover the C-shaped core region of naturally occurring PHF and SF in AD brains, 
questioning their use in aggregation experiments. [220] Furthermore, the large variety of differently 
sized fragments makes a comparison between them tricky and transferring knowledge from one to 
the other might be difficult. 
2.4.5.2 Pseudophosphorylation is employed to mimic phosphorylation 
Introducing phosphorylations, or other modifications, site-specifically into full-length proteins is a 
biochemical challenge. One method to address this issue is called pseudophosphorylation, where the 
site of phosphorylation is replaced by a glutamic or aspartic acid to mimic the negative charge of 
the phosphate, albeit the phosphate carries two negative charges, not one. The principle behind this 
approach is based on the idea that the addition of a negative charge is responsible for the altered 
behavior of tau. This approach is convenient, because it can be easily achieved at molecular level 
and several “modifications” can be introduced into the same protein. The electrophoretic mobility, 
which allows a comparison of size and electronics, of an additional Glu or Asp and a phosphate is 
similar. Furthermore, some studies have shown that pseudophosphorylation and phosphorylation 
have induced similar structural and aggregation properties in tau’s behavior. [334] These results 
should be treated with caution, since enzyme-induced phosphorylation is often not suitable to 
reproduce site-specific and quantitative patterns. It has recently been pointed out that the salt bridges 
formed between phosphate and Lys residues are stronger than between Glu/Asp and Lys, so 
structural transitions in phosphorylated proteins are likely to proceed slower than in their 
pseudophosphorylated counterparts. [335] Overall, they are expected to yield similar structural 
changes.  
2.4.5.3 Enzymatic phosphorylation cannot generate specific and quantitative patterns 
Numerous kinases and phosphatases are involved in the regulation of tau phosphorylation. Their 
manner of phosphorylation is tightly regulated by co-factors and by pre-installed post-translational 
modifications and up to this date, it is not known which sites are phosphorylated by which kinase. 
Employing them in an experimental setup is therefore difficult, also because we do not have the 
same control over their activity as the cell does. While it is possible to predict phosphorylation 
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patterns by now, the degree of phosphorylation they induce on each residue can vary between 
experiments. The efficiency of enzymes depends on their expression, purification and storage, as 
well as on the quality of their template. Furthermore, specific phosphorylations are difficult to 
induce, especially if the aim is the modification of one or two residues only, because the interplay 
between kinases and phosphatases is not fully understood. One way to achieve specific patterns is 
to choose an enzyme which is known to modify the site of interest and then mutate out the remaining 
phosphorylation sites in the protein it could potentially label as well. Serine and threonines are 
usually replaced by alanine residues and tyrosines are substituted by phenylalanines. Needless to 
say, these replacements can potentially change the characteristics of the protein and need to be 
investigated in detail for discrepancies. Despite of all these weaknesses, enzymatic phosphorylation 
remains the most used phosphorylation methodology. 
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2.4.5.4 Site-specific modifications by protein semi-synthesis 
Protein semi-synthesis can be used to insert site-specific modifications into complex biomolecules. 
In comparison to the biochemical routes of modification, protein semi-synthesis can deliver the full-
length, natural protein in a homogenous fashion with a minimum number of mutations.  
This approach was already successfully used by Hackenberger and co-workers to introduce site-
specific phosphorylations and O-GlcNAcylations within the PHF-1 epitope (S396/S400/S404) at the 
C-terminus of the tau protein. In the first published semi-synthesis of this protein in 2012, Broncel 
et al. delivered a homogeneously phosphorylated tau at S404. [336] The ligation strategy is shown in 
Figure 31. The protein was generated by EPL between a recombinant protein thioester Tau[1-389] 
derived from the IMPACT system and a 52-aa long synthetic peptide Tau[390-441] featuring pS404 
and a biotinylated lysine bK438. The ligation site contained a Ala390Cys mutation, which was 
shown to have no effect on the aggregation behavior with a mutated recombinantly expressed 
protein. The ligated protein was first purified from the excess of peptide by spin-filtration and then 
passed over avidin beads to immobilize the ligated protein and wash off any unreacted Tau[1-389]. 
The protein was analyzed by WB with a pS404-specific antibody and biochemical assays shows that 
a single phosphorylation at S404 does not have any effect on the tubulin polymerization behavior.  
To further minimize the number of mutations in the final construct, Reimann et al. published a 
purification protocol based on a tracelessly photo-cleavable biotin tag attached to K438. [95] After 
ligation, the protein was immobilized on streptavidin beads and was then desulfurized while still 
attached to the solid support, which allowed the easy and straight-forward removal of all impurities 
from the ligation and the desulfurization process. The protein was then released by irradiation at 297 
nm for 10 mins. It therefore served two purposes at once – it enabled a facile desulfurization process 
and avoided the previous Ala390Cys mutation and also left no remains of a purification tag behind.  
Figure 31: The semi-synthetic scheme of first EPL to generate a tau protein with a single site-specific 
phosphorylation at S404. Tau[1-389] was expressed as intein fusion protein and immobilized on chitin beads. 
The protein was then ligated on beads with Tau[Cys390-441] to yield the homogenously modified full-length 
tau protein. 
INTRODUCTION 
 
86 
 
The same purification strategy was then used by Schwagerus et al. in the semi-synthesis of a tau 
protein featuring a O-GlcNAcylation at S400. [337] While the EPL site remained unchanged, the 52-
aa tau peptide was assembled by NCL between Tau[Cys426-441], which contained the tracelessly 
photo-cleavable biotin tag at K438, and Tau[Cys390-425]-Dbz(Me) featuring the O-GlcNAcylation 
at S400. After EPL with the expressed Tau[1-389] thioester and spin-filtration to remove the excess 
of peptide, the EPL mixture was once again immobilized on streptavidin beads and elution by 
irradiation resulted in the release of the pure full-length protein. This was confirmed by SDS-PAGE 
and MALDI-MS. The same ligation procedure was used for the generation of 13C/15N-labelled tau 
protein by ligating the synthetic peptide with isotopically labelled Tau[1-389] thioester. 
Lashuel’s group recently published a versatile tau semi-synthetic scheme that allows to incorporate 
modifications into the C-terminal region of tau, reaching from residue 246 to 441. [338] This includes 
MTBD and the C-terminal tail, which play important parts in the formation of NFTs during the 
development of AD. This strategy is therefore highly valuable to explore the effects of modifications 
like phosphorylation, acetylation, nitration and glycosylation in this region. In their study, Haj-
Yahya et al. demonstrated the value of their strategy by exploring the effect of K280 acetylation on 
the structure and function of tau. They found that acK280 increases the aggregation, has a negative 
influence on the binding affinity of tau to microtubules and promotes the formation of toxic 
oligomers. While most of these results are in agreement with the current literature, the authors 
remark that the formation of oligomers was more pronounced in their semi-synthetic acK280 tau 
than in previous studies, where K280Q mimics were used to study the polymerization behavior. This 
Scheme 31: Hal-Yahya et al. published a tau semi-synthesis that allows to introduce modifications into the 
C-terminal part of tau (from residue 246 to 441) encompassing the MTBD and the C-terminal tail.  
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highlights the need for semi-synthetic protein ligation strategies to investigate the effect of post-
translational modifications on the structure and function.  
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3 Objectives 
3.1 Project 1: The development of a photo-cleavable phosphonamidate tag 
The increasing demand for cleavable tags in chemical biology has led to the development of several 
methodologies that allow for a spatiotemporal release of a modification from a biomolecule and they 
have been successfully applied in proteomics, molecular imaging and affinity purification (see chapter 
2.2.1). One of the mildest cleavage conditions available up to date relies on the use of UV light, because 
it advances at reasonable speeds in mild buffers and it requires a very specific impulse to proceed. The 
cleavable tags are mostly incorporated into the target of interest via additional reactive handles like 
NHS-esters, maleimides or azides and alkynes, addressing lysines, cysteines and alkyne- or azide-
functionalized biomolecules respectively. Despite the recent advances in the field, the tags often suffer 
from unspecific release and exchange reactions involving the cleavable moiety as well as the additional 
handle through which it is attached to the target. Furthermore, the cleavage is often not traceless, 
resulting in a modified target of interest, which can result in undesired side effects in the target’s 
structure and in its analysis. In consequence, there is still a need for an easy-to-incorporate cleavable 
tag that is traceless upon release and does not suffer from pre-mature cleavage under physiologically 
relevant conditions. 
The aim of this project was therefore the development of a novel, photo-cleavable tag which can be 
incorporated into biomolecules with high specificity and permit a traceless cleavage to release an 
unmodified target of interest. Furthermore, the tag’s versatility was to be ensured by the design of a 
easily-modifiable core structure that can be equipped various functional modules like, for example, 
fluorophores and affinity tags without increasing the complexity of the synthesis.  
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3.2 Project 2: Towards the semi-synthesis of tau proteins modified in the 
proline-rich domain 
As described in chapter 2.4.4.3, the usually highly soluble tau protein forms neurofibrillary tangles of 
aggregated, hyperphosphorylated protein during the outbreak of Alzheimer’s disease. The elucidation 
of the mechanisms leading to the misbehavior of tau could provide valuable insights for the development 
of effective medication to combat this disease. Several interesting phosphorylation epitopes that are 
associated with the outbreak of Alzheimer’s disease are located within the proline-rich domain of tau 
(see chapter 2.4.4.4.3), which is positioned in the middle of the protein.  
Biochemical approaches to study hyperphosphorylation rely on the use of enzymes, which yield 
mixtures of heterogeneously modified tau proteins, as well as on pseudophosphorylation and protein 
mutations, which can only serve as approximation to phosphorylation (for more see chapter 2.4.5). To 
circumvent these issues, this part of the thesis aims to use protein semi-synthesis (see chapter 2.3.2) to 
design a reliable strategy to incorporate specific post-translational modifications within the proline-rich 
domain of tau with adding as little additional mutations as possible. This builds up on previously 
published protein semi-synthetic strategies to obtain C-terminally modified tau proteins (see chapter 
2.4.5.4) and aims to expand the range of residues that can already be addressed by these existing 
methodologies. [95,336–338] 
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4 Results and Discussion 
4.1 Development of photo-cleavable triazole-phosphonamidate conjugates 
The design of the novel phosphonamidate-based photo-cleavable tag aimed to provide a versatile azido-
reactive core structure that permitted a straight-forward and reversible functionalization of any azido-
containing molecule with, for example, affinity tags, fluorophores or PEG units. Scheme 32 illustrates 
the proposed core structure of the tag and shows its application as a removable biotin affinity tag.  
 
Scheme 32: An overview of a traceless photo-cleavable biotin tag for the chemoselective incorporation into an 
azido-containing molecule. The design commences from core structure 1, a borane-protected P(III) species with 
one alkyne and two photo-cleavable 2-nitrobenzyl alcohol substituents. Functionalization of 1 by CuAAC with 
an azido molecule, here illustrated by biotin azide, yields triazole-phosphonite 2. Next, triazole-phosphonite 2 is 
borane-deprotected and reacted with an azido-containing target molecule 3 to yield phosphonamidate 4, ready for 
immobilization on streptavidin coated beads. Upon irradiation at 297 nm, 2-nitrosobenzaldehyde is cleaved and 
phosphonamidate acid 5 is formed. Due an increase in P-N bond lability, it will cleave readily and amine 6 is 
released from the solid support. 
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The borane-protected core structure 1 features two photocleavable 2-nitrobenzyl alcohol substituents 
and one alkyne for functionalization with biotin azide (or any other azide) by a CuAAC reaction to yield 
borane-protected triazole-phosphonamidate 2. The borane group ensured the stability of the central 
building block to make it storable and unreactive towards oxidation and hydrolysis. When used in a 
reaction, 2 is borane-deprotected and then attached to the azido moiety of target molecule 3 in a 
Staudinger-phosphonite ligation to form phosphonamidate conjugate 4. The biotin tag of conjugate 4 
can now be used to immobilize the phosphonamidate on streptavidin beads. Once immobilized, bead 
irradiation cleaves the 2-nitrobenzyl alcohol to generate phosphonamidate acid 5. Unlike 4, the P-N 
bond is labile to mild acidic hydrolysis and easily cleavable to release the final molecule 6 as an amine 
with no trace of the tag.  
4.1.1 Synthesis of core structure 1 
Two principle synthesis routes could be envisioned for the synthesis of alkyne-phosphonite 1, both of 
which are outlined in Scheme 33. The first route uses trichlorophosphine as starting material and relies 
on the step-wise substitution of the chlorides. 2-nitrobenzyl alcohols are introduced to the phosphorus 
first, followed by a Grignard reaction for the addition of the alkyne moiety (Scheme 33, Route 1). The 
second route commences with bis(diisopropylamino)chlorophosphine. Here, the substitution is reversed 
and the alkyne is added first, followed by the introduction of the alcohols (Scheme 33, Route 2).  
Route 1 had previously been employed for the synthesis of hexaethylene glycol substituted alkyne-
phosphonites. [47] Trichlorophosphine 7 was initially reacted with 2 eq. of 2-nitrobenzyl alcohol and 
2 eq. of triethylamine at -78 °C in a mixture of toluene and THF. The reaction was monitored by 31P-
NMR and the progress was estimated by comparing the integral area of each phosphorus peak. Unlike 
in previous syntheses, this procedure did not yield the expected disubstituted bis(2-
nitrobenzyl)chlorophosphine 8 as main product. Instead, the monosubstituted dichloro(2-
nitrobenzyl)phosphine was the predominant phosphorus species formed during the reaction. This result 
Scheme 33: Two synthesis routes can be used to obtain core 1, either starting from PCl3 (route 1) or from 
bis(diisopropylamino)chlorophosphine (route 2). Reaction conditions: a: 2-nitrobenzyl alcohol (2.5 eq.), 
Et3N (2.25 eq.), THF/Tol, o.n., -78 °C to RT; b: ethynylmagnesium bromide (1.5 eq.), THF, 2 hrs, -78 °C to RT; 
c: ethynylmagnesium bromide (1 eq.), THF, 2 hrs, 0°C to RT; d: 2-nitrobenzylalcohol (2.5 eq.), 
tetrazole (6.4 eq.), MeCN, 2 hrs, 0 °C to RT; e: BH3.THF (1.5 eq.), THF, 2 hrs, 0 °C to RT.  
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was rationalized by the reduced nucleophilicity of the 2-nitrobenzyl alcohol in comparison to previously 
used hexaethylene glycol alcohols in this step. The reaction was optimized by using 3 eq. of 2-
nitrobenzyl alcohol and 2.5 eq. of triethylamine and the reaction time was increased to 16 hrs. This 
yielded phosphine 8 as predominant product. Despite it being the predominant product (70 % as 
estimated by 31P-NMR), the formation of mono- (10 %) and trisubstituted (20 %) phosphine could not 
be fully avoided. The subsequent Grignard reaction with ethynylmagnesium bromide was performed 
for 2 hrs at -78 °C, followed by borane protection with BH3.THF. The final compound 1 was isolated 
by silica gel column chromatography at 40 % yield.  
Route 2 has already proven valuable in the synthesis of some bis(alkenyl) ethynyl-phosphonates in the 
past. [339] Instead of trichlorophosphine, it uses bis(diisopropylamino)chlorophosphine 10 as starting 
material. Unlike with route 1, the two different substituents at the phosphorus atom could be replaced 
by alternative chemistries, thereby securing a fixed substitution pattern. The chloride was first 
substituted with an alkyne by a Grignard reaction, yielding compound 11 is quantitative yield (as 
estimated by 31P-NMR). The replacement of the two diisopropylamino substituents was effectuated by 
reaction 2.5 eq. of 2-nitrobenzyl alcohol and 6.4 eq. of fresh tetrazole at RT. After borane protection, 
the final core compound 1 could be isolated in a good yield of 65% over three steps. Thanks to its 
superior yield and easier handling, route 2 became the procedure of choice for the synthesis of core 
structure 1. 
4.1.2 Functionalization of core structure 1 by CuAAC 
Having established a reliable synthetic route for core structure 1, its modification by CuAAC was 
investigated. As test substrate, the simple small molecule azide 12a was chosen and reacted in a set of 
different reaction conditions, with varying copper catalysts, additives and solvents. The conversion to 
13a was analyzed by 31P-NMR, where the broad signal of 1 was shifted significantly from 108 ppm to 
123 ppm upon the formation of 13a. The results are summarized in Table 4. Surprisingly, the most 
commonly used combination of catalyst CuSO4 with the reduction agent sodium ascorbate and 
stabilizing reagent tris-(hydroxypropyltriazolylmethyl) amine (THPTA), only resulted low conversions 
(Table 5, entry 1). Instead, borane deprotection and subsequent hydrolysis and oxidation were observed. 
Although often discouraged to use because of low stability, better conversions were achieved by 
employing Cu(I) salts. The use of base was detrimental to the success of the reaction (Table 4, entries 2 
and 4), because the lack of an internal base, like for example from the solvent, hindered the release of 
the final compound from the copper catalyst at the end of the catalytic cycle. [49] 
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# Copper catalyst Additive Solvent Conversion to 13a 
1 CuSO4 Na ascorbate DMF 30 
2a [Cu(MeCN)4]PF6 - THF 40 
3a CuBr(PPh3)3 - MeCN 30 
4b [Cu(MeCN)4]PF6 2,6-lutidine MeCN >95 
5b CuI DIPEA 
AcOH 
MeCN >95 
6b CuI 2,6-lutidine 
DIPEA 
MeCN >95 
7 CuI, CuBr(PPh3)3 DIPEA THF 70 
Additionally, acetonitrile was a better chose of solvent than THF due to easier handling and less 
evaporation during the reaction. Despite the potential formation of polynuclear acetylide complexes [54], 
excellent conversions were obtained with copper iodide as sole catalyst (Table 4, entries 5 and 6), which 
showed the same efficiency as the more expensive coordinated copper catalyst [Cu(MeCN)4]PF6 (Table 
4, entry 4), after only 16 hrs at room temperature. Finally, copper iodide with 2,6-lutidine and DIPEA 
as additives in MeCN were chosen for future experiments. 
 
# Azide Isolated yield (%) Product 
8 12a 93 13a 
9 12b 86 13b 
10 12c 71 13c 
11 12d 81 13d 
12 12e 81 13e 
N3
N3
S
NH
HN N3
O
12b 12c 12d
HO
O
O
N3
12e
Table 4: The CuAAC reaction of 1 with model azide 12a was monitored by 31P-NMR. Unless specified otherwise, 
reactions were performed at room temperature over 72 hrs. aReactions were performed at 40 °C. bThe reaction 
time was 16 hrs. 
Table 5:Staudinger-phosphonite reaction with triazole phosphonite 13a. All compounds were isolated by silica 
gel column chromatography. Reaction conditions: a: DABCO (1.5 eq.), DMF, 80 °C, 4 hrs; b: Azide 12a-c (3 
eq.), 60 °C, 5 hrs. aDue to lower conversions at high temperatures, the reaction was performed for 16 hrs at 25 °C. 
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To test the versatility of the chosen reaction conditions, they were repeated with other model azides, as 
shown in Table 5. All reactions proceeded to completion (as determined by 31P-NMR) and could be 
isolated successfully by silica gel column chromatography in good to excellent yields. The 
functionalization of core building block 1 with biotin azide 12d to triazole-phosphonite 13d should be 
emphasized in particular, because it yielded 81 % despite solubility problems of 12d. Furthermore, the 
reaction scope allows for the incorporation of all azides, regardless of their electronic properties, which 
further highlights the potential of core building block 1 in the versatile labeling of azido-containing 
molecules.  
4.1.3 Small-molecule Staudinger-phosphonite ligations with 2-nitrobenzyl substituted 
triazole-phosphonites  
After the successful derivatization of core structure 1 with a variety of different azides, the reactivity of 
borane-protected triazole-phosphonite 13a was examined in Staudinger-phosphonite ligations with 
model azides 12a-c. 13a was first deprotected with the tertiary amine DABCO in DMF at 80 °C for 
4 hrs. After complete borane deprotection, indicated by a single sharp peak at δ = 147 ppm in the 31P-
NMR analysis, the reaction mixture was allowed to cool down to 60 °C and the corresponding azide 
was added. The reaction progress was constantly monitored by 31P-NMR. The results of the 
Staudinger-phosphonite ligations are shown in Table 6. 
# Azide (R’-N3) Product Isolated yield (%) 
13 12a 14a 85 
14 12b 14b 86 
15 12c 14c 50a 
In all reactions, triazole-phosphonite 13a was fully consumed after 5 hrs reaction time, but product 
formation to 14a and 14b differed strongly to that of 14c. While no differences in conversion could be 
for azides 12a and 12b, reaction with azide 12c delivered significantly less of the desired product, 
especially when it was conducted at high temperatures. 31P-NMR analysis revealed the formation of the 
corresponding phosphonate side product due to the elimination of the aniline instead of the alcohol in 
the phosphonimidate intermediate (see Scheme 34). This is in accordance with previously published 
results of Vallée et al., who observed the same behavior of the azide in Staudinger-phosphonite ligations 
with ethyl substituted phosphonites. [47] By lowering the reaction temperature to 25 °C, the side product 
Table 6: CuAAC functionalization of core building block 1 with model azides 12b-e. Reaction conditions: 
CuI (30 %), DIPEA, 2,6-lutidine, MeCN, room temperature, 16 hrs. 
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formation could be reduced to 30 % and derivative 14c was isolated at 50 % yield. (Table 6, entry 15). 
14a and 14b, meanwhile, were isolated at very good yields of 85 % and 86 % respectively (Table 6, 
entries 13-14). 
4.1.4 Stability of newly generated, 2-nitrobenzyl substituted phosphonamidates 
The newly synthesized phosphonamidates described in section 4.1.3 had so far not been described in 
literature. To find out more about the stability of the weakest link in the molecule – the P-N bond – 
phosphonamidate 14a was dissolved in a series of different buffers and pHs and its stability was 
monitored by HPLC over a period of 24 hrs. The decay of 14a was referenced to the internal standard 
inosine and the pH of the buffer was controlled regularly. The results of the stability studies are 
displayed in Table 7. 
The aliphatic phosphonamidate was stable at pH 2-11 over 24 hrs at room temperature. The 
phosphonamidate’s stability at pH 11 was surprising, where no decay could be observed, although the 
molecule was exposed to strongly basic conditions. The molecule was not stable at pH 1.7 (solvent 
containing 0.1 % TFA) and after 24 hrs only 37 % of phosphonamidate 14a was intact. It should be 
remarked that the decay was neglectable in the first hours of the experiment, which justifies the use of 
solvents with 0.1 % TFA for MS and HPLC analysis.  
Scheme 34 :Hydrolysis of the phosphonimidate intermediate formed during the Staudinger-phosphonite ligation 
of borane-deprotected triazole-phosphonite 13a with model azide 12c can go via two pathways, either resulting in 
the formation of a phosphonate when the aniline acts as leaving group (left) or the desired product 
phosphonamidate 14a if 2-nitrobenzyl alcohol is eliminated. 
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pH Time (h) Phosphonamidate 
14a (%) 
1.7 0.5 100 
 5 98 
 9 95 
 13 74 
 18 47 
 24 37 
2.3 24 100 
4.2 24 100 
6.2 24 100 
11 24 100 
 
4.1.5 UV irradiation of small molecule phosphonamidates 
Next, phosphonamidate 14a was subjected to irradiation at 297 nm to test the system’s suitability for 
molecule release. As shown in Scheme 35, 14a was dissolved in a buffered mixture of TRIS and MeCN 
at pH 6 and then irradiated in a Quartz cuvette at a wavelength of 297 nm for 10 min. 31P-NMR analysis 
showed quick consumption of the starting material, while a new peak appeared at δ = -0.31 ppm, which 
lies within the characteristic 31P shift range of phosphonates. This suggested not only a successful 
cleavage of the 2-nitrosobenzaldehyde by irradiation , but also hinted towards a swift P-N bond cleavage 
at pH 6. While an enhanced lability of the P-N bond was expected, its cleavage at near neutral pH 
without the need to acidify the solution would be an additional advantage of this photocleavable tag.  
Table 7: Stability analysis of phosphonamidate 14a at pH 1.7, 2.3, 4.2, 6.2 and 11 over 24 hrs. The decay at pH 1.7 
is further illustrated in the line graph (right). All probes were stored at room temperature during the measurements. 
Scheme 35: Proposed release of amine 16 from phosphonamidate 14a upon irradiation at 297 nm: The 
irradiation of phosphonamidate 14a leads to 2-nitrosobenzaldehyde expulsion and formation of 
phosphonamidate salt 15. The cleavage of the P-N bond is expected to proceed under acidic conditions to release 
amine 16. The irradiation was monitored by HPLC and 2D-NMR 1H-31P-HMBC, where one signal corresponded 
to the correlation between 31P and the benzylic 1H protons (orange) and a second signal belonged to the 
correlation between 31P and the methyl 1H protons of the amino-substituent (green).  
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The irradiation progress was also monitored by analytical HPLC. As with NMR, the complete 
disappearance of 14a over the course of 15 mins (see Figure 32) was observed. A new peak at an earlier 
retention time emerged, which was assigned to amine 16 (m/z 136.4 [M+H]+) by MS analysis. As the 
HPLC analysis was conducted under acidic conditions, no further conclusions could be drawn about the 
P-N bond cleavage of phosphonamidate acid 15 at neutral pH, since it could have been induced during 
the measurement. 
Next, additional NMR experiments were performed to gain more insight into the bond cleavage and to 
find further evidence for the quick hydrolysis of the P-N bond after the UV-induced release of 
2-nitrosobenzaldyde at neutral pH. The irradiation was repeated in partially deuterated solvent and 1H-
31P-HMBC spectra were recorded before and after irradiation at 600 MHz.  
Figure 32 shows the recorded 2D-NMR spectrum after 10 mins irradiation. Axis F1 displays the shift 
of the P-nuclei, while F2 shows the proton shift. Two peaks can be seen in the 31P-NMR, where the peak 
in the lower field at δ = 14.9 ppm corresponds to phosphonamidate 14a, confirmed by the 1H-31P 
correlation to the benzylic protons of 2-nitrobenzyl alcohol (in green in Scheme 35 and Figure 33) and 
a second correlation to the methyl protons of the amino-substituent (in orange in in Scheme 35 and 
Figure 33). The new peak at δ = -0.3 ppm after irradiation does not have either of those two correlations, 
confirming 1) the successful release of the photocleavable moiety and 2) the efficient and swift P-N 
bond cleavage. No other peak was observed in the 31P-NMR, suggesting that phosphonamidate salt 15 
is highly unstable and cannot be detected on this time scale.   
Figure 32: The irradiation of 14a was monitored over 15 mins by analytical HPLC at 272 nm. The 
phosphonamidate 14a (*) and a new peak (+) corresponding to amine 16 appeared. 
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4.1.6 Staudinger-phosphonite ligations of 2-nitrobenzyl substituted 
triazole-phosphonites with aliphatic azido-peptides  
4.1.6.1 Azido-lysine as reactive handle for the Staudinger-phosphonite ligation  
Encouraged by the fast reaction of triazole-phosphonite 13a with the small-molecule aliphatic azide 12a 
(chapter 4.1.3) and the fast UV-induced release of amine 16 from phosphonamidate 14a (chapter 4.1.5), 
a test peptide 17 featuring an azido-lysine was synthesized by SPPS and reacted in a series of 
Staudinger-phosphonite ligations to test the conversion on the more challenging peptide level (see Table 
8). The reaction was monitored using 31P-NMR and UPLC-MS.  
Like previously described for the small molecule ligations, the borane deprotection was carried out in 
degassed DMF at 70 °C for 5 hrs. Completion of the borane removal was monitored by 31P-NMR, once 
more revealing a single peak at δ = 147 ppm. The Staudinger-phosphonite ligation was performed at 21 
and 37 °C and the conversion was monitored by UPLC-MS over 5 days. The final conversion was 
estimated by UV integration of the peaks assigned to the peptide 17 and peptide phosphonamidate 18. 
While almost no phosphonamidate formation could be observed at 21 °C, the reaction delivered the 
desired phosphonamidate 18 at 37 °C. After 5 days, the conversion to 18 was at 79 % (Table 8, entry 
17). To increase the reaction rate, the temperature was raised to 50 °C and the number of phosphonite 
equivalents to peptide were increased to 5, resulting in a 81 % conversion after 3 days (Table 8, entry 
Figure 33: 1H-31P-HMBC correlation spectrum recorded directly from the irradiation mixture at 600 MHz. Green 
circle: P-NH-CH2 correlation, orange circle: P-O-CH2 correction, both illustrated in Scheme 35. Phosphonamidate 
14a:  δ = 14.9 ppm, phosphonate: δ = -0.31 ppm. 
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18). Product formation did not increase with longer reaction times, presumably due the hydrolysis and 
oxidation of the borane-deprotected triazole-phosphonite. So while the reaction proceeded faster at 
elevated temperatures, the decomposition of the P(III) species was also accelerated and no higher 
conversions were possible, even when the number of phosphonite to peptide equivalents was further 
augmented.  
To test whether the borane deprotection and the Staudinger-phosphonite ligation could be carried out in 
a one-step procedure, DABCO and peptide were added simultaneously to the phosphonite and reacted 
for 3 days at 70 °C (lower temperatures often result in incomplete borane deprotection). This resulted 
in a conversion of 55 %, consistent with the observation that higher temperatures lead to faster 
phosphonite degradation (Table 8, entry 19). 
Entry # Temperature (°C) Reaction time (d) Phosphonite equivalents to 
peptide 
Conversion (%) 
 
16 21 5 3 0 
17 37 5 3 79 
18 50 3 5 81 
19 70 3 5 55 
Despite optimization efforts, the conversion could not be further improved. Diethyl and hexaethylene 
glycol substituted triazole-phosphonites have previously been used successfully in Staudinger-
phosphonite ligations with aliphatic azides. [47][48] The difference in reactivity can be reasoned by the 
electron-donating nature of these substituents, which render the P(III) a better nucleophile than the 
electron-withdrawing 2-NB substituents. To obtain better conversions during the Staudinger-
phosphonite ligations, the use of a different handle (see 4.1.7) or the modification of the 2-nitrobenzyl 
substituents was considered next. 
  
Table 8: Staudinger-phosphonite reaction of triazole-phosphonite 13a with peptide 17 at different temperatures. 
The phosphonite concentration was constant at 0.02 M. The conversion was determined by UV integration 
(220 nm) of starting material and product. Peptide sequence: H2N-LYRK(N3)AGKAYLG-NH2. 
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4.1.6.2 The peptidic Staudinger-phosphonite ligation on solid phase as alternative to an 
in-solution reaction 
An attractive alternative to performing the chemoselective reaction in solution is to do it on the solid 
support during SPPS. This procedure has two advantages: 1) Any phosphorus impurities can be easily 
removed by continuous washing and 2) only one purification is necessary to obtain the desired product. 
As it is of particular interest for the synthesis of functionalized peptides, it was investigated whether our 
photocleavable tag can be first be incorporated into a growing peptide chain during SPPS.  
As the P-N bond is unstable to harsh acidic conditions, the use of acid-labile solid support was not 
feasible. Instead, a base-labile HMBA TentaGel® solid support was chosen (see Scheme 36). While the 
P-N bond is not stable to prolonged treatment with hydroxyl ions, as they can attack the 
phosphonamidate at the benzylic position of the 2-nitrobenzyl alcohol and promote its hydrolysis, it was 
reported to be sufficiently stable to basic conditions for a short period of time under cooling. [44]  
The first amino acid was loaded to the base-labile HMBA resin with MSNT as coupling reagent and 1-
methylimidazole as base. The rest of peptide 19 was extended using standard Fmoc-based couplings. 
Before performing the Staudinger-phosphonite ligation, all side-chain protecting groups are removed 
with 95 % TFA, followed by washes with 10 % DIPEA to neutralize any residual acid. The resin loaded 
with peptide 19 was then subjected to a Staudinger-phosphonite ligation with freshly deprotected 
triazole-phosphonite 13d in DMF. The progress of the reaction was monitored by peptide test cleavages 
and injection into the UPLC-MS system. Conversion to the desired phosphonamidate peptide was 
observed (m/z 657.85) and after three days of reaction time, the full peptide was cleaved from the resin, 
purified by semi-preparative HPLC and lyophilized. The overall yield of phosphonamidate 20, 
calculated back from the actual resin loading, was determined to be satisfying 9 %. 
The Staudinger ligation’s compatibility with SPPS adds to its suitability in the chemoselective 
modification of peptides and its use in the installation of photocleavable modifications.  By reducing 
Scheme 36: Peptide 19 was extended on base-labile HMBA resin and all protecting groups were removed by TFA. 
The peptide was then subjected to the Staudinger-phosphonite reaction with triazole-phosphonite 13d. Peptide-
phosphonamidate 20 was cleaved from the solid support with NaOH in dioxane at 0 °C. 
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the number of purification steps, the target peptides can be isolated at better yields, despite the use of 
harsh basic conditions for the final cleavage of the peptide from the solid support.  
4.1.6.3 Irradiation of aliphatic peptide phosphonamidates 
To test whether the irradiation and release of our photocleavable phosphonamidates was feasible for the 
peptide conjugates, a fluorescent peptide 21 was synthesized and then reacted with biotin-triazole 
phosphonite 13d to yield phosphonamidate 22 at 30 % yield after semi-preparative HPLC purification 
and lyophilization (see Scheme 37). 
The irradiation was monitored by fluorescence HPLC. Analysis of phosphonamidate 22 revealed about 
15 % premature P-N bond cleavage. Premature P-N bond cleavage is often observed for aliphatic 
phosphonamidates that have been subjected to lyophilization in TFA-containing solvents after HPLC 
purification. To avoid this, the phosphonamidates can be purified in slightly basic ammonium acetate 
buffer. In case of 22, the product and the phosphorus-containing side products could be not be separated 
from each other at basic pH. Neutralization of the purified peptide prior to lyophilization is an option, 
Figure 34: Blue line: Trace of reaction mixture before irradiation (up, blue) and after 15 mins irradiation at 
297 nm (below, red). All of phosphonamidate 22 (ret. time: 38.6 min) had disappeared and the only product was 
amine  23 (ret. time: 32.6 min). Some amine 23 was detected in the injection before irradiation, which was a 
result of P-N cleavage during lyophilization and not due to premature P-N bond cleavage in buffer.  
Scheme 37: Staudinger-phosphonite ligation between triazole-phosphonite 13d and fluorescent peptide 21 yielded 
phosphonamidate 22. 5(6)-carboxyfluorescein (CF) was used as fluorophore. The peptide sequence is: (CF)HN-
AYDK(N3)GRKAFA-NH2. 
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but the resulting TFA-containing salts would prevent the exact yield determination and the correct 
handling in future experiments.  
After irradiating phosphonamidate 22 for 10 min at 297 nm, only a single peak could be observed in the 
fluorescence HPLC chromatogram, which corresponded to amine 23 (see Figure 34). Like previously 
described in chapter 4.1.5, no phosphonamidate acid intermediate could be detected. 
4.1.6.4 Streptavidin immobilization and release of a fluorescent peptide phosphonamidate 
As described in chapter 4.1.6.3, the Staudinger-phosphonite ligation between the azido-containing 
peptide 21 and the biotin containing triazole-phosphonite 13d yielded the photo-cleavable peptide 
phosphonamidate 22, which was readily cleaved upon irradiation at 297 nm. To show the potential of 
the photocleavable tag in combination with immobilization on solid support, the presence of the biotin 
moiety was exploited and 22 was subjected to immobilization and subsequent release from streptavidin 
beads (see Scheme 38). 
Thanks to the 5(6)-carboxyfluorescein (CF) at the N-terminus of 22, the release of the peptide from the 
streptavidin-coated beads could be monitored by fluorescence spectrometry. Here, the pH sensitivity of 
the fluorophore had to be taken into consideration before each measurement, because the fluorescence 
emission of CF depends strongly on the surrounding environment. This was ensured by constant 
monitoring and adjustment of the pH. Furthermore, a linear, concentration-dependent increase of the 
fluorescence of product 23 was confirmed in preliminary experiments, where the fluorescence of 
different concentrations of the synthetically prepared product 23 (peptide S4) were measured and 
correlated (see 6.2.10.1.1 in the experimental part). After immobilization of 22 and thorough washing 
of the beads, the solid support was irradiated with UV light and the fluorescence of the elutions was 
recorded. The intensities were compared to fluorescence signal of a reference sample, where the 
synthetically prepared amine product S4 was diluted to the maximum release concentration (i.e. 100 % 
release of amine from the beads). 
Scheme 38: Peptide phosphonamidate 22 is immobilized on streptavidin beads, then washed thoroughly, before 
being irradiated for 10 mins in a 20 mM NH4OAc buffer at pH 7.0. The release is quantified by fluorescence 
spectrometry. 
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The results of the bead irradiation are displayed in Figure 35. After one minute, a weak fluorescent 
signal could be detected, which increased over longer exposure times. No significant increase was 
measured after 7 mins and the release was declared complete after 10 mins. The reference (green line) 
is the fluorescent intensity of reference amine peptide S4 at the highest possible elution concentration. 
The elution yield was quantified to be about 70 % over three separate measurements.  
 
  
Figure 35: Fluorescence measurements of elution during irradiation of streptavidin beads bound with peptide 
phosphonamidate 22. 
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4.1.7 Staudinger-phosphonite ligations of 2-nitrobenzyl substituted 
triazole-phosphonites with electron-deficient azido-peptides  
The electron-deficient 2-nitrobenzyl substituted triazole-phosphonites only reacted slowly with the 
electron-rich azido-lysine containing peptides. The lack of reactivity was initially not visible on small 
molecule level, but it became apparent on the more interesting and complex peptide level. Two 
approaches were feasible at this point:  
1) The electron-deficient nature of the phosphonite could be modified by increasing the electron 
density of the nitro-substituted aromatic ring of the substituents by, for example, introducing an 
electron-donating group like hexaethylene glycol and O-methyl para to the benzylic alcohol. 
The addition of a methyl group at the benzylic position would also aid in increasing the electron 
density at the P(III) center. These differently substituted aromatics were already used in 
Staudinger-phosphite reactions before. [340] Another alternative would be a different 
photocleavable group with reduced electron-pulling properties. [341] O-nitro-2-
phenethylhydroxyl groups, for instance, originally published by Hasan et al.,  [342] then refined 
further by Schelkle et al., [343] are less electron-withdrawing and follow an entirely different 
elimination mechanism, despite their high structural similarities to 2-NB.  
2) The second way to modify the overall reactivity of the system is to modify the reactive azido 
handle. By decreasing the electron-density of the azide, the initial step of the Staudinger-
phosphonite ligation is accelerated. Additionally, the employment of a more electron-deficient 
azido handle is also likely to work at lower reaction temperatures. Two alternative azides that 
can be easily incorporated into peptides are azido-glycine and azido-phenylalanine at the 
N-terminus. 
4.1.7.1 Azido-glycine and azido-phenylalanine as reactive handles 
Two peptides containing either a N-terminal azido-glycine (24) or a N-terminal azido-
phenylalanine (25) were synthesized as depicted in Figure 36.  
The peptides were subjected to a Staudinger-phosphonite ligation with triazole-phosphonite 13d at 37 
and 50 °C and the reaction progress was monitored by analyzing the amount of remaining peptides 24 
and 25 at set time intervals by UPLC-MS. As seen in Table 9, both reactive handles resulted in better 
overall azide consumption than with the previously used azido-lysines in chapter 4.1.6.1. 
Figure 36: Peptides 24 and 25 with more electron-deficient N-terminal azido handles for improved reactivity. 
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Entry # Peptide 
24 or 25 
Temperature 
(°C) 
Time (h)  Azide 
consumed (%) 
Isolated yield 
(%) 
Product 
20 24 50 36 80 68 26 
21 24 37 36 42 - 26 
22 25 50 < 16 100 - 27 
23 25 37 16 100 - 27 
24 25 37 24 100 41 27 
25 25 25 24 100 63 27 
80 % of peptide 24 was consumed after 36 hrs reaction time at 50 °C (Table 9, entry 20). In comparison, 
similar conversions with the aliphatic azide took twice as long (see chapter 4.1.6.1). Furthermore, the 
reaction also proceeded at lower temperatures, with 37 % of azide used up after 36 hrs (Table 9, see 
entry 21). Peptide 26 was the only product formed during the Staudinger-phosphonite ligation between 
peptide 24 and triazole-phosphonite 13d, so no other side reactions (i.e. amine formation) were 
observed. The final peptide 26 could be isolated at a very good yield of 68 % by semi-preparative HPLC.  
With this clear evidence in hand that electron-deficient azides react more readily with the 2-nitrobenzyl 
triazole-phosphonites, the Staudinger-phosphonite reaction was repeated with peptide 25. Satisfyingly, 
the peptide was fully consumed after less than 16 hrs at 50 °C (Table 9, entry 22) and after 16 hrs at 
37 °C (Table 9, entry 23). The reaction also proceeded at convenient 25 °C (Table 9, entry 25). Unlike 
with the azido-glycine handle, undesired amine elimination during the phosphonimidate stage was 
observed, just like during the small molecule study. This effect was most prominent at 50 °C, where a 
varying degree of amine formation ranging between 25 to 50 % was detected. With lower temperatures 
this side product occurred less. At 25 °C, the reaction yielded 85 % of phosphonamidate peptide 27 and 
only 15 % of amine. Peptide 27 was isolated at a very good yield of 63 % by semi-preparative HPLC.  
After synthesizing and isolating peptide phosphonamidates 26 and 27, they were subjected to 
immobilization and UV irradiation experiments to test their behavior as photocleavable tags. 
Table 9: Staudinger-phosphonite ligation of 13d with peptides 24 and 25 to yield peptide phosphonamidates 26 
and 27 respectively. The amount of consumed azide was estimated by SIR measurements. Isolated yields are given 
after purification of the products by semi-preparative HPLC and lyophilization. 
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4.1.7.2 Streptavidin immobilization and irradiation of the electron-deficient phosphonamidate 
conjugates 
Following the excellent conjugation yields achieved during the Staudinger-phosphonite ligation 
between the 2-nitrobenzyl substituted triazole-phosphonites and the electron-deficient azides, the 
peptide phosphonamidates 26 and 27 were immobilized on streptavidin beads and then irradiated at 
297 nm to release the respective amine peptides 30 or 31 (see Scheme 39). 
In both cases, the successful immobilization was checked by UPLC-MS, where a decrease in UV and 
MS intensity before and after immobilization showed that the beads had retained the peptide 
phosphonamidates 26 and 27. In contrast to the previous immobilization experiments with the aliphatic 
phosphonamidate 22, where the desired amine 23 was released during irradiation at 297 nm (see chapter 
4.1.6.4), the expected peptide amines 30 and 31 could not be observed in the elutions after UV treatment 
of 26 and 27.  
From this it could be concluded that the new conjugates had different stability profiles in comparison 
to the aliphatic phosphonamidates. It was concluded that upon cleavage of the 2-nitrosobenzaldehyde 
by UV, the phosphonamidate salts 28 and 29 remained firmly attached to the beads, because pH 7 was 
not sufficient to initiate P-N bond cleavage. This hypothesis was tested by incubating the beads with 
buffers ranging from pH 3 to 6. 
Conjugate 26 was incubated with streptavidin beads and then irradiated at 297 nm at pH 7 in 
20 mM NH4HCO3 buffer. Afterwards, the beads were incubated for a total of 48 hrs at pH 3 to 6. The 
UPLC chromatogram of the resulting elution after incubation at pH 3 is shown in Figure 37. It depicts 
nicely how a new peak at ret. time = 1.5 mins appears after 48 hrs (marked with *), which corresponds 
to the desired peptide amine 30 (m/z 556.45 [M+2H]2+). Interestingly, the intensity of this peak increases 
the lower the pH used for the incubation of the beads gets, suggesting that a significant change in pH is 
Scheme 39: Release of peptide amines 30 and 31 after streptavidin immobilization and irradiation of peptide 
phosphonamidates 26 and 27 in 20 mM NH4HCO3 buffer at pH 7.0. 
RESULTS AND DISCUSSION 
 
108 
 
required to enable a quantitative release of the amine (see 6.2.9.3.1 in the experimental part). Overall, 
this data supports the suggestion that irradiation at pH 7 does not automatically lead to the hydrolysis 
of the P-N bond and that lower pHs are required for the release of amine 30, which stands in strong 
contrast to the previously obtained results. 
While the elution did proceed to a certain extent at lower pHs, the appearance of other peaks 
accompanied the amine release. One of these peaks could be assigned to phosphonamidate acid 28 (ret. 
time: 1.73 min, m/z 728.03 [M+2H]2+), which likely arises from unspecific release from the streptavidin 
beads, induced by prolonged treatment with the acidic buffer. Besides this, other peptidic species could 
also be detected, but not allocated to any structure. The use of buffers containing sodium ascorbate and 
semicarbazide as radical scavengers yielded similar results. Furthermore, it was attempted to reduce 
irradiation times, change the UV irradiation to a higher wavelength (365 nm) and use a lower loading 
of the streptavidin beads, but none of these actions led to a complete disappearance of the side products.  
The immobilization of the aromatic phosphonamidate 27 on streptavidin beads, with irradiation and 
follow-up incubation resulted in the release of peptide amine 31, without any side products (see 6.2.9.3.2 
in the experimental part). With this positive result in hand, the irradiation and P-N bond cleavage 
behavior of 27 was investigated further to find ideal incubation conditions for the cleavage.  
4.1.7.3 Release optimization for aromatic phosphonamidate conjugates 
To illustrate and confirm the stepwise release of the amine from the phosphonamidate via the 
phosphonamidate salt after UV irradiation at pH 7 and incubation at pH 3, the irradiation was performed 
in solution without immobilization. For easier monitoring, peptide conjugate 32 was tagged with 5(6)-
carboxyfluorescein and fluorescence-based HPLC was used for the analysis. All peaks were collected 
and further tested by MS.  
Figure 37: UPLC chromatogram after an additional acidic incubation at pH 3 of streptavidin beads that had been 
bound with conjugate 26 and irradiated at pH 7 at 297 nm for 10 mins. *: Peptide amine 30. 
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The experimental outline and results are shown in Figure 38. The irradiation was performed in neutral 
buffer for 20 mins, after which no more phosphonamidate 32 (*) was visible (red trace). Two new peaks 
of different heights had formed, corresponding to the phosphonamidate salt 33 (+) and amine 34 (#). 
Noticeably, 33 (m/z 938.15 [M+H]+) was the dominant species, while 34 (m/z 766.46 [M+H]+) was only 
present in traces. The buffer was then acidified to pH 3 and incubated overnight. The next measurement 
showed that all of 33 had disappeared – while only a single peak belonging to amine 34 remained (blue 
trace). This was confirmed by MS and by comparison to a synthesized reference peptide with the same 
structure as 34 (purple trace, S3). 
An even lower pH was likely to speed up the P-N bond cleavage further. This had previously been 
avoided, because the P-N bond of the phosphonamidates often displayed a limited stability to pH < 3. 
Surprisingly, phosphonamidate 32 was found to be fully stable to treatment with 0.1% TFA/H2O during 
overnight incubation (see 6.2.8.3.3). The irradiation was therefore repeated with 0.1% TFA/H2O as 
solvent for the irradiation as well as incubation. After 20 mins of irradiation, the dominant species was 
amine 34, with only traces of 33 remained, which disappeared fully after overnight incubation and left 
34 as sole product (see Figure 39). 
Figure 38: Fluorescence-based HPLC chromatograms of the photo-induced release of the tag. Legend: *: 
Phosphonamidate 32. +: Phosphonamidate salt 33. #: Amine 34. The double peaks arise from the two 
stereoisomers of the carboxyfluorescein. 
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4.1.7.4 Quantification of amine release from aromatic phosphonamidates 
To quantify the release, the SIR signal of product 34 (m/z 766.46 [M+H]+) was quantified by integration 
and the obtained area was compared to a standard curve generated by measuring different concentrations 
of a reference peptide with the same structure as 34 (S3, see 6.2.10.2. in the experimental part). 
Three separate measurements were performed, where the concentration of peptide was always kept 
constant. Each time, the peptide was irradiated for 30 mins to ensure the full cleavage of 
2-nitrosobenzaldehyde and then left to incubate overnight in 0.1% TFA/H2O. The SIR signal was 
integrated and used to calculate the concentration of amine 34 in the solution. The percentage of release 
was compared to the maximum concentration possible. The results of quantification are displayed in 
Table 10. A release of 84 % (± 2.5 %) was determined, which lies in the range of previously published 
release methods. [95] 
 SIR integrated area (m/z 766.46) Concentration (mM) Release (%) 
1 9970971 0.054 87 
2 9539093 0.052 84 
3 9404347 0.051 82 
  
Table 10: Integration SIR areas of m/z 766.46 and the calculated concentrations (based on the standard curve) are 
shown. 
Figure 39: Irradiation and incubation of phosphonamidate 32 in 0.1% TFA/H2O. The double peaks arise from the 
two stereoisomers of the carboxyfluorescein. 
RESULTS AND DISCUSSION 
 
111 
 
4.1.7.5 Streptavidin immobilization and release assays with aromatic phosphonamidates 
As mentioned in chapter 4.1.7.2, the elution yields from streptavidin beads were only moderate when 
incubating the beads at pH 3. Consequently, the elution pH was lowered to pH 2 to achieve a better 
result. As in all previous cases, phosphonamidate 32 was immobilized on streptavidin beads, which 
were then irradiated at pH 7, before they were further incubated in 0.1% TFA/H2O. The result of this 
experiment can be seen in the fluorescence-based HPLC chromatogram in Figure 40.  
The elution fraction (red trace) depicts a strong, broad signal running at the same retention time as 
reference probe 34 (green) and injection into the MS confirmed that it is the desired amine. The elution 
fractions contained two peptidic masses on the whole, belonging to phosphonamidate salt 33 (+) and 
amine 34, but other polymeric masses could also be found. To investigate their source, the stability of 
the streptavidin beads towards 0.1% TFA/H2O was tested separately. This revealed the partial 
degradation of the beads, resulting in the unspecific co-elution of impurities, which were previously not 
visible when incubating the aromatic phosphonamidates at higher pHs (see 6.2.9.3.5 in the experimental 
part). 
Up to this point, only purified phosphonamidates had been used for the immobilization and release from 
streptavidin beads. To show the potential of the system in the isolation of the tagged species from a 
mixture of compounds, an unpurified Staudinger-phosphonite ligation mixture containing some 
unreacted azide, some amine side product and the biotin-tagged phosphonamidate was subjected to 
purification by streptavidin immobilization. The mixture was desalted by acetone precipitation first and 
then added straight to the beads (Figure 41, blue trace). The flow-through (Figure 41, red trace, FT) 
showed that the phosphonamidate had been enriched on the beads. The beads were then irradiated at 
Figure 40: Phosphonamidate 32 (*) was immobilized on streptavidin beads (blue trace), then irradiated at pH 7. 
Afterwards, the beads were incubated in 0.1% TFA/H2O overnight. The elution (red trace) shows release of 
phosphonamidate salt 33 (+) and amine 34 (#) in a broad peak with some polymeric side products. A reference 
probe of 34 (green line) was measured as comparison. 
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pH 7 and incubated in 0.1% TFA/H2O (Figure 41, purple trace). The elution trace shows primarily the 
release of the desired amine, with some phosphonamidate salt co-eluting due to bead degradation and 
loss of binding affinity to the biotin tag.  
Overall, these experiments show the feasibility of our system in immobilization and release 
experiments. The biotin-tagged phosphonamidates were successfully immobilized on the streptavidin 
beads, regardless of whether they were added as a pure compound or in a mixture with other peptide 
species. Irradiation and incubation at acidic pH then permitted the elution of the corresponding amine. 
The degradation of the streptavidin beads upon exposure to 0.1% TFA/H2O led to the unspecific release 
of the phosphonamidate salt intermediates that form as a result of the irradiation of the 
phosphonamidates and where the P-N bonds had not yet been cleaved. The photo-cleavable 
phosphonamidates are therefore limited to acid-stable applications.  
4.1.7.6 Traceless release from aromatic phosphonamidates  
While the efficiency of the Staudinger-phosphonite ligation with aromatic azides and the high stability 
of the resulting phosphonamidates are strong arguments for the use of this type of azide as reactive 
handle, the photo-cleavage leaves behind an aniline moiety in the target molecule. 
For this reason, an alternative handle suitable for traceless release was designed and tested. Scheme 40 
shows the structure of the new handle. Instead of attaching the aromatic system directly to the amine, a 
self-immolating 1,6-benzyl carbamate is inserted between the aromatic azide and the target amine. 
Through the introduction of this simple modification, two issues were addressed:  
Figure 41: The reaction mixture after the Staudinger-phosphonite ligation (blue) contained unreacted azide (§), 
phosphonamidate (*) and amine (#). The elution contained the desired amine (#) and traces of phosphonamidate 
salt (+) that co-eluted due to bead degradation. 
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1) The handle can be installed at any amine. After irradiation and elimination, the open amine on 
the aromatic ring can undergo a 1,6-benzylic elimination, thereby liberating the amine again 
without leaving a trace behind. 
2) The 1,6-benzylic elimination is an energetically favorable process, because it increases the 
system’s overall entropy. Its insertion into the photocleavable tag could be a potential driving 
factor for an easier P-N bond cleavage. 
To explore the potential of this simple technique, the carbonate building block 37 suitable for the 
incorporation of the azidobenzyl carbamate into an amine-containing compound was synthesized 
according to a previously published protocol, as shown in Scheme 41. [344] The mixed carbonate 
molecule contains the moiety of interest as well as a good leaving group for optimal installation by 
nucleophilic attack into a target molecule.  
In a first experiment, the direct Staudinger-phosphonite ligation on building block 37 was attempted. 
This resulted in the complete decomposition of 37, likely because the carbonate was not stable to the 
reaction conditions. Consequently, the building block had to be coupled to the amine first before the 
Staudinger-phosphonite ligation could be performed. To find ideal reaction conditions, 37 was first 
reacted with a small, commercially available amine using catalytic amounts of HOBt.H2O and 40 was 
isolated by silica gel column chromatography at an excellent yield of 92 %. Initial attempts to install 
the small molecule onto test peptide 38 using the same conditions failed to yield any product. This 
problem was solved by switching to a solvent mixture of DCM/DMF and removing the coupling reagent 
from the reaction. Peptide 39 was then isolated at a good yield of 61 % by semi-preparative HPLC (see 
Scheme 41). 
Scheme 40: By installing a 1,6-elimination linker between the target of interest and the photocleavable tag, the 
UV irradiation and subsequent P-N bond cleavage will result in the formation of an unstable benzylic system that 
will self-eliminate and leave behind a free amine. 
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Next, 39 was reacted with borane-protected triazole-phosphonite 13d in a Staudinger-phosphonite 
ligation as shown in Scheme 42. As before, 13d was first borane-deprotected with DABCO and then 
added to azide 39. Room temperature was chosen for this reaction to avoid carbamate hydrolysis. All 
of the starting material had been consumed after 36 hrs. MS analysis revealed that 85 % had been 
converted to the desired phosphonamidate 41, while 15 % of amine hydrolysis was detected. Isolation 
by semi-preparative HPLC with acidic or basic conditions resulted in the degradation of compound 41, 
but was successful when employing neutral conditions. The isolation was not optimized and difficult 
due to the high hydrophilicity of the peptide, resulting in only 30 % isolated yield. It should be noted 
that this is not representative of the efficiency of the reaction and can be solved by further improvement 
of the purification and will change when a more hydrophobic peptide sequence is employed for the 
reaction. 
Following its isolation, compound 41 was dissolved in three different buffers with pH 2, 4 and 7 for 
irradiation to analyze the molecule’s behavior to UV irradiation. The results of these experiments are 
illustrated in Figure 42. The UV irradiation worked very efficiently, with all of the phosphonamidate 
gone after 20 minutes in all cases. Satisfyingly, when performing the experiment at pH 2 (Figure 42, 
red trace), target amine 38 was the only peptidic product detected by HPLC and MS, a clear proof that 
Scheme 41: Staudinger-phosphonite ligation with azidobenzyl carbamate peptide 39 to yield phosphonamidate 41. 
Scheme 42: Synthesis of carbonate building block 37 and azidobenzyl carbamate peptide 39 
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the photocleavage and P-N bond cleavage were followed by a swift 1,6-benzyl elimination to yield a 
free amine. At pH > 2, a mixture of phosphonamidate salt 42 and amine 38 was observed, which is a 
similar result as previously obtained with the azido-phenylalanine handle (see 4.1.7.3). While only little 
product amine formation was observed at pH 7 (Figure 42, purple trace), amine 38 was the predominant 
product when the irradiation was performed at pH 4 (Figure 42, green trace). It is expected that longer 
incubation times will lead to full P-N bond cleavage, but this was not yet tested. 
One drawback of this linker is that the resulting carbamate is not stable to standard Fmoc-SPPS synthesis 
with TFA, since highly acidic pHs lead to the premature elimination of the linker. [345] Consequently, 
the coupling of the building block has to be carried out either in solution or can be attempted in 
combination with base-labile resin after full removal of the protecting groups with TFA.  
By combining a self-immolating 1,6-benzyl carbamate linker with our Staudinger-phosphonite ligation, 
we were able to exploit the high reactivity of our P(III) compounds with aromatic azides and generate 
a traceless photocleavable tag that can be attached to any amine. The photocleavage of the 
phosphonamidates proceeded readily at pH 2, 4 and 7 and, unlike in the absence of the self-immolating 
1,6-benzyl carbamate, the hydrolysis of the P-N bond after photocleavage could be performed at pH 4. 
Further investigation will be necessary to determine the optimal release conditions, but the here 
presented results demonstrate the high potential of this system.  
  
Figure 42: Irradiation and incubation of phosphonamidate 41 (*) at different pHs. Legend: +: 
phosphonamidate salt 42, amine: 38. 
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4.1.8 Associated publications 
The results from chapter 4.1 were partially published in the manuscript:  
Kristina D. Siebertz, Christian P. R. Hackenberger 
Chemical Communications, 2018, 54, 763-766.  
Chemoselective triazole-phosphonamidate conjugates suitable for photo-release. 
Abstract: Herein, we describe a new method for the conjugation of azide-containing target compounds 
that can be readily released as amines by irradiation with near UV light. This concept is based on a two-
step protocol employing the chemoselective CuAAC and Staudinger-phosphonite reactions to deliver 
photo-cleavable phosphonamidate conjugates in high yields starting from 2-nitrobenzyl substituted 
phosphonites. 
Summary of content: The need for reliable and efficient chemoselective reactions for the site-specific 
incorporation of unnatural chemical modifications is high. Azides stand out as remarkably useful 
functionalities, because of its small size, specific reactivity and high stability. Besides the well-known 
copper-assisted 1,3-dipolar cycloaddition (CuAAC), azides are also targetable by a diversity of 
Staudinger ligations with phosphines, phosphites and phosphonites. Most of the recent advances in the 
development of chemoselective reactions rely on the formation of covalent and stable linkages. 
Sometimes, it can be desirable to install removable modifications, which are released upon a specific 
impulse. Reported cleavable strategies are often rendered complicated by extensive synthetic efforts 
combined with a lack of versatility and difficulty in incorporation.  
In this publication, we introduce o-nitrobenzyl-substituted phosphonamidate conjugates as highly 
adaptable and photo-cleavable chemoselective modifications. Generated by a Staudinger ligation, the 
conjugate cleavability is only induced after its incorporation into any azide-containing molecule and is 
therefore easier to handle than other protocols. Our concept is based on the previously published 
Staudinger-phosphonite reaction, where a two-step protocol permits the functionalization of a general 
and easily accessible central building block via CuAAC, before it is installed to the target via a 
Staudinger ligation in the second step. The detachment of the conjugation is induced by irradiation at 
UV light, which increases the P-N bond lability and renders it sensitive to acidic hydrolysis to release 
an amine.  
We present two syntheses of the central borane-protected P(III) building block carrying two o-
nitrobenzyl groups as well as a ethynyl group. After synthesis optimization, the desired compound could 
be isolated at 65 % yield. The synthesis commences with a Grignard reaction, where ethynylmagnesium 
bromide is first reacted with bis(diisopropylamino)chlorophosphine, before 2-nitrobenzyl alcohol and 
tetrazole are added to replace the diisopropylamines from the P(III). In a final step, the phosphorus 
center is protected by a borane group.  
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In a set of subsequent reactions, we demonstrated the straight-forward and high-yielding CuAAC to 
modify out building block with a variety of different azides, all of which could be isolated at good to 
excellent isolated yields (71-93%) after optimization. Following borane deprotection, we could show 
the successful Staudinger ligation of our new P(III) compound with azido-containing small molecules 
as well as peptides in excellent conversions (as analyzed by 31P-NMR) and good isolated yields.  
Finally, we irradiated a fluorescent phosphonamidate-peptide conjugate at 297 nm in acidic buffer to 
demonstrate the applicability of our photocleavable phosphonamidate conjugates. Fluorescence HPLC 
and UPLC/MS revealed the formation of a single amine species and cleavage of the tag within 20 
minutes. We quantified the amount of release by MS to be 84 %, which lies well within range of other 
release methodologies. In a second experiment, we used a biotin-tagged phosphonamidate peptide in 
immobilization and release studies to further underline the versatility of our methodology. We 
successfully demonstrated the immobilization of our peptide on streptavidin-covered support, followed 
by its irradiation and acidic release of the desired amine peptide as final product.  
In summary, we published a novel P(III) building block for the chemoselective modification of azido-
containing compounds that, after conjugation, can be cleaved by UV irradiation to release an amine. 
We demonstrated the straight-forward functionalization of our tag and its incorporation into small 
molecules and peptides. The feasibility of the irradiation could be shown by fluorescence HPLC and 
UPLC/MS and we furthermore showed a first application of our tag in immobilization and release 
experiments.  
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4.2 Towards the semi-synthesis of tau proteins modified in the proline-rich 
domain 
As described in chapter 2.4.4.3, the usually highly soluble tau protein forms neurofibrillary tangles of 
aggregated, hyperphosphorylated protein during the outbreak of Alzheimer’s disease. [346] The 
elucidation of the mechanisms leading to the misbehavior of tau could provide valuable insights for the 
development of effective medication to combat this disease. Several interesting phosphorylation 
epitopes that are associated with the outbreak of Alzheimer’s disease are located within the proline-rich 
domain of tau (see chapter 2.4.4.4.3), which is located in the middle of the protein. [206] While 
biochemical methodologies can provide good approximations of the effect of individual 
phosphorylation patterns on tau structure and function, they rely on the use of pseudophosphorylations 
or heterogeneously phosphorylated tau protein mixtures (see chapter 2.4.5). Protein semi-synthesis, 
which refers to the assembly of a protein by chemoselective ligations and amide bond formations 
between smaller peptides and/or proteins fragments, is an attractive methodology to introduce site-
specific phosphorylations into tau, while only adding a minimal number of mutations into the protein 
(see chapter 2.3.2). [347] This ensures a high sequence analogy between the synthetic and the natural tau 
protein, rendering the synthetic variant a highly attractive tool for studying the effect of the post-
translational modifications on the structure and function of tau.  
As previously mentioned in chapter 2.3.2.2.3, protein semi-synthesis can either be carried out from N- 
to C-terminus or from C- to N-terminus, each offering its own advantages and disadvantages. To find a 
solid ligation strategy, both approaches were investigated and will be described further in the following 
chapters. 
4.2.1 A N-to C-terminal ligation strategy 
As the proline-rich domain is located in the middle of the tau protein, a three-fragment ligation was 
designed to allow for the incorporation of a synthetic peptide in between two recombinantly expressed 
proteins. The initial design therefore divided tau into the three fragments Tau[1-196]-SR, 
Tau[(β-SH)Tyr197-227]-NHNH2 and Tau[Cys228441] (Figure 43). 
Due to the lack of naturally occurring cysteines and alanines in the proline-rich region of the tau protein 
and the recent successes in using thiol-substituted amino acid derivatives as ligation partners, [145] the 
first ligation site was placed between Gly196 and Tyr197 with the goal to develop a novel 
β-mercaptotyrosine that can serve as a reactive handle for ligation between the recombinantly expressed 
Tau[1-196]-SR thioester (43) and the synthetic peptide Tau[(β-SH)Tyr197-227]-NHNH2 (44). The 
expressed protein thioester was obtainable via the IMPACT system (see chapter 2.3.2.3.1) and featured 
a natural C-terminal glycine, which is ideal for ligation purposes. The peptide furthermore contained, 
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besides the N-terminal β-mercaptotyrosine, a C-terminal acyl hydrazine as thioester precursor that can 
be activated separately after the first ligation. The length of the peptide was within the restrictions of 
SPPS, while covering a large number of possible post-translational modifications sites. Following the 
first ligation, the β-mercaptotyrosine could be selectively desulfurized to yield the naturally occurring 
tyrosine residue at position 197.  
The second ligation site was placed between Ala227 and Val228. The N-terminal fragment 
Tau[Cys228-441] (45) was designed with a valine/cysteine mutation at position 228 to enable ligation 
to the full-length tau protein. The natural tau protein features two cysteines at positions 291 and 322, 
which are thought to play a role in preventing the protein to stabilize microtubules during aging. [295] To 
maintain the integrity of these residues, no desulfurization of the second ligation site was possible. This 
proposed three-fragment ligation scheme therefore yields the full-length tau protein with a single 
Val228Cys mutation.  
A single phosphorylation at pSer214 was envisioned as first modification target, because it was shown 
to promote downstream phosphorylation by GSK-3. [267] It is incorporated into the synthetic fragment 
with the commercially available Fmoc-Ser(O(OP(OBzl)OH)-OH building block. 
  
Figure 43: A three segment N-to C-terminal ligation strategy was devised. The first ligation was placed between 
Gly196 and Tyr197 and the second ligation site was between A227 and V228. Consequently, two recombinant 
Tau fragments (Tau[1-196]-SR and Tau[Cys228-441]) and one synthetic fragment (Tau[(β-SH)Tyr197-227]-
NHNH2 with a novel β-mercaptotyrosine derivative at the N-terminus and an acyl hydrazine C-terminus as 
thioester precursor. 
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4.2.1.1 Cloning and ligation of Tau[1-196]  
Tau[1-196] was cloned from human MAPT and fused into a pTXB1 vector from the IMPACT® system. 
The vector is equipped with a self-splicing intein, where the cleavage is initiated by the addition of a 
thiol like DTT or MesNa to release a C-terminal thioester. Besides the intein, the vector also contains a 
chitin binding domain (CBD) for immobilization on chitin binding resin (see chapter 2.3.2.3.1).  
The protein was expressed in E. coli T7 express cells and a small sample of lysate was analyzed using 
SDS-PAGE to confirm overexpression of the protein (see Figure 85). The cell lysate was immobilized 
on chitin binding resin. After thorough washing, the intein cleavage was induced by the addition of 50 
mM DTT overnight at room temperature. The DTT thioester is known for its quick hydrolysis upon 
release. A single band at about 25 kDa showed the release of Tau[1-196] (43) the next day (see Figure 
86). 
Having Tau[1-196] in hand, the accessibility and efficiency of its thioester and the ligation side was 
assessed. For this, peptide Tau[Cys197-228]-NHNH2 without and with a pSer214 residue (47a and 47b 
respectively) were synthesized, with a provisionary mutation at Tyr197Cys as reaction handle to check 
whether the ligation site was accessible or not. Due to the high proline and valine content, as well as the 
large number of serine and threonine residues, peptide 47a contains several sterically challenging 
couplings. To give enough room to the extending peptide, it was synthesized on a low-loading NovaPEG 
HMPB resin, known for its excellent swelling properties. Prolines and valines were double-coupled, 
while threonine was subjected to longer coupling times. Despite the challenging synthesis, peptide 47 
was successfully isolated after cleavage with 95:2:2:1 TFA:TIS:DTT:thioanisole and used further to 
test the feasibility of the EPL with Tau[1-196] (see Scheme 43).  
The EPL was performed at the same time as the intein cleavage on beads in a one-pot reaction. For this 
purpose, the Tau[1-196]-intein-CBD was first immobilized onto the chitin beads and the resin was 
thoroughly washed. Afterwards, a buffer containing peptide 47a and 100 mM MesNa at pH 8.5 was 
added and the ligation was allowed to proceed overnight at room temperature. Analysis by SDS-PAGE 
revealed two bands, one belonging to the unligated Tau[1-196], while the second was assigned to the 
ligated Tau[1-227]Cys197-NHNH2 (48) (see Figure 86 in the experimental part). The ligation yield was 
estimated to be 85 % (by SDS-PAGE). The success of this ligation demonstrated the accessibility of the 
chosen site for expressed protein ligation.  
Scheme 43: Intein cleavage of Tau[1-196] is induced by incubation with 100 mM MesNa and the generated 
thioester 43 immediately reacts with the Tau[Cys197-227]-NHNH2 (47a) to yield Tau[1-228]-NHNH2 (48). 
RESULTS AND DISCUSSION 
 
122 
 
4.2.1.2 Expression and ligation of Tau[Cys228-441] 
Following the successful expression and enrichment of Tau[Cys228-441], the His-Tag was removed 
enzymatically by Factor Xa. For this purpose, a set of cleavage conditions were screened to test the His-
Tag removal from 10 μg His-tagged Tau[Cys228-441]. Different Factor Xa concentrations (0.3 μg/μL 
and 0.5 μg/μL) and different temperatures (20 °C, 25 °C) were tested for efficiency over a period of 22 
hrs, in which samples were taken at specific time points to evaluate the progress (see Figure 44). 
Independent from temperature and enzyme concentration, protein loss was observed when the cleavage 
time was extended to over 6 hrs. The highest cleavage efficiency was observed for the mildest conditions 
at 20 °C and an enzyme concentration of 0.3 μg/μL with roughly 80 % (Figure 44, lane 13, as estimated 
by SDS-PAGE). The mildest conditions (0.3 μg/μL enzyme and 20 °C) were chosen for further testing 
and the cleavage was scaled up to 100 μg protein. Unfortunately, the enzyme’s efficiency could not be 
reproduced during the cleavage of larger amounts of protein (see Figure 88 in the experimental part) 
with only about 50 % of cleavage after 6 hrs (as estimated by SDS-PAGE).  
Since the upscale of Factor Xa mediated His-tag cleavage could not be further optimized, an alternative 
protease was considered. Both thrombin and TEV have been reported to be compatible for the release 
of N-terminal cysteinyl proteins. [348][349] After careful evaluation, a TEV cleavage was chosen, because 
the enzyme can be expressed in the laboratory in large quantities. It is furthermore known for its high 
specificity and superior efficiency at low temperatures.  
The DNA was re-cloned to contain the TEV cleavage site at the N-terminus (ENLYFQ_C) and was 
then ligated into a pET16b vector (Novagen) at the restriction sites BamHI and XhoI. While the 
mutagenesis was straight-forward, the insertion into the new vector was challenging. It finally 
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Figure 44: Upscaling of His-Tag cleavage from His-tagged Tau[Cys228-441] with Factor Xa using 10 and 90 μg 
of protein. The cleavage was conducted at 20 °C and with an enzyme concentration of 0.3 μg/μL. The efficiency 
of cleavage decreased with larger amounts of protein used. 
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succeeded when the vector and insert digest were performed with the BamHI-HF® and XhoI enzymes 
from NEB instead of the FastDigestTM enzymes, and fresh T4 ligaseTM was used for ligation.  
The new protein was expressed in E. coli T7 express cells and the cell lysate was purified by His-Tag 
affinity chromatography and concentrated in a TEV suitable buffer, containing 50 mM TRIS.HCl (pH 
8.0), 0.5 mM EDTA and 1 mM DTT. This yielded a thick band in the expected region on the SDS-
PAGE and the desired mass was observed by MALDI.  
The His-Tag cleavage efficiency was tested again and the protein was subjected to different 
protein:enzyme ratios at 4 or 20 °C. To do so, the temperature-sensitive TEV protease was freshly 
expressed and stored at -80 °C in glycine-enriched buffers to increase its lifetime (see 6.3.2 in the 
experimental part). Excellent results were obtained for the largest protein:enzyme 100:1 ratio and 20 
°C, where over 90 % of cleavage was detected by SDS-PAGE after 24 hrs of incubation with no side 
product formation due to unspecific cleavage (see Figure 45, lane 7 and section 6.3.1.4 in the 
experimental part).  
To purify the protein from traces of undigested protein and TEV protease (which was equipped with a 
His-Tag), it was passed over Ni-NTA beads again (see Figure 46). To avoid unspecific binding of the 
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3: after 1 hr 
4: after 2 hrs 
5: after 4 hrs
6: after 6 hrs
7: after 24 hrs
8: pos. control
9: neg. control
1 2 3 4 5 6 7 8 9
Figure 45: TEV cleavage at 20 °C with a protein:enzyme of 100:1 monitored over 24 hrs with freshly expressed 
protein. The positive control was performed with a commercially available TEV protease and no enzyme was 
added to the negative control. 
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Figure 46: Ni-NTA affinity chromatography was used to separate non-tagged Tau[Cys228-441] from still tagged 
Tau[Cys228-441] to obtain a pure protein. 
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digested Tau[Cys228-441] to the metal-coated beads, a minimum of 20 mM imidazole had to be added 
to the incubation buffer. It was found that the use of too much imidazole inhibited the immobilization 
of the His-tagged Tau protein. Following this procedure, Tau[Cys228-441] (45) could be obtained in 
high purity for future ligations.  
To test the reactivity of the N-terminal cysteine, the short test peptide Tau[200-227]-NHNH2 (49) was 
synthesized and tagged N-terminally with a biotin tag to be able to detect the ligation product by Western 
blotting with an anti-biotin antibody. As thioester precursor, a hydrazine was chosen. This was activated 
in a two-step process, where the peptide was first oxidized to the corresponding hydrazide with NaNO2 
at -10 °C for 15 mins. Afterwards, the peptide was added to the buffered protein solution containing 
100 mM of activating thiol at pH 7.0. The reaction was quenched after 24 hrs with TCEP to reduce any 
peptide hydrazide and disulfides.  
Two different activating thiols (MesNa or MMBA) and buffers were tested (see Figure 47). While 
MesNa is less reactive, it has a higher stability than the MMBA thioester, which reacts faster, but is 
prone to hydrolysis. Peptide 49 reacted readily with tau protein 45 in both buffers with MesNa as 
activating thiol. In all cases, ligation product 50 was visible, indicated by the formation of a new band 
at a slightly higher shift than the starting material 45. After 24 hrs, the ligation with MesNa had 
proceeded to > 90 % of product 50 (quantified by SDS-PAGE). The ligation with MMBA progressed 
more quickly than with MesNa, but did not yield more than 80 % of ligated protein (quantified by SDS-
PAGE) in sodium phosphate buffer. It was difficult to handle because of the limited solubility of MMBA 
at pH 7.0. Product formation was confirmed for both cases by Western Blot with an anti-biotin antibody.  
Figure 47: Protein ligation of Tau[Cys228-441] with short Tau peptide[200-227], tagged with a biotin for detection 
by Western Blotting with anti-biotin antidy. All ligations were carried out at pH 7.0. 
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The successful ligation of the short peptide to Tau[Cys228-441] confirmed the availability of the N-
terminal cysteine for protein ligations. Furthermore, the acyl hydrazine as thioester precursor was shown 
to undergo ligation in both buffers with two different thiols. After confirming the accessibility of both 
proposed ligation sites, we proceeded with the design and synthesis of the novel β-mercaptotyrosine 
amino acid building block to be inserted as ligation handle at Tyr196. 
4.2.1.3 Design and synthesis of β-mercaptotyrosine 
The synthesis route for β-mercaptotyrosine was based on the synthesis of β-mercaptophenylalanine as 
described by Crich et al. and encompasses an initial bromination step and oxazolidinone formation to 
yield enantiomerically pure β-hydroxytyrosine. The hydroxyl group is then activated to a good leaving 
group and subsequently replaced by thioacetic acid by nucleophilic substitution (SN2). In a final step, 
SPPS-compatible protecting groups are introduced into the molecule (see Scheme 44). [144]  
The carboxylic acid of N-Boc tyrosine 51 was first protected with a methyl group and with a second 
Boc group to minimize the risk of side reactions during the subsequent radical bromination step with 
N-bromosuccinimide in freshly distilled and refluxing carbon tetrachloride to yield the corresponding 
diastereomeric bromide 53 in a 1:1 ratio. Oxazolidinone formation was induced by the addition of silver 
nitrate in acetone, yielding diastereoisomers 54a and 54b. The ring was hydrolyzed with Cs2CO3 in 
acetone and the enantiomerically pure (2S,3S)-hydroxytyrosine 55 was obtained in good yields. [350] 
Scheme 44: Proposed synthesis for β-mercaptotyrosine starting from Boc-Tyr(OtBu)-OMe. After bromination 
and oxazolidinone formation, ring opening results in the formation of enantiomerically pure (2S,3S)-
hydroxytyrosine. The hydroxyl group is activated and replaced by thioacetic acid to yield β-mercaptotyrosine. 
Deprotection of the carboxylic acid and replacement of the thiol protecting group to SPPS-suitable disulfide 
completes the synthetic route. 
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Next, the substitution of the hydroxyl was addressed. For this purpose, the alcohol was treated with 
mesylene chloride and triethylamine in DCM at 0 °C and then reacted without further purification with 
thioacetic acid and DBU to generate 56. Only very little product formation could be detected by MS 
(m/z 426.6 [M+H]+). To find the source of the low yield, the activation was repeated to ensure 
mesylate 58 has successfully formed (see Scheme 45). Instead of detecting the mesylate, elimination 
product 59 (m/z 350.5 [M+H]+) was the major product after alcohol activation. This suggested that the 
mesylate did form at first, but is then such a good leaving group that it eliminates straightaway in the 
presence of excess of triethylamine via an E2 mechanism. When reducing the amount of base to avoid 
the premature elimination, the activation did not occur at all and only starting material was detected 
after overnight reaction at room temperature. In an attempt to reduce the leaving group propensity, tosyl 
chloride instead of mesyl chloride was used to see whether the tosylate was less prone for elimination 
than the mesyl, but the same result was obtained and only elimination product was detected by MS.  
Other alcohol activation methods were also employed to achieve a successful replacement with 
thioacetic acid. A Mitsunobu-type of reaction, where triphenylphosphine is first reacted with DIAD to 
form a highly reactive phosphonium salt, which can activate the alcohol for nucleophilic 
substitution. [351] The reaction is highly specific with complete inversion of the stereocenter. Despite 
using a low reaction temperature of -40 °C to avoid potential side reactions, only elimination product 
could be detected and no product formation was observed. Equally unsuccessful was a method published 
by Kawano et al., which uses the Vilsmeier reagent generated by the reaction between DMF and oxalyl 
chloride as mild activation reagent. [352] As similar problems were previously not reported for 
β-hydroxyphenylalanine, a potential problem was assigned to the activating role of the p-OtBu group. 
Scheme 45: Activation of the hydroxyl group of Boc-(β-OH)Tyr(OtBu)-OMe with mesyl chloride and Et3N did 
not result in the formation of the activated amino acid derivative 58, but in elimination to compound 59.  
Scheme 46: Lewis acid-catalyzed thioesterification as described by Gauthier et al. 
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We hypothesized that the electron-donating properties of the phenol protecting group increased the 
electron density at the β-carbon, thereby promoting the formation of a carbocation during the 
substitution reactions and increasing the chance of an elimination reaction to occur.  
To avoid the use of a base in the reaction, a different approach developed by Gauthier et al. was 
taken. [353] In contrast to before, the thioesterification is catalyzed by the Lewis acid zinc iodide in the 
presence of thioacetic acid (see Scheme 46). The reaction was reported to proceed well with benzylic 
alcohols attached to aromatic rings with electron-donating groups in the para position. While 55 was 
fully used up during the reaction, product 60 could not be observed in the MS or isolated by silica gel 
column chromatography.  
The silver-promoted oxazolidinone formation (53 to 54a/b) as shown in Scheme 44 relies on the good 
leaving group properties of the β-bromide and the presence of a suitable nucleophile, in this case the 
carbamate of the Boc-group, in the vicinity. In fact, Easton et al. used a similar approach to synthesize 
β-hydroxytyrosine from a β-bromotyrosine, where silver nitrate helped to abstract the bromide and 
water acted as a nucleophile. [354] 
With this in mind, a β-bromotyrosine 61 was synthesized by irradiating Boc-Tyr(OtBu)-OMe in the 
presence of NBS and reacted with potassium thioacetate in DMF. [355] However, despite adding additives 
like silver nitrate, silver oxide or potassium carbonate and screening different solvents, compound 60 
could not be obtained (see 6.3.5.4.5). 
To change the electronic properties of the system and thereby reduce the tendency of the system to 
eliminate, a change in the protecting group of the phenol was undertaken next and the tert-butyl group 
was replaced by an electron-withdrawing benzyl group.  
As the benzyl group is not stable to the radical bromination step used in the previous synthesis, a 
different route had to be designed to incorporate a hydroxyl function at the β-position. It is based on 
Sharpless’ asymmetric aminohydroxylation, originally published in 1997, which permits the installation 
of 1,2-amino alcohols into alkenes with N-halocarbamates using a catalytic amount of OsO4. [356] In 
particular, this reaction can be adjusted to the needs of the synthesis in a straight-forward manner. The 
regio- and enantioselectivity is determined by the nature of the chiral ligand used. The regioselectivity 
Scheme 47: Reaction of β-bromotyrosine 61 to β-mercaptotyrosine 60. 
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is influenced by the use of a phthalazine (PHAL) or an anthraquinone (AQN)-based scaffold, whereas 
the enantiomeric ratio depends on whether dihydroquinine or dihydroquinidine moieties are 
employed. This is further illustrated in Figure 48.   
As the target of the synthesis was to be an amino acid with a β-hydroxyl group a AQN-based scaffold 
was chosen. To obtain the correct stereochemistry of the α-proton, the DHQD-substituted AQN would 
have to be used in the synthesis. This would result in the inverted stereochemistry of the β-proton than 
in the previously used synthetic route, but as previously mentioned no significant change in NCL 
reactivity was expected to arise from this inversion.  
Unfortunately, the (DHQD)2AQN ligand was commercially unavailable at the time of the experiments. 
Assuming that the success of the thioesterification was not dependent on the stereochemistry of the α-
proton, the reactions were consequently carried out with the available (DHQ)2AQN ligand. If successful, 
the reactions would then have to be repeated with the correct ligand at a later point in time.  
Figure 48: The regio- and enantioselectivity of the asymmetric aminohydroxylation depends on the use of the 
correct ligand. It is also depend on the character of the carboxylic acid and phenol protecting groups. 
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As shown in Scheme 48, the carboxylic acid of cinnamic acid 62 was first methyl-protected to yield 
cinnamate 63. The olefin was then reacted with a catalytic amount of potassium osmate dihydrate, the 
alkaloid ligand and a carbamate in the presence of an oxidant to yield the β-hydroxytyrosine derivates 
64a/b in good yields. In the final step, the phenol was protected with benzyl bromide and Cs2CO3 and 
compounds 65a/b were isolated in excellent yields. The phenol protection was left until the end to 
increase the regioselectivity of the asymmetric aminohydroxylation. [357] 
Compound 65a was subjected to the same series of thioesterification reactions as tried before, including 
a zinc-promoted replacement by thioacetic acid as well as a Vilsmeier-based and a Mitsunobu-type of 
reaction. When attempting to activate the alcohol with mesyl or tosyl chloride, the picture was quite 
different to before. Instead of obtaining an elimination product as a result of the activation, either no 
activation at all or very little activation was observed by MS. Bromination of compounds 65a/b failed 
to yield the correct products as well.  
The difficulties in the design of a synthetic route for β-mercaptotyrosine let to a re-evaluation of the 
amino acid derivative in SPPS. While β-hydroxyphenylalanine and β-mercaptophenylalanine were 
stable to piperidine-promoted Fmoc removal and the strongly acidic cleavage conditions, the 
elimination propensity of β-hydroxytyrosine in a variety of different organic reactions show that this 
amino acid acts quite differently. While β-mercaptotyrosine was not available as a substrate to test its 
stability to SPPS conditions, it is very likely that it behaves analogously to β-hydroxytyrosine. 
Compound 65a was first subjected to TFA cleavage conditions with and without the cationic scavenger 
thioanisole to catch the benzyl cations formed during the deprotection. [358] 
 TFA (%) H2O (%) Thioanisole (%) 
Cocktail 1 90 10 0 
Cocktail 2 80 10 10 
Cocktail 3 65 10 25 
Table 11: Different TFA cocktails used to evaluate the stability of the β-hydroxyl group of β-hydroxytyrosine 65a 
during SPPS. 
Scheme 48: Synthesis of β-hydroxytyrosine via aminohydroxylation with a benzyl-protected phenol and a Boc- 
or Cbz-protected amine. 
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After use of either of these three cleavage cocktails, no intact β-hydroxytyrosine derivative 65a could 
be detected by analytical HPLC and MS. Instead, the most dominant species was the β-elimination 
product, followed by an adduct of thioanisole and tyrosine, where thioanisole was linked at the 
β-position. When thioanisole was used, the benzyl group was found attached to the β-position instead. 
Further literature research showed that β-hydroxytyrosine 65a had so far not been built into a 
fully-protected peptide using Fmoc-based SPPS. As part of the total synthesis of vancomycin, it was 
introduced as unprotected amino acid into a hexa- or heptapeptide of equally unprotected building 
blocks on 2-chlorotrityl resin. The final cleavage only required 0.6 % TFA in DCM, for which the 
incorporated β-hydroxytyrosine building block was sufficiently stable. [359] Konno et al. reported that 
β-hydroxytyrosine showed some stability to 4N HCl/dioxane, although this would still not be enough 
to incorporate the building block into a long peptide with a wide variety of different protecting groups 
that require harsher cleavage conditions. [360] 
In knowledge of the instability of β-hydroxytyrosine to strongly acidic conditions and the difficulty to 
replace the hydroxyl group with a thiol functionality, the synthesis of β-mercaptotyrosine was 
discontinued. Instead, a different ligation site was chosen that circumvented the use of the tyrosine 
derivative and instead settled on the use of the previously published β-mercaptoaspartic acid. [361] 
Aspartic acid is a natural amino acid at position 193 of the tau protein and is therefore a suitable 
alternative for this semi-synthesis.  
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4.2.2 A revised N-to C-terminal ligation strategy 
In this altered strategy, the first ligation is moved to Gly192 and Asp193, while the second ligation site 
is left between Ala227 and Cys228. Asp193 is replaced by β-mercaptoaspartic acid in the peptide for 
ligation and the C-terminus is still synthesized with an acyl hydrazine as thioester precursor.  
4.2.2.1 Synthesis of β-mercaptoaspartic acid 
Payne’s group published a robust synthesis protocol for the synthesis of β-mercaptoaspartic acid 72 (see 
Scheme 49). [361] Boc-Asp(OtBu)-OH was first protected with an allyl group to yield 68. The β-proton 
was removed by LiHMDS and the molecule was then sulfenylated to 71 with freshly synthesized 
sulfenylating reagent 70. A final allyl deprotection by reaction with a 10 mol % of Pd(PPh3)4 and 
Figure 49: A revised N-to C-terminal ligation strategy with a new ligation site between Gly192 and Asp193 was 
designed, where the second ligation site between Ala227 and Cys228 remained the same. The end product after 
two ligations and one intermediate desulfurization is the same as in the original N- to C- ligation. (protein 46). 
Scheme 49: Synthesis scheme for β-mercaptoaspartic acid 72 by Thompson et al.. 
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phenylsilane in acetonitrile afforded the final, enantiomerically pure product 72 (as determined by 
1H-NMR) at 62 % yield.  
4.2.2.2 Cloning and ligation of Tau[1-192] to Tau[1-227]-NHNH2 
Due to the changes in the ligation strategy, a new N-terminal fragment Tau[1-192] was cloned into the 
pTXB vector starting from the full-length human MAPT. The expression of the protein was optimized 
for cell lines, IPTG induction concentration and temperature. The best results were achieved in E. coli 
BL21 (DE3) cells induced with 0.5 mM IPTG and incubated at 28 °C during expression. After 
purification over chitin beads and intein cleavage in 50 mM TRIS, 0.5 M NaCl and 0.1 % Triton with 
100 mM MesNa at pH 8.5, the protein could be detected by SDS-PAGE and MALDI. 
Before incorporating β-mercaptoaspartic acid into the ligation, Tau[Cys193-228]-NHNH2 (73a) was 
synthesized to optimize the first ligation. Peptide 73a was synthesized on hydrazine-functionalized resin 
in a yield of 18 %. Another peptide synthesis yielded the peptide with a pSer214 residue (73b). For the 
ligation, the freshy expressed and lysed tau intein fusion protein was first immobilized on CBD beads, 
thoroughly washed to remove all unwanted proteins, before a reaction mixture of peptide 73a with either 
2, 5 or 10 eq. and 100 mM MesNa in 50 mM TRIS buffer with 0.1 % Triton was added over a period of 
24 hrs. The reaction was performed at room temperature as well as at 37 °C and its progress was 
evaluated by SDS-PAGE. Product formation was furthermore confirmed by MALDI (see 6.3.4.3 in the 
experimental part). As shown in Figure 50, higher peptide equivalents and elevated temperatures 
resulted in better ligation yields. Nevertheless, there was a nonnegligible amount of co-elution from 
non-cleaved tau-intein-CBD fusion protein during the on-bead ligation. Additionally, cleaved CDB-
intein was also released, although it should have remained attached to the beads. While the ligation itself 
worked readily and went towards completion when employing 5 eq. of peptide at 37 °C, the ligation 
Figure 50: Screening for optimal ligation conditions to obtain Tau[1-227]-NHNH2 (74). Temperature and peptide 
equivalents were tested over a period of 24 hrs. Co-elution of CBD-intein and uncleaved Tau[1-192] intein fusion 
protein was observed. 
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conditions have to be improved further to avoid additional purification at later stages. This is particularly 
important, because the full-length Tau[1-441] and the fusion protein have similar molecular weights, 
rendering them difficult to separate once the second ligation has been performed. The most straight-
forward way to remove the CBD-functionalized proteins from the solution – repassing them over new 
chitin beads – did not yield the desired result. 
Two potential reasons were identified for causing the undesired co-elution of the fusion protein and the 
CBD-intein. Firstly, it was previously reported that preliminary release of chitin constructs can occur 
when the intein cleavage from the fusion protein does not proceed well (General FAQ for NEB IMPACT 
kit). While the ligation efficiency of the Tau[1-192] thioester to Tau[1-227]-NHNH2 looks promising, 
this gives no indication about the efficiency of the intein cleavage itself. A look at the boiled chitin 
beads after intein cleavage with 100 mM MesNa showed that only a portion of the fusion protein was 
cleaved with the intein cleavage conditions used until this point (see Figure 92 in the experimental part). 
This implies that increasing the efficiency of the intein cleavage could help to avoid the release of the 
uncleaved fusion protein. Secondly, the use of detergents, in this case 0.1 % Triton, can also increase 
the potential of co-elution of the fusion protein. Detergents are meant to minimize any interaction of the 
newly generated protein thioesters with the chitin beads to maximize the amount of eluted protein 
thioester. Surprisingly, Figure 92 shows that some of the cleaved protein thioester also remained 
attached to the beads, despite the use of detergent in the buffer. Moreover, detergents are difficult to 
remove afterwards. They are either removed by continuous dilution and concentration or the addition 
of expensive absorption beads. Instead of using Triton to increase the elution power from the beads, a 
higher salt concentration can perform the same function without disturbing the binding affinity between 
chitin and the CBD. By altering the buffer system, we hoped to also increase the cleavage efficiency of 
the intein fusion protein and thereby address two issues at once. 
Several buffers with altering salt concentrations, but without detergent, were screened for the specific 
release of Tau[1-192] from the CBD beads. Besides, 4 °C as well as 23 °C were evaluated to gather 
more information about the effect of temperature on the co-elution and cleavage efficiency of the fusion 
protein. The results are shown in Figure 51. Performing the intein cleavage at higher temperatures 
resulted in the elution of more protein thioester, which can be explained by a slower overall intein 
cleavage rate at 4 °C in comparison to 23 °C. Furthermore, the use of a lower intein cleavage temperature 
also led to a higher elution of fusion protein. It is unclear whether this is a result of a poorer intein 
cleavage or whether the lower temperature affects the binding affinity of the fusion protein to the beads. 
A clear trend for the co-elution of fusion protein could be observed when increasing the salt 
concentration of the cleavage buffer at 23 °C (Figure 51, lanes 2 to 7). Higher salt concentrations 
resulted in less fusion protein co-elution and also had a positive effect on the amount of protein thioester 
released from the beads. The cleanest Tau[1-192] thioester 66 was acquired with 1.5 M NaCl at 23 °C 
after 24 hrs, while some co-elution was observed again once the intein cleavage time was increased to 
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40 hrs (Figure 51, lane 6 and 7). The beads, meanwhile, were devoid of any intein-cleaved Tau[1-192] 
thioester 66 and only retained the CBD-containing proteins (see 6.3.1.5.1, Figure 94). The optimized 
intein cleavage was able to provide a cleaner protein thioester for the first ligation, augmented the 
amount of eluted Tau[1-227]-NHNH2 (74) for the next ligation step and avoided the need to introduce 
an additional purification step to remove co-eluted fusion protein before the second ligation. 
4.2.2.3 Ligation between Tau[1-227]-NHNH2 and Tau[Cys228-441] 
Tau[1-227]-NHNH2 (74) was obtained using the optimized EPL conditions described in chapter 4.2.2.2 
in a 50 mM TRIS buffer at pH 8.5. For the second ligation, the protein had to be rebuffered to 0.2 M 
NaH2PO4 with 6 M guanidinium hydrochloride (Gn.HCl) at pH 3, since the activation of the acyl azide 
at the C-terminus can only be performed at acidic pH. Thanks to tau’s lack of a secondary structure and 
intramolecular interactions, the protein was expected to be stable to the drastic change in pH for a short 
period of time.  
The correct method of rebuffering had to be identified at first. The protein was first transferred to a 
buffer with 0.2 M NaH2PO4 and 6 M Gn.HCl at pH 7. A gradual decrease of pH by slow addition of 
1 M HCl led to protein precipitation. To avoid protein precipitation, spin-filtration was used to slowly 
rebuffer the protein to pH 5 first, before the protein was transferred to pH 3. In this case, all of the 
protein remained in solution. For activation, 10 eq. of NaNO2 were added at -15 °C for 15 minutes under 
continuous stirring. Tau[Cys228-441] (45) was added in a 0.2 M NaH2PO4 and 6 M Gn.HCl at pH 7 
containing 100 mM MesNa and the pH was adjusted to pH 7. The ligation was performed overnight and 
Figure 51: Optimization of the intein cleavage of N-terminal Tau[1-192]-intein-CBD for a clean release of 
Tau[1-192] MesNa thioester 66. The unclear bands are due to the high salt concentrations for the intein 
cleavage. 
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then analyzed by SDS-PAGE (see Figure 105 in the experimental part). Unligated Tau[Cys228-441] 
(45) and a sample of inactivated Tau[1-227]-NHNH2 (74) served as references. No product formation 
could be observed by SDS-PAGE. Instead, a closer look at the probe of Tau[1-227]-NHNH2 (74) 
revealed the formation of a multitude of new bands, suggesting that some protein degradation had taken 
place during rebuffering with spin-filtration.  
Before continuing to work on the second protein ligation, the stability of Tau[1-227]-NHNH2 (74) to 
pH changes was investigated further. For this, protein aliquots were taken during the step-wise 
rebuffering by spin-filtration and analyzed by SDS-PAGE. As shown in Figure 52, the amount of 
Tau[1-227]-NHNH2 (74) in solution decreased gradually as the pH of the buffer decreased (lanes 1 to 
3). Figure 52 also shows that once the protein was successfully transferred to pH 3 and activated by the 
addition of NaNO2, no further significant decrease in protein was could be detected (lanes 3 to 5). This 
suggests that the problem of protein loss might be solved by a different method of rebuffering and is 
not directly related to the low pH.  
As first alternative, stepwise dialysis was attempted, but this led to the same decrease of dissolved 
protein (see 6.3.4.4.2 in the experimental part). To circumvent a procedure where the protein was 
gradually transferred to pH 3 from neutral pH, a routine was established where the protein was first 
transferred into an ammonium bicarbonate buffer that is removable by lyophilization. The protein could 
then be stored at -20 °C as white solid until it was dissolved in acidic medium for activation. As shown 
in Figure 53, this technique resulted in no protein loss or degradation, despite the additional step. 
26
34
43
1 2 3 4 5
1 = 6 M Gn.HCl (pH 7)
2 = 6 M Gn.HCl (pH 5)
3 = 6 M Gn.HCl (pH 3)
4 = 6 M Gn.HCl + 10 mM NaNO2
 (15 min)
5 = 6 M Gn.HCl + 10 mM NaNO2
 (40 min)
Tau[1-227]-NHNH2
Tau[1-192]
Figure 52: Tau[1-227]-NHNH2 was gradually rebuffered to 6 M Gn.HCl buffer (pH 3) using spin-filtration (lanes 
1 to 3). The process of rebuffering resulted in a high loss of protein. Afterwards, the protein was activated with 10 
mM NaNO2 and SDS probes were taken to analyze the stability of the protein to these conditions (lanes 4 and 5). 
Exposure to NaNO2 did not result in a significant decrease of protein. 
34
43
55
1 2
1: Before transfer, lyophilization and dissolving
2: After transfer, lyophilization and dissolving
Tau[1-227]-NHNH2
Tau[1-192]
Figure 53: Rebuffering of Tau[1-227] by transfer to 20 mM NH4HCO3, lyophilization and dissolving just 
before use did not result in protein loss. 
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After having established a reliable procedure to transfer Tau[1-227]-NHNH2 (74) into the activation 
buffer, 74 was converted into an active thioester by activation with NaNO2 and addition of MesNa. 
Before focusing on performing the ligation to generate full-length tau with Tau[Cys228-441] (45), 
activated 74 was ligated overnight to a short test peptide first (peptide 75, MWG: 830 g/mol) to check 
whether the thioester formation had succeeded (see Scheme 50). The ligation was analyzed by MALDI, 
because the change in molecular weight between unligated and ligated protein would be too small to 
show a shift in the SDS-PAGE. Protein 76 was detected by MALDI and a conversion of roughly 50:50 
was noted, despite using unoptimized ligation conditions (see 6.3.4.5). Importantly, no reaction was 
observed when the thiol was omitted from the protocol, ensuring that it was the thioester that had reacted 
in the ligation, not the activated hydrazide. This indicates that the C-terminal activation had been 
successful. 
Unfortunately, the ligation between tau fragment Tau[1-227]-NHNH2 (74) and Tau[Cys228-441] (45) 
did not yield the desired full-length Tau[1-441] so far. None of ligations yielded a product that was 
distinctively detectable by the tau-46 antibody (which recognizes the C-terminus of the tau protein) or 
by MALDI. On one hand, the lack of product formation was accounted to the harsh activation conditions 
of the peptide acyl hydrazine and the acidic medium the protein was exposed to, which resulted in 
protein precipitation and degradation, accompanied with low overall protein concentrations. In future 
experiments, this could be counteracted by using more protein and peptide for the first ligation to obtain 
a sufficient amount of 74 for the second ligation. On the other hand, a recent publication by Lashuel’s 
group showed that the excess of oxidizing agent sped up the hydrolysis of the protein thioester, 
rendering it unavailable to ligation. [338] The accelerated hydrolysis of the active protein thioester of 74 
would explain why the ligation to the small peptide 75 succeeded, while the ligation to protein 45 failed. 
The ligation would proceed considerably faster with a smaller, less bulky partner like peptide 75 than 
with a protein and therefore be able to compete with thioester hydrolysis. The ligation to the protein, on 
the other hand, would be too slow to do the same and no reaction could occur. To prevent this, the 
activated protein thioester of 74 should be separated from the oxidizing reagent before ligation.  
Even though Tau[1-441] could not successfully be generated with this strategy, some core challenges 
were addressed. Firstly, the proteins were successfully cloned and expressed and the peptide synthesis 
of the intermediate fragment was optimized. Secondly, the intein cleavage of Tau[1-192] was optimized 
to prevent an additional purification step after the first ligation and ideal conditions for the first ligation 
to Tau[1-227]-NHNH2 were determined. Thirdly, the accessibility of the two ligation sites was 
Scheme 50: Test ligation of Tau[1-227]-NHNH2 (69) and short peptide 75 to protein 76. 
RESULTS AND DISCUSSION 
 
137 
 
demonstrated with test peptides. While further optimization of the second ligation is needed, the strategy 
looks promising in developing an approach to site-specifically modify the tau protein within the proline-
rich domain. 
4.2.3 A C- to N-terminal ligation strategy 
The C- to N-terminal strategy is an established mean in the semi-synthesis of proteins, because it doesn’t 
require the harsh acidic conditions for C-terminal activation as employed during the N- to C-terminal 
strategy in chapter 4.2.1. The C- to N-terminal strategy differs in two aspects from the previous route:  
1) The final product will, in order to maintain the natural cysteine residues in the C-terminal 
fragment, contain two unnatural cysteine residues at the ligation sites. Alternatively, the 
cysteines can be reduced in entirety to ease the handling of the protein and to avoid the 
formation of unwanted secondary interactions between the unnatural and natural cysteines. 
2) The middle synthetic fragment will change significantly at the N- as well as the C-terminus. A 
thiazolidine will serve as a N-terminal cysteine protecting group to prevent internal cyclization. 
The thiazolidine is stable to SPPS conditions and to the reaction conditions needed for the first 
ligation. Its deprotection is performed by methoxylamine at pH 4 and the produced cysteine can 
then undergo the second ligation. The C-terminus, which will be used for the first ligation, is a 
Dbz-thioester precursor that is easily exchanged with MesNa to form a reactive thioester. The 
use of the C-terminal acyl hydrazine was not possible at this stage, because of the 
incompatibility with the deprotection conditions of the N-terminal thiazolidine. 
Figure 54: A C- to N-terminal ligation strategy. The synthetic fragment 77 features a Dbz thioester precursor at 
the C-terminus and a thiazolidine as N-terminal protecting group. The first ligation takes place between 
Tau[Cys228-441] (45) and peptide 77. No desulfurization will be performed to leave the natural cysteines intact. 
The second ligation will yield full-length tau 78 with two cysteine mutations. 
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Besides the changes in the middle fragment, no additional cloning work has to be performed to realize 
this methodology, since the ligation sites remain the same.  
4.2.3.1 Ligation of Tau[Thz193-227]-Dbz and Tau[Cys228-441] 
Peptide 77 was first synthesized on pre-loaded Nbz resin purchased from Novabiochem. The Nbz linker 
was first protected with Alloc to avoid the formation of a second side chain during SPPS. The peptide 
was then elongated to the end, before the Alloc group was removed and the available amine was reacted 
with p-nitrochloroformate and DIPEA to generate the final Dbz linker. [156] After full cleavage from the 
resin with TFA, peptide 77 was purified and isolated at 8 % yield. To avoid the additional Alloc 
protection and deprotection, the synthesis was later performed with the N-methylated version of Dbz 
that does not require this step and generated peptide 79 in fewer steps with a higher reliability. [157]  
The first protein ligation between peptide 77 and Tau[Cys228-441] (45) was performed at pH 8.0 in 
0.2 M NaH2PO4 and 6 M GnHCl buffer with 100 mM MesNa. A clear shift was visible after ligation 
and the yield of protein 80 was estimated to be 50 %. Product formation was also confirmed by MALDI 
analysis. 
4.2.3.2 Ligation of Tau[1-192]-SCH2CH2SO3- and Tau[Thz193-441] 
The second ligation can be performed either on beads or in solution. A reaction on beads can occur 
immediately after thioester formation, reducing the risk of thioester hydrolysis before the ligation can 
take place. On the other hand, this type of ligation gives no indication about the amount of protein 
released after intein cleavage and it is possible that the ligated protein aggregates or interacts strongly 
Scheme 51: Synthesis of peptides 77 and 79. 
Figure 55: The first ligation between Tau[Thz193-227]-Dbz and Tau[Cys228-441] to form Tau[Thz193 441]. 
The conversion was about 50 % (as determined by SDS-PAGE). 
RESULTS AND DISCUSSION 
 
139 
 
with the beads. A ligation in solution circumvents these problems, but the stability of the thioester has 
to be taken into consideration.  
For both approaches, the N-terminal thiazolidine of protein 79 was deprotected with 1 M 
methoxylamine and 0.1 M TCEP at pH 4 for 4 hrs at RT. The N-terminal Tau[1-192]-intein-CBD was 
loaded onto chitin resin, washed and a cleavage cocktail containing 50 mM TRIS (pH 8.5), 1.5 M NaCl, 
100 mM MesNa and thiazolidine-deprotected protein 79 was added for ligation. The beads were 
incubated at 23 °C for 16 hrs and the reactions were analyzed by SDS-PAGE. No ligation could be 
observed in the gel, nor did the tau antibody detected the formation of full-length Tau[1-441] (78).  
A similar approach in solution, where the N-terminal fragment was first eluted after 16 hrs of incubation 
and then mixed with the deprotected protein 73 also yielded no product. Since the elution was carried 
out at pH 8.5 with MesNa and it is known that the thioester hydrolysis proceeds faster at basic than 
neutral pHs, the integrity of the eluted thioester was tested. To do so, protein thioester 66 was eluted at 
pHs 7.5, 8.0 and 8.5 and then reacted with Tau[Cys193-228]-NHNH2 (68) overnight at pH 7.5. 
The clear increase in ligation product formation from pHs 8.5 to 7.5 showed that the intein cleavage has 
to be performed at neutral pHs to generate a stable thioester. Unsure of whether any thioester remained 
attached to the beads after elution, the beads were boiled and checked by SDS-PAGE. Gel analysis 
showed that no protein thioester 66 remained on the beads when eluting at pH 7.5 and no undesired co-
elution was observed (see Figure 94 in chapter 6.3.1.5.1). 
Several challenges still have to be addressed to complete the three-fragment C- to N-terminal ligation 
to full-length tau. Although not yet optimized, the first ligation to generate Tau[Thz193-441] delivered 
50 % conversion. While there is still room to improve the ligation yield, it is essential to find a reliable 
method to remove any traces of unligated Tau[Cys228-441] before tackling the second ligation. Unless 
removed from the mixture, Tau[Cys228-441] will compete with the deprotected Tau[Thz193-441] for 
ligation with Tau[1-192]-SR, which will result in a difficult-to-purify mixture of proteins and decrease 
the overall yield of full-length tau. Tau[Thz193-441] will therefore have to purified, either by HPLC or 
Figure 56: The pHs of the intein cleavage were changed to evaluate the stability of the thioester. All ligations were 
carried out at pH 7.5. 
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by immobilizing unligated Tau[Cys228-441] on aldehyde-functionalized solid support before it is used 
in the final ligation. Furthermore, the deprotection of Tau[Thz193-441] has to be investigated further to 
ensure the N-terminal cysteine is free to undergo the next ligation. Once these two issues are attended 
to, pure Tau[Cys193-441] can be used in the final ligation. A protocol for generating active 
Tau[1-192]-SR has been developed within this thesis and the ligation is therefore expected to proceed 
readily to deliver the desired full-length tau protein. 
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5 Conclusion & Outlook 
5.1 Project 1: Development of photo-cleavable triazole-phosphonamidate 
conjugates 
The easy and straightforward incorporation of photo-cleavable tags into peptides and proteins is a highly 
relevant tool in chemical biology. The Staudinger-phosphonite ligation allows for the selective 
introduction of a P(III) species carrying two different functionalities into an azido-containing molecule. 
Up to this point it had not been used in the context of producing removable phosphonamidates. 
In the context of this work, a new P(III) core was developed, which featured 2-nitrobenzyl substituents 
for the first time. An alkyne could be functionalized by CuAAC with any azido-containing molecule (as 
long as the phosphorus remained borane-protected) to yield 2-nitrobenzyl substituted triazole-
phosphonites. These could then be inserted into an azido-containing molecules by the Staudinger-
phosphonite reaction to generate photo-cleavable phosphonamidates.  
The weakest link of the phosphonamidate is the P-N bond. While it is sufficiently stable at physiological 
pHs, irradiation of the phosphonamidate was expected to lead to the release of 2-nitrosobenzaldeyde 
and result in the formation of a phosphonamidate acid. In this molecule, the P-N bond is less stabilized 
and becomes increasingly labile to hydrolysis. It was expected that the addition of a weak acid would 
be sufficient to fully release the tag from the molecule. Of particular interest in this context was the use 
of azido-lysine as reactive handle in the target molecule, because the cleavage of the tag leads to the 
formation of a natural lysine residue.  
2-nitrobenzyl substituted triazole-phosphonites were reacted with peptides containing either an azido-
lysine, an azido-glycine or azido-phenylalanine for attachment. The Staudinger-phosphonite reaction 
proceeded very slowly with the electron-rich azido-lysine, while going steadily with the more electron-
deficient azido-glycine and azido-phenylalanine handles. The best result was obtained with azido-
phenylalanine, where the reaction was completed after 16 hrs at 37 °C and even proceeded at room 
temperature.  
All conjugates were subjected to irradiation experiments to test the functionality of the system. The 
azido-lysine based peptidic phosphonamidates displayed excellent irradiation behavior. After 10 mins 
of irradiation at 297 nm, the corresponding lysine peptides were eluted at neutral pH without any further 
manipulation. To show the applicability of the generated aliphatic photo-cleavable phosphonamidates, 
the triazole-phosphonites were modified with biotin and immobilization and release experiments with 
streptavidin-coated beads were performed and the release of the target amine could be observed. 
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The electron-deficient phosphonamidates generated by reaction with azido-glycine and azido-
phenylalanine were more stable towards irradiation. After irradiation and release of 2-
nitrosobenzaldhyde, the P-N bond showed remarkable stability to low pHs. In case of the azido-glycine 
based phosphonamidates, side product formation was observed when the pH was lowered. To permit 
full release of the amino-tyrosine peptide from the aromatic phosphonamidate acid, incubation with 0.1 
% TFA/H2O was necessary. Similar streptavidin immobilization and release experiments as with the 
aliphatic phosphonamidates were performed to show the applicability of the aromatic 
phosphonamidates. While the specific release of the amino-tyrosine peptides could be verified, the 
streptavidin beads showed signs of degradation during prolonged treatment with 0.1 % TFA/H2O.  
To combine the enhanced reactivity of the azido-phenylalanine in the Staudinger-phosphonite reaction 
with a traceless cleavage mechanism, a 1,6 elimination linker was inserted between the aromatic ligation 
handle and the N-terminal amine. Like before, the Staudinger-phosphonite reaction proceeded well and 
irradiation of this compound resulted in the traceless elimination of the phosphonamidate.  
Further explorations of this system will focus on increasing the nucleophilic character of the 
triazole-phosphonites by adding electron-donating groups to the 2-nitrobenzyl alcohol substituents. The 
incorporation of methoxy and PEG units will serve the increase the reactivity of the system in 
Staudinger-phosphonite ligations and could also have a positive influence on the solubility of the 
molecule. Furthermore, the introduction of a methyl group at the benzylic position should be considered. 
Besides being electron-donating, the presence of this group ensures the release of a less-reactive ketone 
instead of an aldehyde during irradiation. Furthermore, the combination of the phosphonamidate-based 
tag with the 1,6-benzyl carbamate self-immolating linker will be investigated in more detail to improve 
the amine elution conditions and to extend the application to proteins. 
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5.2 Project 2: Towards the semi-synthesis of tau proteins modified in the 
proline-rich domain 
The proline-rich region of the tau protein remains one of the most intriguing area of post-translational 
modifications, hosting a number of important antibody epitopes, phosphorylation and glycosylation 
sites. To be able to introduce site-specific modifications into this part of the protein could give useful 
insights into their biological effect on structure and on downstream regulation processes. 
Two approaches were devised to address the site-specific incorporation of modifications into the middle 
of the tau protein. The chosen region encompassed residue 193 to 227, which contains several disease-
relevant AD epitopes. The ligation strategies differed in the direction of assembly and the 
desulfurization steps. Tau has two natural cysteines at residues 291 and 322 respectively, which have 
an important implication in the stabilization of the transient secondary structure and also play a part in 
tau aggregation. A ligation from the N-to the C-terminus would allow the desulfurization of the first 
ligation site without affecting the integrity of the natural residues at the C-terminus. Consequently, the 
final full-length tau protein would only contain one mutation at the second ligation site. The C- to N-
terminal semi-synthesis, on the other hand, would not offer this possibility and the final construct would 
feature two mutations at both ligation sides. Nevertheless, it is an attractive option for generating the 
full-length protein, because it exposes the protein to milder reaction conditions than in the N- to C-
terminal strategy.  
The N-to C-terminal strategy encompassed a ligation between a N-terminal recombinant protein 
fragment thioester from the IMPACT system with a N-cysteinyl peptide, which was equipped with a C-
terminal acyl hydrazine that acted as thioester precursor for the second protein ligation with a N-
cysteinyl recombinant tau protein fragment to complete the full-length protein. One feature of the 
project, the synthesis of a new β-mercaptotyrosine building block as ligation handle, did not succeed 
due to the unsuccessful hydroxyl-thiol exchange in the β-hydroxytyrosine precursor. Hence, 
β-mercaptoaspartate was chosen instead and the ligation sites were adapted accordingly. Thanks to an 
extensive intein cleavage optimization, the first ligation between Tau[1-192]-thioester with 
Tau[Cys193-227]-NHNH2 proceeded at high yields and no intermediate protein purification was 
necessary prior to the second protein ligation. Activation of Tau[Cys193-227]-NHNH2 to generate the 
active thioester required rebuffering to pH 3, which initially resulted in high protein loss until it was 
found that dissolving Tau[Cys193-227]-NHNH2 in the correct buffer after lyophilization can overcome 
this issue. The successful generation of the protein thioester Tau[Cys193-227]-SR following activation 
with NaNO2 and MesNa was shown by reaction with a short test peptide, delivering about 50 % 
conversion before optimization. The ligation to Tau[Cys228-441] did not yet yield any product at this 
point, assumingly because the thioester hydrolyzes quickly in the presence of an excess of NaNO2 and 
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the ligation is too slow to compete with this process. [338] The next step will therefore be the isolation of 
Tau[Cys193-227]-SR after activation, followed by the repetition of the final ligation.  
The C-to N-terminal ligation strategy used the same ligation sites and recombinant protein fragments, 
but required a redesign of the middle peptide. It was equipped with a N-terminal thiazolidine and a C-
terminal Dbz thioester precursor to allow ligation in the opposite direction as before. The first ligation 
was carried out between Tau[Cys228-441] and Tau[Thz193-227]-Dbz and successfully delivered 
Tau[Thz193-441]. As there were still remains of Tau[Cys228-441] in the ligation mixture after the 
reaction, a suitable method will have to be identified next to remove the unligated protein in order to 
avoid side reactions with the Tau[1-192] thioester. In this regard, the intein cleavage of Tau[1-192] was 
revised further to reduce the amount of thioester hydrolysis upon release from the fusion protein to 
ensure a successful second ligation.  
During this thesis, a variety of challenges were addressed to find a suitable semi-synthetic strategy for 
the delivery of full-length tau proteins that can be modified within the proline-rich domain. The cloning 
and expression of the recombinant fragments and the peptide synthesis of the middle fragments for both 
ligation directions were optimized. Furthermore, the first protein ligations for the N- to C- terminal as 
well as the C- to N- terminal direction were successfully performed and important insights were gained 
to ensure the second ligations in both pathways will be successful during the continuation of this project. 
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6 Experimental part 
6.1 General information 
Analytical HPLC was conducted on a SHIMADZU HPLC system (Shimadzu Corp., Japan) with a 
SIL-20A autosampler, 2 pumps LC2 AAT, a 2489 UV/Visible detector, a CTO-20A column oven and 
an RF-10 A X2 fluorescence detector (Em = 495 nm, Ex = 517 nm). The flow rate was 1 mL/min. 
Reagents and solvents were, unless stated otherwise, commercially available as reagent grade and did 
not require further purification. Chemicals were purchased either from Sigma-Aldrich or TCI. Resins 
and Fmoc-protected amino acids were purchased from IRIS BioTech (Germany) or Novabiochem 
(Germany). All water and air-sensitive reactions were carried out under Schlenk-conditions.  
Peptide synthesis: Peptides were either synthesised manually or using the automated PTI Tribute 
(Gyros Protein Technologies) via standard Fmoc-based conditions (fast-Fmoc protocol with 
HBTU/HOBt/NMM). Fmoc deprotection was carried out using 20% piperidine in DMF (3 x 3 min). 
Single couplings were performed for all standard amino acids (aa), using 5. eq. aa, 5 eq. HBTU, 5 eq. 
HOBt and 5 eq. DIPEA. Unnatural amino acids were incorporated using 2 eq. aa, 2 eq. HATU and 4 
eq. DIPEA. Peptides were synthesised on Rink Amide resin and, if not specified otherwise, in 0.1 mmol 
scale. All peptides were cleaved using 95:2.5:2.5 TFA:TIS:H2O for 2 hrs. Before purification, all 
peptides were precipitated in cold diethyl ether. Unless specified otherwise, the crude peptides were all 
purified by preparative HPLC using a gradient from 10-90% in 50 mins (Solvent A: H2O + 0.1% TFA, 
solvent B: MeCN + 0.1 % TFA). All peptides were characterized either by analytical HPLC or by 
UPLC-MS.  
Analytical UPLC: UPLC-UV traces were obtained on a Waters H-class instrument equipped with a 
Quaternary Solvent Manager, a Waters autosampler and a Waters TUV detector connected to a 3100 
mass or QDaTM detector with an Acquity UPLC-BEH C18 1.7 μm, 2.1 x 50 mm RP column with a 
flow rate of 0.6 mL/min (Water Corp., USA). UPLC-UV chromatograms were recorded at 220 nm. 
 
Preparative HPLC: Acidic purification was performed on a Gilson PLC 2020 system (Gilson Inc., WI, 
Middleton, USA) using a reverse-phase Macherey-Nagel Nucleodur C18 HTec Spum column 
(Macherey-Nagel GmbH & Co. Kg, Germany). Unless specified otherwise, the following gradient was 
used: (A = H2O + 0.1% TFA, B = MeCN + 0.1% TFA) flow rate 30 mL/min, 10% B 0-5 min, 10-100% 
B 5-55 min, 100 % B 35-40 min.  
 
Basic purification was performed on a SHIMADZU HPLC system (Shimadzu Corp., Japan) with a 2 
pumps LC2 AAT and a 2489 UV/Visible detector using a reverse-phase Macherey-Nagel Nucleodur 
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C18 column. The following solvents were used: A = 10 mM ammonium acetate (pH 9), B = MeCN + 
10 % ammonium acetate (pH 9). 
 
Silica gel column chromatography was performed on silica gel (Acros Silica gel 60 Å, 
0.035 0.070 mm). 
 
NMR spectra were either recorded with a Bruker Ultrashield 300 MHz spectrometer oder a Bruker 
Ultrashield 600 MHz (both Bruker Corp., USA) at ambient temperature. The chemical shifts are 
reported in ppm relative to the residual solvent peak.  
UV irradiation was carried out with a LOT Hg (Xe) arc lamp (LOT-QuantumDesign GmbH, D-64293 
Darmstadt, Germany) using a 297 nm filter from the Andover Incorporation with 15 % transmission. 
Probes were positioned in 20 cm distance and irradiated while stirring.  
Streptavidin beads were purchased from GE Healthcare (“Streptavidin Sepharose High Performance” 
with a binding capacity of 300 nmol/mL) or from Novagen EMD Chemicals (“Streptavidin Agarose 
with a binding capacity > 85 nmol/mL). 
Fluorescence spectra were recorded using a FP-6500 fluorescence spectrometer (Jasco, Tokyo, Japan). 
SDS-PAGE gels were prepared using standard protocols. All probes were boiled in SDS sample buffer 
containing β-mercaptoethanol or DTT prior to loading. Gels were run in a Mini-PROTEAN system 
from Bio-Rad at 250 V for 30 mins. Bands were detected with standard Coomassie stain.  
Western Blots were performed directly after SDS-PAGE. The gels were incubated in transfer buffer 
and then transferred to a PDVF membrane in a Mini-Trans Blot chamber from Bio-Rad (250 A, 1 hr). 
The membrane was blocked with Roti-block for 1 hr and then washed with TBS-T (3 x 10 mins), 
following incubation with the respective antibody (1:2000 antibody and 1:100 Roti-block in TBS-T) for 
90 mins at 4 °C. The membrane was then washed with TBS-T (2 x 5 mins) and TBS (2 x 5 mins). All 
antibodies used were either directly tagged with HRP or incubated with a HRP-tagged secondary 
antibody before visualization. The membrane was treated with Western ECL Blotting substrates (from 
Bio-Rad) for visualization and the bands were detected with a ChemiDoc Imaging System from 
Bio-Rad. 
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6.2 Project 1: The development of a photocleavable phosphonamidate-
based tag 
6.2.1 Synthesis of central building block (1) 
P
O
O
O2N
NO2
BH3
1
2
3
4
6
5
7
8 9
 
Route 1 via PCl3: 
PCl3 (0.41 g, 3 mmol) was cooled to -96 °C and triethylamine (0.83 mL, 6 mmol. 2 eq.) was added 
dropwise. 2-Nitrobenzylalcohol (0.92 g, 6 mmol, 2 eq., dissolved in 1:9 THF:Toluene, 36 mL) was 
added, stirred for 10 mins at -78 °C and was then warmed to room temperature overnight. The reaction 
was then cooled to 0 °C and triethylamine (0.11 mL, 0.75 mmol, 0.25 eq.) and 2-nitrobenzylalcohol 
(0.23 g, 1.5 mmol, 0.5 eq., dissolved in 1:9 THF:Toluene, 9 mL) was slowly added. The reaction was 
warmed to room temperature and stirred for 2 hrs. After cooling down to -78 °C again, 
ethynylmagnesium bromide (9 mL, 4.5 mmol, 1.5 eq., 0.5 M in THF) was added dropwise and the 
reaction was stirred under cooling for 10 mins before it was warmed to room temperature and allowed 
to react for 2 hrs. BH3.THF (4.5 mL, 4.5 mmol, 1.5 eq., 1 M in THF) was then added under cooling at 
0 °C and stirred for 2 hrs at room temperature. The solvent was removed in vacuo and the compound 
was purified by silica gel column chromatography (Hex 5: EtOAc 1) to yield the desired product 1 as 
white powder (0.45 g, 1.2 mmol, 40 %).  
Route 2 via bis(diisopropylamino)chlorophosphine:  
Bis(diisopropylamino)chlorophosphine (0.2 g, 0.79 mmol) was suspended in dry THF (1 mL) and 
ethynylmagnesium bromide (1.6 mol, 0.8 mmol, 1.01 eq., 0.5 M in THF) was added dropwise at 0 °C, 
before the reaction was stirred for 2 hrs at room temperature. 2-Nitrobenzylalcohol (0.3 g, 1.98 mmol, 
2.5 eq., dissolved in 2 mL dry MeCN) and tetrazole (9 mL, 4 mmol, 6.4 eq., 0.45 M in MeCN) was 
added at 0 °C and stirred for further 2 hrs at room temperature. BH3.THF (1.1 mL, 1.1 mmol, 1.4 eq., 1 
M in THF) was added at 0°C and reacted for 2 hrs at room temperature. The solvent was removed in 
vacuo and the compound was purified by silica gel column chromatography (Hex 5: EtOAc 1) to yield 
the desired product 1 as white powder (0.190 mmol, 0.51 mmol, 65 %). 
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Analytical data of 1: 
1H-NMR (CDCl3, 300 MHz) δ 8.16 (d, J = 8.1 Hz, 2H, C5-H), 7.79-7.70 (m, 2H), 7.56-7.51 (m, 1H, 
C4-H), 5.66-5.53 (m, 4H, C7-2H), 3.32 (d, J = 7.35, 1H, C9-H) 
13C-NMR (CDCl3, 75 MHz) δ 146.7 (s, C6), 134.4 (s, C2), 132.0 (d, J = 8 Hz, C8), 129.2 (s, C3), 
128.6 (s, C4), 125.3 (s, C5), 94.9 (d, J = 25 Hz, C9), 66.5 (d, J = 5 Hz, C7) 
31P-NMR (CDCl3, 121 MHz) δ 108.9 (dd, J = 360, 123 Hz) 
HRMS (ESI, m/z) calcd for C16H16BN2O6PNa [M+Na]+: 397.0737, found: 397.0736 
 
6.2.2 Synthesis of model azides 
6.2.2.1 3-Phenylpropyl azide (12a) 
 
N3
 
 
3-Phenylpropyl bromide (2 g, 10 mmol) was diluted in dry DMSO (20 mL) and sodium azide (1.2 g, 18 
mmol, 1.8 eq.) was added. The reaction was stirred overnight at room temperature. The reaction mixture 
was diluted with water (50 mL) and extracted with Et2O (5 x 50 mL). The organic layer was washed 
with H2O (3 x 50 mL) and brine. It was dried with MgSO4, filtered and the solvent was removed in 
vacuo. Product 2a was isolated as oil (1.66g, 10 mmol, 100 %).  
Analytical data of 12a: 
1H NMR (CDCl3, 300 MHz) δ 7.31 (m, 2H), 7.23 – 7.16 (m, 3H), 3.30 (t, J = 6.8 Hz, 2H), 2.72 (t, J = 
7.6 Hz, 2H), 2.01 – 1.83 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 140.75, 128.43, 128.37, 126.05, 50.56, 32.68, 30.36. 
All values were according to literature. [362] 
 
6.2.2.2 Benzyl azide (12b) 
N3
 
Benzyl bromide (1.71 g, 10 mmol) was dissolved in 4:1 acetone:H2O (20 mL) and sodium azide (1.9 g, 
30 mmol, 3 eq.) was added. The reaction was stirred overnight at room temperature. The reaction 
mixture was extracted with Et2O (3 x 50 mL) and the organic phase was washed with H2O (50 mL) and 
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brine (50 mL). The organic phase was dried with MgSO4, filtered and the solvent was removed in vacuo 
to yield the desired product 2b as oil (1.3 g, 9.8 mmol, 98 %).  
Analytical data of 12b: 
1H NMR (CDCl3, 300 MHz) δ 7.48 – 7.29 (m, 5H), 4.35 (s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 135.29, 128.77, 128.25, 128.16, 54.73. 
All values were according to literature. [363] 
 
6.2.2.3 Phenyl azide (12c) 
N3
 
Aniline (3.1 g, 33 mmol) was dissolved in H2O (25 mL) and conc. H2SO4 (10.5 mL) was added at 0 °C. 
NaNO2 (2.6 g, 38 mmol, 1,15 eq.) dissolved in H2O (15 mL), and added dropwise. Hexane (50 mL), 
followed by sodium azide (2.6 g, 40 mmol, 1.2 eq.) in H2O (10 mL) was added and the reaction was 
stirred for 3 hrs at room temperature. The organic phase was separated, washed with H2O (3 x 50 mL), 
dried with MgSO4 and filtered. The solvent was removed in vacuo, yielding compound 3c as oil (2.75 
g, 23.1 mmol, 70 %).  
Analytical data of 12c: 
1H NMR (CDCl3, 300 MHz) δ 7.41 – 7.32 (m, 2H), 7.20 – 7.11 (m, 1H), 7.08 – 7.01 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 140.10, 129.88, 124.99, 119.14. 
All values were according to literature. [364] 
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6.2.2.4 Biotin azide (12d) via biotinol 
HO
S
HN
NH
O
O
HO
S
HN
NH
O
N3
S
HN
NH
O
1) SOCl2,
 MeOH
2) LiAlH4,
 THF 1) TsCl, pyr
2) NaN3,
 DMF
S1 2d  
Synthesis of biotinol S1 
HO
S
HN
NH
O
1
2 3
4
5 6
7
8
9
10
 
Biotin (5 g, 20.5 mmol) was suspended in dry MeOH (60 mL) and thionyl chloride (7.4 g, 4.5 mL, 62 
mmol (3 eq.) was added dropwise at 0 °C. The reaction was stirred overnight at room temperature and 
the solvent was removed in vacuo. The biotin methyl ester was used without further purification. It was 
suspended in dry THF (300 mL) and a suspension of LiAlH4 (3.1 g, 82 mmol, 4 eq.) in dry THF (120 
mL) was added dropwise at 0 °C. The reaction was stirred at room temperature overnight, before it was 
quenched with MeOH (50 mL) and H2O (50 mL) at 0 °C. Afterwards a solution of conc. Na2SO4 (50 
mL) was added and the reaction mixture was stirred for another 20 mins. The solvent was removed in 
vacuo and a 1:4 MeOH:DCM (20 mL) mixture was added and stirred for 1 hr. The white solid was 
filtered off over celite and washed with 1:4 MeOH:DCM and the filtrate was reduced in vacuo. Product 
S1 was isolated by silica gel column chromatography (DCM: 10% MeOH) as white powder (2.91 g, 
12.6 mmol, 62 %, over two steps).  
Analytical data of S1: 
1H NMR (DMSO, 300 MHz) δ 6.44 (s, 1H, NH), 6.36 (s, 1H, NH), 4.35-4.28 (m, 2H, OH, C9-H), 
4.17 – 4.06 (m, 1H, C7-1H), 3.37 (m, 2H, C1-2H), 3.10 (m, 1H, C6-H), 2.82 (dd, J = 12.4, 5.0 Hz, 
1H, C10-1H), 2.57 (d, J = 12.4 Hz, 1H, C10-1H), 1.68-1-52 (br s, 1H, OH), 1.52 – 1.20 (m, 8H, C2-
5). 
13C NMR (DMSO, 75 MHz) δ 162.74, 61.10, 60.67, 59.21, 55.59, 32.36, 28.57, 28.37, 25.58. Carbon 
C6 is hidden underneath the signal of the deuterated solvent.  
HRMS (ESI, m/z) calcd for C10H19N2O2S [M+H]+: 231.1167, found: 231.1161 
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Synthesis of biotin azide 12d 
N3
S
HN
NH
O
1
2 3
4
5 6
7
8
9
10
 
Biotinol (2.91 g, 12.6 mmol) was dissolved in dry pyridine (50 mL) and tosyl chloride (5.76 g, 30.2 
mmol, 2.4 eq.) was added in two portions at 0 °C. The reaction was stirred overnight at room 
temperature. The reaction was diluted with DCM (100 mL) and the organic phase was extracted with 1 
M H2SO4 (3 x 75 mL), brine (50 mL) and was dried with MgSO4. After filtration, the solvent was 
removed in vacuo and biotin tosylated was used without further purification. The residue was dissolved 
in dry DMF (50 mL) and biotin azide (3.81 g, 60 mmol, 5 eq.) was added. The reaction was stirred at 
80 °C overnight and after removal of the solvent in vacuo, the reaction was purified by silica gel column 
chromatography (DCM: 5 % MeOH). Compound 3d was isolated as white powder (1.07 g, 4.19 mmol, 
33 % in two steps).  
Analytical data of 12d: 
1H NMR (CDCl3, 300 MHz) δ 5.33 (s, 1H, NH), 5.07 (s, 1H, NH), 4.54 (dd, J = 7.7, 5.1 Hz, 1H, C7-
H), 4.33 (dd, J = 8.1, 4.7 Hz, 1H, C9-H), 3.29 (t, J = 6.8 Hz, 2H, C1-2H), 3.21-3.15 (m, 1H, C6-H), 
2.95 (dd, J = 12.8, 5.0 Hz, 1H, C10-1H), 2.75 (d, J = 12.8 Hz, 1H, C10-1H), 1.79 – 1.46 (m, 8H, C2-
5). 
13C NMR (CDCl3, 75 MHz) δ 163.57, 61.97, 60.01, 55.51, 51.29, 40.52, 28.53, 28.44, 26.57. Due to 
overlapping carbon resonances in the aliphatic chain, one peak is missing. 
HRMS (ESI, m/z) calcd for C10H19N2O2S [M+H]+: 256.1232, found: 256.1223 
  
EXPERIMENTAL PART 
 
152 
 
6.2.2.5 OH-PEG-N3 (12e) 
N3 O
O OH  
 
Compound 12e was synthesized starting from commercially available Cl-TEG-N3 using a previously 
published protocol. 
Analytical data of 12e: 
1H NMR (CDCl3, 300 MHz) δ 3.75 – 3.70 (m, 2H), 3.70 – 3.64 (m, 6H), 3.63 – 3.58 (m, 2H), 3.39 (t, 
J = 5.0 Hz, 2H). 
13C NMR (CDCl3, 75 MHz) δ 72.59, 70.74, 70.46, 70.14, 61.84, 50.74. 
All values were according to literature. [365] 
 
6.2.2.6 Azide 40 
O NH
O
N3
O O
O
N3
NO2
OH
N3
36
O O
O
O2N NO2
DIPEA, DMF, o.n. HOBt.H2O, DIPEA
DMF, o.n.
NH2
37 40
H+
 
Aminobenzyl alcohol (5.00 g, 40.60 mmol) was dispersed in HCl (6 N, 40 mL) and was slowly added 
to a solution of sodium nitrite (4.00 g, 60 mmol, 1.5 eq., in 100 mL H2O) at 0 °C. After 30 mins stirring, 
EtOAc (50 mL) was added to the reaction mixture, before sodium azide (10.40 g, 160 mmol, 4 eq.) was 
added in small portions. The reaction was stirred overnight. It was then extracted with EtOAc (3 x 100 
mL), washed with sat. NaHCO3 (3 x 100 mL) and brine (100 mL). After drying with MgSO4, the volume 
was reduced in vacuo. Azidobenzyl alcohol 36 was obtained as yellow oil (5.50 g, 37 mmol, 92 %) and 
was used without further purification.  
Azidobenzyl alcohol 36 (0.50 g, 3.40 mmol) was dissolved in dry DMF (10 mL) and bisnitrophenyl 
carbonate (1.50 g, 5.00 mmol, 1.5 eq.) was added together with DIPEA (1.30 g, 1.78 mL, 10.20 mmol, 
3 eq.). The reaction mixture was stirred overnight and the solvent was removed in vacuo. The crude was 
purified by silica gel column chromatography (3 Hex: 1 EtOAc) to yield compound 37 as a white powder 
(0.770 g, 2.45 mmol, 72 %). 
Analytical data of 37: 
1H NMR (CDCl3, 300 MHz) δ 8.31 – 8.23 (m, 2H), 7.48 – 7.40 (m, 2H), 7.40 – 7.33 (m, 2H), 7.10 – 
7.03 (m, 2H), 5.26 (s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 155.57, 152.54, 145.55, 141.12, 130.90, 130.62, 125.45, 121.88, 
119.48, 70.48 
All values were according to literature. [345] 
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Compound 37 (0.140 g, 0.45 mmol) was dissolved in dry DMF (5 mL) and 3-phenyl-1-propylamine 
(0.060 g, 0.45 mmol, 1 eq.) was added. Afterwards, DIPEA (0.58 g, 0.78 mL, 4.5 mmol, 10 eq.) was 
added slowly, followed by HOBt.H2O (8.00 mg, 0.05 mmol, 10 mol %). The reaction was stirred 
overnight and the solvent was removed in vacuo. The crude product was purified by silica gel column 
chromatography (5 Hex: 1 EtOAc) to yield azide 40 as a white powder (0.128 g, 0.41 mmol, 92 %).  
Analytical data of 40: 
1H NMR (CDCl3, 300 MHz) δ 7.34 (d, J = 9 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.23 – 7.12 (m, 3H), 7.04 – 
6.99 (m, 2H), 5.06 (s, 2H), 3.23 (q, J = 6 Hz, 2 H), 2.65 (t, J = 6 Hz, 2 H) 1.84 (quint, J = 6 Hz, 2 H), 
1.28 – 1.24 (m, 1 H). 
13C NMR (CDCl3, 75 MHz) δ 156.34, 141.32, 139.94, 133.50, 129.84, 128.49, 128.36, 126.05, 
119.13, 66.06, 40.71, 33.04, 31.57 
HRMS (ESI, m/z) calcd for C17H19BN4O2 [M+H]+: 311.36, found: 311.56 
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6.2.3 Synthesis of borane-protected triazole-phosphonites 
To a solution of phosphonite 1 in degassed MeCN (0.03 M), the corresponding azide (1 eq.), 
2,6-lutidine (3 eq.), DIPEA (3 eq.) and CuI (30 %) were added. The reaction was stirred overnight at 
room temperature and purified by silica gel column chromatography (3 Hex: 1 EtOAc), if not otherwise 
specified.  
6.2.3.1 Compound 13a 
P
O
O
NO2
O2N
N
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BH31
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Isolated yield: 93 % 
Analytical data of 13a: 
1H NMR (CDCl3, 300 MHz) δ 8.10 (dd, J = 8.2, 1.3 Hz, 2H, C4-H), 8.01 (s, 1H, C9-H), 7.80 (dd, J = 
7.8, 1.4 Hz, 2H, C7-H), 7.66 (td, J = 7.6, 1.3 Hz, 2H, C6-H), 7.47 (td, J = 7.8, 1.5, 2H, C5-H), 7.35 – 
7.28 (m, 2H, C14-H, C18-H), 7.25 – 7.15 (m, 3H, C15-C17-H), 5.68 – 5.50 (m, 4H, C1-2H), 4.43 (t, J 
= 7.2 Hz, 2H, C10-2H), 2.69 (t, J = 7.4 Hz, 2H, C12-2H), 2.39 – 2.25 (m, 2H, C11-2H). 
13C NMR (CDCl3, 75 MHz) δ 146.83 (C3), 139.74 (C13), 134.29 (C6), 132.43 (d, J = 11 Hz, C9), 
130.92 (d, J = 34 Hz, C8), 129.09 (C7), 128.89 (C14), 128.87 (C15), 128.56 (C5), 126.70 (C16), 
125.13 (C4) , 66.34 (d, J = 6 Hz, C1), 49.98 (C12), 32.55 (C11), 31.51 (C10). 
31P-NMR (CDCl3, 121 MHz) δ 122.32 (dd, J = 153.2, 58.1)  
HRMS (ESI, m/z) calcd for C25H28BN5O6P [M+H]+: 536.1871, found: 536.1858 
 
6.2.3.2 Compound 13b 
P
O
O
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Isolated yield: 87 % 
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Analytical data of 13b: 
1H-NMR (CDCl3, 300 MHz) δ 8.09 (dd, J = 8.2, 1.3 Hz, 2H, C4-H), 7.96 (s, 1H, C9-H), 7.78 (dd, J = 
7.9, 1.3 Hz, 2H, C7-H), 7.64 (td, J = 7.6, 1.3 Hz, 2H, C6-H), 7.51 – 7.46 (m, 2H, C5-H), 7.44 – 7.39 
(m, 3H, arom. H), 7.35 – 7.27 (m, 2H, arom. H), 5.66 – 5.48 (m, 6H, C1-2H, C10-2H). 
13C-NMR (CDCl3, 75 MHz) δ 146.76 (C3), 139.52 (d, J = 103.5, C2), 134.28 (C6), 133.52 (C11), 
132.43 (d, J = 6.75 Hz, C8), 130.72 (d, J = 33.8 Hz, C9), 129.52 (C5), 129.39 (C13), 129.05 (C7), 
128.81 (C12), 128.51 (C14), 125.10 (C4), 66.32 (d, J = 3.75 Hz, C1), 54.59 (C10). 
31P-NMR (CDCl3, 121 MHz) δ 122.5 – 121.4 (m) 
HRMS (ESI, m/z) calcd for C23H23BN5O6PNa [M+Na]+: 530.1377, found: 530.1379 
 
6.2.3.3 Compound 13c 
 
Isolated yield: 71 % 
Analytical data of 13c: 
1H-NMR (CDCl3, 300 MHz) δ 8.48 (s, 1H, C9), 8.10 (dd, J = 8.2, 1.3 Hz, 2H, C4-H), 7.83 (dd, J = 
7.8, 1.4 Hz, 2H, C7-H), 7.80 – 7.73 (m, 2H, C11-H), 7.68 (td, J = 7.6, 1.3 Hz, 2H, C6-H), 7.61 – 7.45 
(m, 5H, C12-2H, C13-H, C5-2H), 5.64 (m, 4H, C1-2H). 
13C-NMR (CDCl3, 75 MHz) δ 146.84 (C3), 139.96 (d, J = 103.5 Hz, C2), 136.23 (C10), 134.32 (C6), 
132.31 (d, J = 7.5 Hz, C8), 130.13 (C12), 129.83 (C5), 129.16 (C7), 129.03 (d, J = 33.75 Hz, C9), 
128.91 (C13), 125.14 (C4), 121.12 (C11), 66.50 (d, J = 3.75 Hz, C1). 
31P-NMR (CDCl3, 121 MHz) δ 123.43-121.12 (m) 
HRMS (ESI, m/z) calcd for C22H21BN5O6PNa [M+Na]+: 516.1221, found: 516.1216 
 
6.2.3.4 Compound 13d 
 
Compound 13d was isolated by silica gel column chromatography using 5 % MeOH in DCM as eluent. 
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Isolated yield: 81 % 
Analytical data of 13d: 
1H NMR (DMSO, 300 MHz) δ 8.84 (s, 1H, C9-H), 8.12 (dd, J = 8.2, 1.2 Hz, 2H, C6-H), 7.85 – 7.70 
(m, 4H, C4-H, C3-H), 7.62 (dd, J = 8.1, 1.7 Hz, 2H, C5-H), 5.60 – 5.42 (m, 4H, C1-2H), 4.47 (t, J = 
7.1 Hz, 2H,, C10-2H), 4.29 (dd, J = 7.7, 4.8 Hz, 1H, C18-1H), 4.12 (dd, J = 7.8, 4.4 Hz, 1H, C16-1H), 
3.11 – 3.05 (m, 1H, C15-1H), 2.80 (dd, J = 12.5, 5.1 Hz, 1H, C19-1H), 2.56 (d, J = 12.4 Hz, 1H, C19-
1H), 1.87 (quint, J = 7.4 Hz, 2H, C11-2H), 1.50 – 1.25 (m, 6H, C12, C13, C14). 
13C NMR (DMSO, 75 MHz) δ 162.71 (C17), 146.62 (C7), 137.15 (d, J = 109 Hz, C2), 134.38 (C4), 
131.75 (d, J = 6.8 Hz, C9), 129.41 (C3), 128.52 (C5), 124.90 (C6), 65.45 (d, J = 4.1 Hz, C1), 61.00 
(C16), 59.19 (C18), 55.42 (C15), 49.74 (C10), 40.34 (C19), 29.38 (C11), 28.09 (C13), 27.91 (C14), 
25.81 (C12). 
31P-NMR (CDCl3, 121 MHz) δ 122.85 – 120.90 (s br) 
HRMS (ESI, m/z) calcd for C10H19N2O2SNa [M+Na]+: 652.1891, found: 652.1882 
 
6.2.3.5 Compound 13e 
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Isolated yield: 81 % 
Analytical data of 13e: 
1H NMR (CDCl3, 300 MHz) δ 8.31 (s, 1H, C9-H), 8.09 (dd, J = 8.2, 1.3 Hz, 2H, C4-H), 7.81 (dd, J = 
7.8, 1.3 Hz, 2H, C7-H), 7.67 (td, J = 7.6, 1.3 Hz, 2H, C6-H), 7.52 – 7.43 (m, 2H, C5-H), 5.58 (qd, J = 
14.9, 7.5 Hz, 4H, C1-2H), 4.65 (t, J = 4.9 Hz, 2H, C10-2H), 3.92 (dd, J = 5.5, 4.4 Hz, 2H, C11-2H), 
3.78 – 3.60 (m, 9H, C12-2H, C13-H, C14-2H, OH), 3.59 – 3.53 (m, 2H, C15-2H). 
13C NMR (CDCl3, 75z MHz) δ 146.77 (C3), 134.31 (C6), 132.48 (d, J = 7.5 Hz, C9), 132.32 (d, J = 
33.8 Hz, C8), 129.04 (C7), 128.83 (C5), 125.09 (C4), 72.59, 70.78, 70.40, 69.06 (C11), 66.26 (d, J = 
4.5 Hz, C1) 61.79, 50.64 (C10). 
31P-NMR (CDCl3, 121 MHz) δ 123.50 – 121.25 (s br) 
HRMS (ESI, m/z) calcd for C22H29BN5O9PNa [M+Na]+: 572.1694, found: 572.1686 
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6.2.4 Synthesis of small-molecule phosphonamidates 
6.2.4.1 Phosphonamidate 14a 
 
 
Triazole-phosphonite 13a (70 mg, 0.130 mmol) was dissolved in dry, degassed DMF (0.65 mL, 0.2 M) 
under argon and DABCO (21 mg, 0.195 mmol, 1.5 eq.) was added. The reaction was heated to 80 °C 
for 4 hrs. The temperature was decreased to 60 °C and azide 12a (63 mg, 0.39 mmol, 3 eq.) was added 
for 5 hrs. The solvent was removed by lyophilisation in 50:50 H2O:MeCN and the crude was purified 
by silica gel column chromatography (20 % acetone in hexane  EtOAc). Product 14a was isolated as 
colourless oil (57 mg, 0.110 mmol, 85 %). 
Analytical data of 14a: 
1H NMR (CDCl3, 300 MHz) δ 8.12 (d, J = 8.2 Hz, C4-H), 8.03 (s, 1H, C9-1H), 7.88 (d, J = 7.8 Hz, 
1H, C7-1H), 7.67 (t, J = 7.6 Hz, 1H, C6-1H), 7.47 (t, J = 7.7 Hz, 1H, C5-1H), 7.36 – 7.10 (m, 10H, 
C14-C16-5H, C21-C23-5H), 5.62 – 5.42 (m, 2H, C1-2H), 4.42 (t, J = 7.1 Hz, 2H, C10-2H), 3.34 (m, 
1H, NH), 3.15 (m, 2H, C17-2H), 2.66 (m, C19-2H, C12-2H), 2.29 (m, J = 7.3 Hz, 2H, C11-2H), 1.86 
(p, J = 7.3 Hz, 2H, C18-2H). 
13C-NMR (CDCl3, 150 MHz): δ 146.74 (C3), 141.39 (C20), 139.85 (C13), 139.30 (d, J = 436 Hz, C2) 
134.21 (C6), 133.25 (d, J = 8.25 Hz, C9), 129.9 (d, J = 32 Hz, C8), 129.68 (C7), 128.81 (C5), 128.64 
(C14), 128.62 (C15), 128.52 (C21), 128.43 (C22), 126.60 (C16), 126.04 (C23), 124.99 (C4), 63.40 (d, 
J = 3.8 Hz, C1), 49.75 (C12), 40.55 (C19), 33.58 (C18), 33.50 (C17), 32.51 (C11), 31.60 (C10) 
31P-NMR (CDCl3, 121 MHz): 12.5 
HRMS (ESI, m/z) calcd for C10H19N2O2S [M+Na]+: 542.1928, found: 542.1932 
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6.2.4.2 Phosphonamidate 14b 
 
Triazole-phosphonite 13a (22.5 mg, 0.042 mmol) was dissolved in dry, degassed DMF (0.2 mL, 0.2 M) 
under argon and DABCO (7 mg, 0.062 mmol, 1.5 eq.) was added. The reaction was heated to 80 °C for 
4 hrs. The temperature was decreased to 60 °C and azide 12b (17 mg, 0.13 mmol, 3 eq.) was added for 
5 hrs. The solvent was removed by lyophilisation in 50:50 H2O:MeCN and the crude was purified by 
silica gel column chromatography (20 % acetone in hexane  EtOAc). Product 14b was isolated as 
colourless oil (18 mg, 0.036 mmol, 86 %). 
Analytical data of 14b: 
1H NMR (CDCl3, 600 MHz) δ 8.10 (dd, J = 8.2, 1.3 Hz, 1H, C4-1H), 7.99 (s, 1H, C9-1H), 7.79 (dd, J 
= 7.9, 1.3 Hz, 1H, C7-1H), 7.63 (dd, J = 7.7, 1.3 Hz, 1H, C6-1H), 7.47 – 7.43 (m, 1H, C5-1H), 7.34 – 
7.26 (m, 6H, arom. H), 7.25 – 7.21 (m, 2H, arom. H), 7.19 – 7.16 (m, 2H, arom. H), 5.53 – 5.45 (m, 
2H, C1-2H), 4.41 (td, J = 7.1, 2.8 Hz, 2H, C10-2H), 4.33 – 4.28 (m, 2H, C17-2H), 2.68 (t, J = 7.4 Hz, 
2H, C12-2H), 2.32 – 2.26 (m, 2H, C11-2H). 
13C-NMR (CDCl3, 150 MHz): δ 146.78 (C3), 139.88 (C13), 139.44 (d, J = 876 Hz, C2), 139.31 (d, J = 
24 Hz, C18), 134.21 (C6), 133.21 (d, J = 36 Hz, C8), 130.00 (d, J = 126 Hz, C9), 128.87 (C5), 128.75 
(C6), 128.65 (C14), 128.56 (C15), 127.60 (C19), 127.56 (C21), 126.67 (C16), 125.00 (C4), 63.65 (d, J 
= 18 Hz, C1), 49.81 (C10), 44.84 (C17), 32.56 (C12), 31.60 (C11). 
31P-NMR (CDCl3, 242 MHz) δ 12.27 
HRMS (ESI, m/z) calcd for C25H26N5O4PNa [M+Na]+: 514.1620, found: 514.1625 
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6.2.4.3 Phosphonamidate 14c 
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22
 
 
Triazole-phosphonite 13a (22.5 mg, 0.042 mmol) was dissolved in dry, degassed DMF (0.2 mL, 0.2 M) 
under argon and DABCO (7 mg, 0.062 mmol, 1.5 eq.) was added. The reaction was heated to 80 °C for 
4 hrs. The temperature was decreased to 60 °C and azide 12c (15 mg, 0.13 mmol, 3 eq.) was added for 
5 hrs. The solvent was removed by lyophilisation in 50:50 H2O:MeCN and the crude was purified by 
silica gel column chromatography (20 % acetone in hexane  EtOAc). Product 14c was isolated as 
colourless oil (12 mg, 0.021 mmol, 50 %). 
Analytical data of 14c: 
1H NMR (CDCl3, 600 MHz) δ 8.11 (dd, J = 8.1, 1.1 Hz, 1H, C4-1H), 8.04 (s, 1H, C9-1H), 7.90 (d, J = 
7.9 Hz, 1H, C7-1H), 7.65 (td, J = 7.6, 1.4 Hz, 1H, C6-1H), 7.46 (t, J = 7.6 Hz, 1H, C5-1H), 7.29 (m, 
2H, C14-2H), 7.24 – 7.18 (m, 3H, C16-H, C15-2H), 7.16 – 7.11 (m, C18-1H, C19-1H, C20-1H, C21-
1H), 6.96 (td, J = 7.3, 1.1 Hz, 1H, C20-H), 5.93 (d, J = 7.8 Hz, 1H, NH), 5.70 – 5.57 (m, 2H, C1-2H), 
4.39 (t, J = 7.1 Hz, 2H, C10-2H), 2.63 (td, J = 7.4, 2.4 Hz, 2H, C12-2H), 2.27 (p, J = 7.3 Hz, 2H, C11-
2H). 
13C-NMR (CDCl3, 150 MHz) δ 146.82 (C3), 139.30 (d, J = 147 Hz, C2), 134.30 (C6), 132.75 (d, J = 9 
Hz, C8), 130.63 (d, J = 33 Hz, C9), 129.56 (C7), 128.89 (C5), 128.85 (C19/C21), 128.55 (C15/C14), 
126.66 (C16), 125.07 (C4), 122.78 (C20), 118.74 (C18/22), 118.69 (C18/22), 64.13 (d, J = 15 Hz, 
C1), 49.90 (C10), 32.49 (C11), 31.49 (C12). 
31P-NMR (CDCl3, 242 MHz) δ 6.68 
HRMS (ESI, m/z) calcd for C24H24N5O4PNa [M+Na]+: 500.1464, found: 500.1470 
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6.2.5 Stability studies with phosphonamidate 14a 
Buffers used:  
pH 1.7: 
0.1 % TFA/H2O 
pH 2.3: 
0.2 M KCl 
(adjusted with HCl) 
pH 4.2: 
0.1 M NaOAc 
(adjusted with AcOH) 
pH 6.2: 
0.1 M NH4OAc 
(adjusted with AcOH) 
pH 11: 
0.05 M NaHCO3 
(adjusted with NaOH) 
   
 
Phosphonamidate 14a (5 mg, 0.01 mmol) was dissolved in the buffer with MeCN for solubility reasons 
(final concentration: 3 mM). Inosine (5 mM) was added as internal standard. The pH was adjusted and 
the stability of 14a was then analyzed after 0.5, 5, 9, 13, 18 and 24 hrs using analytical HPLC.  
No degradation was observed at pH 2.3, pH 4.2, pH 6.2 and pH 11. Phosphonamidate 14a was not stable 
to prolonged exposure at pH 1.7 (see Table 7). The degradation was quantified by comparison to the 
internal standard. 
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6.2.6 Peptide synthesis 
6.2.6.1 Azido-lysine peptide 17 
LYRKAGKAYLG NH2
O
H2N
N3  
Synthesized by automated SPPS on the PTI Tribute. 
Analytical data of 17: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-90 % B in 15 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 3.31 min 
Yield: 57.6 mg, 0.0455 mmol, 45.5%  
LRMS (ESI, m/z) calcd for C55H78N18O13 [M+2H]2+: 633.25, found: 633.27 
 
6.2.6.2 On-bead Staudinger-phosphonite ligation 
6.2.6.2.1 Synthesis of peptide 19 on base-labile resin 
LYRKAGK
O
H2N
N3
HMBA resin
 
Hydroxymethyl resin (HMBA resin, loading: 0.22 mmol/g, 0.1 mmol) was swelled in DMF for 30mins. 
The first amino acid was loaded by dissolving Lys (5 eq.), MeIm (3.75 eq.) and MSNT (5 eq.) in DMF 
Figure 57: Purified peptide 17. 
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(3 mL) and adding the mixture to the resin. After 1 hr, the reagents were exchanged and the same 
coupling was repeated for 1 hr. The resin was then capped with a mixture of DMF:Ac2O:DIPEA (8:1:1) 
for 10 mins. All remaining amino acids were coupled using the standard Fmoc-based procedures 
described in the general section.  
After the peptide was fully elongated, the final Fmoc protecting group was cleaved using standard 
conditions. The resin was then treated with a TFA cleavage cocktail (95:5 TFA:TIS) to remove all amino 
acid protecting groups for 1 hr. Afterwards, the resin was washed several times with 10% DIPEA in 
DMF, DMF and DCM to remove all traces of acid. It was then dried under HV for 1 hr and stored at 
4 °C.  
To check the integrity of the peptide, a test cleavage from the resin was performed by treating a few 
beads with a solution consisting of dioxane:1 M NaOH (3:1) for 10 mins at 0 °C. After neutralization 
with diluted HCl, the cleavage was analyzed by UPLC-MS.  
Analytical data of 19: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95% in 15.50 min  (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 4.52 min, 7.13 min (partially uncleaved Pbf protecting group) 
LRMS (ESI, m/z) calcd for C38H64N14O9 [M+H]+: 861.51, found: 861.81 ; calcd for C51H81N14O12S 
[M+Pbf+2H]2+: 557.30, found: 557.65 (*: not peptidic) 
  
Figure 58: Test cleavage of peptide 19 after full extension of the peptide. One Pbf-group still remained partially 
attached (7.13 min). Otherwise only the desired peptide 19 was obtained (4.52 min). 
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6.2.6.2.2 On-bead Staudinger ligation to peptide 20 
0.01 mmol of resin was swelled in a peptide reaction vessel in dry DMF. It was was then suspended in 
dry DMF (2 mL) in a glass vial filled with nitrogen gas. Borane-protected triazole-phosphonite 13d (31 
mg, 0.05 mmol) was deprotected with DABCO (8.4 mg, 0.075 mmol) at 70 °C in dry DMF (3 mL) for 
4 hrs. 1.5 mL of borane-deprotected 13d was added to the reactor and allowed to react for 24 hrs, after 
which the remaining 1.5 mL were added and reacted for another 24 hrs at 70 °C.  
 
The peptide was cleaved by the addition of 1 mL of dioxane:1 M NaOH (3:1) for 15 mins at 0°C. The 
cleavage solution was immediately neutralized with 0.2 M NaH2PO4 buffer until pH 7 was reached. 
After lyophilization, the peptide was purified by basic semi-preparative HPLC at pH 9 (see general 
information).  
 
Analytical data of 20: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 10-90 % B in 2.75 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 1.65 min 
Yield: 1.15 mg, 0.88 μmol, 8.8 % (85 % purity, by UV) 
LRMS (ESI, m/z) calcd for C57H89N18O14PS [M+2H]2+: 657.32, found: 657.76 
  
Figure 59: Peptide 20 after basic cleavage and basic purification. 
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6.2.6.3 Carboxyfluorescein-tagged azido-lysine peptide 21 
 
 
AYDKGRKAFA NH2
O
H
N
O
O
HO
HO
O
O N3
 
 
Synthesized by automated SPPS on the PTI Tribute. For the final coupling, 3 eq. of 5,6-
carboxyfluorescein, 3 eq. of HCTU and 6 eq. of DIPEA were used. 
 
Analytical data of 21: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 3.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 2.23 min 
Yield: 60 mg, 0.039 mmol, 39 %  
LRMS (ESI, m/z) calcd for C72H91N18O19 [M+2H]2+: 755.83, found: 755.55 
  
Figure 60: Purified peptide 21. 
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6.2.6.4 N-terminal azidoglycine peptide 24: 
YDKGRKAFA
O
N3
NH2
O
 
Synthesized by automated SPPS on the PTI Tribute. For the final coupling, 5 eq. of N-azidoglycine, 
5 eq. of HCTU and 5 eq. of DIPEA were used and coupled for 2 hrs. 
 
Analytical data of 24: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 13.2 min 
Yield: 61.9 mg, 0.0544 mmol, 54.4%  
HRMS (ESI, m/z) calcd for C55H78N18O13 [M+2H]2+: 569.2992, found: 569.3021 
  
Figure 61: Purified peptide 24. 
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6.2.6.5 N-terminal azido-phenylalanine peptide 25: 
YDKGRKAFA
O
N3
NH2
O
 
Synthesized by automated SPPS on the PTI Tribute. 5 eq. of N-azido-phenylalanine, 5 eq. of HCTU 
and 5 eq. of DIPEA were used for the final coupling and reacted for 2 hrs. 
Analytical data of 25:  
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 15.4 min 
Yield: 59.8 mg, 0.0498 mmol, 49.8 % 
HRMS (ESI, m/z) calcd for C50H76N18O13 [M+2H]2+: 600.3071, found: 600.3097  
Figure 62: Purified peptide 25. 
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6.2.6.6 Carboxyfluorescein-tagged N-terminal azido-phenylalanine peptide S2 
 
5,6-Carboxyfluorescein was installed via Lys(ivdee), which was selectively deprotected on-resin after 
capping of the peptide with azidobenzoic acid using hydrazine solution (2 % in DMF, 5 x 2 min). 5,6-
Carboxyfluorescein was coupled by using 2 eq. of fluorophore,. 2 eq. of HATU, 2 eq. of HOBt.H2O and 
4 eq. of DIPEA.  
Analytical data of S2: 
Column: Phenomenex Synergi 4u Hydro-RP, 4.6 x 250 mm (analytical HPLC) 
Gradient: 0-60 % B in 25 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 24.7 min 
Yield: 26 mg, 0.017 mmol, 8.5 %  
HRMS (ESI, m/z) calcd for C55H78N18O13 [M+2H]2+: 779.3309, found: 779.3339 
  
Figure 63: Purified peptide S2. 
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6.2.6.7 N-terminal p-aminophenylalanine peptide as reference S3 
 
 
Peptide S3 was synthesized by reduction of peptide S2 (4 mg, 2.6 µmol) with TCEP (1.5 mg, 5.2 µmol, 
2 eq.) for 1 hr in 20 mM NH4HCO3 with 10 % MeCN (1 mL, 2.6 mM). The peptide was purified over 
a SepPak column (1 g) and the product was isolated as a yellow powder in quantitative yield.  
 
Analytical data of S3: 
 
Column: Phenomenex Synergi 4u Hydro-RP, 4.6 x 250 mm (analytical HPLC) 
Gradient: 0-60 % B in 25 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 22.4 min (Remark: The double peak arises from the two diastereoisomers of the 5,6-
carboxyfluorescein. They both have the same mass.) 
HRMS (ESI, m/z) calcd for C55H78N18O13 [M+2H]2+: 766.3357, found: 766.3388 
  
YDKGRKAFA
O
H2N
NH2
O
HN
O
OHO OH
O
O
Figure 64: Purified peptide S3. 
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6.2.6.8 Carboxyfluorescein-tagged lysine peptide S4 as reference 
 
Synthesized by automated SPPS on the PTI Tribute. For the final coupling, 3 eq. of 5,6-
carboxyfluorescein, 3 eq. of HCTU and 6 eq. of DIPEA were used. 
 
Analytical data of S4: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 3.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 1.91 min (Remark: The double peak arises from the two diastereoisomers of the 5,6-
carboxyfluorescein. They both have the same mass.) 
Yield: 55 mg, 0.039 mmol, 39 %  
LRMS (ESI, m/z) calcd for C72H93N16O19 [M+2H]2+: 742.84, found: 742.59 
  
Figure 65: Purified peptide S4. 
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6.2.6.9 Peptide 39 with 1,6-elimination linker 
6.2.6.9.1 Peptide synthesis of 38 
 
The sequence H2N-GYRSA-NH2 was synthesized by automated SPPS on the PTI Tribute on Rink 
Amide AM resin.  
Column: Nucleodur C18 H Tec 5 μm (4x250 mm)  
Gradient: 5-95 % B in 40 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Yield: 25.6 mg, 0.046 mmol, 46 %. 
LRMS (ESI, m/z) calcd for C23H38N9O7 [M+H]+: 552.29, found: 552.19 
6.2.6.9.2 Synthesis of building block 37 
Sodium nitrite (4.00 g, 60 mmol) was dissolved in H2O (100 mL) and cooled to 0 °C. Aminobenzyl 
alcohol (5.00g, 40.6 mmol) was dispersed in 6 N HCl and then added drop-wise to the sodium nitrite 
solution. After finishing the addition, the reaction was stirred for 20 mins, before EtOAc (50 mL) was 
added to the aqueous solution. NaN3 (10.4 g, 160 mmol) dissolved in H2O (100 mL) was added slowly 
and stirred overnight. The reaction mixture was extracted with EtOAc (3 x 100 mL) and the organic 
layer was washed with sat. NaHCO3 (3 x100 mL) and brine (100 mL). The organic layer was dried with 
MgSO4 and the solvent was removed in vacuo. This yielded compound 36 as a yellow oil in quantitative 
yield. 
36 (0.5 g, 3.4 mmol) was dissolved in dry DMF (10 mL). Bisnitrophenyl carbonate (1.5, 5.0 mmol, 1.5 
eq.) and DIPEA (1.78 mL, 10.2 mmol, 3 eq.) was added and the reaction was stirred overnight at room 
temperature. The solvent was removed in vacuo and the residue was purified by silica gel column 
Figure 66: HPLC chromatogram of purified peptide. 
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chromatography using 3:1 Hex:EtOAc. This yielded 37 as white powder in 72 % yield (0.77 g, 
2.45 mmol).  
Analytical data of 37: 
1H NMR (CDCl3, 600 MHz) δ 8.27 (d, J = 8.5 Hz, 2 H), 7.44 (d, J =, 9 H, 2 H), 7.37 (d, J =, 8 H, 2 
H), 7.06 (d, J =, 8 H, 2 H), 5.26 (s, 2 H). 
13C-NMR (CDCl3, 150 MHz) δ 155.57, 152.54, 145.55, 141.12, 130.90, 130.62, 125.45, 121.88, 
119.48, 70.48 
All values were according to literature. [344] 
 
6.2.6.9.3 Coupling of building block 37 to peptide 38 
Building block 37 (4.3 mg, 1.3 μmol) was dissolved in DCM (0.5 mL) and DIPEA (6.5 μL, 36 μmol) 
was added at 4 °C. The peptide (5 mg, 9 μmol) was dissolved in DMF (0.5 mL) and added to the building 
block. More DIPEA (6.5 μL, 36 μmol) was then added. The reaction mixture was stirred for 5 mins at 
4 °C, then it was warmed to RT for 2 hrs.  
The solvent was removed in vacuo and peptide 39 was purified by semi-preparative HPLC.  
Yield: 4.0 mg, 5.5 μmol, 61 % 
LRMS (ESI, m/z) calcd for C31H43N12O9 [M+H]+: 727.33, found: 727.30 
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6.2.7 Synthesis of peptidic phosphonamidates 
6.2.7.1 Peptide conjugate 18 
 
This is the procedure for the optimized condition as described in Table 8, entry #18. For entries #16, 
17 and 19, temperature, reaction time and phosphonite equivalents can vary.  
Triazole-phosphonite 13a (23.2 mg, 43.9 µmol) was dissolved in dry, degassed DMF (2.2 mL, 20 mM) 
under argon and DABCO (7.2 mg, 65 µmol, 1.5 eq.) was added for 4 hrs at 80 °C, after which 1.1 mL 
of the solution was added to peptide 17 (1.1 mg, 0.96 µmol, 0.2 eq.) and the reaction was stirred for 16 
hrs, before the remaining deprotected triazole-phosphonite (1.1 mL) was added and stirred for another 
24 hrs. The reaction was run at 21, 37, 50 or 70 °C. The reaction was monitored by UPLC-MS and the 
progress was estimated by UV integration at 220 nm. The product was not isolated. 
Analytical data of 18: 
 
Figure 67: An example of a UPLC-MS measurement is given. The important peaks are labelled with the 
corresponding m/z ratio (azido peptide 17, m/z 622.23 and phosphonamidate 18, m/z 812.46). The UV peaks were 
integrated to get an estimate of the reaction’s progress. No peptidic side products occurred and the other peaks are 
phosphorus side products from degrading P(III) reagent. 
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Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 15.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 5.45 min 
LRMS (ESI, m/z): calcd for C76H112N21O17P [M+2H]2+: 811.92, found: 812.44 
 
6.2.7.2 Peptide conjugate 22 
 
Triazole-phosphonite 13d (17.8 mg, 28.3 µmol) was dissolved in dry, degassed DMF (0.6 mL, 20 mM) 
under argon and DABCO (1.8 mg, 42.9 µmol, 1.5 eq.) was added for 4 hrs at 80 °C. The solution was 
cooled to 50 °C and peptide 17 (6 mg, 4 µmol, 0.15 eq.) was added. The reaction was stirred for 3 d at 
50 °C. The reaction was monitored by UPLC-MS. Afterwards, the reaction was lyophilized with 50:50 
H2O:MeCN and purified by acidic semi-preparative HPLC. Compound 22 was isolated as white powder 
(2.5 mg, 1.2 µmol, 30 %). 
Analytical data of 22: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 2.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 2.02 min 
Figure 68: Purified peptide 22. 
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LRMS (ESI, m/z): calcd for C91H114N22O24PS [M+2H]2+: 982.40, found: 982.05 
6.2.7.3  Peptide conjugate 26 
 
 
Triazole-phosphonite 13d (5 mg, 6 µmol) was dissolved in dry, degassed DMF (0.8 mL, 6 mM) under 
argon and DABCO (1.0 mg, 9.0 µmol, 1.5 eq.) was added for 4 hrs at 80 °C. The solution was cooled 
to room temperature and peptide 24 (1.36 mg, 1.2 µmol, 0.2 eq.) was added. The reaction was stirred 
for 24 hrs at room temperature. The reaction was monitored by UPLC-MS. Afterwards, the reaction 
was lyophilized with 50:50 H2O:MeCN and purified by semi-preparative HPLC. Compound 26 was 
isolated as white powder (1.3 mg, 0.82 µmol, 68 %).  
Analytical data of 26: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 2.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 1.97 min 
HRMS (ESI, m/z): calcd for C74H105N22O18PS [M+2H]2+: 826.3712, found: 826.3752 
  
Figure 69: Purified peptide 26. 
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7.7.4 Peptide conjugate 27 
 
Triazole-phosphonite 13d (3 mg, 4.8 µmol) was dissolved in dry, degassed DMF (0.8 mL, 6 mM) under 
argon and DABCO (0.8 mg, 7.2 µmol, 1.5 eq.) was added for 4 hrs at 80 °C. The solution was cooled 
to room temperature and peptide 25 (1.2 mg, 0.96 µmol, 0.2 eq.) was added. The reaction was stirred 
for 24 hrs at room temperature. The reaction was monitored by UPLC-MS. Afterwards, the reaction 
was lyophilized with 50:50 H2O:MeCN and purified by semi-preparative HPLC. Compound 27 was 
isolated as white powder (1 mg, 0.61 µmol, 63 %). 
Analytical data of 27: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 2.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 1.97 min 
HRMS (ESI, m/z): calcd for C74H105N22O18PS [M+2H]2+: 826.3712, found: 826.3752 
  
Figure 70: Purified peptide 27. 
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6.2.7.4 Peptide conjugate 32  
 
Triazole-phosphonite 13d (5 mg, 8 µmol) was dissolved in dry, degassed DMF (0.8 mL, 6 mM) under 
argon and DABCO (1.1 mg, 12 µmol, 1.5 eq.) was added for 4 hrs at 80 °C. Peptide S2 (2.5 mg, 1.6 
µmol, 0.2 eq.) was added at 37 °C and stirred overnight. The reaction was monitored by UPLC-MS. 
Afterwards, the reaction was lyophilized with 50:50 H2O:MeCN and purified by semi-preparative 
HPLC. Compound 32 was isolated as yellow powder (1.45 mg, 0.72 µmol, 45 %). 
Analytical data of 32: 
Column: Phenomenex Synergi 4u Hydro-RP, 4.6 x 250 mm (analytical HPLC) 
Gradient: 0-60 % B in 25 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 26.0 min 
HRMS (ESI, m/z): calcd for C95H116N22O24PS [M+3H]3+: 670.9336, found: 670.9361 
  
Figure 71: Purified peptide 32. 
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6.2.7.5 Peptide conjugate 41 
 
Triazole-phosphonite 13d (5 mg, 8 µmol) was dissolved in dry, degassed DMF (0.8 mL, 6 mM) under 
argon and DABCO (1.1 mg, 12 µmol, 1.5 eq.) was added for 4 hrs at 80 °C. Peptide 39 (1.4 mg, 
1.2 µmol, 0.2 eq.) was added at room temperature and stirred overnight. The reaction was monitored by 
UPLC-MS. Afterwards, the reaction was lyophilized with 50:50 H2O:MeCN and purified by semi-
preparative HPLC. Compound 41 was isolated as white powder (1.0 mg, 0.85 µmol, 43 %). 
Analytical data of 41: 
 
Column: Phenomenex Synergi 4u Hydro-RP, 4.6 x 250 mm (analytical HPLC) 
Gradient: 0-60 % B in 25 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Retention time: 23.9 min 
 
Figure 72: Purified peptide conjugate 41. 
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6.2.8 Irradiation of phosphonamidates 
6.2.8.1 Irradiation of small-molecule phosphonamidate 14a 
Phosphonamidate 14a (1.48 mg, 2.7 µmol) was dissolved in a mixture of 50 mM TRIS (pH 6): MeCN 
(50:50) to a final concentration of 1.5 mM. The solution was placed in a Quartz cuvette and irradiated 
at 297 nm for 15 minutes until complete disappearance of 14a. The progress was monitored by analytical 
HPLC (see Figure 32).  
6.2.8.1.1 Monitoring of irradiation by NMR 
Phosphonamidate 14a (1.5 mg, 2.9 µmol) was dissolved in 1 mL of a mixture of 50 mM TRIS (pH 6): 
d3-MeCN (50:50). The solution was placed in a Quartz cuvette and irradiated at 297 nm for 15 mins. 
0.6 mL of the solution was then placed into a clean NMR tube and submitted to a 2D 1H-31P-HMBC 
correlation analysis at the 600 MHz (with water suppression). The measured spectrum is depicted in 
Figure 33. 
6.2.8.2 Irradiation of peptide phosphonamidate 22 
Peptide phosphonamidate 22 (0.23 mg, 0.117 µmol) was dissolved in 20 mM NH4HCO3 (pH 7) to a 
final concentration of 100 µM. The solution was placed in a Quartz cuvette and irradiated at 297 nm for 
15 mins. The reaction was monitored by analytical fluorescence-based HPLC and UPLC-MS. About 
15 % of peptide conjugate 22 has been hydrolyzed during lyophilization after HPLC purification with 
0.1 % TFA (Figure 34, blue trace). After irradiation (Figure 34, red trace), only amine 23 was present 
in the solution. 
Conditions for Figure 34: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 38.6 min, detected: m/z 982.12 [M+2H]2+ (= phosphonamidate 22, calc.: m/z 982.40) 
Ret. time: 32.6 min , detected: m/z 742.95 [M+2H]2+ (= amine 23, calc.: m/z 743.34)  
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6.2.8.3 Irradiation and incubation of peptide phosphonamidate 32 
6.2.8.3.1 Evaluation of different pHs 
 
Phosphonamidate 32 (0.11 mg, 0.055 µmol) was dissolved in 50:50 NH4HCO3:MeCN (pH 7) to a final 
concentration of 0.038 mM. The probe was irradiated for 20 min at 297 nm and then analyzed by UPLC-
MS. The dominant mass (m/z 938.15 [M+H]+) corresponded to phosphonamidate acid 33 (see Figure 
S2) and only little amine 34 was observed. Similarly, the largest peak observed by fluorescence HPLC 
did not have the same retention time as our reference probe S3. To initiate P-N bond cleavage, the 
solution was acidified to pH 3 with citric acid, incubated for 16 hrs and analyzed by fluorescence HPLC. 
Phosphonamidate acid 33 had disappeared and only amine 34 was observed, which had the same 
retention time as reference peptide S3.  
Conditions for Figure 38: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
 
6.2.8.3.2 In 0.1% TFA/H2O 
Phosphonamidate 32 (0.11 mg, 0.055 µmol) was dissolved in 0.1% TFA/H2O (pH 2) to a final 
concentration of 0.038 mM. The probe was irradiated for 20 min at 297 nm and then incubated for 
16 hrs at room temperature. It was then analyzed by fluorescence HPLC (see Figure 3) and UPLC-MS. 
Only amine 34 (m/z 766.46) was observed.  
Conditions for Figure 39: 
Column: Phenomenex Synergi 4u Hydro-RP, 4.6 x 250 mm (analytical HPLC) 
Gradient: 0-60 % B in 25 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
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6.2.8.3.3 Stability of phosphonamidate 32 in 0.1% TFA/H2O 
Phosphonamidate peptide 32 was incubated for 16 hrs in 0.1 % TFA/H2O (pH 2) and the stability was 
controlled by fluorescence HPLC. In case of P-N bond cleavage, amine 34 would be formed and have 
the same retention time as peptide S3, which was synthesized as a reference for P-N bond cleavage. 
No formation of amine 34 was observed after 16 hrs incubation, indicating that the P-N bond of 
phosphonamidate 32 is stable in 0.1 % TFA/H2O. 
Conditions for Figure 73: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
  
Figure 73: Phosphonamidate 32 did not degrade during overnight incubation with 0.1 % TFA/H2O. 
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6.2.9 Immobilization & irradiation procedures. 
6.2.9.1 General procedure 
For the immobilization of the biotin-phosphonamidates, the beads were first thoroughly washed with 
20 mM NH4HCO3 (pH 7) buffer to remove the storage buffer. The biotin-phosphonamidates were 
dissolved in 20 mM NH4HCO3 (pH 7) with 5 % MeCN and added to the beads for 2 hrs at room 
temperature. The beads were then washed 3 times with 20 mM NH4HCO3 (pH 7) and 2 times with 
elution buffer. The beads were then transferred to a UV cuvette with a stirrer and were irradiated for 1 
hr at 297 nm. Afterwards, the beads were incubated for further 16 hrs at room temperature, before the 
beads were filtered. The elution was further analyzed by UPLC-MS or fluorescence HPLC. 
6.2.9.2 Peptide conjugate 22 
Peptide conjugate 22 was dissolved in 20 mM NH4HCO3 (pH 7) with 5 % MeCN and added to 
thoroughly washed and NH4HCO3-conditioned beads for 2 hrs at room temperature. The beads were 
washed and then transferred to a UV cuvette for irradiation. The beads were irradiated for 20 mins. The 
filtered elution was analyzed by UPLC-MS.  
Analytical data for immobilization and irradiation of 22: 
Conditions for Figure 74: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 15.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 6.40 min, detected: m/z 982.00 [M+2H]2+ (= phosphonamidate 22, calc.: m/z 982.40) 
Ret. time: 4.87 min , detected: m/z 742.83 [M+2H]2+ (= amine 23, calc.: m/z 743.34)  
Figure 74: Phosphonamidate 22 (blue trace) was immobilized on streptavidin beads. The beads were then 
irradiated for 20 mins at 297 nm and the elute (red trace) was analyzed by UPLC-MS.  
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6.2.9.3 N-terminal peptide conjugates  
6.2.9.3.1 Peptide conjugate 26 
Peptide conjugate 26 was dissolved in 20 mM NH4HCO3 (pH 7) with 5 % MeCN and added to 
thoroughly washed and NH4HCO3-conditioned beads for 2 hrs at room temperature. The beads were 
washed and then transferred to a UV cuvette irradiation. The beads were irradiated for 1 hr. The beads 
were then split up into four equal parts and incubated in different buffers at pH 3-6 for 48 hrs. The 
filtered elution was lyophilized and analyzed by UPLC-MS.  
The elution of the desired amine 30 increased with higher pHs. The highest elution was achieved at 
pH 3. At pH 4, a clear product peak is visible as well as unspecific co-elution of phosphonamidate acid 
28, arising from bead degradation. 
Analytical data for irradiation of 26: 
   
Conditions for Figure 75: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
5-95 % B in 15.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 3.02 min, detected: m/z 795.36 [M+2H]2+ (= phosphonamidate 26, calc.: m/z 795.36) 
Ret. time: 3.25 min , detected: m/z 742.83 [M+2H]2+ (= phosphonamidate acid 28, calc.: m/z 727.85) 
 
6.2.9.3.2 Peptide conjugate 27 
Peptide conjugate 27 was dissolved in 20 mM NH4HCO3 (pH 7) with 5 % MeCN and added to 
thoroughly washed and NH4HCO3-conditioned beads for 2 hrs at room temperature. The beads were 
washed and then transferred to a UV cuvette irradiation. The beads were irradiated for 1 hr. The beads 
were then incubated at pH 3 (citric acid buffer) for 48 hrs. The filtered elution was lyophilized and 
analyzed by UPLC-MS.  
The elution contained the desired amine 31 with no side-products visible and no co-elution of 
phosphonamidate acid 29, hinting at a quicker P-N cleavage than for non-aromatic construct. 
Figure 75: UPLC chromatograms of the elutions after immobilization and irradiation of conjugate 26 were 
recorded after the beads were incubated at pHs 6 (left), 5 (middle) and 4 (right) over 48 hrs. 
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Analytical data for 27: 
Conditions for Figure 76: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
5-95 % B in 15.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 3.80 min, detected: m/z 1173.21 [M+H]+ (= amine 31, calc.: m/z 1172.62) 
 
6.2.9.3.3 Fluorescent N-terminal peptide conjugate 32 
Phosphonamidate 32 (0.19 mg, 0.094 µmol) was dissolved in 400 µL 20 mM NH4HCO3 (pH 7) with 
5 % MeCN and added to 200 µL beads (dead volume) of GE Healthcare Sepharose Streptavidin beads. 
The beads were shaken for 2 hrs at room temperature and were then washed three times with 500 µL 
20 mM NH4HCO3 (pH 7) and two times with 500 µL 0.1 % TFA/H2O (pH 2). The beads were suspended 
in 500 µL 0.1 % TFA/H2O (pH 2), transferred into an UV Quartz cuvette and irradiated for 1 hr at room 
temperature at 297 nm, followed by 16 hrs incubation. The elute was lyophilized, re-dissolved in 50 µL 
50:50 H2O:MeCN each and analyzed by fluorescence HPLC (see Figure 39).  
HPLC conditions for Figure 39: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 19.90 min, detected: m/z 671.61 [M+3H]3+ (= phosphonamidate 32, calc.: m/z 671.89) 
Ret. time: 17.40 min, detected: m/z 938.00 [M+H]+ (= phosphonamidate acid 33, calc.: m/z 938.15) 
Ret. time: 15.40 min, detected: m/z 766.43 [M+2H]2+ (= amine 34, calc.: m/z 776.34) 
 
Figure 76: Elution from streptavidin beads after immobilization of peptide conjugate 27, irradiation and incubation 
at pH 3 showing the specific release of amine 31. 
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6.2.9.3.4 Evaluation of different buffers for release of peptide 
Streptavidin beads only have a limited stability below pH 3. We therefore wanted to evaluate whether 
the release of phosphonamidate 27 from streptavidin beads could be carried out at pH 3 instead of pH 
2. To do so, the phosphonamidate-conjugate was immobilized at pH 7 and the irradiation and incubation 
was carried out in a citric acid-phosphate buffer at pH 3. To check if all the peptide had eluted, the beads 
were additionally incubated at pH 2 to see whether any more fluorescent peptide was released. 
Phosphonamidate 27 (0.1 mg, 0.049 µmol) was dissolved in 300 µL 20 mM NH4HCO3 (pH 7) with 5 
% MeCN and added to 150 µL streptavidin beads (dead volume). The beads were shaken for 2 hrs at 
room temperature and then washed three times with 300 µL NH4HCO3 (pH 7) and two times with 300 
µL 0.1 % TFA/H2O (pH 2). The beads were suspended in 300 µL citric acid-phosphate buffer (pH 3), 
transferred into an UV Quartz cuvette and irradiated for 1 hr at room temperature at 297 nm, followed 
by 16 hrs incubation. The beads were washed 3 times with 300 µL citric acid-phosphate buffer (pH 3) 
and once quickly with 300 µL 0.1 % TFA/H2O (pH 2), before they were suspended in 300 µL 
0.1 % TFA/H2O (pH 2) for 2 hrs. The elutes were lyophilized, re-dissolved in 50 µL 50:50 H2O:MeCN 
each and analyzed by fluorescence HPLC (see Figure 77) and UPLC-MS.  
As shown in Figure 77, pH 3 could initiate P-N bond cleavage. Unfortunately, not all of amine 31 was 
released. Incubation at pH 2 led to additional elution of amine 31, suggesting that pH 3 is not sufficient 
to achieve full P-N bond cleavage of phosphonamidate acid 29 on beads. 
As control, beads were loaded with phosphonamidate 27, but the beads were only incubated at pH 2 
without irradiation. The elute was analyzed by UPLC-MS and no release could be observed. 
Figure 77: Phosphonamidate 27 (*, blue) was immobilized on streptavidin beads, then irradiated and incubated at 
pH 3 (red), where the release of amine 31 (+) was observed. Further incubation at pH 2 (green) resulted in the 
elution of more amine 31 (+). 
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6.2.9.3.5 Streptavidin beads degradation in 0.1% TFA/H2O 
To probe the stability of streptavidin beads in 0.1% TFA/H2O, a sample of streptavidin beads was 
incubated in 0.1% TFA/H2O overnight and the elute was analyzed by UPLC-MS. The UV trace was 
measured at 220 nm and 272 nm. A broad elution peak could be seen, suggesting that the beads only 
have limited stability in 0.1% TFA/H2O. 
  
Figure 78: Streptavidin beads were incubated for 16 hrs and the elute was analyzed by UPLC-MS. The UV traces 
for 220 and 272 nm are shown. 
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6.2.10 Quantification of amine release 
6.2.10.1 Quantification by fluorescence spectroscopy (peptide conjugate 22) 
To quantify the release of amine after immobilization on streptavidin beads and subsequent irradiation, 
a fluorescent read-out was chosen. All measurements were carried out at fixed wavelengths of λEx = 492 
nm and λEm = 517 nm. Before each measurement, the pH was checked and adjusted to pH 7.0. 
6.2.10.1.1 Linear regression of fluorescent signal 
To ensure the correct concentration was chosen and that the fluorescent signal could be quantified by a 
linear regression, the fluorescence of peptide S4 was measured at different concentrations (0.5, 1, 2, 3, 
4 and 5 μM) in 20 mM NH4HCO3 (pH 7.0) buffer. 
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Figure 79: The fluorescence signal of peptide S4 was measured at different concentrations to ensure a linear 
regression. 
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Figure 80: The linear regression of peptide S4 is shown. 
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Concentration (μM) Experiment 1 Experiment 2 Experiment 3 Mean Standard deviation 
0,5 49,07 42,89 62,04 51,33 7,98 
1 140,88 142,07 135,68 139,54 2,77 
2 306,12 262,67 219,31 262,70 35,44 
3 520,6 489,64 469,37 493,20 21,07 
4 661,57 710,14 690,75 687,49 19,96 
5 859,7 897,65 864,62 873,99 16,85 
For concentrations up to 5 μM, a linearity was given. Higher concentrations resulted in fluorescent 
quenching. All following experiments were carried out within this acceptable concentration range. 
6.2.10.1.2 Immobilization and irradiation 
A 100 μM stock solution of peptide 22 was prepared. 40 nmol (400 μL from the stock solution) was 
diluted with 20 mM NH4HCO3 to a volume of 1 mL and then immobilized on 500 μL streptavidin beads 
(binding capacity > 85 nmol free biotin/mL) for 1 hr. The beads were then centrifuged down at 
14000 rpm and were washed with 1 mL of 20 mM NH4HCO3 at pH 7 (5 x). All fractions were checked 
for the correct pH and then analyzed by fluorescence spectroscopy (see Figure 81).  
Afterwards, the beads were suspended in a UV quartz cuvette in 2 mL of 20 mM NH4HCO3 at pH 7. 
200 μL aliquots were taken at 1, 2, 5, 7 and 10 mins and filled up to 1 mL with 20 mM NH4HCO3 at 
pH 7. The data was compared to a reference probe of 22 that was irradiated at 297 nm in solution for 10 
mins. The results are shown in Figure 35. 
 
Table 12: Fluorescence values of all concentrations and measurements, including the mean and standard deviation. 
Figure 81: The fluorescence measurements of the flow-through (FT) and the washes (W1-5) after immobilization 
of phosphonamidate 22 for 1 hr. 
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Probe elution (λEm = 517 nm) Experiment 1 Experiment 2 Experiment 3 
E10 117,266 121,358 120,387 
Reference 162,117 177,424 168,374 
% 72,1 68,4 71,5 
Average % 70,7 (±1,6 %)   
6.2.10.2 Quantification by SIR (peptide conjugate 32) 
6.2.10.2.1 Standard curve for quantification 
To quantify the release, we measured the selected ion recording signal of product 34 by integration (see 
Figure 82) and compared the obtained area to a standard curve. Completion of irradiation and P-N bond 
cleavage was verified by UPLC-MS. 
The standard curve was generated by measuring the selection ion recording series of a dilution series of 
peptide S3 (0.1 mM, 0.05 mM, 0.01 mM, 0.005 mM, 0.001 mM). As ion, the double charged species 
[M+2H]2+ = m/z 766.46 was chosen. 10 µL of each dilution was measured and the SIR area was 
recorded. In total, 3 dilution series were prepared and measured individually. The average of the three 
measurements was taken for each concentration and the values were plotted and evaluated using 
GraphPad Prism (see Figure 83). 
 
  
Table 13: Fluorescence measurement values at λEm = 517 nm after 10 min irradiation in comparison to the 
reference representing the maximum possible release from the beads. The premature P-N bond hydrolysis of 
phosphonamidate 22 prior to immobilization was disregarded. 
Figure 82: Example of SIR integration (m/z 766.46) for 0.01 mM: 2993497 
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All integrated area values: 
Concentration 
(mM) 
Area m/z 766.46 
1 2 3 
0,1 17277860 17051690 21153450 
0,05 10683560 10972540 11944450 
0,025 3547550 3678688 3957134 
0,01 2482786 2993497 3347351 
0,005 1660579 1582266 1671098 
0,001 337230 364484 512056 
 
Slope: y = 183807092x 
6.2.10.2.2 Quantification of release 
Peptide 32 (0.25 mg, 0.124 µmol) was dissolved in 150 µL 2:1 H2O:MeCN (containing 0.1 % TFA). 
Concentration of peptide 32: 0.826 mM. 
Three probes were prepared as follows: 15 µL (0.025 mg, 0.0124 µmol) of the stock solution of peptide 
32 were diluted to 200 µL 0.1 % TFA/H2O (pH 2). Final peptide concentration: 0.062 mM. 
Each probe was irradiated for 30 mins at 297 nm, then stirred for 2 hrs at room temperature to ensure 
P-N bond cleavage. The probes were then analyzed by SIR integration (m/z 766.46): The results are 
shown in Table 10. 
  
Table 14: All area values from the SIR integration of S3. 
Figure 83: The standard curve generated from the integrated SIR areas.  
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6.3 Project 2: Towards the semi-synthesis of tau proteins modified in the 
proline-rich domain 
6.3.1 Cloning and expression of the tau protein fragments 
The target cDNA was amplified from the wild-type cDNA in a pET15b vector using the high-fidelity 
Phusion polymerase from ThermoScientific. The amplified cDNA was cut using restriction enzymes 
provided by NEB and then ligated into the target vector using T4 DNA ligase from ThermoScientific. 
The cDNA was then transformed into chemically competent DH5α by heat shock, spread out on an agar 
plate with the correct antibiotic resistance and incubated overnight at 37 °C. Colonies were grown in 
LB medium overnight at 37 °C. The cells were centrifuged, the cDNA was isolated and sequenced.  
6.3.1.1 Full-length MAPT protein sequence 
 
6.3.1.2 Tau[1-196] thioester (43) 
The cDNA of Tau[1-196] was cloned into a pTXB1 vector using the NdeI and SapI restriction sites. 
The upstream primer contained a 6 bp long overhang for efficient cleavage by restriction enzymes, a 
NdeI cleavage site and a sequence complementary to the first amino acids of MAPT. The downstream 
Figure 84: Full-length human MAPT sequence. 
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primer consisted of a 6 bp overhang, a SapI cleavage site, and a sequence complementary to the last 
amino acids of MAPT (ending with Gly196). 
The vector was transformed into T7 express cells and 20 mL of overnight culture was grown in LB 
medium supplemented with ampicillin. 2 mL of overnight culture was added to 200 mL LB medium 
with ampicillin the next day and the cells were grown until an OD 0.8 was reached. Expression was 
then induced by the addition of IPTG (final concentration: 1 mM) and conducted at 37 °C for 4 hrs. The 
cells were harvested at 6000 rpm and the pellet was resuspended in 10 mL buffer in PBS.  
A small sample of the pellet was boiled in SDS sample buffer and analyzed by SDS-PAGE. A thick 
band ran at the height where Tau[1-196]-intein-CBD (Calculated mass: 48.1 kDa) was expected (see 
Figure 85). Incubation of the beads with 50 mM DTT in 50 mM TRIS.HCl, 0.5 M NaCl and 0.1 % 
Triton at pH 8.5 resulted in the release of Tau[1-196] (Calculated mass: 20.1 kDa), while the uncleaved 
Tau protein and the cleaved intein-CBD remained attached to the beads (see Figure 86, lanes 3 and 4). 
Ligation of Tau[1-196] and peptide 47a was performed in 6 M Gn.HCl, 0.2 M NaH2PO4 and 100 mM 
MesNa at pH 7 at a peptide concentration of 5 mM (see Figure 86, lane 1 and 2).  
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Figure 85: Tau[1-196]-intein-CBD 
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Figure 86: Tau[1-196] was immobilized on chitin beads. Lane 1: Elution with peptide 47a and 100 mM MesNa; 
Lane 2: Beads after elution 1; Lane 3: Elution with 50 mM DTT; Lane 4: Beads after elution 3  
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6.3.1.3 Tau[Cys228-441] (45) with FXa cleavage site 
The cDNA of Tau[Cys228-441] was cloned into a pET16b vector using the XhoI and BamHI restriction 
sites. 
The expression was performed in BL21(DE3) cells and the expression was induced at OD 0.9 with 
1 mM IPTG concentration at 37 °C for 4 hrs. The cells were lysed with the French press using a buffer 
containing 50 mM NaH2PO4, 0.3 M NaCl, 10 mM imidazole, 5 mM mercaptoethanol and Roche 
protease inhibitor at pH 7.5. The cell lysate was centrifuged for 50 mins at 20000 g. 
The supernatant was purified by affinity column chromatography (HisTrap, GE Healthcare, 5 mL): 
Equilibration buffer: 50 mM NaH2PO4 (pH 7.5), 0.3 M NaCl, 10 mM imidazole, 5 mM 
β-mercaptoethanol 
Elution buffer: 50 mM NaH2PO4 (pH 7.5), 0.3 M NaCl, 500 mM imidazole, 5 mM β-mercaptoethanol 
The fractions with protein were collected and desalted (HiTrap 26/10): 
Storage buffer: 20 mM Tris.HCl (pH 8.0), 100 mM NaCl and 2 mM CaCl2. 
The desalted protein was concentrated by spin-centrifugation, aliquoted into 250 μL portions and then 
frozen at -80 °C. The His-Tag was removed freshly before each use. 
Factor Xa enzyme was purchased from NEB. The His-Tag cleavage was performed for 10 μg of protein 
at different temperatures (20 °C and 25 °C) and different enzyme concentrations (0.3 μg/μL and 0.5 
μg/μL) in a total volume of 50 μL. The cleavage was monitored over 22 hrs by SDS-PAGE (see Figure 
44). Long incubation times (over 6 hrs) resulted in a noticeable protein loss in all cases. The best result 
was achieved at 20 °C with an enzyme concentration of 0.3 μg/μL and a cleavage time of 6 hrs. 
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Figure 87: Tau[Cys228-441] with His-Tag after purification 
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Upscaling was tested with 100 μg of protein (see Figure 88) using these conditions. After 6 hrs, only 
about 50 % of the protein had been cleaved from the His-Tag. 
6.3.1.4 Tau[Cys228-441] (45) with TEV cleavage site 
The cDNA of Tau[Cys228-441] was cloned into a pET16b vector using the XhoI and BamHI restriction 
sites. The primer sequences were:  
(forward) 5’- GTTGTTCTCGAGGAAAACCTGTATTTTCAGTGTGTCCGTACTCCACCCA-3’ 
(reverse) 5’- AACAACGGATCCTCACAAACCCTGCTTGGC-3’ 
The upstream primer contained a 6 bp long overhang for efficient cleavage by restriction enzymes, a 
XhoI cleavage site, the TEV cleavage site sequence (ENLYFQ_C) and a Val228Cys mutation. The 
downstream primer consisted of a 6 bp overhang, a BamHI cleavage site, and a sequence 
complementary to the last amino acids of MAPT (ending with Leu441). 
The expression was tested in BL21(DE3), T7 express and Rosetta cells, at 0.5 mM and 1 mM IPTG 
induction concentration and at 18, 27 and 37 °C to determine the best conditions (procedure listed 
below).   
The vector was transformed into Bl21 (DE3) cells and 20 mL of overnight culture was grown in LB 
medium supplemented with ampicillin. These were added to 2 L LB medium with ampicillin the next 
day and the cells were grown until an OD 0.8 was reached. Expression was then induced by the addition 
of IPTG (final concentration: 1 mM) and conducted at 28 °C for 4 hrs. The cells were harvested at 6000 
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Figure 88: FXa cleavage of His-Tag from His-tagged Tau[Cys228-441] at larger scale showed only about 50 % 
digest after 6 hrs. 
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rpm and the pellet was resuspended in 100 mL buffer with 50 mM TRIS.HCl (pH 8.0), 400 mM NaCl, 
20 mM imidazole and 5 mM β-mercaptoethanol. The cells were lysed by homogenization and the cell 
debris was centrifuged at 20000 g for 30 mins at 4 °C.   
The supernatant was purified by affinity column chromatography (HisTrap, GE Healthcare, 5 mL): 
Equilibration buffer: 50 mM Tris-HCl (pH 8), 400 mM NaCl, 20 mM imidazole, 5 mM 
β-mercaptoethanol 
Elution buffer: 50 mM Tris-HCl (pH 8), 400 mM NaCl, 500 mM imidazole, 5 mM β-mercaptoethanol 
The fractions with protein were collected and desalted (HiTrap 26/10): 
Storage buffer: 50 mM Tris-HCl (pH 8), 0.5 M EDTA, 1 mM DTT 
The desalted protein was concentrated by spin-centrifugation, aliquoted into 250 μL portions and then 
frozen at -80 °C. The His-Tag was removed freshly before each use. 
For the TEV cleavage trials, 0.6 μg of protein aliquots were treated with different ratios of TEV enzyme 
(100:1, 50:1, 10:1) and the digest was performed either at 4 °C or 20 °C. The progress was evaluated 
by SDS-PAGE after 1, 2, 4, 6 and 24 hrs (see Figure 90). All cleavages were performed using freshly 
expressed TEV protease (containing a His-Tag for post-removal), except for the positive control, where 
commercially available TEV protease was used. No enzyme was added to the negative control. 
Tau[Cys228-441] was further analyzed by MALDI (see Figure 91). 
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Figure 89: His-tagged Tau[Cys228-441] after affinity chromatography and desalting. 
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Calc.: m/z 22.62 [M+H]+ 
Exp: m/z 22.70 [M+H]+ 
When applicable, the protein was passed over Ni-NTA beads to remove the His-tagged TEV enzyme 
and any uncleaved protein. In this case, the buffer was supplemented with 1 M imidazole to a final 
concentration of 40 mM. The protein was then passed over Ni-NTA beads previously washed with a 
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Figure 91: MALDI of Tau[Cys228-441] after His-Tag removal by TEV cleavage. 
Figure 90: His-Tag removal from His-tagged Tau[Cys228-441] using different protein:TEV concentrations, 
temperatures and cleavage times. The progress was evaluated by SDS-PAGE analysis. 
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buffer made up of 50 mM TRIS.HCl (pH 8.0) and 40 mM imidazole. After 1 hr of incubation at 20 °C, 
the flow-through containing the desired protein was collected and rebuffered to an imidazole-free buffer 
for ligation, i.e. 0.2 M NaH2PO4. 
6.3.1.5 Tau[1-192] thioester (66) 
The cDNA of Tau[1-192] was cloned into a pTXB1 vector using the NdeI and SapI restriction sites. 
The primer sequences were:  
(forward) 5’-GTTGTTCATATGGCTGAGCCCCGC-3’ 
(reverse) 5’-GTTGTTGCTCTTCTGCACCCTGATTTTGGAGGTTCACC-3’ 
The upstream primer contained a 6 bp long overhang for efficient cleavage by restriction enzymes, a 
NdeI cleavage site and a sequence complementary to the first amino acids of MAPT. The downstream 
primer consisted of a 6 bp overhang, a SapI cleavage site, and a sequence complementary to the last 
amino acids of MAPT (ending with Gly192). 
The expression was tested in BL21(DE3), T7 express and Rosetta cells, at 0.5 mM and 1 mM IPTG 
induction concentration and at 18, 27 and 37 °C to determine the best conditions (procedure listed 
below).   
The vector was transformed into Rosetta cells and 20 mL of overnight culture was grown in LB medium 
supplemented with ampicillin. These were added to 2 L LB medium with ampicillin the next day and 
the cells were grown until an OD 0.8 was reached. Expression was then induced by the addition of IPTG 
(final concentration: 1 mM) and conducted at 18 °C overnight. The cells were harvested at 6000 rpm 
and the pellet was resuspended in 100 mL buffer in PBS. The suspension was aliquoted into 2 mL 
portions and frozen at -80 °C until use. 4 mL of suspension were defrozen, lysed by ultrasonification 
and the cell debris was centrifuged down at 20000 g for 30 mins at 4 °C. The supernatant was incubated 
with 0.5 mL chitin beads at 4 °C for 1 hr. The beads were then washed with buffer made up of 50 mM 
Tris.HCl (pH 8.0) and 0.5 M NaCl. The intein cleavage was induced by addition of buffer with 50 mM 
TRIS.HCl (pH 8.0), 0.5 M NaCl, 0.1 % Triton and 100 mM MesNa and performed overnight at RT. 
The eluted protein was analyzed by SDS-PAGE and MALDI. 
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6.3.1.5.1 Intein cleavage optimization 
Optimization for buffers with differing NaCl and detergent concentration:  
Buffers tested: 
Buffer A:  
50 mM TRIS.HCl (pH 8.5) 
0.5 M NaCl 
0.1 % Triton 
100 mM MesNa 
Buffer B: 
50 mM TRIS.HCl (pH 8.5) 
1.0 M NaCl 
100 mM MesNa 
Buffer C: 
50 mM TRIS.HCl (pH 8.5) 
1.5 M NaCl 
100 mM MesNa 
 
1 mL of chitin beads (2 mg/mL binding capacity) were suspended in 3 mL PBS-buffered lysis solution 
of a fresh Tau[1-192]-intein-CBD expression. The protein was immobilized for 2 hrs at 4 °C. The beads 
were thoroughly washed with PBS (70 mL) and then split into six equal portions. The beads were 
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Tau[1-192]-intein-CBD
Tau[1-192]-SCH2CH2SO3
-
intein-CBD
1: Before induction
2: After induction
3: After lysis
4: Flow-through
5: Wash
6: Immobilization on beads
7: Cleavage with 100 mM MesNa
8: Beads after cleavage
Figure 92: Tau[1-192] expression in Rosetta cells, immobilization on CBD beads after cell lysis and elution by 
incubation with 100 mM MesNa. The beads should retention of cleaved Tau[1-192] thioester. A co-elution of 
uncleaved Tau[1-192] fusion protein was observed. 
calc.: m/z 19.65 kDa [M+H]+, m/z 9.83 kDa [M+2H]2+
exp.: m/z 19.67 kDa [M+H]+, m/z 9.81 kDa [M+2H]2+
Figure 93: MALDI of Tau[1-192] after intein fusion cleavage with MesNa. 
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equilibrated with intein cleavage buffers A-C without MesNa, before the intein cleavage was induced 
with 500 μL of MesNa-containing buffers A-C.  
The cleavage was evaluated at 4 °C and 23 °C and the cleavage solution was analyzed after 24 hrs and 
40 hrs by SDS-PAGE (see Figure 51). 
Optimization of thioester stability:  
Buffers tested: 
Buffer D:  
50 mM TRIS.HCl (pH 7.5) 
1.5 M NaCl 
100 mM MesNa 
Buffer E: 
50 mM TRIS.HCl (pH 8.0) 
1.5 M NaCl 
100 mM MesNa 
Buffer F: 
50 mM TRIS.HCl (pH 8.5) 
1.5 M NaCl 
100 mM MesNa 
 
3 mL of chitin beads (2 mg/mL binding capacity) were suspended in 6 mL PBS-buffered lysis solution 
of a fresh Tau[1-192]-intein-CBD expression. The protein was immobilized for 2 hrs at 4 °C. The beads 
were thoroughly washed with PBS (70 mL) and then split into three equal portions. The beads were 
equilibrated with intein cleavage buffers D-F without MesNa, before the intein cleavage was induced 
with 500 μL of MesNa-containing buffers D-F.  
The elutions were then rebuffered into a ligation buffer containing 6 M Gn.HCl, 0.2 M NaH2PO4, 
30 mM TCEP and 30 mM MPAA at pH 7.5. Peptide Tau[193Cys-227]-NHNH2 (73) was added (final 
peptide concentration: 4 mM in 80 μL total volume). The ligation pH was readjusted to pH 7.5 and the 
ligation was carried out overnight at 23 °C.  
The ligations were evaluated by SDS-PAGE. The beads of the intein cleavages were boiled in SDS 
buffer to ensure full and selective release of the cleaved protein. 
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Tau[1-192] thioester
intein-CBD
1 2 3 4 5 6
1: Elution at pH 7.5
2: Beads at pH 7.5
3: Elution at pH 8.0
4: Beads at pH 8.0
5: Elution at pH 8.5
6: Beads at pH 8.5
Figure 94: The cleavage of Tau[1-192]-intein-CBD was tested at different pHs and its full elution from the beads 
was confirmed. 
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The intein cleavage was tested again with the optimal conditions. To check whether the intein cleavage 
could be upscaled, the intein cleavage of 20 mL lysate was tested together with smaller portion of 4 mL 
lysate. The intein cleavage buffer consisted of: 50 mM TRIS.HCl (pH 7.5), 1.5 M NaCl, 100 mM 
MesNa.  
The corresponding SDS-PAGE is shown below. The intein cleavage also worked with more lysate (the 
smearing of the protein band in the larger elution is due to the high salt concentration combined with an 
overloading of the gel). No Tau[1-192] thioester remained attached to the beads and there is only barely 
visible co-elution of uncleaved Tau[1-192]-intein-CBD. It remains attached to the beads, as well as the 
cleaved intein-CBD. 
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1: Elution of 20 mL lysate
2: Beads after elution of 20 mL lysate
3:Elution of 4 mL lysate
4: Beads after elution of 4 mL lysate
Figure 95: The intein cleavage of Tau[1-192]-intein-CBD with optimized conditions. 
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6.3.2 TEV protease expression  
The TEV protease used initially was a non-optimized enzyme (without mutation at Ser219) and the 
cDNA was stored in a kanamycin- and chloramphenicol resistant vector. In later experiments, the 
Ser219Val mutant (from addgene, #8827) was used to avoid auto-inactivation by self-induced cleavage. 
The TEV protease vector was transformed into Rosetta (DE3) pLysS cells and a 20 mL overnight culture 
was prepared in LB supplemented with kanamycin and chloramphenicol. A 2 L culture was inoculated 
the next day and the cells were grown at 37 °C until an OD 0.8 was reached. Protein expression was 
induced with 1 mM IPTG and conducted overnight at 18 °C. The cells were harvested at 6000 rpm and 
the pellet was resuspended in 100 mL buffer with 50 mM TRIS.HCl (pH 8.0), 400 mM NaCl, 20 mM 
imidazole and 5 mM β-mercaptoethanol. The cells were lysed by homogenization and the cell debris 
was centrifuged at 30000 g for 45 mins at 4 °C.   
The supernatant was purified by affinity column chromatography (HisTrap, GE Healthcare, 5 mL): 
Equilibration buffer: 50 mM TRIS.HCl (pH 8), 400 mM NaCl, 20 mM imidazole, 5 mM 
β-mercaptoethanol 
Elution buffer: 50 mM TRIS.HCl (pH 8), 400 mM NaCl, 500 mM imidazole, 5 mM β-mercaptoethanol 
The fractions with protein were collected and desalted (HiTrap 26/10): 
Storage buffer: 50 mM TRIS.HCl (pH 8), 0.5 M EDTA, 1 mM DTT 
The desalted protein was aliquoted into 250 μL portions and 250 μL of glycerol was added to each stock 
(Final concentration: 0.03 mg/mL). All aliquots were stored at -80 °C.  
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6.3.3 Synthesis of tau-derived peptides for ligation 
6.3.3.1 Tau[Cys197-227]-NHNH2 (47a) 
 
The peptide was synthesized on pre-loaded hydrazine resin (0.05 mmol, for the procedure see 6.3.3.3) 
and elongated by automated SPPS on the PTI Tribute. All prolines were installed by double couplings 
with HCTU. All threonine coupling times were elongated to 1 hr and the couplings were performed 
with HCTU. 
Analytical data of 47a: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and always 
eluted with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
Yield: 27.0 mg, 8.0 μmol, 8 % 
LRMS (ESI, m/z): calcd for C132H227N44O43S [M+3H]3+: 1049.89, found: 1050.26 
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Figure 96: MS of purified peptide 47a. 
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6.3.3.2 Tau[Cys197-227]-NHNH2 with pSer214 (47b) 
 
The peptide was synthesized on pre-loaded hydrazine resin (0.05 mmol, for the procedure see 7.12.2) 
and elongated by automated SPPS on the PTI Tribute using HCTU as coupling reagent. All prolines, 
threonines, valines and alanines were installed by double couplings. pSer214 was introduced by 
coupling Fmoc-Ser(OPO(Bzl)O)-OH (0.2 mmol, 2 eq.) with HCTU (0.2 mmol, 2 eq.) and DIPEA 
(0.4 mmol, 4 eq.) for 2 hrs, followed by capping for 10 mins with 8:1:1 DMF:Ac2O:2,6-lutidine. Boc-
Cys(Trt)-OH was used for the last coupling. 
Analytical data of 47b: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and always 
eluted with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
Yield: 27.0 mg, 8.0 μmol, 8 % 
LRMS (MALDI-TOF, m/z): calcd for C132H226N44O46PS [M+H]+: 3228.56, found: 3227.49 
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Figure 97: MS of purified peptide 47b. 
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6.3.3.3 Tau[220-227]-NHNH2 with N-terminal biotin (49) 
 
2-chlorotrityl resin (0.1 mmol, 1.24 mmol/g) was swelled in 50:50 DMF:DCM for 15 mins and then 
refluxed with thionyl chloride (0.12 mmol, 1.2 eq., 14.2 mg, 8.7 μL) and pyridine (0.24 mmol, 2.4 eq., 
19 mg, 19.3 μL) in dry DCM for 2 hrs. The resin was transferred into a peptide reactor and washed with 
DCM (3 x), DMF (3 x) and DCM (3 x). Afterwards, a 5 % hydrazine monohydrate solution in DMF 
was added (0.15 mL NH2NH2.H2O + 2.85 mL DMF) for 30 mins (2 x). The resin was capped with a 5 
% MeOH solution in DMF for 10 mins. The resin was washed with DCM (3 x), DMF (3 x) and DCM 
(3 x).  
The peptide was synthesized by automated SPPS on the PTI Tribute. The final coupling was performed 
with 5 eq. of biotin, 5 eq. of HCTU and 5 eq. DIPEA. 
Analytical data of 49: 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
5-95 % B in 15.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 1.28 min 
Yield: 7.0 mg, 6.0 μmol, 6 % 
LRMS (ESI, m/z): calcd for C50H89N17O13S [M+H]+: 1169.44, found: 1168.98 
 
Figure 98: Purified peptide 49. 
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6.3.3.4 Tau[Cys193-227]-NHNH2 (73a) 
 
2-chlorotrityl resin (0.1 mmol, 1.24 mmol/g) was swelled in 50:50 DMF:DCM for 15 mins and then 
refluxed with thionyl chloride (0.12 mmol, 1.2 eq., 14.2 mg, 8.7 μL) and pyridine (0.24 mmol, 2.4 eq., 
19 mg, 19.3 μL) in dry DCM for 2 hrs. The resin was transferred into a peptide reactor and washed with 
DCM (3 x), DMF (3 x) and DCM (3 x). Afterwards, a 5 % hydrazine monohydrate solution in DMF 
was added (0.15 mL NH2NH2.H2O + 2.85 mL DMF) for 30 mins (2 x). The resin was capped with a 5 
% MeOH solution in DMF for 10 mins. The resin was washed with DCM (3 x), DMF (3 x) and DCM 
(3 x).  
The peptide was synthesized by automated SPPS on the PTI Tribute. All prolines were installed by 
double couplings using HCTU as coupling reagent. The coupling time of threonines was extended to 
1 hr and HCTU was used as coupling reagent. Boc-Cys(Trt)-OH was used as building block for the last 
coupling. 
Analytical data of 73a: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and eluted 
with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
Yield: 15.0 mg, 4.1 μmol, 4.1 % 
LRMS (ESI, m/z): calcd for C152H256N51O49S [M+3H]3+: 1204.29, found: 1204.95 
 
 
Figure 99: MS of purified peptide 73a. 
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6.3.3.5 Tau[Cys193-227]-NHNH2 (73b) with pSer214 
 
The peptide was synthesized on pre-loaded hydrazine resin (0.05 mmol, for the procedure see 7.12.2) 
and elongated by automated SPPS on the PTI Tribute using HCTU as coupling reagent. All prolines, 
threonines, valines and alanines were installed by double couplings. pSer214 was introduced by 
coupling Fmoc-Ser(OPO(Bzl)O)-OH (0.2 mmol, 2 eq.) with HCTU (0.2 mmol, 2 eq.) and DIPEA 
(0.4 mmol, 4 eq.) for 2 hrs, followed by capping for 10 mins with 8:1:1 DMF:Ac2O:2,6-lutidine. Boc-
Cys(Trt)-OH was used for the last coupling. 
Analytical data of 73b: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and eluted 
with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
Yield: 8.5 mg, 2.3 μmol, 4.6 % 
LRMS (MALDI-TOF, m/z): calcd for C152H253N51O52SP [M+H]+:3692.05, found: 3691.78 
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Figure 100: MALDI of purified peptide 73b. 
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6.3.3.6 H2N-CDGKTKIA-NH2 (70) 
 
The peptide was synthesized by automated SPPS on the PTI Tribute on Rink Amide AM resin.  
Analytical data of 70: 
 
Column: Acquity UPLC-BEH C18 1.7 µm, 2.1x 50 mm RP (UPLC-MS) 
Gradient: 5-95 % B in 2.5 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
Ret. time: 1.54 min 
Yield: 47.2 mg, 0.057 mmol, 57 % 
LRMS (ESI, m/z): calcd for C34H64N11O11S [M+H]+: 834.45, found: 834.08 
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6.3.3.7 Tau[Thz193-227]-Dbz (77) 
 
0.1 mmol of Dbz-functionalized AM resin was treated with allyl chloroformate (530 μL) and DIPEA 
(35 μL) in dry DCM (3 mL) for 2 hrs to protect the o-aminoanilide to avoid branching during the 
couplings.   
The peptide was elongated by automated SPPS on the PTI Tribute. All prolines were installed by double 
couplings using HCTU as coupling reagent. The coupling time of threonines was extended to 1 hr and 
HCTU was used as coupling reagent. Boc-Thz-OH was used as building block for the last coupling.  
The allyl protection was removed by incubation with Pd(PPh3)3 (0.017 mmol, 17 mol %, 20 mg), 
phenylsilane (0.25 mmol, 2.5 eq., 300 μL) in dry DCM (3 mL) for 1 hr (2 x). The resin was washed 
with DCM (3 x), DMF (3 x) and DCM (3 x). p-Nitrophenylchloroformate (0.5 mmol, 5 eq., 100 mg) in 
dry DCM (3 mL) was added for 1 hr, followed by incubation with a 10 % solution of DIPEA in DMF. 
The final cleavage was performed with TFA:TIS:H2O (95:2.5:2.5). 
Analytical data of 77: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and eluted 
with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
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Figure 101: ESI-MS of purified peptide 77. 
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Yield: 10.3 mg, 2.7 μmol, 2.7 % 
LRMS (ESI, m/z): calcd for C161H259N52O51S [M+3H]3+:1256.63, found: 1257.63 
6.3.3.8 Tau[Thz193-227]-Dbz(Me) (79) 
 
0.1 mmol of Rink-Amide AM resin was reacted with Fmoc-(Me)Dbz-OH (0.2 mmol, 2 eq., 77 mg), 
HCTU (0.2 mmol, 2 eq., 82 mg) and DIPEA (0.4 mmol, 4 eq., 70 μL) in DMF (3 mL) for 2 hrs. The 
resin was then capped with a 8:1:1 mixture of DMF:Ac2O:2,6-lutidine. 
The peptide was elongated by automated SPPS on the PTI Tribute. All prolines were installed by double 
couplings using HCTU as coupling reagent. The coupling time of threonines was extended to 1 hr and 
HCTU was used as coupling reagent. Boc-Thz-OH was used as building block for the last coupling.  
The final cleavage was performed with TFA:TIS:H2O (95:2.5:2.5). 
Analytical data of 79: 
Due to the high hydrophilicity of this peptide, it did not retain on the analytical column and eluted 
with the injection peak. Therefore, only direct injections of the purified fractions are shown. 
Yield: 13.0 mg, 3.4 μmol, 3.4 % 
LRMS (MALDI-TOF, m/z): calcd for C162H261N52O51S [M+3H]3+: 3783.23 found: 3778.95 
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Figure 102: MALDI of purified peptide 79. 
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6.3.4 Protein ligations 
6.3.4.1 Tau[1-196] thioester with Tau[Cys197-228]-NHNH2 (48) 
2 mL of cell lysate containing Tau[1-196]-intein-CBD was immobilized for 1 hr at 4 °C on chitin beads 
(2 mg/mL binding capacity) in a buffer with 50 mM TRIS.HCl and 500 mM NaCl at pH 7.5. 250 μL of 
beads were then incubated with 1 mL intein cleavage buffer (50 mM TRIS.HCl, 500 mM NaCl, 0.1 % 
Triton, 1.75 mg peptide 47a (0.4 mM), 100 mM MesNa, pH 8.5) for 24 hrs at 23 °C.  
The ligation was analyzed by SDS-PAGE. A band at about 25 kDa was visible, which fits to the 
expected mass of Tau[1-227]-NHNH2 (48) (24.32 kDa). 
6.3.4.2 Tau[Cys228-441] with biotin-NH-Tau[220-227] (50) 
Tau[Cys228-441] (100 μg, 4.32 nmol) was transferred into NaH2PO4 (0.2 M)/TRIS (0.5 M) buffer to a 
final concentration of 28 μM (140 μL). The protein solution was split in two for a ligation and a control 
experiment (50 μg, 2.16 nmol each). To the protein for the ligation was added MPAA/MesNa (final 
concentration 100 mM); no thiol was added to the control reaction.  
Biotin-NH-Tau[220-227] (0.25 mg, 0.216 μmol) was dissolved in NaH2PO4 (0.2 M)/TRIS (0.5 M) 
buffer to a final concentration of 5 mM (43 μL) and cooled to -15 °C in a ice/salt bath. NaNO2 (0.5 M 
solution, 4.32 μL, 2.16 μmol, 10 eq.) was added and stirred for 20 mins.  
The activated peptide (24 μL, 0.108 μmol, 50 eq. to protein) was added to the ligation and control protein 
and the pH was adjusted to 7 for ligation. The ligation was performed at 23 °C overnight. Aliquots were 
taken out after 5 and 24 hrs and boiled in SDS sample buffer. The reactions were analyzed by SDS-
PAGE and WB (see general section). The gels are displayed in Figure 47. 
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Figure 103: Tau[1-196] was immobilized on chitin beads. Lane 1: Elution with Peptide 47 and 100 mM MesNa; 
Lane 2: Beads of elution 1; Lane 3: Elution with 50 mM DTT; Lane 4: Beads of elution 3  
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6.3.4.3 Tau[1-192] thioester with Tau[Cys193-228]-NHNH2 (74) 
2 mL of cell lysate containing Tau[1-192]-intein-CBD were defrozen was incubated with 1 mL chitin 
beads (binding capacity = 2 mg/mL = 0.101 μM of Tau[1-192] when beads are saturated) at 4 °C for 
1 hr. The beads were then washed with buffer made up of 50 mM Tris.HCl (pH 8.0) and 0.5 M NaCl. 
The intein cleavage was induced by addition of buffer with 50 mM TRIS.HCl (pH 8.0), 0.5 M NaCl, 
0.1 % Triton, 100 mM MesNa and peptide 73a (2 eq. (0.2 μM), 5 eq. (0.5 μM) or 10 eq. (1 μM)) and 
performed overnight at RT or 37 °C. The eluted protein was analyzed by SDS-PAGE and MALDI. 
The MALDI result for EPL performed with 10 eq. of peptide 73a at 23 °C (RT) overnight is shown 
below:  
Tau[1-227]-NHNH2 (74):  
calc.: m/z 23.25 kDa ([M+H]+) 
exp.: m/z 23.26 kDa ([M+H]+) 
 
 
6.3.4.4 Tau[1-227]-NHNH2 (74) with Tau[Cys228-441] (45) 
6.3.4.4.1 Ligation procedure 
Tau[Cys228-441] (45) (700 μg) was transferred to buffer containing 0.2 M NaH2PO4, 6 M Gn.HCl and 
100 mM MesNa at pH 7 after TEV cleavage. 
Tau[1-227]-NHNH2 (74) (250 μg, 10.7 nmol) was transferred to buffer containing 0.2 M NaH2PO4 and 
6 M Gn.HCl (pH 3) by gradually lowering the pH of the buffer during spin-filtration (starting from 
pH 7) and cooled to -15 °C in an ice/salt bath. NaNO2 (0.2 μL from 0.5 M NaNO2 solution, 0.1 μmol, 
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Figure 104: MALDI of Tau[1-228]-NHNH2 (74) after EPL. 
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10 eq.) was added and the protein was gently shaken for 15 mins. Tau[Cys228-441] was added and the 
pH was adjusted to 7. The ligation had a total volume of 200 μL. 
No band could be assigned to the full-length Tau[1-441]. Instead, the formation of dozens of new bands 
were observed in the Tau[1-227]-NHNH2 after rebuffering to 0.2 M NaH2PO4 and 6 M Gn.HCl (pH 3).  
6.3.4.4.2 Stability/efficient transfer studies at pH 3  
Tau[1-227]-NHNH2 during rebuffering with dialysis: 
The concentration of protein before and after dialysis differ strongly. To achieve a similar intensity of 
the protein bands after dialysis in comparison to before, 4 x higher volume has to be added to the gel.  
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Figure 105: Tau[1-227]-NHNH2 was activated with NaNO2 at pH 3 and then added to Tau[Cys228-441] for an 
overnight ligation with 100 mM MesNa at pH 7.0. No product was obtained. Instead, a lot of new other proteins 
were observed (lane 3). Analysis of a probe of Tau[1-227]-NHNH2 after rebuffering, but without activation 
showed significant protein degradation (lane 2). 
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Figure 106: Dialysis of Tau[1-228]-NHNH2 into 6 M Gn.HCl buffer at pH 3 showed a significant increase of 
protein material (direct comparison between lanes 1 and 2). 
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Tau[1-227]-NHNH2 rebuffering by transferring to 20 mM NH4HCO3 (pH 7), lyophilization and 
dissolving: 
The concentration before and after the rebuffering procedure remained the same. 
6.3.4.5 Tau[1-227]-NHNH2 (74) with H2N-CDGKTKIA-NH2 (75) 
Small scale: 
Tau[1-227]-NHNH2 (74) (60 μg, 2.58 nmol, 300 μL) in buffer containing 0.2 M NaH2PO4 and 
6 M Gn.HCl (pH 3) was cooled to -15 °C with an ice/salt bath and activated with 10 mM NaNO2 for 15 
mins. Peptide 75 (1.48 mg, 1.77 μmol) was dissolved in 100 μL buffer containing 0.2 M NaH2PO4, 
6 M Gn.HCl and 400 mM MPAA (pH 7) and added to the protein after activation (final MPAA 
concentration: ⁓ 100 mM). The pH was adjusted to 7 and the reaction was left overnight at 25 °C.  
The reaction was rebuffered into 20 mM NH4HCO3 (pH 7.0) and analyzed by MALDI.  
MALDI: 
Tau[1-227]-CDGKTKIA-NH2 (76):  
calc.: m/z 24.04 kDa ([M+H]+), as disulfide with MPAA: m/z 24.21 kDa ([M+H+MPAA]+) 
exp.: m/z 24.09 kDa ([M+H]+), as disulfide with MPAA: m/z 24.25 kDa ([M+H+MPAA]+) 
 
24
24
6.
30
5
24
08
7.
76
1
24
37
8.
20
9
24
40
3.
91
7
24
47
5.
66
1
19
52
1.
30
4
24
54
1.
38
9
23
24
5.
34
5
24
72
9.
38
7
19
37
6.
83
8
23
92
0.
07
4
24
98
0.
48
9
25
22
0.
62
9
0
100
200
300
400
500
600
In
te
ns
. [
a.
u.
]
16000 18000 20000 22000 24000 26000 28000
m/z
34
43
55
1 2
1: Before transfer, lyophilization and dissolving
2: After transfer, lyophilization and dissolving
Tau[1-227]-NHNH2
Tau[1-192]
Figure 107: Rebuffering of Tau[1-227]-NHNH2 by transfer to 20 mM NH4HCO3, lyophilization and dissolving 
just before use did not result in protein loss. 
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Figure 108: MALDI of Tau[1-227]- CDGKTKIA-NH2 (76) as MPAA disulfide. 
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To check whether the major peak did correspond to the disulfide, the protein was incubated with TCEP 
for 2 hrs at 23 °C and the measurement was repeated. Only traces of m/z 24.25 kDa remained and a new, 
large peak at m/z 23.92 kDa appeared. 
MALDI: 
Tau[1-227]-CDGKTKIA-NH2 (76):  
calc.: m/z 24.04 kDa ([M+H]+) 
exp.: m/z 23.95 kDa ([M+H]+) 
 
Upscaling: 
Tau[1-227]-NHNH2 (0.5 mg, 0.0214 μmol, 65 μL, 0.3 mM) in buffer containing 0.2 M NaH2PO4 and 
6 M Gn.HCl (pH 3) was cooled to -15 °C with an ice/salt bath and activated with 10 mM NaNO2 for 15 
mins. Peptide 75 (1.37 mg, 1.65 μmol, 77 eq.) was dissolved in 10 μL buffer containing 0.2 M NaH2PO4, 
6 M Gn.HCl and 700 mM MesNa (pH 7). MesNa was used, because MPAA was not sufficiently soluble. 
The peptide was added to the protein after activation (final MesNa concentration: ⁓ 100 mM). The pH 
was adjusted to 7 and the reaction was left overnight at 23 °C.  
The ligation was incubated with TCEP for 2 hrs at 23 °C and then rebuffered into 20 mM NH4HCO3 for 
MALDI analysis. The conversion was not as good as in the previous experiment, where less protein was 
used for the ligation.  
As control, the same procedure was followed, but no MesNa was added. No reaction was observed. 
MALDI: 
Tau[1-227]-CDGKTKIA-NH2 (76):  
calc.: m/z 24.04 kDa ([M+H]+) 
exp.: m/z 23.96 kDa ([M+H]+) 
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Figure 109: MALDI of Tau[1-227]-CDGKTKIA-NH2 (76) after incubation with TCEP. 
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Control reaction: 
MALDI: 
exp.: m/z 23.12 kDa ([M+H]+) (corresponds to Tau[1-227]-NHNH2 (74)) 
6.3.4.6 Tau[Cys193-227]-Dbz (77) with Tau[Cys228-441] (45) 
All buffers were degassed by sonification and flushed with argon prior to use. 
Tau[Cys228-441] (0.500 μg, 22 nmol) was transferred into 500 μL 0.2 M NaH2PO4, 100 mM MesNa 
and 1 mM TCEP at pH 8.0 and peptide 77 (0.4 mg, 0.11 μmol, 5 eq.) was added for ligation overnight 
at 23 °C. 
The ligation was rebuffered into 20 mM NH4HCO3 buffer and analyzed by MALDI, SDS-PAGE (see 
Figure 112) and WB (tau-46 antibody recognizes an epitope within the C-terminal part of tau). 
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Figure 110: MALDI of Tau[1-227]-CDGKTKIA-NH2 (76) after ligation and TCEP incubation 
Figure 111: MALDI of control reaction with no MesNa added. 
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MALDI: 
Tau[Thz193-441] (80):  
calc.: m/z 26.21 kDa ([M+H]+) 
exp.: m/z 26.80 kDa ([M+H]+) 
 
17
26
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6.3.4.7 Tau[Thz193-441] with Tau[1-192] thioester 
4 mL of cell lysate containing Tau[1-192]-intein-CBD in PBS was added to 1.5 mL of chitin beads and 
incubated for 2 hrs. 5 mL of intein cleavage buffer (50 mM TRIS.HCl, 1.5 M NaCl, 100 MesNa, pH 
8.5) was added and incubated overnight at 23 °C. The volume was reduced to 1 mL by spin-filtration 
and the buffer was exchanged to 0.2 M NaH2PO4. 
Tau[Thz193-441] (78) was treated with 30 mM TCEP and 130 mM MeONH2 at pH 4 for 4 hrs directly 
after the first ligation to deprotect the thiazolidine. The reagents were removed by spin-filtration and 
the protein was transferred into 0.2 M NaH2PO4. 
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Figure 112: MALDI and WB of Tau[Thz193-441] (78). 
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Figure 113: Ligation of Tau[Thz193-441] (78) with Tau[1-192] thioester (45). No ligation product could be 
detected. 
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The two proteins were mixed in 1 CT: 1 NT, 2 CT: 1 NT and 3 CT: 1 NT ratios (volume). No product 
formation was observed by MALDI, SDS-PAGE or WB (tau-46). 
6.3.5 Synthesis of β-mercaptotyrosine 
6.3.5.1 N,N-di-tert-butoxycarbonyl protected tyrosine (52) 
O
COOMe
(Boc)2N
 
Boc-Asp(OtBu)-OH (1.00 g, 2.96 mmol) was dissolved in dry DCM (5 mL) and DMAP (0.18 g, 
1.48 mmol, 0.5 eq.) and dry MeOH (0.38 g, 0.48 mL, 11.8 mmol, 4 eq.) was added. The reaction mixture 
was cooled down and EDC.HCl (0.62 g, 3.26 mmol, 1.1 eq.) was added and stirred overnight at 23 °C. 
The solvent was removed in vacuo and the residue was re-dissolved in EtOAc (30 mL) and H2O (10 
mL). The organic layer was separated and washed with sodium carbonate (2 x 15 mL) and H2O (2 x 15 
mL). After drying with Na2SO4, the solvent was removed in vacuo and the resulting white solid (0.97 
g, 2.76 mmol, 93 %) was used without further purification.  
The solid was dissolved in dry MeCN (10 mL) and Boc anhydride (1.81 g, 8.28 mmol, 3 eq.) in dry 
MeCN (5 mL) was added, along with DMAP (0.34 g, 2.76 mmol, 1 eq.). The reaction was stirred 
overnight at 23 °C. The solvent was evaporated and the crude product was purified by silica gel column 
chromatography with 10:1 Hex:EtOAc. Product 52 was isolated as colorless oil (1.11 g, 2.45 mmol, 
89 %). 
Analytical data of 52: 
1H NMR (CDCl3, 300 MHz) δ 7.07 (d, J = 9 Hz, 2 H), 6.88 (d, J = 6 Hz, 2 H), 5.14 (dd, J = 3 Hz, J = 
10.5 Hz, 1 H), 3.74 (s, 3 H), 3.39 (dd, J = 3 Hz, J = 15 Hz, 1 H), 3.16 (dd, J = 9 Hz, J = 12 Hz, 1 H), 
1.40 (s, 18 H), 1.31 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.16, 154.13, 151.77, 132.52, 130.06, 124.14, 83.09, 78.33, 59.47, 
52.40, 35.54, 28.93, 28.04 
LRMS (ESI, m/z): calcd for C24H38NO7 [M+H]+: 452.57, found: 452.36  
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6.3.5.2 Oxazolidinone (54) 
O
NBoc
O
O
CO2Me
 
Boc2N-Asp(OtBu)-OMe 52 (3.78 g, 8.38 mmol) was dissolved in freshly distilled carbon tetrachloride 
(170 mL, 0.05 M) and NBS (1.63 g, 9.21 mmol, 1.1 eq.) was added. The solution was refluxed and 
irradiated with a 300 V lamp for 2 hrs under argon. The reaction mixture was cooled down, filtered and 
the solvent was removed in vacuo. The residue was dissolved in acetone and silver nitrate (2.13 g, 12.57 
mmol, 1.5 eq.) was added. The reaction was stirred in the dark for 2 hrs at 23 °C. The solids were then 
removed by filtration over Celite and the solvent was reduced in vacuo. The crude product was purified 
by silica gel column chromatography with 4:1 Hex:EtOAc. Product 54 was isolated as colorless oil 
(1.11 g, 2.85 mmol, 35 %). 
Analytical data of 54: 
1H NMR (CDCl3, 300 MHz) δ 7.28 (d, J = 9 Hz, 2 H), 7.05 (d, J = 9 Hz, 2 H), 5.34 (d, J = 6 Hz, 1 H), 
4.66 (d, J = 3 Hz, 1 H), 3.88 (s, 3 H), 1.51 (s, 9 H), 1.37 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 169.18, 156.71, 150.83, 148.61, 131.46, 126.09, 124.45, 84.98, 79.24, 
75.97, 63.74, 53.34, 28.91, 27.92 
LRMS (ESI, m/z): calcd for C20H28NO7 [M+H]+: 394.44, found: 394.37 
 
6.3.5.3 Boc-(β-OH)Tyr(OtBu)-OMe (55) 
O
COOMe
BocHN
OH
 
Oxazolidinone 54 (1.11 g, 2.85 mmol) was dissolved in dry MeOH (25 mL) and cesium carbonate (0.47 
g, 1.43 mmol, 0.5 eq.) was added. The reaction was stirred for 3 hrs at 23 °C, before the solvent was 
removed in vacuo and the residue was re-dissolved in EtOAc (60 mL). The organic phase was extracted 
with conc. NH4Cl (2 x 60 mL), H2O (60 mL) and brine (60 mL). It was dried with Na2SO4, filtered and 
the solvent was evaporated. The crude product was purified by silica gel column chromatography with 
4:1 Hex:EtOAc. Product 55 was isolated as colorless oil (0.66 g, 1.80 mmol, 63 %).   
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Analytical data of 67: 
1H NMR (CDCl3, 300 MHz) δ 7.25 (d, J = 9 Hz, 2 H), 6.95 (d, J = 9 Hz, 2 H), 5.35 (d, J = 6 Hz, 1 H), 
5.17 (br s, 1 H), 4.51 (d, J = 6 Hz, 1 H), 3.72 (s, 3 H), 1.34 (s, 9 H), 1.32 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.58, 155.30, 134.74, 126.75, 124.10, 78.75, 73.89, 59.54, 52.64, 
28.93, 28.32 
LRMS (ESI, m/z): calcd for C19H30NO6 [M+H]+: 368.45, found: 368.33 
 
6.3.5.4 β-mercaptotyrosine syntheses  
These reaction procedures were also used for the thioesterification of the other hydroxytyrosine 
derivatives synthesized via aminohydroxylation.  
6.3.5.4.1 Mesylation of β-hydroxytyrosine 
Boc-(β-OH)Tyr(OtBu)-OMe 55 (0.106 g, 0.29 mmol) was dissolved in dry DCM (2 mL) and 
triethylamine (44 mg, 56 μL, 0.43 mmol, 1.5 eq.) was added at 0 °C. Mesyl chloride (40 mg, 27 μL, 
0.35 mmol, 1.2 eq.) was added and the reaction was stirred for 1 hr, before it was quenched with conc. 
NH4Cl (1 mL). The organic layer was diluted to 10 mL with DCM and washed with H2O (10 mL) and 
brine (10 mL). It was then dried with Na2SO4 and filtered. The solvent was removed in vacuo and the 
resulting residue was used without further purification.  
DBU (0.15 g, 0.15 mL, 1.01 mmol, 3.5 eq.) and thioacetic acid (0.11 g, 0.10 mL, 1.44 mmol, 5 eq.) was 
dissolved in dry DMF (0.41 mL). The residue, dissolved in DMF (0.83 mL), was added and the reaction 
was stirred overnight at 23 °C. The mixture was concentrated and re-dissolved in EtOAc (20 mL). It 
was extracted with conc. NH4Cl (3 x 30 mL), H2O (30 mL) and brine (30 mL). the organic phase was 
dried with Na2SO4, filtered and the solvent was removed in vacuo. Several compounds were isolated by 
silica gel column chromatography with 5:1 Hex:EtOAc. Product 56 could not be isolated as pure product 
and only at very poor yields. The NMR suggests that the product is present as a mixture of (2S, 3S) and 
(2S, 2R) diastereoisomers, together with elimination product 59. Starting material 55 could also be re-
isolated. 
Analytical data: 
LRMS (ESI, m/z): calcd for compound 56 C21H32NO6S [M+H]+: 426.55, found: 426.28 
LRMS (ESI, m/z): calcd for compound 59 C19H28NO5 [M+H]+: 350.43, found: 350.22 
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6.3.5.4.2 Thioesterification by Mitsunobu-type substitution 
DIAD (60 mg, 0.27 mmol, 2 eq.) was added to a solution of triphosphorous chloride in THF (0.075 mg, 
0.27 mmol, 2 eq., 1 mL) in a flask at 0 °C. The mixture was stirred at 0 °C for 1 hr. Boc-(β-
OH)Tyr(OtBu)-OMe 55 (0.050 g, 0.14 mmol) and thioacetic acid (22 mg, 0.27 mmol, 2 eq.) were added 
dropwise at -40 °C and stirred for 15 mins, before it was allowed to warm to 23 °C. The solvent was 
evaporated and the crude mixture was purified by silica gel column chromatography with 10:1 
Hex:EtOAc. Only elimination product 59 was formed. 
O
COOMe
BocHN
 
Analytical data of 59: 
1H NMR (CDCl3, 300 MHz) δ 7.48 (d, J = 6 Hz, 2 H), 6.96 (d, J = 6 Hz, 2 H), 6.20-6.11 (m, 1 H), 
3.83 (s, 3 H), 1.36 (s, 18 H) 
LRMS (ESI, m/z): calcd for compound 59 C19H28NO5 [M+H]+: 350.43, found: 350.30 
6.3.5.4.3 Thioesterification with Vilsmeier reagent 
DMF (22 μL, 0.154 mmol, 1.1 eq.) in dry DCM (1 mL) was cooled to 0 °C and oxalyl chloride (12 μL, 
0.14 mmol, 1 eq.) was added. It was stirred for 5 mins and the solvent was removed in vacuo. The 
resulting solid was suspended in dry THF (1 mL) and cooled to 0°C. Boc-(β-OH)Tyr(OtBu)-OMe 55 
(0.050 g, 0.14 mmol), triethylamine (38 μL, 0.28 mmol, 2 eq.) and thioacetic acid (6 μL, 0.094 mmol, 
0.67 eq.) were added sequentially. The reaction was stirred for 48 hrs at 23 °C. No product formation 
(56) could be observed by ESI-MS. 
6.3.5.4.4 Lewis-acid catalysed thioesterification 
Boc-(β-OH)Tyr(OtBu)-OMe 55 (57 mg, 0.16 mmol) was dissolved in dichloromethane (2.5 mL) and 
zinc iodide (25 mg, 0.077 mmol, 0.5 eq.) as well as thioacetic acid (14 mg, 0.19 mmol, 1.2 eq.) were 
added at 0 °C. The reaction was stirred overnight at 23 °C. The reaction mixture was diluted with DCM 
(20 mL) and the organic phase was extracted with H2O (2 x 20 mL) and brine (20 mL). It was dried 
with Na2SO4, filtered and the solvent was removed in vacuo. The crude reaction was purified by silica 
gel column chromatography with 1:1 Hex:EtOAc. No product formation (56) could be observed by 
ESI-MS in any of the fractions. 
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6.3.5.4.5 Thioesterification from the bromide 
Boc-(β-Br)Tyr(OtBu)-OMe 61 was reacted using the following reaction conditions, none of which 
resulted in the formation of product 60. 
Entry # Solvent HSAc KSAc Base (1.2 eq.) Additive (1 eq.) 
1 MeOH 1.2 eq.  K2CO3  
2 THF 1.2 eq.  K2CO3  
3 Acetone 1.2 eq.  K2CO3  
4 MeOH  1 eq.   
5 Acetone  1 eq.   
6 MeOH  1 eq.  Ag2O 
7 Acetone  1 eq.  Ag2O 
8 DMF  5 eq.   
9 MeCN  5 eq.  AgNO3 
 
6.3.5.5 Cinnamic ester 63 
OH
COOMe
 
Cinnamic acid (1 g, 12.2 mmol) was dissolved in dry MeOH (10 mL) and a few drops of conc. H2SO4 
were added. The reaction was refluxed overnight. After solvent removal, the residue was dissolved in 
EtOAc (100 mL) and the organic phase was extracted with H2O (2 x 50 mL), sat. NaHCO3 (2 x 50 mL) 
and brine (50 mL). The organic phase was dried with MgSO4, filtered and the solvent was removed in 
vacuo. Product 63 was isolated as white powder at quantitative yield. 
Analytical data of 63: 
1H NMR (d3-MeCN, 300 MHz) δ 7.61 (d, J = 15 Hz, 1 H), 7.50 (d, J = 9 Hz, 2 H), 7.46 (br s, 1 H), 
6.84 (d, J = 9 Hz, 2 H), 6.30 (d, J = 15 Hz, 1 H), 3.72 (s, 3 H) 
13C-NMR (d3-MeCN, 75 MHz) δ 168.30, 160.09, 145.27, 130.99, 127.18, 118.26, 116.59, 115.60, 
51.92 
LRMS (ESI, m/z): calcd for C10H11O3 [M+H]+: 179.19, found: 178.07 
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6.3.5.6 β-hydroxytyrosine synthesis via Sharpless aminohydroxylation 
Tert-butanol hypochlorite was freshly synthesized by mixing NaOCl (2 eq.) with tBuOH (1 eq.) and 
AcOH (13.36 ml/mmol) for 10 mins. The organic phase was extracted with conc. NaHCO3 (3 x 30 mL) 
and H2O (3 x 30 mL). The organic phase was then stored over dried CaCl2 in a flask at -20 °C. 
6.3.5.6.1 With Boc carbamate (64a) 
OH
COOMe
BocHN
OH
 
Tert-butyl carbamate (0.53 g, 3.48 mmol, 3.1 eq.) was dissolved in isopropanol (4.2 mL). 0.4 M NaOH 
(8.4 mL, 3.36 mmol, 3.05 eq.) was added, followed by tBuOCl (0.36 g, 0.38 mL, 3.36 mmol, 3.3 eq.) 
and stirred for 7 mins in the dark. The reaction was then cooled to 0 °C.  
(DHQ)2AQN (58 mg, 0.067 mmol, 0.06 eq.) was dissolved in isopropanol (4.2 mL) and added to the 
cooled solution. Cinnamate ester 63 (0.2 g, 1.12 mmol, 1 eq.) was dissolved in isopropanol (8.4 mL) 
and added too, immediately followed by K2OsO2(OH)4 (16.5 mg, 0.045 mmol, 4 mol %) in 0.4 M NaOH 
(0.42 mL). The reaction was then stirred for 2 hrs at 0 °C.  
The solvent was removed in vacuo and the residue was diluted with EtOAc (30 mL) and H2O (30 mL). 
The organic phase was washed with H2O (2 x 30 mL), brine (30 mL), then dried with MgSO4 and 
filtered. The solvent was evaporated and the crude product was purified by silica gel column 
chromatography with 2:1 to 1:1 Hex:EtOAc. Product 64a was isolated as white powder (0.21 g, 
0.67 mmol, 60 %). 
Analytical data of 64a: 
1H NMR (CDCl3, 300 MHz) δ 7.37 (d, J = 6 Hz, 2 H), 7.24 (br s, 1 H), 6.92 (d, J = 6 Hz, 2 H), 5.73 
(d, J = 9 Hz, 1 H), 5.35 (br s, 1 H), 4.68 (d, J = 6 Hz, 1 H), 3.95 (s, 3 H), 1.58 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.46, 156.02, 131.65, 127.50, 115.45, 77.37, 73.80, 60.61, 52.74, 
28.36 
LRMS (ESI, m/z): calcd for C15H22NO6 [M+H]+: 312.34, found: 312.20 
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6.3.5.6.2 With Cbz carbamate (64b) 
OH
COOMe
CbzHN
OH
 
Cbz carbamate (0.56 g, 3.72 mmol, 3.1 eq.) was dissolved in isopropanol (5.5 mL). 0.4 M NaOH 
(8.8 mL, 3.05 eq.) was added, followed by tBuOCl (0.45 mL, 3.96 mmol, 3.3 eq.) and stirred for 7 mins 
in the dark. The reaction was then cooled to 0 °C.  
(DHQ)2AQN (62 mg, 0.072 mmol, 0.06 eq.) was dissolved in isopropanol (4.5 mL) and added to the 
cooled solution. Cinnamate ester 63 (0.22 g, 1.2 mmol, 1 eq.) was dissolved in isopropanol (9 mL) and 
added too, immediately followed by K2OsO2(OH)4 (17.2 mg, 0.048 mmol, 4 mol %) in 0.4 M NaOH 
(0.5 mL). The reaction was then stirred for 2 hrs at 0 °C.  
The solvent was removed in vacuo and the residue was diluted with EtOAc (30 mL) and H2O (30 mL). 
The organic phase was washed with H2O (2 x 30 mL), brine (30 mL), then dried with MgSO4 and 
filtered. The solvent was evaporated and the crude product was purified by silica gel column 
chromatography with 2:1 to 1:1 Hex:EtOAc. Product 64b was isolated as white powder (0.26 g, 
0.76 mmol, 63 %). 
Analytical data of 64b: 
1H NMR (CDCl3, 300 MHz) δ 7.44-7.26 (m, 7 H), 7.02 (d, J = 9 Hz, 2 H), 5.88 (br s, 1 H), 5.60 (d, J 
= 4 Hz, 1 H), 5.08 (s, 2 H), 4.29 (d, J = 4 Hz, 1 H), 3.85 (s, 3 H) 
LRMS (ESI, m/z): calcd for C18H19NNaO6 [M+H]+: 368.34, found: 368.23 
All values were according to literature. [357] 
  
EXPERIMENTAL PART 
 
223 
 
6.3.5.7 Phenol protection of β-hydroxytyrosine derivatives 65a/b 
6.3.5.7.1 Boc-(β-OH)Tyr(OBzl)-OMe (65a) 
O
COOMe
BocHN
OH
 
 
64a (0.16 g, 0.51 mmol) was dissolved in dry MeCN (6 mL) and Cs2CO3 (0.165 g, 0.51 mmol, 1 eq.) 
was added. The reaction was cooled to 0 °C and benzyl bromide (87 mg, 0.51 mmol, 1 eq.) was added 
in four portions over an hour and then allowed to stir overnight. The mixture was diluted with EtOAc 
(50 mL) and the organic phase was extracted with H2O (2 x 30 mL) and brine (30 mL). After drying 
with MgSO4, the organic phase was filtered and the solvent was removed in vacuo. The crude product 
was purified by silica gel column chromatography with 3:1 Hex:EtOAc. Product 65a was isolated as 
white powder (0.13 g, 0.33 mmol, 65 %). 
Analytical data of 65a: 
1H NMR (CDCl3, 300 MHz) δ 7.45-7.28 (m, 7 H), 6.97 (d, J = 9 Hz, 2 H), 5.35 (d, J = 9 Hz, 1 H), 
5.17 (br s, 1 H), 5.07 (s, 2 H), 4.51 (d, J = 6 Hz, 1 H), 3.76 (s, 3 H), 1.37 (s, 9 H) 
LRMS (ESI, m/z): calcd for C22H27NNaO6 [M+Na]+: 424.45, found: 424.29 
All values were according to literature. [366] 
 
6.3.5.7.2 Cbz-(β-OH)Tyr(OBzl)-OMe (65b) 
 
O
COOMe
CbzHN
OH
 
 
64b (0.26 g, 0.76 mmol) was dissolved in dry MeCN (6 mL) and Cs2CO3 (0.25 g, 0.76 mmol, 1 eq.) 
was added. The reaction was cooled to 0 °C and benzyl bromide (0.13 g, 0.76 mmol, 1 eq.) was added 
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in four portions over an hour and then allowed to stir overnight. The mixture was diluted with EtOAc 
(50 mL) and the organic phase was extracted with H2O (2 x 40 mL) and brine (40 mL). After drying 
with MgSO4, the organic phase was filtered and the solvent was removed in vacuo. The crude product 
was purified by silica gel column chromatography with 3:1 Hex:EtOAc. Product 65b was isolated as 
white powder (0.28 g, 0.65 mmol, 85 %). 
Analytical data of 65b: 
1H NMR (CDCl3, 300 MHz) δ 7.44-7.27 (m, 12 H), 6.94 (d, J = 9 Hz, 2 H), 5.56 (d, J = 7.5 Hz, 1 H), 
5.22 (br s, 1 H), 5.05-5.03 (m, 4 H), 4.57 (d, J = 7.5 Hz, 1 H), 3.76 (s, 3 H) 
LRMS (ESI, m/z): calcd for C25H26NO6 [M+H]+: 436.48, found: 436.30 
All values were according to literature. [357] 
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6.3.5.8 Stability studies of β-hydroxytyrosine 65a 
Small samples of 65a were dissolved in TFA cleavage cocktails (see Table 11) for 30 mins. The TFA 
was evaporated and the residue was dissolved in 10:90 MeCN:H2O. All probes were analyzed by 
analytical HPLC. The peaks were collected and injected into the MS for further analysis.  
HPLC: 
Column: Agilent Eclipse XDB C18, 4.6 x 250 mm (analytical HPLC) 
Gradient: 5-95 % B in 30 mins (Solvent A: H2O + 0.1% TFA, solvent B: MeCN + 0.1 % TFA) 
In all cases, 65a had fully disappeared (ret. time: 27.6 min). The mass of the β-elimination product 
(m/z 284.5) was found in all injection peaks. Other identified peaks are described below: 
S
thioanisole adduct
OH
tyrosine adduct
H2N COOMe
OH
β-elimination product
H2N COOMe
 
 
Identified products formed during TFA treatment: 
Ret. time of 65a: 27.6 min 
Ret. time of thioanisole: 26.4 min 
Ret. time of thioanisole adduct: 14.1 min 
Ret. time of tyrosine adduct: 17.4 min 
Figure 114: HPLC chromatogram of 65a before TFA incubation. 
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90 % TFA, 10 % H2O: 
 
80 % TFA, 10 % H2O, 10 % thioanisole:  
 
Figure 115: 55 after incubation with 90 % TFA and 10 % H2O. 
Figure 116: 55 after incubation with 65 % TFA, 10 % H2O and 25 % thioanisole. 
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65 % TFA, 10 % H2O, 25 % thioanisole: 
 
6.3.6 Synthesis of β-mercaptoaspartic acid 
6.3.6.1 Boc-Asp(OtBu)-OAllyl (68) 
BocHN
O
O
OtBu
O
 
Boc-Asp(OtBu)-OH (5 g, 15 mmol) was dissolved in dry DMF and purged with argon. 
Diisopropylethylamine (2.96 g, 3.9 mL, 22.5 mmol, 1.5 eq.) was added and reaction was stirred for 
3 hrs, before allyl bromide (2.38 g, 1.7 mL, 22.2 mmol, 1.48 eq.) was added and stirred overnight. The 
solvent was removed in vacuo and the crude product was purified by silica gel column chromatography 
with 4:1 Hex:EtOAc. Product 68 was isolated as white solid (4.40 g, 13.4 mmol, 89 %). 
Analytical data of 68: 
1H NMR (CDCl3, 300 MHz) δ 5.94-5.83 (m, 1 H), 5.35-5.29 (m, 1 H), 5.29-5.22 (m, 1 H), 4.66-4.62 
(m, 2 H), 4.57-4.53 (m, 1 H), 3.01 (dd, J = 1.5 Hz, 17.5 Hz, 1 H), 2.72 (dd, J = 1.5 Hz, 17.5 Hz), 1.45 
(s, 9 H), 1.43 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.14, 170.24, 155.61, 131.73, 118.70, 81.80, 80.13, 66.24, 50.29, 
38.06, 28.44, 28.15 
LRMS (ESI, m/z): calcd for C16H28NO6 [M+H]+: 330.40, found: 330.34 
All values were according to literature. [361] 
  
Figure 117:55 after incubation with 80 % TFA, 10 % H2O and 10 % thioanisole. 
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6.3.6.2 2,4,6-trimethoxybenzyl alcohol (69) 
OH
OO
O  
2,4,6-trimethoxybenzyl aldehyde (3.00 g, 15.2 mmol) was dissolved in MeOH:1 M NaOH (1:1.5 mL) 
and cooled to 0 °C. NaBH4 (0.86 g, 22.8 mmol, 1.5 eq.) was added in portions. The reaction was warmed 
to RT and stirred overnight. The volume was reduced in vacuo and then extracted with diethyl ether (3 
x 50 mL) and brine (50 mL). The organic phase was dried with MgSO4, filtered and the solvent was 
removed in vacuo. Product 69 was isolated as white powder (2.92 g, 14.7 mmol, 97 %). 
Analytical data of 69: 
1H NMR (CDCl3, 300 MHz) δ 1.96 (s, 2 H), 4.72 (s, 2H), 3.84 (s, 6 H), 3.83 (s, 3 H) 
13C-NMR (CDCl3, 75 MHz) δ 161.18, 159.34, 110.07, 90.64, 55.85, 55.50, 54.55 
LRMS (ESI, m/z): calcd for C10H13O3 [M-H2O]+: 181.09, found: 181.16 
All values were according to literature. [361] 
 
6.3.6.3 Sulfenylating reagent (70) 
S
S
OO
O
O
O
 
 
Potassium p-toluenethiosulfonate (3.32 g, 14.7 mmol) and 2,4,6-trimethoxybenzyl alcohol 67 (2.92 g, 
14.7 mmol) were suspended in MeOH (60 mL) and cooled to 0 °C. TFA (1.85 g, 1.2 mL, 16.2, 1.1 eq.) 
was added dropwise and stirred for 15 mins. Upon acidification, the suspension cleared and a new white 
precipitate formed, which was filtered, washed and dried in vacuo. The solid was re-crystallized in 
EtOAc. Product 70 was collected as white crystals (2.21 g, 6.0 mmol, 65 %). 
Analytical data of 70: 
1H NMR (CDCl3, 300 MHz) δ 7.86 (d, J =  9 Hz, 2 H), 7.32 (d, J =  6 Hz, 2 H), 6.01 (s, 2 H), 4.29 (s, 
2 H), 3.77 (s, 3 H), 3.69 (s, 6 H), 2.45 (s, 3 H)  
13C-NMR (CDCl3, 75 MHz) δ 161.57, 159.24, 144.08, 142.56, 129.56, 127.28, 102.62, 90.48, 55.79, 
55.47, 29.24, 21.74 
LRMS (ESI, m/z): calcd for C17H21O5S2 [M+H]+: 368.46, found: 368.33 
All values were according to literature. [361]  
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6.3.6.4 Boc-(β-S(Tmob)-Asp(OtBu)-OAllyl (71) 
BocHN
O
O
S
OtBu
O
OO
O
 
Boc-Asp(OtBu)-OAllyl 68 (0.86 g, 2.6 mmol) was dissolved in dry THF (25 mL) and cooled to -78 °C. 
LiHMDS (3.7 mL from a 1.3 M solution, 4.8 mmol, 2.2 eq.) was added and the reaction was stirred for 
2 hrs at -78 °C. Sulfenylating reagent 70 (1.36 g, 3.7 mmol, 1.4 eq.) in THF (15 mL, 0.25 M) was added 
dropwise over 10 mins and stirred for 2 hrs more. The reaction was quenched with NH4OAc (10 mL) 
and the solvent was reduced in vacuo. The residue was extracted with EtOAc (50 mL), NH4OAc (3 x 
50 mL) and brine (50 mL). The organic phase was dried with MgSO4, filtered and reduced in vacuo. 
The crude product was purified by silica gel column chromatography with 6:1 Hexane:EtOAc. 
Product 71 was isolated as colorless oil (0.80 g, 1.48 mmol, 57 %).  
Analytical data of 71: 
1H NMR (CDCl3, 300 MHz) δ 6.10 (s, 2 H), 5.90-5.81 (m, 1 H), 5.71 (d, J = 9 Hz, 1 H), 5.34-5.29 (m, 
1 H), 5.28-5.20 (m, 1H), 4.82-4.72 (m, 1 H), 4.66-4.55 (m, 1 H), 3.98 (br s, 1 H), 3.92 (s, 1 H), 3.81 
(s, 6 H), 3.80 (s, 3 H), 1.45 (s, 9 H), 1.42 (s, 6 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.07, 170.59, 160.69, 159.12, 156.06, 131.76, 118.58, 107.04, 83.82, 
79.84, 66.15, 55.88, 55.47, 49.13, 28.43, 28.09, 25.08 
LRMS (ESI, m/z): calcd for C26H39NO9S [M+Na]+: 564.65, found: 564.42 
All values were according to literature. [361] 
 
6.3.6.5 Boc-(β-S(Tmob)-Asp(OtBu)-OH (72) 
BocHN
OH
O
S
OtBu
O
OO
O
 
Boc-(β-S(Tmob)-Asp(OtBu)-OAllyl 71 (72 mg, 0.136 mmol) and phenylsilane (29.6 mg, 0.274 mmol, 
2 eq.) were dissolved in dry, degassed MeCN (5 mL). Pd(PPh3)4 (15 mg, 0.0136 mmol, 10 mol %) was 
added and the reaction was stirred overnight at 23 °C. The solvent was removed in vacuo and the crude 
product was purified by silica gel column chromatography with 75:24:1 Hex:EtOAc:AcOH. Product 72 
was isolated as colorless oil (42 mg, 0.084 mmol, 62 %). 
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Analytical data of 72: 
1H NMR (CDCl3, 300 MHz) δ 6.11 (s, 2 H), 5.88 (d, J = 9 Hz, 1 H), 5.34-5.29 (m, 1 H), 4.70-4.66 (m, 
1 H), 4.02-3.96 (m, 1 H), 3.93-3.89 (br s, 1 H), 3.81 (s, 6 H), 3.80 (s, 3 H), 1.47 (s, 9 H), 1.43 (s, 9 H) 
13C-NMR (CDCl3, 75 MHz) δ 171.81, 160.82, 159.07, 106.82, 90.72, 83.52, 80.73, 55.88, 55.47, 
48.36, 28.41, 27.98, 25.71 
LRMS (ESI, m/z): calcd for C23H35NNaO9S [M+Na]+: 524.58, found: 524.34 
All values were according to literature. [361]
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8 Appendix 
8.1 NMR of core structure 1 
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8.2 NMRs of borane-protected triazole-phosphonites 
8.2.1 Compound 13a 
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8.2.2 Compound 13b 
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8.2.3 Compound 13c 
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8.2.4 Compound 13d 
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8.2.5 Compound 13e 
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8.3 NMRs of small-molecule phosphonamidates 
8.3.1 Compound 14a 
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8.3.2 Compound 14b 
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8.3.3 Compound 14c 
 
 
